



(51) International Patent Classification:

C07D 401/12 (2006.01) A61P 17/06 (2006.01)
 C07D 401/14 (2006.01) A61P 19/02 (2006.01)
 C07D 495/04 (2006.01) A61P 29/00 (2006.01)
 C07K 5/062 (2006.01) A61K 31/4545 (2006.01)
 A61P 11/00 (2006.01)

(21) International Application Number:

PCT/US2021/062995

(22) International Filing Date:

13 December 2021 (13.12.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/124,877 14 December 2020 (14.12.2020) US

(71) Applicant: BIOTHERYX, INC. [US/US]; 7966 Arjons Drive, San Diego, California 92126 (US).

(72) Inventors: CHAN, Kyle W.H.; 5132 Greenwillow Lane, San Diego, California 92130 (US). ERDMAN, Paul E.; 8570 Ivory Coast Drive, San Diego, California 92126 (US). FUNG, Leah M.; 12255 Mannix Road, San Diego, California 92129 (US). HECHT, David Aaron; 1201 Morgan Hill Drive, Chula Vista, California 91913 (US). MERCURIO, Frank; P.O. Box 1513, Rancho Santa Fe, California 92067 (US). SULLIVAN, Robert W.; 2235 Tierra Verde Road, Vista, California 92084 (US).

(74) Agent: YU, Lin; 11597 Tree Hollow Lane, San Diego, California 92128 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,



SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: PDE4 DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS



(57) Abstract: Provided herein are phosphodiesterase 4 (PDE4) degraders, e.g., a compound of Formula (I) or (IA), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a PDE4-mediated disease, disorder, or condition.



PDE4 DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS

CROSS REFERENCE TO RELATED APPLICATION

[0001] This application claims the benefit of the priority of U.S. Provisional Application No. 63/124,877, filed December 14, 2020; the disclosure of which is incorporated herein by reference in its entirety.

FIELD

[0002] Provided herein are phosphodiesterase 4 (PDE4) degraders and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a PDE4-mediated disease, disorder, or condition.

BACKGROUND

[0003] Aberrant protein function or protein imbalance is a hallmark of many disease states. For example, the functioning of the immune system is finely balanced by the activities of pro-inflammatory and anti-inflammatory mediators or cytokines. Some cytokines promote inflammation (pro-inflammatory cytokines), whereas other cytokines suppress the activity of the pro-inflammatory cytokines (anti-inflammatory cytokines). For example, interleukin-4 (IL-4), interleukin-10 (IL-10), and interleukin-13 (IL-13) are potent activators of B lymphocytes, and also act as anti-inflammatory agents. They are anti-inflammatory cytokines by virtue of their ability to suppress genes for pro-inflammatory cytokines, such as interleukin-1 (IL-1), a tumor necrosis factor (TNF), and chemokines.

[0004] Unregulated activities of these mediators can lead to the development of serious inflammatory conditions. For example, autoimmune diseases arise when immune system cells (lymphocytes and macrophages) become sensitized against the “self.” Lymphocytes as well as macrophages are usually under control in this system. However, a misdirection of the system toward the body’s own tissues may happen in response to still unexplained triggers. One hypothesis is that lymphocytes recognize an antigen which mimics the “self” and a cascade of activation of different components of the immune system takes place, ultimately leading to tissue


destruction. Genetic predisposition has also been postulated to be responsible for autoimmune disorders.

[0005] For example, a phosphodiesterase 4 (PDE4) is involved in the cytokine production of inflammatory cells, angiogenesis, and the functional properties of other cell types such as keratinocytes, in part, through degradation of cyclic adenosine monophosphate (cAMP). cAMP is an important second messenger that regulates inflammatory responses. Accordingly, inhibitors of PDE4 may block the synthesis of several pro-inflammatory cytokines and chemokines, such as tumor necrosis factor alpha (TNF- α), interleukin-23 (IL-23), chemokine ligand 9 (CXCL9, also known as monokine induced by interferon gamma (MIG)), and chemokine ligand 10 (CXCL10, also known as interferon gamma-induced protein 10 (IP-10)) in multiple cell types, and may interfere with the production of leukotriene B4, inducible nitric oxide synthase, and matrix metalloproteinases. This interference reduces certain inflammatory processes, such as dendritic cell infiltration, epidermal skin thickening, and joint destruction, for example, in psoriasis and other inflammatory and/or autoimmune diseases such as arthritis, ankylosing spondylitis, osteoarthritis, rheumatoid arthritis, Behcet's disease, inflammatory bowel diseases (*e.g.*, Crohn's disease and ulcerative colitis), psoriasis, atopic dermatitis, and contact dermatitis.

[0006] Psoriasis is an autoimmune skin disease caused by pro-inflammatory cytokines, interferon gamma (IFN- γ) and TNF- α . The psoriatic immune response involves monocytes, dendritic cells, neutrophils and T cells, which all contribute to aberrant keratinocyte proliferation. PDE4 inhibition may reduce production of multiple mediators, including TNF- α , IFN- γ , CXCL9, CXCL10, interleukin-2 (IL-2), interleukin-12 (IL-12), interleukin-23 (IL-23), macrophage inflammatory protein-1-alpha (MIP-1 α), monocyte chemoattractant protein-1 (MCP1), and granulocyte macrophage-colony stimulating factor (GM-CSF) from PBMCs. Thus, there is a continued need for small molecule PDE4 modulators as an effective therapy for treating an inflammatory disease.

SUMMARY OF THE DISCLOSURE

[0007] Provided herein is a compound of Formula (I):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:

L is a linker;

X is $-\text{CH}_2-$ or $-\text{C}(\text{O})-$;

Y is C_{1-6} alkylene or C_{3-10} cycloalkylene;

R^{E} is an E3 ubiquitin ligase binding moiety;

R^1 is (i) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (ii) $-\text{OR}^{1\text{a}}$ or $-\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$;

R^2 is hydrogen or deuterium;

$\text{R}^{3\text{a}}$, $\text{R}^{3\text{d}}$, and $\text{R}^{3\text{e}}$ are each independently (i) hydrogen, deuterium, cyano, halo, or nitro; (ii) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (iii) $-\text{C}(\text{O})\text{R}^{1\text{a}}$, $-\text{C}(\text{O})\text{OR}^{1\text{a}}$, $-\text{C}(\text{O})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{C}(\text{O})\text{SR}^{1\text{a}}$, $-\text{C}(\text{NR}^{1\text{a}})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{C}(\text{S})\text{R}^{1\text{a}}$, $-\text{C}(\text{S})\text{OR}^{1\text{a}}$, $-\text{C}(\text{S})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{OR}^{1\text{a}}$, $-\text{OC}(\text{O})\text{R}^{1\text{a}}$, $-\text{OC}(\text{O})\text{OR}^{1\text{a}}$, $-\text{OC}(\text{O})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{OC}(\text{O})\text{SR}^{1\text{a}}$, $-\text{OC}(\text{NR}^{1\text{a}})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{OC}(\text{S})\text{R}^{1\text{a}}$, $-\text{OC}(\text{S})\text{OR}^{1\text{a}}$, $-\text{OC}(\text{S})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{OS}(\text{O})\text{R}^{1\text{a}}$, $-\text{OS}(\text{O})_2\text{R}^{1\text{a}}$, $-\text{OS}(\text{O})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{OS}(\text{O})_2\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{NR}^{1\text{a}}\text{C}(\text{O})\text{R}^{1\text{d}}$, $-\text{NR}^{1\text{a}}\text{C}(\text{O})\text{OR}^{1\text{d}}$, $-\text{NR}^{1\text{a}}\text{C}(\text{O})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{NR}^{1\text{a}}\text{C}(\text{O})\text{SR}^{1\text{d}}$, $-\text{NR}^{1\text{a}}\text{C}(\text{NR}^{1\text{d}})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{NR}^{1\text{a}}\text{C}(\text{S})\text{R}^{1\text{d}}$, $-\text{NR}^{1\text{a}}\text{C}(\text{S})\text{OR}^{1\text{d}}$, $-\text{NR}^{1\text{a}}\text{C}(\text{S})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{NR}^{1\text{a}}\text{S}(\text{O})\text{R}^{1\text{d}}$, $-\text{NR}^{1\text{a}}\text{S}(\text{O})_2\text{R}^{1\text{d}}$, $-\text{NR}^{1\text{a}}\text{S}(\text{O})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{NR}^{1\text{a}}\text{S}(\text{O})_2\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{SR}^{1\text{a}}$, $-\text{S}(\text{O})\text{R}^{1\text{a}}$, $-\text{S}(\text{O})_2\text{R}^{1\text{a}}$, $-\text{S}(\text{O})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, or $-\text{S}(\text{O})_2\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$;

$\text{R}^{3\text{b}}$ and $\text{R}^{3\text{c}}$ are each independently C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl;

each $\text{R}^{4\text{a}}$ is independently (i) deuterium, cyano, halo, or nitro; (ii) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (iii) $-\text{C}(\text{O})\text{R}^{1\text{a}}$, $-\text{C}(\text{O})\text{OR}^{1\text{a}}$, $-\text{C}(\text{O})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{C}(\text{O})\text{SR}^{1\text{a}}$, $-\text{C}(\text{NR}^{1\text{a}})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{C}(\text{S})\text{R}^{1\text{a}}$, $-\text{C}(\text{S})\text{OR}^{1\text{a}}$, $-\text{C}(\text{S})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{OR}^{1\text{a}}$, $-\text{OC}(\text{O})\text{R}^{1\text{a}}$, $-\text{OC}(\text{O})\text{OR}^{1\text{a}}$, $-\text{OC}(\text{O})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{OC}(\text{O})\text{SR}^{1\text{a}}$, $-\text{OC}(\text{NR}^{1\text{a}})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{OC}(\text{S})\text{R}^{1\text{a}}$, $-\text{OC}(\text{S})\text{OR}^{1\text{a}}$, $-\text{OC}(\text{S})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{OS}(\text{O})\text{R}^{1\text{a}}$,

$-\text{OS}(\text{O})_2\text{R}^{1a}$, $-\text{OS}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{OS}(\text{O})_2\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{C}(\text{O})\text{R}^{1d}$, $-\text{NR}^{1a}\text{C}(\text{O})\text{OR}^{1d}$,
 $-\text{NR}^{1a}\text{C}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{C}(\text{O})\text{SR}^{1d}$, $-\text{NR}^{1a}\text{C}(\text{NR}^{1d})\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{C}(\text{S})\text{R}^{1d}$, $-\text{NR}^{1a}\text{C}(\text{S})\text{OR}^{1d}$,
 $-\text{NR}^{1a}\text{C}(\text{S})\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{S}(\text{O})\text{R}^{1d}$, $-\text{NR}^{1a}\text{S}(\text{O})_2\text{R}^{1d}$, $-\text{NR}^{1a}\text{S}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{S}(\text{O})_2\text{NR}^{1b}\text{R}^{1c}$,
 $-\text{SR}^{1a}$, $-\text{S}(\text{O})\text{R}^{1a}$, $-\text{S}(\text{O})_2\text{R}^{1a}$, $-\text{S}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, or $-\text{S}(\text{O})_2\text{NR}^{1b}\text{R}^{1c}$;

each R^{1a} , R^{1b} , R^{1c} , and R^{1d} is independently hydrogen, deuterium, C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; and


a is an integer of 0, 1, 2, 3, or 4;

wherein each alkyl, alkylene, heteroalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylene, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q, wherein each Q is independently selected from: (a) deuterium, cyano, halo, imino, nitro, and oxo; (b) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, and heterocyclyl, each of which is further optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a ; and (c) $-\text{C}(\text{O})\text{R}^a$, $-\text{C}(\text{O})\text{OR}^a$, $-\text{C}(\text{O})\text{NR}^b\text{R}^c$, $-\text{C}(\text{O})\text{SR}^a$, $-\text{C}(\text{NR}^a)\text{NR}^b\text{R}^c$, $-\text{C}(\text{S})\text{R}^a$, $-\text{C}(\text{S})\text{OR}^a$, $-\text{C}(\text{S})\text{NR}^b\text{R}^c$, $-\text{OR}^a$, $-\text{OC}(\text{O})\text{R}^a$, $-\text{OC}(\text{O})\text{OR}^a$, $-\text{OC}(\text{O})\text{NR}^b\text{R}^c$, $-\text{OC}(\text{O})\text{SR}^a$, $-\text{OC}(\text{NR}^a)\text{NR}^b\text{R}^c$, $-\text{OC}(\text{S})\text{R}^a$, $-\text{OC}(\text{S})\text{OR}^a$, $-\text{OC}(\text{S})\text{NR}^b\text{R}^c$, $-\text{OP}(\text{O})(\text{OR}^a)\text{OR}^d$, $-\text{OS}(\text{O})\text{R}^a$, $-\text{OS}(\text{O})_2\text{R}^a$, $-\text{OS}(\text{O})\text{NR}^b\text{R}^c$, $-\text{OS}(\text{O})_2\text{NR}^b\text{R}^c$, $-\text{NR}^b\text{R}^c$, $-\text{NR}^a\text{C}(\text{O})\text{R}^d$, $-\text{NR}^a\text{C}(\text{O})\text{OR}^d$, $-\text{NR}^a\text{C}(\text{O})\text{NR}^b\text{R}^c$, $-\text{NR}^a\text{C}(\text{O})\text{SR}^d$, $-\text{NR}^a\text{C}(\text{NR}^d)\text{NR}^b\text{R}^c$, $-\text{NR}^a\text{C}(\text{S})\text{R}^d$, $-\text{NR}^a\text{C}(\text{S})\text{OR}^d$, $-\text{NR}^a\text{C}(\text{S})\text{NR}^b\text{R}^c$, $-\text{NR}^a\text{S}(\text{O})\text{R}^d$, $-\text{NR}^a\text{S}(\text{O})_2\text{R}^d$, $-\text{NR}^a\text{S}(\text{O})\text{NR}^b\text{R}^c$, $-\text{NR}^a\text{S}(\text{O})_2\text{NR}^b\text{R}^c$, $-\text{SR}^a$, $-\text{S}(\text{O})\text{R}^a$, $-\text{S}(\text{O})_2\text{R}^a$, $-\text{S}(\text{O})\text{NR}^b\text{R}^c$, and $-\text{S}(\text{O})_2\text{NR}^b\text{R}^c$, wherein each R^a , R^b , R^c , and R^d is independently (i) hydrogen or deuterium; (ii) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a ; or (iii) R^b and R^c together with the N atom to which they are attached form heterocyclyl, optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a ;

wherein each Q^a is independently selected from: (a) deuterium, cyano, halo, nitro, imino, and oxo; (b) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, and heterocyclyl; and (c) $-\text{C}(\text{O})\text{R}^e$, $-\text{C}(\text{O})\text{OR}^e$, $-\text{C}(\text{O})\text{NR}^f\text{R}^g$, $-\text{C}(\text{O})\text{SR}^e$, $-\text{C}(\text{NR}^e)\text{NR}^f\text{R}^g$, $-\text{C}(\text{S})\text{R}^e$, $-\text{C}(\text{S})\text{OR}^e$, $-\text{C}(\text{S})\text{NR}^f\text{R}^g$, $-\text{OR}^e$, $-\text{OC}(\text{O})\text{R}^e$, $-\text{OC}(\text{O})\text{OR}^e$,

$-\text{OC}(\text{O})\text{NR}^{\text{f}}\text{R}^{\text{g}}$, $-\text{OC}(\text{O})\text{SR}^{\text{e}}$, $-\text{OC}(\text{NR}^{\text{e}})\text{NR}^{\text{f}}\text{R}^{\text{g}}$, $-\text{OC}(\text{S})\text{R}^{\text{e}}$, $-\text{OC}(\text{S})\text{OR}^{\text{e}}$, $-\text{OC}(\text{S})\text{NR}^{\text{f}}\text{R}^{\text{g}}$,
 $-\text{OP}(\text{O})(\text{OR}^{\text{f}})\text{OR}^{\text{g}}$, $-\text{OS}(\text{O})\text{R}^{\text{e}}$, $-\text{OS}(\text{O})_2\text{R}^{\text{e}}$, $-\text{OS}(\text{O})\text{NR}^{\text{f}}\text{R}^{\text{g}}$, $-\text{OS}(\text{O})_2\text{NR}^{\text{f}}\text{R}^{\text{g}}$, $-\text{NR}^{\text{f}}\text{R}^{\text{g}}$,
 $-\text{NR}^{\text{e}}\text{C}(\text{O})\text{R}^{\text{h}}$, $-\text{NR}^{\text{e}}\text{C}(\text{O})\text{OR}^{\text{f}}$, $-\text{NR}^{\text{e}}\text{C}(\text{O})\text{NR}^{\text{f}}\text{R}^{\text{g}}$, $-\text{NR}^{\text{e}}\text{C}(\text{O})\text{SR}^{\text{f}}$, $-\text{NR}^{\text{e}}\text{C}(\text{NR}^{\text{h}})\text{NR}^{\text{f}}\text{R}^{\text{g}}$,
 $-\text{NR}^{\text{e}}\text{C}(\text{S})\text{R}^{\text{h}}$, $-\text{NR}^{\text{e}}\text{C}(\text{S})\text{OR}^{\text{f}}$, $-\text{NR}^{\text{e}}\text{C}(\text{S})\text{NR}^{\text{f}}\text{R}^{\text{g}}$, $-\text{NR}^{\text{e}}\text{S}(\text{O})\text{R}^{\text{h}}$, $-\text{NR}^{\text{e}}\text{S}(\text{O})_2\text{R}^{\text{h}}$, $-\text{NR}^{\text{e}}\text{S}(\text{O})\text{NR}^{\text{f}}\text{R}^{\text{g}}$,
 $-\text{NR}^{\text{e}}\text{S}(\text{O})_2\text{NR}^{\text{f}}\text{R}^{\text{g}}$, $-\text{SR}^{\text{e}}$, $-\text{S}(\text{O})\text{R}^{\text{e}}$, $-\text{S}(\text{O})_2\text{R}^{\text{e}}$, $-\text{S}(\text{O})\text{NR}^{\text{f}}\text{R}^{\text{g}}$, and $-\text{S}(\text{O})_2\text{NR}^{\text{f}}\text{R}^{\text{g}}$; wherein each R^{e} , R^{f} , R^{g} , and R^{h} is independently (i) hydrogen or deuterium; (ii) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (iii) R^{f} and R^{g} together with the N atom to which they are attached form heterocyclyl.

[0008] Also provided herein is a compound of Formula (IA):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:

L is a linker;

R^{E} is an E3 ubiquitin ligase binding moiety;

each $\text{R}^{5\text{a}}$ is independently (i) deuterium, cyano, halo, or nitro; (ii) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (iii) $-\text{C}(\text{O})\text{R}^{1\text{a}}$, $-\text{C}(\text{O})\text{OR}^{1\text{a}}$, $-\text{C}(\text{O})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{C}(\text{O})\text{SR}^{1\text{a}}$, $-\text{C}(\text{NR}^{1\text{a}})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{C}(\text{S})\text{R}^{1\text{a}}$, $-\text{C}(\text{S})\text{OR}^{1\text{a}}$, $-\text{C}(\text{S})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{OR}^{1\text{a}}$, $-\text{OC}(\text{O})\text{R}^{1\text{a}}$, $-\text{OC}(\text{O})\text{OR}^{1\text{a}}$, $-\text{OC}(\text{O})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{OC}(\text{O})\text{SR}^{1\text{a}}$, $-\text{OC}(\text{NR}^{1\text{a}})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{OC}(\text{S})\text{R}^{1\text{a}}$, $-\text{OC}(\text{S})\text{OR}^{1\text{a}}$, $-\text{OC}(\text{S})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{OS}(\text{O})\text{R}^{1\text{a}}$, $-\text{OS}(\text{O})_2\text{R}^{1\text{a}}$, $-\text{OS}(\text{O})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{OS}(\text{O})_2\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{NR}^{1\text{a}}\text{C}(\text{O})\text{R}^{1\text{d}}$, $-\text{NR}^{1\text{a}}\text{C}(\text{O})\text{OR}^{1\text{d}}$, $-\text{NR}^{1\text{a}}\text{C}(\text{O})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{NR}^{1\text{a}}\text{C}(\text{O})\text{SR}^{1\text{d}}$, $-\text{NR}^{1\text{a}}\text{C}(\text{NR}^{1\text{d}})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{NR}^{1\text{a}}\text{C}(\text{S})\text{R}^{1\text{d}}$, $-\text{NR}^{1\text{a}}\text{C}(\text{S})\text{OR}^{1\text{d}}$, $-\text{NR}^{1\text{a}}\text{C}(\text{S})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{NR}^{1\text{a}}\text{S}(\text{O})\text{R}^{1\text{d}}$, $-\text{NR}^{1\text{a}}\text{S}(\text{O})_2\text{R}^{1\text{d}}$, $-\text{NR}^{1\text{a}}\text{S}(\text{O})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{NR}^{1\text{a}}\text{S}(\text{O})_2\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, $-\text{SR}^{1\text{a}}$, $-\text{S}(\text{O})\text{R}^{1\text{a}}$, $-\text{S}(\text{O})_2\text{R}^{1\text{a}}$, $-\text{S}(\text{O})\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$, or $-\text{S}(\text{O})_2\text{NR}^{1\text{b}}\text{R}^{1\text{c}}$;

R^6 is hydrogen, C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl;

R^{7a} , R^{7b} , R^{7c} , and R^{7d} are each independently (i) hydrogen, deuterium, cyano, halo, or nitro; (ii) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (iii) $-C(O)R^{1a}$, $-C(O)OR^{1a}$, $-C(O)NR^{1b}R^{1c}$, $-C(O)SR^{1a}$, $-C(NR^{1a})NR^{1b}R^{1c}$, $-C(S)R^{1a}$, $-C(S)OR^{1a}$, $-C(S)NR^{1b}R^{1c}$, $-OR^{1a}$, $-OC(O)R^{1a}$, $-OC(O)OR^{1a}$, $-OC(O)NR^{1b}R^{1c}$, $-OC(O)SR^{1a}$, $-OC(NR^{1a})NR^{1b}R^{1c}$, $-OC(S)R^{1a}$, $-OC(S)OR^{1a}$, $-OC(S)NR^{1b}R^{1c}$, $-OS(O)R^{1a}$, $-OS(O)_2R^{1a}$, $-OS(O)NR^{1b}R^{1c}$, $-OS(O)_2NR^{1b}R^{1c}$, $-NR^{1b}R^{1c}$, $-NR^{1a}C(O)R^{1d}$, $-NR^{1a}C(O)OR^{1d}$, $-NR^{1a}C(O)NR^{1b}R^{1c}$, $-NR^{1a}C(O)SR^{1d}$, $-NR^{1a}C(NR^{1d})NR^{1b}R^{1c}$, $-NR^{1a}C(S)R^{1d}$, $-NR^{1a}C(S)OR^{1d}$, $-NR^{1a}C(S)NR^{1b}R^{1c}$, $-NR^{1a}S(O)R^{1d}$, $-NR^{1a}S(O)_2R^{1d}$, $-NR^{1a}S(O)NR^{1b}R^{1c}$, $-NR^{1a}S(O)_2NR^{1b}R^{1c}$, $-SR^{1a}$, $-S(O)R^{1a}$, $-S(O)_2R^{1a}$, $-S(O)NR^{1b}R^{1c}$, or $-S(O)_2NR^{1b}R^{1c}$;

each R^{1a} , R^{1b} , R^{1c} , and R^{1d} is independently hydrogen, deuterium, C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; and

b is an integer of 0, 1, 2, 3, or 4;

wherein each alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q , wherein each Q is independently selected from: (a) deuterium, cyano, halo, imino, nitro, and oxo; (b) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, and heterocyclyl, each of which is further optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a ; and (c) $-C(O)R^a$, $-C(O)OR^a$, $-C(O)NR^bR^c$, $-C(O)SR^a$, $-C(NR^a)NR^bR^c$, $-C(S)R^a$, $-C(S)OR^a$, $-C(S)NR^bR^c$, $-OR^a$, $-OC(O)R^a$, $-OC(O)OR^a$, $-OC(O)NR^bR^c$, $-OC(O)SR^a$, $-OC(NR^a)NR^bR^c$, $-OC(S)R^a$, $-OC(S)OR^a$, $-OC(S)NR^bR^c$, $-OP(O)(OR^a)OR^d$, $-OS(O)R^a$, $-OS(O)_2R^a$, $-OS(O)NR^bR^c$, $-OS(O)_2NR^bR^c$, $-NR^bR^c$, $-NR^aC(O)R^d$, $-NR^aC(O)OR^d$, $-NR^aC(O)NR^bR^c$, $-NR^aC(O)SR^d$, $-NR^aC(NR^d)NR^bR^c$, $-NR^aC(S)R^d$, $-NR^aC(S)OR^d$, $-NR^aC(S)NR^bR^c$, $-NR^aS(O)R^d$, $-NR^aS(O)_2R^d$, $-NR^aS(O)NR^bR^c$, $-NR^aS(O)_2NR^bR^c$, $-SR^a$, $-S(O)R^a$, $-S(O)_2R^a$, $-S(O)NR^bR^c$, and $-S(O)_2NR^bR^c$, wherein each R^a , R^b , R^c , and R^d is independently (i) hydrogen or deuterium; (ii) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a ; or (iii) R^b and R^c together with the N atom to which they are attached form heterocyclyl, optionally substituted with one or

more, in one embodiment, one, two, three, or four, substituents Q^a ;

wherein each Q^a is independently selected from: (a) deuterium, cyano, halo, nitro, imino, and oxo; (b) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, and heterocyclyl; and (c) $-C(O)R^e$, $-C(O)OR^e$, $-C(O)NR^fR^g$, $-C(O)SR^e$, $-C(NR^e)NR^fR^g$, $-C(S)R^e$, $-C(S)OR^e$, $-C(S)NR^fR^g$, $-OR^e$, $-OC(O)R^e$, $-OC(O)OR^e$, $-OC(O)NR^fR^g$, $-OC(O)SR^e$, $-OC(NR^e)NR^fR^g$, $-OC(S)R^e$, $-OC(S)OR^e$, $-OC(S)NR^fR^g$, $-OP(O)(OR^f)OR^g$, $-OS(O)R^e$, $-OS(O)_2R^e$, $-OS(O)NR^fR^g$, $-OS(O)_2NR^fR^g$, $-NR^fR^g$, $-NR^eC(O)R^h$, $-NR^eC(O)OR^f$, $-NR^eC(O)NR^fR^g$, $-NR^eC(O)SR^f$, $-NR^eC(NR^h)NR^fR^g$, $-NR^eC(S)R^h$, $-NR^eC(S)OR^f$, $-NR^eC(S)NR^fR^g$, $-NR^eS(O)R^h$, $-NR^eS(O)_2R^h$, $-NR^eS(O)NR^fR^g$, $-NR^eS(O)_2NR^fR^g$, $-SR^e$, $-S(O)R^e$, $-S(O)_2R^e$, $-S(O)NR^fR^g$, and $-S(O)_2NR^fR^g$; wherein each R^e , R^f , R^g , and R^h is independently (i) hydrogen or deuterium; (ii) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (iii) R^f and R^g together with the N atom to which they are attached form heterocyclyl.

[0009] Additionally, provided herein is a pharmaceutical composition comprising a compound of Formula (I) or (IA), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and a pharmaceutically acceptable excipient.

[0010] Furthermore, provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a disorder, disease, or condition mediated by a phosphodiesterase 4 (PDE4) in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of a compound of Formula (I) or (IA), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[0011] Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of an inflammatory disease in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of a compound of Formula (I) or (IA), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a

tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[0012] Provided herein is a method of inhibiting the activity of a PDE4, comprising contacting the PDE4 with an effective amount of a compound of Formula (I) or (IA), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[0013] Provided herein is a method of inducing degradation of a PDE4, comprising contacting the PDE4 with an effective amount of a compound of Formula (I) or (IA), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

DETAILED DESCRIPTION

[0014] To facilitate understanding of the disclosure set forth herein, a number of terms are defined below.

[0015] Generally, the nomenclature used herein and the laboratory procedures in organic chemistry, medicinal chemistry, biochemistry, biology, and pharmacology described herein are those well-known and commonly employed in the art. Unless defined otherwise, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.

[0016] The term “subject” refers to an animal, including, but not limited to, a primate (*e.g.*, human), cow, pig, sheep, goat, horse, dog, cat, rabbit, rat, or mouse. The terms “subject” and “patient” are used interchangeably herein in reference, for example, to a mammalian subject, such as a human subject. In one embodiment, the subject is a human.

[0017] The terms “treat,” “treating,” and “treatment” are meant to include alleviating or abrogating a disorder, disease, or condition, or one or more of the symptoms associated with the disorder, disease, or condition; or alleviating or eradicating the cause(s) of the disorder, disease,

or condition itself.

[0018] The terms “prevent,” “preventing,” and “prevention” are meant to include a method of delaying and/or precluding the onset of a disorder, disease, or condition, and/or its attendant symptoms; barring a subject from acquiring a disorder, disease, or condition; or reducing a subject’s risk of acquiring a disorder, disease, or condition.

[0019] The terms “alleviate” and “alleviating” refer to easing or reducing one or more symptoms (*e.g.*, pain) of a disorder, disease, or condition. The terms can also refer to reducing an adverse effect associated with an active ingredient. Sometimes, the beneficial effect that a subject derives from a prophylactic or therapeutic agent does not result in a cure of the disorder, disease, or condition.

[0020] The term “contacting” or “contact” is meant to refer to bringing together of a therapeutic agent and a biological molecule (*e.g.*, a protein, enzyme, RNA, or DNA), cell, or tissue such that a physiological and/or chemical effect takes place as a result of such contact. Contacting can take place *in vitro*, *ex vivo*, or *in vivo*. In one embodiment, a therapeutic agent is contacted with a biological molecule *in vitro* to determine the effect of the therapeutic agent on the biological molecule. In another embodiment, a therapeutic agent is contacted with a cell in cell culture (*in vitro*) to determine the effect of the therapeutic agent on the cell. In yet another embodiment, the contacting of a therapeutic agent with a biological molecule, cell, or tissue includes the administration of a therapeutic agent to a subject having the biological molecule, cell, or tissue to be contacted.

[0021] The term “therapeutically effective amount” or “effective amount” is meant to include the amount of a compound that, when administered, is sufficient to prevent development of, or alleviate to some extent, one or more of the symptoms of the disorder, disease, or condition being treated. The term “therapeutically effective amount” or “effective amount” also refers to the amount of a compound that is sufficient to elicit a biological or medical response of a biological molecule (*e.g.*, a protein, enzyme, RNA, or DNA), cell, tissue, system, animal, or human, which is being sought by a researcher, veterinarian, medical doctor, or clinician.

[0022] The term “IC₅₀” or “EC₅₀” refers to an amount, concentration, or dosage of a

compound that is required for 50% inhibition of a maximal response in an assay that measures such a response.

[0023] The term “pharmaceutically acceptable carrier,” “pharmaceutically acceptable excipient,” “physiologically acceptable carrier,” or “physiologically acceptable excipient” refers to a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, solvent, or encapsulating material. In one embodiment, each component is “pharmaceutically acceptable” in the sense of being compatible with the other ingredients of a pharmaceutical formulation, and suitable for use in contact with the tissue or organ of a subject (e.g., a human or an animal) without excessive toxicity, irritation, allergic response, immunogenicity, or other problems or complications, and commensurate with a reasonable benefit/risk ratio. See, e.g., *Remington: The Science and Practice of Pharmacy*, 22nd ed.; Allen Ed.; Pharmaceutical Press: London, 2012; *Handbook of Pharmaceutical Excipients*, 8th ed.; Sheskey *et al.*, Eds.; Pharmaceutical Press: London, 2017; *Handbook of Pharmaceutical Additives*, 3rd ed.; Ash and Ash Eds.; Synapse Information Resources: 2007; *Pharmaceutical Preformulation and Formulation*, 2nd ed.; Gibson Ed.; Drugs and the Pharmaceutical Sciences 199; Informa Healthcare: New York, NY, 2009.

[0024] The term “about” or “approximately” means an acceptable error for a particular value as determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined. In certain embodiments, the term “about” or “approximately” means within 1, 2, or 3 standard deviations. In certain embodiments, the term “about” or “approximately” means within 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, or 0.05% of a given value or range.

[0025] The term “alkyl” refers to a linear or branched saturated monovalent hydrocarbon radical, wherein the alkyl is optionally substituted with one or more substituents Q as described herein. For example, C₁₋₆ alkyl refers to a linear saturated monovalent hydrocarbon radical of 1 to 6 carbon atoms or a branched saturated monovalent hydrocarbon radical of 3 to 6 carbon atoms. In certain embodiments, the alkyl is a linear saturated monovalent hydrocarbon radical that has 1 to 20 (C₁₋₂₀), 1 to 15 (C₁₋₁₅), 1 to 10 (C₁₋₁₀), or 1 to 6 (C₁₋₆) carbon atoms, or branched saturated monovalent hydrocarbon radical of 3 to 20 (C₃₋₂₀), 3 to 15 (C₃₋₁₅), 3 to 10 (C₃₋₁₀), or 3

to 6 (C₃₋₆) carbon atoms. As used herein, linear C₁₋₆ and branched C₃₋₆ alkyl groups are also referred as “lower alkyl.” Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl (including all isomeric forms, *e.g.*, *n*-propyl and isopropyl), butyl (including all isomeric forms, *e.g.*, *n*-butyl, isobutyl, *sec*-butyl, and *t*-butyl), pentyl (including all isomeric forms, *e.g.*, *n*-pentyl, isopentyl, *sec*-pentyl, neopentyl, and *tert*-pentyl), and hexyl (including all isomeric forms, *e.g.*, *n*-hexyl, isohexyl, and *sec*-hexyl).

[0026] The term “heteroalkyl” refers to a linear or branched saturated monovalent hydrocarbon radical that contains one or more heteroatoms on its main chain, each independently selected from O, S, and N. The heteroalkyl is optionally substituted with one or more substituents Q as described herein. For example, C₁₋₆ heteroalkyl refers to a linear saturated monovalent hydrocarbon radical of 1 to 6 carbon atoms or a branched saturated monovalent hydrocarbon radical of 3 to 6 carbon atoms. In certain embodiments, the heteroalkyl is a linear saturated monovalent hydrocarbon radical that has 1 to 20 (C₁₋₂₀), 1 to 15 (C₁₋₁₅), 1 to 10 (C₁₋₁₀), or 1 to 6 (C₁₋₆) carbon atoms, or branched saturated monovalent hydrocarbon radical of 3 to 20 (C₃₋₂₀), 3 to 15 (C₃₋₁₅), 3 to 10 (C₃₋₁₀), or 3 to 6 (C₃₋₆) carbon atoms. As used herein, linear C₁₋₆ and branched C₃₋₆ heteroalkyl groups are also referred as “lower heteroalkyl.” Examples of heteroalkyl groups include, but are not limited to, –OCH₃, –OCH₂CH₃, –CH₂OCH₃, –NHCH₃, –ONHCH₃, –NHCH₃, –NHCH₃, –NHCH₃, –SCH₃, –CH₂NHCH₂CH₃, and –NHCH₂CH₂CH₃. Examples of substituted heteroalkyl groups include, but are not limited to, –CH₂NHC(O)CH₃ and –NHC(O)CH₂CH₃.

[0027] The terms “alkylene” and “alkanediyl” are used interchangeably herein in reference to a linear or branched saturated divalent hydrocarbon radical, wherein the alkanediyl is optionally be substituted with one or more substituents Q as described herein. For example, C₁₋₆ alkanediyl refers to a linear saturated divalent hydrocarbon radical of 1 to 6 carbon atoms or a branched saturated divalent hydrocarbon radical of 3 to 6 carbon atoms. In certain embodiments, the alkanediyl is a linear saturated divalent hydrocarbon radical that has 1 to 30 (C₁₋₃₀), 1 to 20 (C₁₋₂₀), 1 to 15 (C₁₋₁₅), 1 to 10 (C₁₋₁₀), or 1 to 6 (C₁₋₆) carbon atoms, or branched saturated divalent hydrocarbon radical of 3 to 30 (C₃₋₃₀), 3 to 20 (C₃₋₂₀), 3 to 15 (C₃₋₁₅), 3 to 10 (C₃₋₁₀), or 3 to 6 (C₃₋₆) carbon atoms. As used herein, linear C₁₋₆ and branched C₃₋₆ alkanediyl groups are also referred as “lower alkanediyl.” Examples of alkanediyl groups include, but are

not limited to, methanediyl, ethanediyl (including all isomeric forms, *e.g.*, ethane-1,1-diyl and ethane-1,2-diyl), propanediyl (including all isomeric forms, *e.g.*, propane-1,1-diyl, propane-1,2-diyl, and propane-1,3-diyl), butanediyl (including all isomeric forms, *e.g.*, butane-1,1-diyl, butane-1,2-diyl, butane-1,3-diyl, and butane-1,4-diyl), pentanediyl (including all isomeric forms, *e.g.*, pentane-1,1-diyl, pentane-1,2-diyl, pentane-1,3-diyl, and pentane-1,5-diyl), and hexanediyl (including all isomeric forms, *e.g.*, hexane-1,1-diyl, hexane-1,2-diyl, hexane-1,3-diyl, and hexane-1,6-diyl). Examples of substituted alkanediyl groups include, but are not limited to, $-\text{C}(\text{O})\text{CH}_2-$, $-\text{C}(\text{O})(\text{CH}_2)_2-$, $-\text{C}(\text{O})(\text{CH}_2)_3-$, $-\text{C}(\text{O})(\text{CH}_2)_4-$, $-\text{C}(\text{O})(\text{CH}_2)_5-$, $-\text{C}(\text{O})(\text{CH}_2)_6-$, $-\text{C}(\text{O})(\text{CH}_2)_7-$, $-\text{C}(\text{O})(\text{CH}_2)_8-$, $-\text{C}(\text{O})(\text{CH}_2)_9-$, $-\text{C}(\text{O})(\text{CH}_2)_{10}-$, $-\text{C}(\text{O})\text{CH}_2\text{C}(\text{O})-$, $-\text{C}(\text{O})-(\text{CH}_2)_2\text{C}(\text{O})-$, $-\text{C}(\text{O})(\text{CH}_2)_3\text{C}(\text{O})-$, $-\text{C}(\text{O})(\text{CH}_2)_4\text{C}(\text{O})-$, or $-\text{C}(\text{O})(\text{CH}_2)_5\text{C}(\text{O})-$.

[0028] The terms “heteroalkylene” and “heteroalkanediyl” are used interchangeably herein in reference to a linear or branched saturated divalent hydrocarbon radical that contains one or more heteroatoms in its main chain, each independently selected from O, S, and N. The heteroalkylene is optionally substituted with one or more substituents Q as described herein. For example, C_{1-6} heteroalkylene refers to a linear saturated divalent hydrocarbon radical of 1 to 6 carbon atoms or a branched saturated divalent hydrocarbon radical of 3 to 6 carbon atoms. In certain embodiments, the heteroalkylene is a linear saturated divalent hydrocarbon radical that has 1 to 20 (C_{1-20}), 1 to 15 (C_{1-15}), 1 to 10 (C_{1-10}), or 1 to 6 (C_{1-6}) carbon atoms, or branched saturated divalent hydrocarbon radical of 3 to 20 (C_{3-20}), 3 to 15 (C_{3-15}), 3 to 10 (C_{3-10}), or 3 to 6 (C_{3-6}) carbon atoms. As used herein, linear C_{1-6} and branched C_{3-6} heteroalkylene groups are also referred as “lower heteroalkylene.” Examples of heteroalkylene groups include, but are not limited to, $-\text{CH}_2\text{O}-$, $-(\text{CH}_2)_2\text{O}-$, $-(\text{CH}_2)_3\text{O}-$, $-(\text{CH}_2)_4\text{O}-$, $-(\text{CH}_2)_5\text{O}-$, $-(\text{CH}_2)_6\text{O}-$, $-(\text{CH}_2)_7\text{O}-$, $-(\text{CH}_2)_8\text{O}-$, $-(\text{CH}_2)_9\text{O}-$, $-(\text{CH}_2)_{10}\text{O}-$, $-\text{CH}_2\text{OCH}_2-$, $-\text{CH}_2\text{CH}_2\text{O}-$, $-(\text{CH}_2\text{CH}_2\text{O})_2-$, $-(\text{CH}_2\text{CH}_2\text{O})_3-$, $-(\text{CH}_2\text{CH}_2\text{O})_4-$, $-(\text{CH}_2\text{CH}_2\text{O})_5-$, $-\text{CH}_2\text{NH}-$, $-\text{CH}_2\text{NHCH}_2-$, $-\text{CH}_2\text{CH}_2\text{NH}-$, $-\text{CH}_2\text{S}-$, $-\text{CH}_2\text{SCH}_2-$, and $-\text{CH}_2\text{CH}_2\text{S}-$. Examples of substituted heteroalkylene groups include, but are not limited to, $-\text{C}(\text{O})\text{CH}_2\text{O}-$, $-\text{C}(\text{O})(\text{CH}_2)_2\text{O}-$, $-\text{C}(\text{O})(\text{CH}_2)_3\text{O}-$, $-\text{C}(\text{O})(\text{CH}_2)_4\text{O}-$, $-\text{C}(\text{O})(\text{CH}_2)_5\text{O}-$, $-\text{C}(\text{O})(\text{CH}_2)_6\text{O}-$, $-\text{C}(\text{O})(\text{CH}_2)_7\text{O}-$, $-\text{C}(\text{O})(\text{CH}_2)_8\text{O}-$, $-\text{C}(\text{O})(\text{CH}_2)_9\text{O}-$, $-\text{C}(\text{O})(\text{CH}_2)_{10}\text{O}-$, $-\text{C}(\text{O})\text{CH}_2\text{OCH}_2\text{CH}_2\text{O}-$, $-\text{C}(\text{O})\text{CH}_2\text{O}(\text{CH}_2\text{CH}_2\text{O})_2-$, $-\text{C}(\text{O})\text{CH}_2\text{O}(\text{CH}_2\text{CH}_2\text{O})_3-$, $-\text{C}(\text{O})\text{CH}_2\text{O}(\text{CH}_2\text{CH}_2\text{O})_4-$, $-\text{C}(\text{O})\text{CH}_2\text{O}(\text{CH}_2\text{CH}_2\text{O})_5-$, $-\text{CH}_2\text{NHC}(\text{O})\text{CH}_2-$, or $-\text{CH}_2\text{CH}_2\text{C}(\text{O})\text{NH}-$.

[0029] The term “alkenyl” refers to a linear or branched monovalent hydrocarbon radical,

which contains one or more, in one embodiment, one, two, three, or four, in another embodiment, one, carbon-carbon double bond(s). The alkenyl is optionally substituted with one or more substituents Q as described herein. The term “alkenyl” embraces radicals having a “*cis*” or “*trans*” configuration or a mixture thereof, or alternatively, a “*Z*” or “*E*” configuration or a mixture thereof, as appreciated by those of ordinary skill in the art. For example, C₂₋₆ alkenyl refers to a linear unsaturated monovalent hydrocarbon radical of 2 to 6 carbon atoms or a branched unsaturated monovalent hydrocarbon radical of 3 to 6 carbon atoms. In certain embodiments, the alkenyl is a linear monovalent hydrocarbon radical of 2 to 20 (C₂₋₂₀), 2 to 15 (C₂₋₁₅), 2 to 10 (C₂₋₁₀), or 2 to 6 (C₂₋₆) carbon atoms, or a branched monovalent hydrocarbon radical of 3 to 20 (C₃₋₂₀), 3 to 15 (C₃₋₁₅), 3 to 10 (C₃₋₁₀), or 3 to 6 (C₃₋₆) carbon atoms. Examples of alkenyl groups include, but are not limited to, ethenyl, propenyl (including all isomeric forms, *e.g.*, propen-1-yl, propen-2-yl, and allyl), and butenyl (including all isomeric forms, *e.g.*, buten-1-yl, buten-2-yl, buten-3-yl, and 2-buten-1-yl).

[0030] The terms “alkenylene” and “alkenediyl” are used interchangeably herein in reference to a linear or branched divalent hydrocarbon radical, which contains one or more, in one embodiment, one, two, three, or four, in another embodiment, one, carbon-carbon double bond(s). The alkenediyl is optionally substituted with one or more substituents Q as described herein. The term “alkenediyl” embraces radicals having a “*cis*” or “*trans*” configuration or a mixture thereof, or alternatively, a “*Z*” or “*E*” configuration or a mixture thereof, as appreciated by those of ordinary skill in the art. For example, C₂₋₆ alkenediyl refers to a linear unsaturated divalent hydrocarbon radical of 2 to 6 carbon atoms or a branched unsaturated divalent hydrocarbon radical of 3 to 6 carbon atoms. In certain embodiments, the alkenediyl is a linear divalent hydrocarbon radical of 2 to 30 (C₂₋₃₀), 2 to 20 (C₂₋₂₀), 2 to 15 (C₂₋₁₅), 2 to 10 (C₂₋₁₀), or 2 to 6 (C₂₋₆) carbon atoms, or a branched divalent hydrocarbon radical of 3 to 30 (C₃₋₃₀), 3 to 20 (C₃₋₂₀), 3 to 15 (C₃₋₁₅), 3 to 10 (C₃₋₁₀), or 3 to 6 (C₃₋₆) carbon atoms. Examples of alkenediyl groups include, but are not limited to, ethenediyl (including all isomeric forms, *e.g.*, ethene-1,1-diyl and ethene-1,2-diyl), propenediyl (including all isomeric forms, *e.g.*, 1-propene-1,1-diyl, 1-propene-1,2-diyl, and 1-propene-1,3-diyl), butenediyl (including all isomeric forms, *e.g.*, 1-butene-1,1-diyl, 1-butene-1,2-diyl, and 1-butene-1,4-diyl), pentenediyl (including all isomeric forms, *e.g.*, 1-pentene-1,1-diyl, 1-pentene-1,2-diyl, and 1-pentene-1,5-diyl), and hexenediyl (including all isomeric forms, *e.g.*, 1-hexene-1,1-diyl, 1-hexene-1,2-diyl, 1-hexene-1,3-diyl, 1-

hexene-1,4-diyl, 1-hexene-1,5-diyl, and 1-hexene-1,6-diyl).

[0031] The terms “heteroalkenylene” and “heteroalkenediyl” are used interchangeably herein in reference to a linear or branched divalent hydrocarbon radical, which contains one or more, in one embodiment, one, two, three, or four, in another embodiment, one, carbon-carbon double bond(s), and which contains one or more heteroatoms each independently selected from O, S, and N in the hydrocarbon chain. The heteroalkenylene is optionally substituted with one or more substituents Q as described herein. The term “heteroalkenylene” embraces radicals having a “*cis*” or “*trans*” configuration or a mixture thereof, or alternatively, a “Z” or “E” configuration or a mixture thereof, as appreciated by those of ordinary skill in the art. For example, C₂₋₆ heteroalkenylene refers to a linear unsaturated divalent hydrocarbon radical of 2 to 6 carbon atoms or a branched unsaturated divalent hydrocarbon radical of 3 to 6 carbon atoms. In certain embodiments, the heteroalkenylene is a linear divalent hydrocarbon radical of 2 to 20 (C₂₋₂₀), 2 to 15 (C₂₋₁₅), 2 to 10 (C₂₋₁₀), or 2 to 6 (C₂₋₆) carbon atoms, or a branched divalent hydrocarbon radical of 3 to 20 (C₃₋₂₀), 3 to 15 (C₃₋₁₅), 3 to 10 (C₃₋₁₀), or 3 to 6 (C₃₋₆) carbon atoms. Examples of heteroalkenylene groups include, but are not limited to, –CH=CHO–, –CH=CHOCH₂–, –CH=CHCH₂O–, –CH=CHS–, –CH=CHSCH₂–, –CH=CHCH₂S–, or –CH=CHCH₂NH–.

[0032] The term “alkynyl” refers to a linear or branched monovalent hydrocarbon radical, which contains one or more, in one embodiment, one, two, three, or four, in another embodiment, one, carbon-carbon triple bond(s). The alkynyl is optionally substituted with one or more substituents Q as described herein. For example, C₂₋₆ alkynyl refers to a linear unsaturated monovalent hydrocarbon radical of 2 to 6 carbon atoms or a branched unsaturated monovalent hydrocarbon radical of 4 to 6 carbon atoms. In certain embodiments, the alkynyl is a linear monovalent hydrocarbon radical of 2 to 20 (C₂₋₂₀), 2 to 15 (C₂₋₁₅), 2 to 10 (C₂₋₁₀), or 2 to 6 (C₂₋₆) carbon atoms, or a branched monovalent hydrocarbon radical of 4 to 20 (C₄₋₂₀), 4 to 15 (C₄₋₁₅), 4 to 10 (C₄₋₁₀), or 4 to 6 (C₄₋₆) carbon atoms. Examples of alkynyl groups include, but are not limited to, ethynyl (–C≡CH), propynyl (including all isomeric forms, *e.g.*, 1-propynyl (–C≡CCH₃) and propargyl (–CH₂C≡CH)), butynyl (including all isomeric forms, *e.g.*, 1-butyn-1-yl and 2-butyn-1-yl), pentynyl (including all isomeric forms, *e.g.*, 1-pentyn-1-yl and 1-methyl-2-butyn-1-yl), and hexynyl (including all isomeric forms, *e.g.*, 1-hexyn-1-yl and 2-hexyn-1-yl).

[0033] The terms “alkynylene” and “alkynediyl” are used interchangeably herein in reference to a linear or branched divalent hydrocarbon radical, which contains one or more, in one embodiment, one, two, three, or four, in another embodiment, one, carbon-carbon triple bond(s). The alkynediyl is optionally substituted with one or more substituents Q as described herein. For example, C₂₋₆ alkynediyl refers to a linear unsaturated divalent hydrocarbon radical of 2 to 6 carbon atoms or a branched unsaturated divalent hydrocarbon radical of 4 to 6 carbon atoms. In certain embodiments, the alkynediyl is a linear divalent hydrocarbon radical of 2 to 30 (C₂₋₃₀), 2 to 20 (C₂₋₂₀), 2 to 15 (C₂₋₁₅), 2 to 10 (C₂₋₁₀), or 2 to 6 (C₂₋₆) carbon atoms, or a branched divalent hydrocarbon radical of 4 to 30 (C₄₋₃₀), 4 to 20 (C₄₋₂₀), 4 to 15 (C₄₋₁₅), 4 to 10 (C₄₋₁₀), or 4 to 6 (C₄₋₆) carbon atoms. Examples of alkynediyl groups include, but are not limited to, ethynediyl, propynediyl (including all isomeric forms, *e.g.*, 1-propyne-1,3-diyl and 1-propyne-3,3-diyl), butynediyl (including all isomeric forms, *e.g.*, 1-butyne-1,3-diyl, 1-butyne-1,4-diyl, and 2-butyne-1,1-diyl), pentynediyl (including all isomeric forms, *e.g.*, 1-pentyne-1,3-diyl, 1-pentyne-1,4-diyl, and 2-pentyne-1,1-diyl), and hexynediyl (including all isomeric forms, *e.g.*, 1-hexyne-1,3-diyl, 1-hexyne-1,4-diyl, and 2-hexyne-1,1-diyl).

[0034] The terms “heteroalkynylene” and “heteroalkynediyl” are used interchangeably herein in reference to a linear or branched divalent hydrocarbon radical, which contains one or more, in one embodiment, one, two, three, or four, in another embodiment, one, carbon-carbon triple bond(s), and which contains one or more heteroatoms in its main chain, each independently selected from O, S, and N. The heteroalkynylene is optionally substituted with one or more substituents Q as described herein. For example, C₂₋₆ heteroalkynylene refers to a linear unsaturated divalent hydrocarbon radical of 2 to 6 carbon atoms or a branched unsaturated divalent hydrocarbon radical of 4 to 6 carbon atoms. In certain embodiments, the heteroalkynylene is a linear divalent hydrocarbon radical of 2 to 30 (C₂₋₃₀), 2 to 20 (C₂₋₂₀), 2 to 15 (C₂₋₁₅), 2 to 10 (C₂₋₁₀), or 2 to 6 (C₂₋₆) carbon atoms, or a branched divalent hydrocarbon radical of 4 to 30 (C₄₋₃₀), 4 to 20 (C₄₋₂₀), 4 to 15 (C₄₋₁₅), 4 to 10 (C₄₋₁₀), or 4 to 6 (C₄₋₆) carbon atoms. Examples of heteroalkynylene groups include, but are not limited to, $\text{--C}\equiv\text{CCH}_2\text{O--}$, $\text{--C}\equiv\text{CCH}_2\text{S--}$, or $\text{--C}\equiv\text{CCH}_2\text{NH--}$.

[0035] The term “cycloalkyl” refers to a cyclic monovalent hydrocarbon radical, which is optionally substituted with one or more substituents Q as described herein. In one embodiment,

the cycloalkyl is a saturated or unsaturated but non-aromatic, and/or bridged or non-bridged, and/or fused bicyclic group. In certain embodiments, the cycloalkyl has from 3 to 20 (C_{3-20}), from 3 to 15 (C_{3-15}), from 3 to 10 (C_{3-10}), or from 3 to 7 (C_{3-7}) carbon atoms. In one embodiment, the cycloalkyl is monocyclic. In another embodiment, the cycloalkyl is bicyclic. In yet another embodiment, the cycloalkyl is tricyclic. In still another embodiment, the cycloalkyl is polycyclic. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptenyl, bicyclo[1.1.1]pentyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl, decalinyl, and adamantyl.

[0036] The terms “cycloalkylene” and “cycloalkanediyl” are used interchangeably herein in reference to a cyclic divalent hydrocarbon radical, which may be optionally substituted with one or more substituents Q as described herein. In one embodiment, cycloalkanediyl groups may be saturated or unsaturated but non-aromatic, and/or bridged, and/or non-bridged, and/or fused bicyclic groups. In certain embodiments, the cycloalkanediyl has from 3 to 30 (C_{3-30}), 3 to 20 (C_{3-20}), from 3 to 15 (C_{3-15}), from 3 to 10 (C_{3-10}), or from 3 to 7 (C_{3-7}) carbon atoms. Examples of cycloalkanediyl groups include, but are not limited to, cyclopropanediyl (including all isomeric forms, *e.g.*, cyclopropane-1,1-diyl and cyclopropane-1,2-diyl), cyclobutanediyl (including all isomeric forms, *e.g.*, cyclobutane-1,1-diyl, cyclobutane-1,2-diyl, and cyclobutane-1,3-diyl), cyclopentanedyl (including all isomeric forms, *e.g.*, cyclopentane-1,1-diyl, cyclopentane-1,2-diyl, and cyclopentane-1,3-diyl), cyclohexanedyl (including all isomeric forms, *e.g.*, cyclohexane-1,1-diyl, cyclohexane-1,2-diyl, cyclohexane-1,3-diyl, and cyclohex-1,4-diyl), cycloheptanedyl (including all isomeric forms, *e.g.*, cycloheptane-1,1-diyl, cycloheptane-1,2-diyl, cycloheptane-1,3-diyl, and cycloheptane-1,4-diyl), decalinedyl (including all isomeric forms, *e.g.*, decaline-1,1-diyl, decaline-1,2-diyl, and decaline-1,8-diyl), and adamantdiyl (including all isomeric forms, *e.g.*, adamant-1,2-diyl, adamant-1,3-diyl, and adamant-1,8-diyl).

[0037] The term “aryl” refers to a monovalent monocyclic aromatic hydrocarbon radical and/or monovalent polycyclic aromatic hydrocarbon radical that contain at least one aromatic carbon ring. In certain embodiments, the aryl has from 6 to 20 (C_{6-20}), from 6 to 15 (C_{6-15}), or from 6 to 10 (C_{6-10}) ring carbon atoms. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, fluorenyl, azulenyl, anthryl, phenanthryl, pyrenyl, biphenyl, and terphenyl.

The aryl also refers to bicyclic or tricyclic carbon rings, where one of the rings is aromatic and the others of which may be saturated, partially unsaturated, or aromatic, for example, dihydronaphthyl, indenyl, indanyl, or tetrahydronaphthyl (tetralinyl). In one embodiment, the aryl is monocyclic. In another embodiment, the aryl is bicyclic. In yet another embodiment, the aryl is tricyclic. In still another embodiment, the aryl is polycyclic. In certain embodiments, the aryl is optionally substituted with one or more substituents Q as described herein.

[0038] The terms “arylene” and “arenediyl” are used interchangeably herein in reference to a divalent monocyclic aromatic hydrocarbon radical or divalent polycyclic aromatic hydrocarbon radical that contains at least one aromatic hydrocarbon ring. In certain embodiments, the arylene has from 6 to 20 (C_{6-20}), from 6 to 15 (C_{6-15}), or from 6 to 10 (C_{6-10}) ring atoms. Examples of arylene groups include, but are not limited to, phenylene (including all isomeric forms, *e.g.*, phen-1,2-diyl, phen-1,3-diyl, and phen-1,4-diyl), naphthylene (including all isomeric forms, *e.g.*, naphth-1,2-diyl, naphth-1,3-diyl, and naphth-1,8-diyl), fluorenylene (including all isomeric forms, *e.g.*, fluoren-1,2-diyl, fluoren-1,3-diyl, and fluoren-1,8-diyl), azulenylenylene (including all isomeric forms, *e.g.*, azulen-1,2-diyl, azulen-1,3-diyl, and azulen-1,8-diyl), anthrylene (including all isomeric forms, *e.g.*, anthr-1,2-diyl, anthr-1,3-diyl, and anthr-1,8-diyl), phenanthrylene (including all isomeric forms, *e.g.*, phenanthr-1,2-diyl, phenanthr-1,3-diyl, and phenanthr-1,8-diyl), pyrenylene (including all isomeric forms, *e.g.*, pyren-1,2-diyl, pyren-1,3-diyl, and pyren-1,8-diyl), biphenylene (including all isomeric forms, *e.g.*, biphen-2,3-diyl, biphen-3,4'-diyl, and biphen-4,4'-diyl), and terphenylene (including all isomeric forms, *e.g.*, terphen-2,3-diyl, terphen-3,4'-diyl, and terphen-4,4'-diyl). Arylene also refers to bicyclic or tricyclic carbon rings, where one of the rings is aromatic and the others of which may be saturated, partially unsaturated, or aromatic, for example, dihydronaphthylene (including all isomeric forms, *e.g.*, dihydronaphth-1,2-diyl and dihydronaphth-1,8-diyl), indenylene (including all isomeric forms, *e.g.*, inden-1,2-diyl, inden-1,5-diyl, and inden-1,7-diyl), indanylene (including all isomeric forms, *e.g.*, indan-1,2-diyl, indan-1,5-diyl, and indan-1,7-diyl), or tetrahydronaphthylene (tetralinylene) (including all isomeric forms, *e.g.*, tetrahydronaphth-1,2-diyl, tetrahydronaphth-1,5-diyl, and tetrahydronaphth-1,8-diyl). In certain embodiments, arylene is optionally substituted with one or more substituents Q as described herein.

[0039] The term “aralkyl” or “arylalkyl” refers to a monovalent alkyl group substituted

with one or more aryl groups. In certain embodiments, the aralkyl has from 7 to 30 (C₇₋₃₀), from 7 to 20 (C₇₋₂₀), or from 7 to 16 (C₇₋₁₆) carbon atoms. Examples of aralkyl groups include, but are not limited to, benzyl, phenylethyl (including all isomeric forms, *e.g.*, 1-phenylethyl and 2-phenylethyl), and phenylpropyl (including all isomeric forms, *e.g.*, 1-phenylpropyl, 2-phenylpropyl, and 3-phenylpropyl). In certain embodiments, the aralkyl is optionally substituted with one or more substituents Q as described herein.

[0040] The term “aralkylene” or “arylalkylene” refers to a divalent alkyl group substituted with one or more aryl groups. In certain embodiments, the aralkylene has from 7 to 30 (C₇₋₃₀), from 7 to 20 (C₇₋₂₀), or from 7 to 16 (C₇₋₁₆) carbon atoms. Examples of aralkylene groups include, but are not limited to, benzylene (including all isomeric forms, *e.g.*, phenylmethdiyl), phenylethylene (including all isomeric forms, *e.g.*, 2-phenyl-ethan-1,1-diyl and 2-phenyl-ethan-1,2-diyl), and phenylpropylene (including all isomeric forms, *e.g.*, 3-phenylpropan-1,1-diyl, 3-phenylpropan-1,2-diyl, and 3-phenylpropan-1,3-diyl). In certain embodiments, the aralkylene is optionally substituted with one or more substituents Q as described herein.

[0041] The term “heteroaryl” refers to a monovalent monocyclic aromatic group or monovalent polycyclic aromatic group that contain at least one aromatic ring, wherein at least one aromatic ring contains one or more heteroatoms, each independently selected from O, S, and N, in the ring. The heteroaryl is bonded to the rest of a molecule through the aromatic ring. Each ring of a heteroaryl group can contain one or two O atoms, one or two S atoms, and/or one to four N atoms; provided that the total number of heteroatoms in each ring is four or less and each ring contains at least one carbon atom. In certain embodiments, the heteroaryl has from 5 to 20, from 5 to 15, or from 5 to 10 ring atoms. In one embodiment, the heteroaryl is monocyclic. Examples of monocyclic heteroaryl groups include, but are not limited to, furanyl, imidazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, thiadiazolyl, thiazolyl, thienyl, tetrazolyl, triazinyl, and triazolyl. In another embodiment, the heteroaryl is bicyclic. Examples of bicyclic heteroaryl groups include, but are not limited to, benzofuranyl, benzimidazolyl, benzoisoxazolyl, benzopyranyl, benzothiadiazolyl, benzothiazolyl, benzothienyl, benzotriazolyl, benzoxazolyl, furopyridyl (including all isomeric forms, *e.g.*, furo[2,3-*b*]pyridinyl, furo[2,3-*c*]pyridinyl, furo[3,2-*b*]-

pyridinyl, furo[3,2-*c*]pyridinyl, furo[3,4-*b*]pyridinyl, and furo[3,4-*c*]pyridinyl), imidazopyridinyl (including all isomeric forms, *e.g.*, imidazo[1,2-*a*]pyridinyl, imidazo[4,5-*b*]pyridinyl, and imidazo[4,5-*c*]pyridinyl), imidazothiazolyl (including all isomeric forms, *e.g.*, imidazo[2,1-*b*]thiazolyl and imidazo[4,5-*d*]thiazolyl), indazolyl, indolizinyl, indolyl, isobenzofuranyl, isobenzothieryl (*i.e.*, benzo[*c*]thienyl), isoindolyl, isoquinolyl, naphthyridinyl (including all isomeric forms, *e.g.*, 1,5-naphthyridinyl, 1,6-naphthyridinyl, 1,7-naphthyridinyl, and 1,8-naphthyridinyl), oxazolopyridinyl (including all isomeric forms, *e.g.*, oxazolo[4,5-*b*]pyridinyl, oxazolo[4,5-*c*]pyridinyl, oxazolo[5,4-*b*]pyridinyl, and oxazolo[5,4-*c*]pyridinyl), phthalazinyl, pteridinyl, purinyl, pyrrolopyridyl (including all isomeric forms, *e.g.*, pyrrolo[2,3-*b*]pyridinyl, pyrrolo[2,3-*c*]pyridinyl, pyrrolo[3,2-*b*]pyridinyl, and pyrrolo[3,2-*c*]pyridinyl), quinolyl, quinoxalyl, quinazolinyl, thiadiazolopyrimidyl (including all isomeric forms, *e.g.*, [1,2,5]thiadiazolo[3,4-*d*]pyrimidinyl and [1,2,3]thiadiazolo[4,5-*d*]pyrimidinyl), and thienopyridyl (including all isomeric forms, *e.g.*, thieno[2,3-*b*]pyridinyl, thieno[2,3-*c*]pyridinyl, thieno[3,2-*b*]pyridinyl, and thieno[3,2-*c*]pyridinyl). In yet another embodiment, the heteroaryl is tricyclic. Examples of tricyclic heteroaryl groups include, but are not limited to, acridinyl, benzindolyl, carbazolyl, dibenzofuranyl, perimidinyl, phenanthrolinyl, phenanthridinyl (including all isomeric forms, *e.g.*, 1,5-phenanthrolinyl, 1,6-phenanthrolinyl, 1,7-phenanthrolinyl, 1,9-phenanthrolinyl, and 2,10-phenanthrolinyl), phenarsazinyl, phenazinyl, phenothiazinyl, phenoxazinyl, and xanthenyl. In certain embodiments, the heteroaryl is optionally substituted with one or more substituents Q as described herein.

[0042] The terms “heteroarylene” and “heteroarenediyl” are used interchangeably herein in reference to a divalent monocyclic aromatic group or divalent polycyclic aromatic group that contains at least one aromatic ring, wherein at least one aromatic ring contains one or more heteroatoms in the ring, each of which is independently selected from O, S, and N. A heteroarylene group has at least one linkage to the rest of a molecule *via* its aromatic ring(s). Each ring of a heteroarylene group can contain one or two O atoms, one or two S atoms, and/or one to four N atoms, provided that the total number of heteroatoms in each ring is four or less and each ring contains at least one carbon atom. In certain embodiments, the heteroarylene has from 5 to 20, from 5 to 15, or from 5 to 10 ring atoms. Examples of monocyclic heteroarylene groups include, but are not limited to, furandiyl, imidazoldiyl, isothiazoldiyl, isoxazoldiyl, oxadiazoldiyl, oxazoldiyl, pyrazindiyl, pyrazoldiyl, pyridazindiyl, pyridindiyl, pyrimidindiyl,

pyrroldiyl, thiadiazoldiyl, thiazoldiyl, thiendiyl, tetrazoldiyl, triazinediyl, and triazoldiyl. Examples of bicyclic heteroarylene groups include, but are not limited to, benzofurandiyl, benzimidazoldiyl, benzoisoxazoldiyl, benzopyrandiyl, benzothiadiazoldiyl, benzothiazoldiyl, benzothiendiyl, benzotriazoldiyl, benzoxazoldiyl, furopyridindiyl (including all isomeric forms, *e.g.*, furo[2,3-*b*]pyridindiyl, furo[2,3-*c*]pyridindiyl, furo[3,2-*b*]pyridindiyl, furo[3,2-*c*]pyridindiyl, furo[3,4-*b*]pyridindiyl, and furo[3,4-*c*]pyridindiyl), imidazopyridindiyl (including all isomeric forms, *e.g.*, imidazo[1,2-*a*]pyridindiyl, imidazo[4,5-*b*]pyridindiyl, and imidazo[4,5-*c*]pyridindiyl), imidazothiazoldiyl (including all isomeric forms, *e.g.*, imidazo[2,1-*b*]thiazoldiyl and imidazo[4,5-*d*]thiazoldiyl), indazoldiyl, indolizindiyl, indoldiyl, isobenzofurandiyl, isobenzothiendiyl (*i.e.*, benzo[*c*]thiendiyl), isoindoldiyl, isoquinolindiyl, naphthyridindiyl (including all isomeric forms, *e.g.*, 1,5-naphthyridindiyl, 1,6-naphthyridindiyl, 1,7-naphthyridindiyl, and 1,8-naphthyridindiyl), oxazolopyridindiyl (including all isomeric forms, *e.g.*, oxazolo[4,5-*b*]pyridindiyl, oxazolo[4,5-*c*]pyridindiyl, oxazolo[5,4-*b*]pyridindiyl, and oxazolo[5,4-*c*]pyridindiyl), phthalazindiyl, pteridindiyl, purindiyl, pyrrolopyridindiyl (including all isomeric forms, *e.g.*, pyrrolo[2,3-*b*]pyridindiyl, pyrrolo[2,3-*c*]pyridindiyl, pyrrolo[3,2-*b*]pyridindiyl, and pyrrolo[3,2-*c*]pyridindiyl), quinolindiyl, quinoxalindiyl, quinazolindiyl, thiadiazolopyrimidindiyl (including all isomeric forms, *e.g.*, [1,2,5]thiadiazolo[3,4-*d*]pyrimidindiyl and [1,2,3]thiadiazolo[4,5-*d*]pyrimidindiyl), and thienopyridindiyl (including all isomeric forms, *e.g.*, thieno[2,3-*b*]pyridindiyl, thieno[2,3-*c*]pyridindiyl, thieno[3,2-*b*]pyridindiyl, and thieno[3,2-*c*]pyridindiyl). Examples of tricyclic heteroarylene groups include, but are not limited to, acridindiyl, benzindoldiyl, carbazoldiyl, dibenzofurandiyl, perimidindiyl, phenanthrolindiyl (including all isomeric forms, *e.g.*, 1,5-phenanthrolindiyl, 1,6-phenanthrolindiyl, 1,7-phenanthrolindiyl, 1,9-phenanthrolindiyl, and 2,10-phenanthrolindiyl), phenanthridindiyl, phenarsazindiyl, phenazindiyl, phenothiazindiyl, phenoxazindiyl, and xanthendiyl. In certain embodiments, heteroarylene is optionally substituted with one or more substituents Q as described herein.

[0043] The term “heterocyclyl” or “heterocyclic” refers to a monovalent monocyclic non-aromatic ring system or monovalent polycyclic ring system that contains at least one non-aromatic ring, wherein one or more of the non-aromatic ring atoms are heteroatoms, each independently selected from O, S, and N; and the remaining ring atoms are carbon atoms. In certain embodiments, the heterocyclyl or heterocyclic group has from 3 to 20, from 3 to 15, from

3 to 10, from 3 to 8, from 4 to 7, or from 5 to 6 ring atoms. The heterocyclyl is bonded to the rest of a molecule through the non-aromatic ring. In certain embodiments, the heterocyclyl is a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may be fused or bridged, and in which nitrogen or sulfur atoms may be optionally oxidized, nitrogen atoms may be optionally quaternized, and some rings may be partially or fully saturated, or aromatic. The heterocyclyl may be attached to the main structure at any heteroatom or carbon atom which results in the creation of a stable compound. Examples of heterocyclyls and heterocyclic groups include, but are not limited to, azepinyl, benzodioxanyl, benzodioxolyl, benzofuranonyl, chromanyl, decahydroisoquinolinyl, dihydrobenzofuranyl, dihydrobenzothiazolyl, dihydrobenzisoxazinyl (including all isomeric forms, *e.g.*, 1,4-dihydrobenzo[*d*][1,3]oxazinyl, 3,4-dihydrobenzo[*c*][1,2]-oxazinyl, and 3,4-dihydrobenzo[*d*][1,2]oxazinyl), dihydrobenzothienyl, dihydroisobenzofuranyl, dihydrobenzo[*c*]thienyl, dihydrofuryl, dihydroisoindolyl, dihydropyranyl, dihydropyrazolyl, dihydropyrazinyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dioxolanyl, 1,4-dithianyl, furanonyl, imidazolidinyl, imidazoliny, indoliny, isochromanyl, isoindoliny, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, oxazolidinonyl, oxazolidinyl, oxiranyl, piperazinyl, piperidinyl, 4-piperidonyl, pyrazolidinyl, pyrazolinyl, pyrrolidinyl, pyrrolinyl, quinuclidinyl, tetrahydrofuryl, tetrahydroisoquinolinyl, tetrahydropyranyl, tetrahydrothienyl, thiamorpholinyl, thiazolidinyl, thiochromanyl, tetrahydroquinolinyl, and 1,3,5-trithianyl. In certain embodiments, the heterocyclyl is optionally substituted with one or more substituents Q as described herein.

[0044] The term “heterocyclylene” refers to a divalent monocyclic non-aromatic ring system or divalent polycyclic ring system that contains at least one non-aromatic ring, wherein one or more of the non-aromatic ring atoms are heteroatoms independently selected from O, S, and N; and the remaining ring atoms are carbon atoms. Heterocyclylene groups are bonded to the rest of a molecule through the non-aromatic ring. In certain embodiments, the heterocyclylene group has from 3 to 20, from 3 to 15, from 3 to 10, from 3 to 8, from 4 to 7, or from 5 to 6 ring atoms. In certain embodiments, the heterocyclylene is a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may be fused or bridged, and in which nitrogen or sulfur atoms may be optionally oxidized, nitrogen atoms may be optionally quaternized, and some rings may be partially or fully saturated, or aromatic. The heterocyclylene may be attached to the main structure at any heteroatom or carbon atom which results in the creation of a stable

compound. Examples of such heterocyclylene groups include, but are not limited to, azepindiyl, benzodioxandiyl, benzodioxoldiyl, benzofuranondiyl, chromandiyl, decahydroisoquinolindiyl, dihydrobenzofurandiyl, dihydrobenzothiazoldiyl, dihydrobenzoxazindiyl (including all isomeric forms, *e.g.*, 1,4-dihydrobenzo[*d*][1,3]oxazindiyl, 3,4-dihydrobenzo[*c*][1,2]oxazindiyl, and 3,4-dihydrobenzo[*d*][1,2]oxazindiyl), dihydrobenzothiendiyl, dihydroisobenzofurandiyl, dihydrobenzo[*c*]thiendiyl, dihydrofurdiyl, dihydroisoindoldiyl, dihydropyrandiyl, dihydropyrazoldiyl, dihydropyrazindiyl, dihydropyridindiyl, dihydropyrimidindiyl, dihydropyrroldiyl, dioxolandiyl, 1,4-dithiandiyl, furanondiyl, imidazolidindiyl, imidazolindiyl, indolindiyl, isochromandiyl, isoindolindiyl, isothiazolidindiyl, isoxazolidindiyl, morpholindiyl, octahydroindoldiyl, octahydroisoindoldiyl, oxazolidinondiyl, oxazolidindiyl, oxirandiyl, piperazindiyl, piperidindiyl, 4-piperidondiyl, pyrazolidindiyl, pyrazolindiyl, pyrrolidindiyl, pyrrolindiyl, quinuclidindiyl, tetrahydrofurdiyl, tetrahydroisoquinolindiyl, tetrahydropyrandiyl, tetrahydrothiendiyl, thiamorpholindiyl, thiazolidindiyl, thiochromandiyl, tetrahydroquinolindiyl, and 1,3,5-trithiandiyl. In certain embodiments, the heterocyclylene is optionally substituted with one or more substituents Q as described herein.

[0045] The term “halogen,” “halide,” or “halo” refers to fluoro, chloro, bromo, and/or iodo.

[0046] The term “optionally substituted” is intended to mean that a group or substituent, such as an alkyl, alkylene, heteroalkyl, heteroalkylene, alkenyl, alkenylene, heteroalkenylene, alkynyl, alkynylene, heteroalkynylene, cycloalkyl, cycloalkylene, aryl, arylene, aralkyl, aralkylene, heteroaryl, heteroarylene, heterocyclyl, or heterocyclylene group, may be substituted with one or more, in one embodiment, one, two, three, or four, substituents Q, each of which is independently selected from, *e.g.*, (a) deuterium (–D), cyano (–CN), halo, imino (=NH), nitro (–NO₂), and oxo (=O); (b) C₁₋₆ alkyl, C₁₋₆ heteroalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, C₆₋₁₄ aryl, C₇₋₁₅ aralkyl, heteroaryl, and heterocyclyl, each of which is further optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a; and (c) –C(O)R^a, –C(O)OR^a, –C(O)NR^bR^c, –C(O)SR^a, –C(NR^a)NR^bR^c, –C(S)R^a, –C(S)OR^a, –C(S)NR^bR^c, –OR^a, –OC(O)R^a, –OC(O)OR^a, –OC(O)NR^bR^c, –OC(O)SR^a, –OC(NR^a)NR^bR^c, –OC(S)R^a, –OC(S)OR^a, –OC(S)NR^bR^c, –OP(O)(OR^a)OR^d, –OS(O)R^a, –OS(O)₂R^a, –OS(O)NR^bR^c, –OS(O)₂NR^bR^c, –NR^bR^c, –NR^aC(O)R^d, –NR^aC(O)OR^d, –NR^aC(O)NR^bR^c,

$-\text{NR}^a\text{C}(\text{O})\text{SR}^d$, $-\text{NR}^a\text{C}(\text{NR}^d)\text{NR}^b\text{R}^c$, $-\text{NR}^a\text{C}(\text{S})\text{R}^d$, $-\text{NR}^a\text{C}(\text{S})\text{OR}^d$, $-\text{NR}^a\text{C}(\text{S})\text{NR}^b\text{R}^c$, $-\text{NR}^a\text{S}(\text{O})\text{R}^d$, $-\text{NR}^a\text{S}(\text{O})_2\text{R}^d$, $-\text{NR}^a\text{S}(\text{O})\text{NR}^b\text{R}^c$, $-\text{NR}^a\text{S}(\text{O})_2\text{NR}^b\text{R}^c$, $-\text{SR}^a$, $-\text{S}(\text{O})\text{R}^a$, $-\text{S}(\text{O})_2\text{R}^a$, $-\text{S}(\text{O})\text{NR}^b\text{R}^c$, and $-\text{S}(\text{O})_2\text{NR}^b\text{R}^c$, wherein each R^a , R^b , R^c , and R^d is independently (i) hydrogen or deuterium; (ii) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a ; or (iii) R^b and R^c together with the N atom to which they are attached form heterocyclyl optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a . As used herein, all groups that can be substituted are “optionally substituted.”

[0047] In one embodiment, each Q^a is independently selected from: (a) deuterium, cyano, halo, imino, nitro, and oxo; (b) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, and heterocyclyl; and (c) $-\text{C}(\text{O})\text{R}^e$, $-\text{C}(\text{O})\text{OR}^e$, $-\text{C}(\text{O})\text{NR}^f\text{R}^g$, $-\text{C}(\text{O})\text{SR}^e$, $-\text{C}(\text{NR}^e)\text{NR}^f\text{R}^g$, $-\text{C}(\text{S})\text{R}^e$, $-\text{C}(\text{S})\text{OR}^e$, $-\text{C}(\text{S})\text{NR}^f\text{R}^g$, $-\text{OR}^e$, $-\text{OC}(\text{O})\text{R}^e$, $-\text{OC}(\text{O})\text{OR}^e$, $-\text{OC}(\text{O})\text{NR}^f\text{R}^g$, $-\text{OC}(\text{O})\text{SR}^e$, $-\text{OC}(\text{NR}^e)\text{NR}^f\text{R}^g$, $-\text{OC}(\text{S})\text{R}^e$, $-\text{OC}(\text{S})\text{OR}^e$, $-\text{OC}(\text{S})\text{NR}^f\text{R}^g$, $-\text{OP}(\text{O})(\text{OR}^f)\text{OR}^g$, $-\text{OS}(\text{O})\text{R}^e$, $-\text{OS}(\text{O})_2\text{R}^e$, $-\text{OS}(\text{O})\text{NR}^f\text{R}^g$, $-\text{OS}(\text{O})_2\text{NR}^f\text{R}^g$, $-\text{NR}^f\text{R}^g$, $-\text{NR}^e\text{C}(\text{O})\text{R}^h$, $-\text{NR}^e\text{C}(\text{O})\text{OR}^f$, $-\text{NR}^e\text{C}(\text{O})\text{NR}^f\text{R}^g$, $-\text{NR}^e\text{C}(\text{O})\text{SR}^f$, $-\text{NR}^e\text{C}(\text{NR}^h)\text{NR}^f\text{R}^g$, $-\text{NR}^e\text{C}(\text{S})\text{R}^h$, $-\text{NR}^e\text{C}(\text{S})\text{OR}^f$, $-\text{NR}^e\text{C}(\text{S})\text{NR}^f\text{R}^g$, $-\text{NR}^e\text{S}(\text{O})\text{R}^h$, $-\text{NR}^e\text{S}(\text{O})_2\text{R}^h$, $-\text{NR}^e\text{S}(\text{O})\text{NR}^f\text{R}^g$, $-\text{NR}^e\text{S}(\text{O})_2\text{NR}^f\text{R}^g$, $-\text{SR}^e$, $-\text{S}(\text{O})\text{R}^e$, $-\text{S}(\text{O})_2\text{R}^e$, $-\text{S}(\text{O})\text{NR}^f\text{R}^g$, and $-\text{S}(\text{O})_2\text{NR}^f\text{R}^g$; wherein each R^e , R^f , R^g , and R^h is independently (i) hydrogen or deuterium; (ii) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (iii) R^f and R^g together with the N atom to which they are attached form heterocyclyl.

[0048] In certain embodiments, “optically active” and “enantiomerically active” refer to a collection of molecules, which has an enantiomeric excess of no less than about 80%, no less than about 90%, no less than about 91%, no less than about 92%, no less than about 93%, no less than about 94%, no less than about 95%, no less than about 96%, no less than about 97%, no less than about 98%, no less than about 99%, no less than about 99.5%, or no less than about 99.8%. In certain embodiments, an optically active compound comprises about 95% or more of one enantiomer and about 5% or less of the other enantiomer based on the total weight of the enantiomeric mixture in question. In certain embodiments, an optically active compound comprises about 98% or more of one enantiomer and about 2% or less of the other enantiomer

based on the total weight of the enantiomeric mixture in question. In certain embodiments, an optically active compound comprises about 99% or more of one enantiomer and about 1% or less of the other enantiomer based on the total weight of the enantiomeric mixture in question.

[0049] In describing an optically active compound, the prefixes *R* and *S* are used to denote the absolute configuration of the compound about its chiral center(s). The (+) and (-) are used to denote the optical rotation of the compound, that is, the direction in which a plane of polarized light is rotated by the optically active compound. The (-) prefix indicates that the compound is levorotatory, that is, the compound rotates the plane of polarized light to the left or counterclockwise. The (+) prefix indicates that the compound is dextrorotatory, that is, the compound rotates the plane of polarized light to the right or clockwise. However, the sign of optical rotation, (+) and (-), is not related to the absolute configuration of the compound, *R* and *S*.

[0050] The term “isotopically enriched” refers to a compound that contains an unnatural proportion of an isotope at one or more of the atoms that constitute such a compound. In certain embodiments, an isotopically enriched compound contains unnatural proportions of one or more isotopes, including, but not limited to, hydrogen (^1H), deuterium (^2H), tritium (^3H), carbon-11 (^{11}C), carbon-12 (^{12}C), carbon-13 (^{13}C), carbon-14 (^{14}C), nitrogen-13 (^{13}N), nitrogen-14 (^{14}N), nitrogen-15 (^{15}N), oxygen-14 (^{14}O), oxygen-15 (^{15}O), oxygen-16 (^{16}O), oxygen-17 (^{17}O), oxygen-18 (^{18}O), fluorine-17 (^{17}F), fluorine-18 (^{18}F), phosphorus-31 (^{31}P), phosphorus-32 (^{32}P), phosphorus-33 (^{33}P), sulfur-32 (^{32}S), sulfur-33 (^{33}S), sulfur-34 (^{34}S), sulfur-35 (^{35}S), sulfur-36 (^{36}S), chlorine-35 (^{35}Cl), chlorine-36 (^{36}Cl), chlorine-37 (^{37}Cl), bromine-79 (^{79}Br), bromine-81 (^{81}Br), iodine-123 (^{123}I), iodine-125 (^{125}I), iodine-127 (^{127}I), iodine-129 (^{129}I), and iodine-131 (^{131}I). In certain embodiments, an isotopically enriched compound is in a stable form, that is, non-radioactive. In certain embodiments, an isotopically enriched compound contains unnatural proportions of one or more isotopes, including, but not limited to, hydrogen (^1H), deuterium (^2H), carbon-12 (^{12}C), carbon-13 (^{13}C), nitrogen-14 (^{14}N), nitrogen-15 (^{15}N), oxygen-16 (^{16}O), oxygen-17 (^{17}O), oxygen-18 (^{18}O), fluorine-17 (^{17}F), phosphorus-31 (^{31}P), sulfur-32 (^{32}S), sulfur-33 (^{33}S), sulfur-34 (^{34}S), sulfur-36 (^{36}S), chlorine-35 (^{35}Cl), chlorine-37 (^{37}Cl), bromine-79 (^{79}Br), bromine-81 (^{81}Br), and iodine-127 (^{127}I). In certain embodiments, an isotopically enriched compound is in an unstable form, that is, radioactive. In certain embodiments, an isotopically enriched compound contains unnatural proportions of one or more isotopes,

including, but not limited to, tritium (^3H), carbon-11 (^{11}C), carbon-14 (^{14}C), nitrogen-13 (^{13}N), oxygen-14 (^{14}O), oxygen-15 (^{15}O), fluorine-18 (^{18}F), phosphorus-32 (^{32}P), phosphorus-33 (^{33}P), sulfur-35 (^{35}S), chlorine-36 (^{36}Cl), iodine-123 (^{123}I), iodine-125 (^{125}I), iodine-129 (^{129}I), and iodine-131 (^{131}I). It will be understood that, in a compound as provided herein, any hydrogen can be ^2H , as example, or any carbon can be ^{13}C , as example, or any nitrogen can be ^{15}N , as example, or any oxygen can be ^{18}O , as example, where feasible according to the judgment of one of ordinary skill in the art.

[0051] The term “isotopic enrichment” refers to the percentage of incorporation of a less prevalent isotope (*e.g.*, D for deuterium or hydrogen-2) of an element at a given position in a molecule in the place of a more prevalent isotope (*e.g.*, ^1H for protium or hydrogen-1) of the element. As used herein, when an atom at a particular position in a molecule is designated as a particular less prevalent isotope, it is understood that the abundance of that isotope at that position is substantially greater than its natural abundance.

[0052] The term “isotopic enrichment factor” refers the ratio between the isotopic abundance in an isotopically enriched compound and the natural abundance of a specific isotope.

[0053] The term “hydrogen” or the symbol “H” refers to the composition of naturally occurring hydrogen isotopes, which include protium (^1H), deuterium (^2H or D), and tritium (^3H), in their natural abundances. Protium is the most common hydrogen isotope having a natural abundance of more than 99.98%. Deuterium is a less prevalent hydrogen isotope having a natural abundance of about 0.0156%.

[0054] The term “deuterium enrichment” refers to the percentage of incorporation of deuterium at a given position in a molecule in the place of hydrogen. For example, deuterium enrichment of 1% at a given position means that 1% of molecules in a given sample contain deuterium at the specified position. Because the naturally occurring distribution of deuterium is about 0.0156% on average, deuterium enrichment at any position in a compound synthesized using non-enriched starting materials is about 0.0156% on average. As used herein, when a particular position in an isotopically enriched compound is designated as having deuterium, it is understood that the abundance of deuterium at that position in the compound is substantially greater than its natural abundance (0.0156%).

[0055] The term “carbon” or the symbol “C” refers to the composition of naturally occurring carbon isotopes, which include carbon-12 (^{12}C) and carbon-13 (^{13}C) in their natural abundances. Carbon-12 is the most common carbon isotope having a natural abundance of more than 98.89%. Carbon-13 is a less prevalent carbon isotope having a natural abundance of about 1.11%.

[0056] The term “carbon-13 enrichment” or “ ^{13}C enrichment” refers to the percentage of incorporation of carbon-13 at a given position in a molecule in the place of carbon. For example, carbon-13 enrichment of 10% at a given position means that 10% of molecules in a given sample contain carbon-13 at the specified position. Because the naturally occurring distribution of carbon-13 is about 1.11% on average, carbon-13 enrichment at any position in a compound synthesized using non-enriched starting materials is about 1.11% on average. As used herein, when a particular position in an isotopically enriched compound is designated as having carbon-13, it is understood that the abundance of carbon-13 at that position in the compound is substantially greater than its natural abundance (1.11%).

[0057] The terms “substantially pure” and “substantially homogeneous” mean, when referred to a substance, sufficiently homogeneous to appear free of readily detectable impurities as determined by a standard analytical method used by one of ordinary skill in the art, including, but not limited to, thin layer chromatography (TLC), gel electrophoresis, high performance liquid chromatography (HPLC), gas chromatography (GC), nuclear magnetic resonance (NMR), and mass spectrometry (MS); or sufficiently pure such that further purification would not detectably alter the physical, chemical, biological, and/or pharmacological properties, such as enzymatic and biological activities, of the substance. In certain embodiments, “substantially pure” or “substantially homogeneous” refers to a collection of molecules, wherein at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.5% by weight of the molecules are a single compound, including a single enantiomer, a racemic mixture, or a mixture of enantiomers, as determined by standard analytical methods. As used herein, when an atom at a particular position in an isotopically enriched molecule is designated as a particular less prevalent isotope, a molecule that contains other than the designated isotope at the specified position is an impurity with respect to the isotopically enriched compound. Thus, for a deuterated compound that has an atom at a particular position

designated as deuterium, a compound that contains a protium at the same position is an impurity.


[0058] The term “solvate” refers to a complex or aggregate formed by one or more molecules of a solute, *e.g.*, a compound provided herein, and one or more molecules of a solvent, which are present in stoichiometric or non-stoichiometric amount. Suitable solvents include, but are not limited to, water, methanol, ethanol, *n*-propanol, isopropanol, and acetic acid. In certain embodiments, the solvent is pharmaceutically acceptable. In one embodiment, the complex or aggregate is in a crystalline form. In another embodiment, the complex or aggregate is in a noncrystalline form. Where the solvent is water, the solvate is a hydrate. Examples of hydrates include, but are not limited to, a hemihydrate, monohydrate, dihydrate, trihydrate, tetrahydrate, and pentahydrate.

[0059] For a divalent group described herein, no orientation is implied by the direction in which the divalent group is presented. For example, unless a particular orientation is specified, the formula --C(O)NH-- represents both --C(O)NH-- and --NHC(O)-- .

[0060] The phrase “an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof” has the same meaning as the phrase “(i) an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant of the compound referenced therein; (ii) a pharmaceutically acceptable salt, solvate, hydrate, or prodrug of the compound referenced therein; or (iii) a pharmaceutically acceptable salt, solvate, hydrate, or prodrug of an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant of the compound referenced therein.”

Compounds

[0061] In one embodiment, provided herein is a compound of Formula (I):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:

L is a linker;

X is $-\text{CH}_2-$ or $-\text{C}(\text{O})-$;

Y is C_{1-6} alkylene or C_{3-10} cycloalkylene;

R^E is an E3 ubiquitin ligase binding moiety;

R^1 is (i) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (ii) $-\text{OR}^{1a}$ or $-\text{NR}^{1b}\text{R}^{1c}$;

R^2 is hydrogen or deuterium;

R^{3a} , R^{3d} , and R^{3e} are each independently (i) hydrogen, deuterium, cyano, halo, or nitro; (ii) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (iii) $-\text{C}(\text{O})\text{R}^{1a}$, $-\text{C}(\text{O})\text{OR}^{1a}$, $-\text{C}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{C}(\text{O})\text{SR}^{1a}$, $-\text{C}(\text{NR}^{1a})\text{NR}^{1b}\text{R}^{1c}$, $-\text{C}(\text{S})\text{R}^{1a}$, $-\text{C}(\text{S})\text{OR}^{1a}$, $-\text{C}(\text{S})\text{NR}^{1b}\text{R}^{1c}$, $-\text{OR}^{1a}$, $-\text{OC}(\text{O})\text{R}^{1a}$, $-\text{OC}(\text{O})\text{OR}^{1a}$, $-\text{OC}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{OC}(\text{O})\text{SR}^{1a}$, $-\text{OC}(\text{NR}^{1a})\text{NR}^{1b}\text{R}^{1c}$, $-\text{OC}(\text{S})\text{R}^{1a}$, $-\text{OC}(\text{S})\text{OR}^{1a}$, $-\text{OC}(\text{S})\text{NR}^{1b}\text{R}^{1c}$, $-\text{OS}(\text{O})\text{R}^{1a}$, $-\text{OS}(\text{O})_2\text{R}^{1a}$, $-\text{OS}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{OS}(\text{O})_2\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{C}(\text{O})\text{R}^{1d}$, $-\text{NR}^{1a}\text{C}(\text{O})\text{OR}^{1d}$, $-\text{NR}^{1a}\text{C}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{C}(\text{O})\text{SR}^{1d}$, $-\text{NR}^{1a}\text{C}(\text{NR}^{1d})\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{C}(\text{S})\text{R}^{1d}$, $-\text{NR}^{1a}\text{C}(\text{S})\text{OR}^{1d}$, $-\text{NR}^{1a}\text{C}(\text{S})\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{S}(\text{O})\text{R}^{1d}$, $-\text{NR}^{1a}\text{S}(\text{O})_2\text{R}^{1d}$, $-\text{NR}^{1a}\text{S}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{S}(\text{O})_2\text{NR}^{1b}\text{R}^{1c}$, $-\text{SR}^{1a}$, $-\text{S}(\text{O})\text{R}^{1a}$, $-\text{S}(\text{O})_2\text{R}^{1a}$, $-\text{S}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, or $-\text{S}(\text{O})_2\text{NR}^{1b}\text{R}^{1c}$;

R^{3b} and R^{3c} are each independently C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl;

each R^{4a} is independently (i) deuterium, cyano, halo, or nitro; (ii) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (iii) $-\text{C}(\text{O})\text{R}^{1a}$, $-\text{C}(\text{O})\text{OR}^{1a}$, $-\text{C}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{C}(\text{O})\text{SR}^{1a}$, $-\text{C}(\text{NR}^{1a})\text{NR}^{1b}\text{R}^{1c}$, $-\text{C}(\text{S})\text{R}^{1a}$, $-\text{C}(\text{S})\text{OR}^{1a}$, $-\text{C}(\text{S})\text{NR}^{1b}\text{R}^{1c}$, $-\text{OR}^{1a}$, $-\text{OC}(\text{O})\text{R}^{1a}$, $-\text{OC}(\text{O})\text{OR}^{1a}$, $-\text{OC}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{OC}(\text{O})\text{SR}^{1a}$, $-\text{OC}(\text{NR}^{1a})\text{NR}^{1b}\text{R}^{1c}$, $-\text{OC}(\text{S})\text{R}^{1a}$, $-\text{OC}(\text{S})\text{OR}^{1a}$, $-\text{OC}(\text{S})\text{NR}^{1b}\text{R}^{1c}$, $-\text{OS}(\text{O})\text{R}^{1a}$,

$-\text{OS}(\text{O})_2\text{R}^{1a}$, $-\text{OS}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{OS}(\text{O})_2\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{C}(\text{O})\text{R}^{1d}$, $-\text{NR}^{1a}\text{C}(\text{O})\text{OR}^{1d}$, $-\text{NR}^{1a}\text{C}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{C}(\text{O})\text{SR}^{1d}$, $-\text{NR}^{1a}\text{C}(\text{NR}^{1d})\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{C}(\text{S})\text{R}^{1d}$, $-\text{NR}^{1a}\text{C}(\text{S})\text{OR}^{1d}$, $-\text{NR}^{1a}\text{C}(\text{S})\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{S}(\text{O})\text{R}^{1d}$, $-\text{NR}^{1a}\text{S}(\text{O})_2\text{R}^{1d}$, $-\text{NR}^{1a}\text{S}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{S}(\text{O})_2\text{NR}^{1b}\text{R}^{1c}$, $-\text{SR}^{1a}$, $-\text{S}(\text{O})\text{R}^{1a}$, $-\text{S}(\text{O})_2\text{R}^{1a}$, $-\text{S}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, or $-\text{S}(\text{O})_2\text{NR}^{1b}\text{R}^{1c}$; and R^4 is hydrogen or R^{4a} .

each R^{1a} , R^{1b} , R^{1c} , and R^{1d} is independently hydrogen, deuterium, C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; and

a is an integer of 0, 1, 2, 3, or 4;

wherein each alkyl, alkylene, heteroalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylene, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q , wherein each Q is independently selected from: (a) deuterium, cyano, halo, imino, nitro, and oxo; (b) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, and heterocyclyl, each of which is further optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a ; and (c) $-\text{C}(\text{O})\text{R}^a$, $-\text{C}(\text{O})\text{OR}^a$, $-\text{C}(\text{O})\text{NR}^b\text{R}^c$, $-\text{C}(\text{O})\text{SR}^a$, $-\text{C}(\text{NR}^a)\text{NR}^b\text{R}^c$, $-\text{C}(\text{S})\text{R}^a$, $-\text{C}(\text{S})\text{OR}^a$, $-\text{C}(\text{S})\text{NR}^b\text{R}^c$, $-\text{OR}^a$, $-\text{OC}(\text{O})\text{R}^a$, $-\text{OC}(\text{O})\text{OR}^a$, $-\text{OC}(\text{O})\text{NR}^b\text{R}^c$, $-\text{OC}(\text{O})\text{SR}^a$, $-\text{OC}(\text{NR}^a)\text{NR}^b\text{R}^c$, $-\text{OC}(\text{S})\text{R}^a$, $-\text{OC}(\text{S})\text{OR}^a$, $-\text{OC}(\text{S})\text{NR}^b\text{R}^c$, $-\text{OP}(\text{O})(\text{OR}^a)\text{OR}^d$, $-\text{OS}(\text{O})\text{R}^a$, $-\text{OS}(\text{O})_2\text{R}^a$, $-\text{OS}(\text{O})\text{NR}^b\text{R}^c$, $-\text{OS}(\text{O})_2\text{NR}^b\text{R}^c$, $-\text{NR}^b\text{R}^c$, $-\text{NR}^a\text{C}(\text{O})\text{R}^d$, $-\text{NR}^a\text{C}(\text{O})\text{OR}^d$, $-\text{NR}^a\text{C}(\text{O})\text{NR}^b\text{R}^c$, $-\text{NR}^a\text{C}(\text{O})\text{SR}^d$, $-\text{NR}^a\text{C}(\text{NR}^d)\text{NR}^b\text{R}^c$, $-\text{NR}^a\text{C}(\text{S})\text{R}^d$, $-\text{NR}^a\text{C}(\text{S})\text{OR}^d$, $-\text{NR}^a\text{C}(\text{S})\text{NR}^b\text{R}^c$, $-\text{NR}^a\text{S}(\text{O})\text{R}^d$, $-\text{NR}^a\text{S}(\text{O})_2\text{R}^d$, $-\text{NR}^a\text{S}(\text{O})\text{NR}^b\text{R}^c$, $-\text{NR}^a\text{S}(\text{O})_2\text{NR}^b\text{R}^c$, $-\text{SR}^a$, $-\text{S}(\text{O})\text{R}^a$, $-\text{S}(\text{O})_2\text{R}^a$, $-\text{S}(\text{O})\text{NR}^b\text{R}^c$, and $-\text{S}(\text{O})_2\text{NR}^b\text{R}^c$, wherein each R^a , R^b , R^c , and R^d is independently (i) hydrogen or deuterium; (ii) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a ; or (iii) R^b and R^c together with the N atom to which they are attached form heterocyclyl, optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a ;


wherein each Q^a is independently selected from: (a) deuterium, cyano, halo, nitro, imino, and oxo; (b) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, and heterocyclyl; and (c) $-\text{C}(\text{O})\text{R}^e$, $-\text{C}(\text{O})\text{OR}^e$, $-\text{C}(\text{O})\text{NR}^f\text{R}^g$, $-\text{C}(\text{O})\text{SR}^e$, $-\text{C}(\text{NR}^e)\text{NR}^f\text{R}^g$, $-\text{C}(\text{S})\text{R}^e$, $-\text{C}(\text{S})\text{OR}^e$, $-\text{C}(\text{S})\text{NR}^f\text{R}^g$, $-\text{OR}^e$, $-\text{OC}(\text{O})\text{R}^e$, $-\text{OC}(\text{O})\text{OR}^e$,

$-\text{OC}(\text{O})\text{NR}^f\text{R}^g$, $-\text{OC}(\text{O})\text{SR}^e$, $-\text{OC}(\text{NR}^e)\text{NR}^f\text{R}^g$, $-\text{OC}(\text{S})\text{R}^e$, $-\text{OC}(\text{S})\text{OR}^e$, $-\text{OC}(\text{S})\text{NR}^f\text{R}^g$,
 $-\text{OP}(\text{O})(\text{OR}^f)\text{OR}^g$, $-\text{OS}(\text{O})\text{R}^e$, $-\text{OS}(\text{O})_2\text{R}^e$, $-\text{OS}(\text{O})\text{NR}^f\text{R}^g$, $-\text{OS}(\text{O})_2\text{NR}^f\text{R}^g$, $-\text{NR}^f\text{R}^g$,
 $-\text{NR}^e\text{C}(\text{O})\text{R}^h$, $-\text{NR}^e\text{C}(\text{O})\text{OR}^f$, $-\text{NR}^e\text{C}(\text{O})\text{NR}^f\text{R}^g$, $-\text{NR}^e\text{C}(\text{O})\text{SR}^f$, $-\text{NR}^e\text{C}(\text{NR}^h)\text{NR}^f\text{R}^g$,
 $-\text{NR}^e\text{C}(\text{S})\text{R}^h$, $-\text{NR}^e\text{C}(\text{S})\text{OR}^f$, $-\text{NR}^e\text{C}(\text{S})\text{NR}^f\text{R}^g$, $-\text{NR}^e\text{S}(\text{O})\text{R}^h$, $-\text{NR}^e\text{S}(\text{O})_2\text{R}^h$, $-\text{NR}^e\text{S}(\text{O})\text{NR}^f\text{R}^g$,
 $-\text{NR}^e\text{S}(\text{O})_2\text{NR}^f\text{R}^g$, $-\text{SR}^e$, $-\text{S}(\text{O})\text{R}^e$, $-\text{S}(\text{O})_2\text{R}^e$, $-\text{S}(\text{O})\text{NR}^f\text{R}^g$, and $-\text{S}(\text{O})_2\text{NR}^f\text{R}^g$; wherein each R^e ,
 R^f , R^g , and R^h is independently (i) hydrogen or deuterium; (ii) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6}
 alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (iii) R^f and R^g
 together with the N atom to which they are attached form heterocyclyl.

[0062] In certain embodiments, in Formula (I), Y is C_{1-6} alkylene, optionally substituted
 with one or more substituents Q. In certain embodiments, in Formula (I), Y is methylene,
 optionally substituted with one or more substituents Q. In certain embodiments, in Formula (I),
 Y is $-\text{CH}_2-$ or $-\text{CD}_2-$. In certain embodiments, in Formula (I), Y is C_{3-10} cycloalkylene,
 optionally substituted with one or more substituents Q. In certain embodiments, in Formula (I),
 Y is cyclopropan-1,1-diyl.

[0063] In certain embodiments, in Formula (I), R^{3a} is hydrogen or deuterium. In certain
 embodiments, in Formula (I), R^{3d} is hydrogen or deuterium. In certain embodiments, in Formula
 (I), R^{3e} is hydrogen or deuterium. In certain embodiments, in Formula (I), R^{3a} , R^{3d} , and R^{3e} are
 each hydrogen.


[0064] In another embodiment, provided herein is a compound of Formula (II):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more
 diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or
 a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^2 , R^{3b} , R^{3c} ,
 R^{4a} , R^E , L, X, and a are each as defined herein.


[0065] In certain embodiments, in Formula (I) or (II), a is an integer of 0, 1, or 2. In certain embodiments, in Formula (I) or (II), a is an integer of 0. In certain embodiments, in Formula (I) or (II), a is an integer of 1. In certain embodiments, in Formula (I) or (II), a is an integer of 2.

[0066] In yet another embodiment, provided herein is a compound of Formula (III):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R¹, R², R^{3b}, R^{3c}, R^E, L, and X are each as defined herein.

[0067] In yet another embodiment, provided herein is a compound of Formula (IV):




or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R¹, R², R^{3b}, R^{3c}, R^E, L, and X are each as defined herein.

[0068] In yet another embodiment, provided herein is a compound of Formula (V):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^2 , R^4 , R^{3b} , R^{3c} , R^E , L , and X are each as defined herein.

[0069] In still another embodiment, provided herein is a compound of Formula (VI):



or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^2 , R^4 , R^{3b} , R^{3c} , R^E , L , and X are each as defined herein.

[0070] In certain embodiments, in any one of Formulae (I) to (VI), R^1 is (i) C_{1-6} alkyl, C_{3-10} cycloalkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more substituents Q ; or (ii) $-OR^{1a}$ or $-NR^{1b}R^{1c}$; wherein R^{1a} , R^{1b} , and R^{1c} are each as defined herein. In certain embodiments, in any one of Formulae (I) to (VI), R^1 is C_{1-6} alkyl or C_{3-10} cycloalkyl, each of which is optionally substituted with one or more substituents Q . In certain embodiments, in any one of Formulae (I) to (VI), R^1 is C_{1-6} alkyl, optionally substituted with one or more substituents Q . In certain embodiments, in any one of Formulae (I) to (VI), R^1 is methyl or cyclopropylmethyl. In certain embodiments, in any one of Formulae (I) to (VI), R^1 is methyl. In certain embodiments, in any one of Formulae (I) to (VI), R^1 is C_{3-10} cycloalkyl, optionally substituted with one or more substituents Q . In certain embodiments, in any one of Formulae (I) to (VI), R^1 is cyclopropyl.

[0071] In certain embodiments, in any one of Formulae (I) to (VI), R^2 is hydrogen. In certain embodiments, in any one of Formulae (I) to (VI), R^2 is deuterium.

[0072] In certain embodiments, in any one of Formulae (I) to (VI), R^{3b} is C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more substituents Q. In certain embodiments, in any one of Formulae (I) to (VI), R^{3b} is C_{1-6} alkyl, C_{1-6} heteroalkyl, or C_{3-10} cycloalkyl, each of which is optionally substituted with one or more substituents Q. In certain embodiments, in any one of Formulae (I) to (VI), R^{3b} is C_{1-6} alkyl, optionally substituted with one or more substituents Q. In certain embodiments, in any one of Formulae (I) to (VI), R^{3b} is methyl, ethyl, or cyclopropylmethyl. In certain embodiments, in any one of Formulae (I) to (VI), R^{3b} is ethyl. In certain embodiments, in any one of Formulae (I) to (VI), R^{3b} is C_{3-10} cycloalkyl, optionally substituted with one or more substituents Q. In certain embodiments, in any one of Formulae (I) to (VI), R^{3b} is cyclopropyl.

[0073] In certain embodiments, in any one of Formulae (I) to (VI), R^{3c} is C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more substituents Q. In certain embodiments, in any one of Formulae (I) to (VI), R^{3c} is C_{1-6} alkyl, C_{1-6} heteroalkyl, or C_{3-10} cycloalkyl, each of which is optionally substituted with one or more substituents Q. In certain embodiments, in any one of Formulae (I) to (VI), R^{3c} is C_{1-6} alkyl, optionally substituted with one or more substituents Q. In certain embodiments, in any one of Formulae (I) to (VI), R^{3c} is methyl, ethyl, or cyclopropylmethyl. In certain embodiments, in any one of Formulae (I) to (VI), R^{3c} is methyl. In certain embodiments, in any one of Formulae (I) to (VI), R^{3c} is C_{3-10} cycloalkyl, optionally substituted with one or more substituents Q. In certain embodiments, in any one of Formulae (I) to (VI), R^{3c} is cyclopropyl.

[0074] In certain embodiments, in any one of Formulae (I) to (VI), R^{3b} and R^{3c} are each independently C_{1-6} alkyl, optionally substituted with one or more substituents Q. In certain embodiments, in any one of Formulae (I) to (VI), R^{3b} and R^{3c} are each independently methyl or ethyl. In certain embodiments, in any one of Formulae (I) to (VI), R^{3b} is methyl and R^{3c} is ethyl. In certain embodiments, in any one of Formulae (I) to (VI), R^{3b} is ethyl and R^{3c} is methyl.


[0075] In certain embodiments, in Formula (V) or (VI), R^4 is hydrogen, deuterium, halo, $-NR^{1b}R^{1c}$, or $-NR^{1a}C(O)R^{1d}$, wherein R^{1a} , R^{1b} , R^{1c} , and R^{1d} are each as defined herein. In certain embodiments, in Formula (V) or (VI), R^4 is hydrogen. In certain embodiments, in Formula (V) or (VI), R^4 is deuterium. In certain embodiments, in Formula (V) or (VI), R^4 is halo. In certain embodiments, in Formula (V) or (VI), R^4 is $-NR^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, in Formula (V) or (VI), R^4 is $-NH_2$. In certain embodiments, in Formula (V) or (VI), R^4 is $-NR^{1a}C(O)R^{1d}$, wherein R^{1a} and R^{1d} are each as defined herein. In certain embodiments, in Formula (V) or (VI), R^4 is $-NHC(O)R^{1d}$, wherein R^{1d} is C_{1-6} alkyl optionally substituted with one or more substituents Q. In certain embodiments, in Formula (V) or (VI), R^4 is $-NHC(O)CH_3$.

[0076] In certain embodiments, in any one of Formulae (I) to (VI), X is $-CH_2-$. In certain embodiments, in any one of Formulae (I) to (VI), X is $-C(O)-$.

[0077] In one embodiment, in any one of Formulae (I) to (VI),
 R^1 is C_{1-6} alkyl or C_{3-10} cycloalkyl;
 R^2 is hydrogen or deuterium;
 R^{3b} and R^{3c} are each independently C_{1-6} alkyl;
 R^4 , if present, is hydrogen or $-NHC(O)R^{1d}$, wherein R^{1d} is C_{1-6} alkyl; and
X is $-CH_2-$ or $-C(O)-$;
wherein each alkyl and cycloalkyl is optionally substituted with one or more substituents Q.


[0078] In another embodiment, in any one of Formulae (I) to (VI),
 R^1 is methyl or cyclopropylmethyl;
 R^2 is hydrogen or deuterium;
 R^{3b} and R^{3c} are each independently methyl or ethyl;
 R^4 , if present, is hydrogen or $-NHC(O)CH_3$; and
X is $-CH_2-$ or $-C(O)-$.

[0079] In one embodiment, provided herein is a compound of Formula (VII):




or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^E and L are each as defined herein.

[0080] In another embodiment, provided herein is a compound of Formula (VIII):



or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^E and L are each as defined herein.

[0081] In one embodiment, provided herein is a compound of Formula (IA):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:

L is a linker;

R^E is an E3 ubiquitin ligase binding moiety;

each R^{5a} is independently (i) deuterium, cyano, halo, or nitro; (ii) C_{1-6} alkyl, C_{1-6}

heteroalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, C₆₋₁₄ aryl, C₇₋₁₅ aralkyl, heteroaryl, or heterocyclyl; or (iii) $-\text{C}(\text{O})\text{R}^{1a}$, $-\text{C}(\text{O})\text{OR}^{1a}$, $-\text{C}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{C}(\text{O})\text{SR}^{1a}$, $-\text{C}(\text{NR}^{1a})\text{NR}^{1b}\text{R}^{1c}$, $-\text{C}(\text{S})\text{R}^{1a}$, $-\text{C}(\text{S})\text{OR}^{1a}$, $-\text{C}(\text{S})\text{NR}^{1b}\text{R}^{1c}$, $-\text{OR}^{1a}$, $-\text{OC}(\text{O})\text{R}^{1a}$, $-\text{OC}(\text{O})\text{OR}^{1a}$, $-\text{OC}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{OC}(\text{O})\text{SR}^{1a}$, $-\text{OC}(\text{NR}^{1a})\text{NR}^{1b}\text{R}^{1c}$, $-\text{OC}(\text{S})\text{R}^{1a}$, $-\text{OC}(\text{S})\text{OR}^{1a}$, $-\text{OC}(\text{S})\text{NR}^{1b}\text{R}^{1c}$, $-\text{OS}(\text{O})\text{R}^{1a}$, $-\text{OS}(\text{O})_2\text{R}^{1a}$, $-\text{OS}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{OS}(\text{O})_2\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{C}(\text{O})\text{R}^{1d}$, $-\text{NR}^{1a}\text{C}(\text{O})\text{OR}^{1d}$, $-\text{NR}^{1a}\text{C}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{C}(\text{O})\text{SR}^{1d}$, $-\text{NR}^{1a}\text{C}(\text{NR}^{1d})\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{C}(\text{S})\text{R}^{1d}$, $-\text{NR}^{1a}\text{C}(\text{S})\text{OR}^{1d}$, $-\text{NR}^{1a}\text{C}(\text{S})\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{S}(\text{O})\text{R}^{1d}$, $-\text{NR}^{1a}\text{S}(\text{O})_2\text{R}^{1d}$, $-\text{NR}^{1a}\text{S}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{S}(\text{O})_2\text{NR}^{1b}\text{R}^{1c}$, $-\text{SR}^{1a}$, $-\text{S}(\text{O})\text{R}^{1a}$, $-\text{S}(\text{O})_2\text{R}^{1a}$, $-\text{S}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, or $-\text{S}(\text{O})_2\text{NR}^{1b}\text{R}^{1c}$; and R⁵ is hydrogen or R^{5a};

R⁶ is hydrogen, C₁₋₆ alkyl, C₁₋₆ heteroalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, C₆₋₁₄ aryl, C₇₋₁₅ aralkyl, heteroaryl, or heterocyclyl;

R^{7a}, R^{7b}, R^{7c}, and R^{7d} are each independently (i) hydrogen, deuterium, cyano, halo, or nitro; (ii) C₁₋₆ alkyl, C₁₋₆ heteroalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, C₆₋₁₄ aryl, C₇₋₁₅ aralkyl, heteroaryl, or heterocyclyl; or (iii) $-\text{C}(\text{O})\text{R}^{1a}$, $-\text{C}(\text{O})\text{OR}^{1a}$, $-\text{C}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{C}(\text{O})\text{SR}^{1a}$, $-\text{C}(\text{NR}^{1a})\text{NR}^{1b}\text{R}^{1c}$, $-\text{C}(\text{S})\text{R}^{1a}$, $-\text{C}(\text{S})\text{OR}^{1a}$, $-\text{C}(\text{S})\text{NR}^{1b}\text{R}^{1c}$, $-\text{OR}^{1a}$, $-\text{OC}(\text{O})\text{R}^{1a}$, $-\text{OC}(\text{O})\text{OR}^{1a}$, $-\text{OC}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{OC}(\text{O})\text{SR}^{1a}$, $-\text{OC}(\text{NR}^{1a})\text{NR}^{1b}\text{R}^{1c}$, $-\text{OC}(\text{S})\text{R}^{1a}$, $-\text{OC}(\text{S})\text{OR}^{1a}$, $-\text{OC}(\text{S})\text{NR}^{1b}\text{R}^{1c}$, $-\text{OS}(\text{O})\text{R}^{1a}$, $-\text{OS}(\text{O})_2\text{R}^{1a}$, $-\text{OS}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{OS}(\text{O})_2\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{C}(\text{O})\text{R}^{1d}$, $-\text{NR}^{1a}\text{C}(\text{O})\text{OR}^{1d}$, $-\text{NR}^{1a}\text{C}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{C}(\text{O})\text{SR}^{1d}$, $-\text{NR}^{1a}\text{C}(\text{NR}^{1d})\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{C}(\text{S})\text{R}^{1d}$, $-\text{NR}^{1a}\text{C}(\text{S})\text{OR}^{1d}$, $-\text{NR}^{1a}\text{C}(\text{S})\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{S}(\text{O})\text{R}^{1d}$, $-\text{NR}^{1a}\text{S}(\text{O})_2\text{R}^{1d}$, $-\text{NR}^{1a}\text{S}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{S}(\text{O})_2\text{NR}^{1b}\text{R}^{1c}$, $-\text{SR}^{1a}$, $-\text{S}(\text{O})\text{R}^{1a}$, $-\text{S}(\text{O})_2\text{R}^{1a}$, $-\text{S}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, or $-\text{S}(\text{O})_2\text{NR}^{1b}\text{R}^{1c}$;

each R^{1a}, R^{1b}, R^{1c}, and R^{1d} is independently hydrogen, deuterium, C₁₋₆ alkyl, C₁₋₆ heteroalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, C₆₋₁₄ aryl, C₇₋₁₅ aralkyl, heteroaryl, or heterocyclyl; and

b is an integer of 0, 1, 2, 3, or 4;

wherein each alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q, wherein each Q is independently selected from: (a) deuterium, cyano, halo, imino, nitro, and oxo; (b) C₁₋₆ alkyl, C₁₋₆ heteroalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, C₆₋₁₄ aryl, C₇₋₁₅ aralkyl, heteroaryl, and heterocyclyl, each of which is further optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a; and (c) $-\text{C}(\text{O})\text{R}^a$, $-\text{C}(\text{O})\text{OR}^a$, $-\text{C}(\text{O})\text{NR}^b\text{R}^c$, $-\text{C}(\text{O})\text{SR}^a$, $-\text{C}(\text{NR}^a)\text{NR}^b\text{R}^c$, $-\text{C}(\text{S})\text{R}^a$, $-\text{C}(\text{S})\text{OR}^a$,

$-C(S)NR^bR^c$, $-OR^a$, $-OC(O)R^a$, $-OC(O)OR^a$, $-OC(O)NR^bR^c$, $-OC(O)SR^a$, $-OC(NR^a)NR^bR^c$,
 $-OC(S)R^a$, $-OC(S)OR^a$, $-OC(S)NR^bR^c$, $-OP(O)(OR^a)OR^d$, $-OS(O)R^a$, $-OS(O)_2R^a$,
 $-OS(O)NR^bR^c$, $-OS(O)_2NR^bR^c$, $-NR^bR^c$, $-NR^aC(O)R^d$, $-NR^aC(O)OR^d$, $-NR^aC(O)NR^bR^c$,
 $-NR^aC(O)SR^d$, $-NR^aC(NR^d)NR^bR^c$, $-NR^aC(S)R^d$, $-NR^aC(S)OR^d$, $-NR^aC(S)NR^bR^c$,
 $-NR^aS(O)R^d$, $-NR^aS(O)_2R^d$, $-NR^aS(O)NR^bR^c$, $-NR^aS(O)_2NR^bR^c$, $-SR^a$, $-S(O)R^a$, $-S(O)_2R^a$,
 $-S(O)NR^bR^c$, and $-S(O)_2NR^bR^c$, wherein each R^a , R^b , R^c , and R^d is independently (i) hydrogen or deuterium; (ii) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a ; or (iii) R^b and R^c together with the N atom to which they are attached form heterocyclyl, optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a ;


wherein each Q^a is independently selected from: (a) deuterium, cyano, halo, nitro, imino, and oxo; (b) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, and heterocyclyl; and (c) $-C(O)R^e$, $-C(O)OR^e$, $-C(O)NR^fR^g$, $-C(O)SR^e$, $-C(NR^e)NR^fR^g$, $-C(S)R^e$, $-C(S)OR^e$, $-C(S)NR^fR^g$, $-OR^e$, $-OC(O)R^e$, $-OC(O)OR^e$, $-OC(O)NR^fR^g$, $-OC(O)SR^e$, $-OC(NR^e)NR^fR^g$, $-OC(S)R^e$, $-OC(S)OR^e$, $-OC(S)NR^fR^g$, $-OP(O)(OR^f)OR^g$, $-OS(O)R^e$, $-OS(O)_2R^e$, $-OS(O)NR^fR^g$, $-OS(O)_2NR^fR^g$, $-NR^fR^g$, $-NR^eC(O)R^h$, $-NR^eC(O)OR^f$, $-NR^eC(O)NR^fR^g$, $-NR^eC(O)SR^f$, $-NR^eC(NR^h)NR^fR^g$, $-NR^eC(S)R^h$, $-NR^eC(S)OR^f$, $-NR^eC(S)NR^fR^g$, $-NR^eS(O)R^h$, $-NR^eS(O)_2R^h$, $-NR^eS(O)NR^fR^g$, $-NR^eS(O)_2NR^fR^g$, $-SR^e$, $-S(O)R^e$, $-S(O)_2R^e$, $-S(O)NR^fR^g$, and $-S(O)_2NR^fR^g$; wherein each R^e , R^f , R^g , and R^h is independently (i) hydrogen or deuterium; (ii) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (iii) R^f and R^g together with the N atom to which they are attached form heterocyclyl.

[0082] In certain embodiments, in Formula (IA), each R^{5a} is independently (i) deuterium; (ii) C_{1-6} alkyl, optionally substituted with one or more substituents Q ; or (iii) $-OR^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, in Formula (IA), each R^{5a} is deuterium. In certain embodiments, in Formula (IA), each R^{5a} is independently C_{1-6} alkyl, optionally substituted with one or more substituents Q . In certain embodiments, in Formula (IA), each R^{5a} is independently $-OR^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, in Formula (IA), each R^{5a} is independently $-OR^{1a}$, wherein R^{1a} is C_{1-6} alkyl optionally substituted with one or more substituents Q . In certain embodiments, in Formula (IA), each R^{5a} is independently methoxy,

difluoromethoxy, trifluoromethoxy, ethoxy, or cyclopropylmethoxy. In certain embodiments, in Formula (IA), each R^{5a} is independently difluoromethoxy or cyclopropylmethoxy.


[0083] In certain embodiments, in Formula (IA), b is an integer of 0, 1, or 2. In certain embodiments, in Formula (IA), b is an integer of 0. In certain embodiments, in Formula (IA), b is an integer of 1. In certain embodiments, in Formula (IA), b is an integer of 2.

[0084] In another embodiment, provided herein is a compound of Formula (IIA):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^5 , R^6 , R^{7a} , R^{7b} , R^{7c} , R^{7d} , R^E , and L are each as defined herein.

[0085] In yet another embodiment, provided herein is a compound of Formula (IIIA):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^5 , R^6 , R^{7a} , R^{7b} , R^{7c} , R^{7d} , R^E , and L are each as defined herein.

[0086] In certain embodiments, in Formula (IIA) or (IIIA), R^5 is (i) hydrogen or

deuterium; (ii) C₁₋₆ alkyl, optionally substituted with one or more substituents Q; or (iii) –OR^{1a}, wherein R^{1a} is as defined herein. In certain embodiments, in Formula (IIA) or (IIIA), R⁵ is hydrogen or deuterium. In certain embodiments, in Formula (IIA) or (IIIA), R⁵ is C₁₋₆ alkyl, optionally substituted with one or more substituents Q. In certain embodiments, in Formula (IIA) or (IIIA), R⁵ is –OR^{1a}, wherein R^{1a} is as defined herein. In certain embodiments, in Formula (IIA) or (IIIA), R⁵ is –OR^{1a}, wherein R^{1a} is C₁₋₆ alkyl optionally substituted with one or more substituents Q. In certain embodiments, in Formula (IIA) or (IIIA), R⁵ is methoxy, difluoromethoxy, trifluoromethoxy, ethoxy, or cyclopropylmethoxy. In certain embodiments, in Formula (IIA) or (IIIA), R⁵ is difluoromethoxy or cyclopropylmethoxy. In certain embodiments, in Formula (IIA), R⁵ is difluoromethoxy. In certain embodiments, in Formula (IIIA), R⁵ is cyclopropylmethoxy.

[0087] In certain embodiments, in Formula (IA), (IIA), or (IIIA), R⁶ is hydrogen or C₁₋₆ alkyl optionally substituted with one or more substituents Q. In certain embodiments, in Formula (IA), (IIA), or (IIIA), R⁶ is hydrogen.


[0088] In certain embodiments, in Formula (IA), (IIA), or (IIIA), R^{7a} is hydrogen, deuterium, halo, or C₁₋₆ alkyl optionally substituted with one or more substituents Q. In certain embodiments, in Formula (IA), (IIA), or (IIIA), R^{7a} is hydrogen, halo, or C₁₋₆ alkyl optionally substituted with one or more substituents Q. In certain embodiments, in Formula (IA), (IIA), or (IIIA), R^{7a} is hydrogen. In certain embodiments, in Formula (IA), (IIA), or (IIIA), R^{7a} is deuterium. In certain embodiments, in Formula (IA), (IIA), or (IIIA), R^{7a} is halo. In certain embodiments, in Formula (IA), (IIA), or (IIIA), R^{7a} is chloro. In certain embodiments, in Formula (IA), (IIA), or (IIIA), R^{7a} is C₁₋₆ alkyl optionally substituted with one or more substituents Q. In certain embodiments, in Formula (IA), (IIA), or (IIIA), R^{7a} is methyl, optionally substituted with one or more substituents Q. In certain embodiments, in Formula (IA), (IIA), or (IIIA), R^{7a} is trifluoromethyl.

[0089] In certain embodiments, in Formula (IA), (IIA), or (IIIA), R^{7b} is hydrogen, deuterium, or C₁₋₆ alkyl optionally substituted with one or more substituents Q. In certain embodiments, in Formula (IA), (IIA), or (IIIA), R^{7b} is hydrogen. In certain embodiments, in Formula (IA), (IIA), or (IIIA), R^{7b} is deuterium.

[0090] In certain embodiments, in Formula (IA), (IIA), or (IIIA), R^{7c} is hydrogen, deuterium, or C_{1-6} alkyl optionally substituted with one or more substituents Q. In certain embodiments, in Formula (IA), (IIA), or (IIIA), R^{7c} is hydrogen. In certain embodiments, in Formula (IA), (IIA), or (IIIA), R^{7c} is deuterium.


[0091] In certain embodiments, in Formula (IA), (IIA), or (IIIA), R^{7d} is hydrogen, deuterium, halo, or C_{1-6} alkyl optionally substituted with one or more substituents Q. In certain embodiments, in Formula (IA), (IIA), or (IIIA), R^{7d} is hydrogen, halo, or C_{1-6} alkyl optionally substituted with one or more substituents Q. In certain embodiments, in Formula (IA), (IIA), or (IIIA), R^{7d} is hydrogen. In certain embodiments, in Formula (IA), (IIA), or (IIIA), R^{7d} is deuterium. In certain embodiments, in Formula (IA), (IIA), or (IIIA), R^{7d} is halo. In certain embodiments, in Formula (IA), (IIA), or (IIIA), R^{7d} is chloro. In certain embodiments, in Formula (IA), (IIA), or (IIIA), R^{7d} is C_{1-6} alkyl optionally substituted with one or more substituents Q. In certain embodiments, in Formula (IA), (IIA), or (IIIA), R^{7d} is methyl, optionally substituted with one or more substituents Q. In certain embodiments, in Formula (IA), (IIA), or (IIIA), R^{7d} is trifluoromethyl.

[0092] In one embodiment, provided herein is a compound of Formula (IVA):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^E and L are each as defined herein.

[0093] In another embodiment, provided herein is a compound of Formula (VA):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^E and L are each as defined herein.

[0094] In certain embodiments, R^E is a moiety of a cereblon (CRBN) E3 ligand, an inhibitors-of-apoptosis protein (IAP) E3 ligand, a mouse double minute 2 homolog (MDM2) E3 ligand, or a von Hippel-Lindau (VHL) E3 ligand.

[0095] In certain embodiments, R^E is a moiety of a CRBN E3 ligand.

[0096] In certain embodiments, R^E is a moiety having the structure of Formula (EC-I):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein:

A^E is a bond, $-O-$, $-N(R^{1b})-$, $-S-$, C_{1-6} alkylene, C_{1-6} heteroalkylene, C_{2-6} alkenylene, C_{2-6} heteroalkenylene, C_{2-6} alkynylene, C_{2-6} heteroalkynylene, C_{3-10} cycloalkylene, C_{6-14} arylene, C_{7-15} aralkylene, heteroarylene, heterocyclylene, C_{1-6} heteroalkylene- C_{6-14} arylene, or C_{2-6} alkynylene-heterocyclylene;

Z is $-CH_2-$ or $-C(O)-$;

one of Z^1 , Z^2 , Z^3 , and Z^4 is $-C=$ and the remaining three of Z^1 , Z^2 , Z^3 , and Z^4 are

each independently $-C(R^{E5})=$; or Z^1 is a bond, one of Z^2 , Z^3 , and Z^4 is $-C=$, and the remaining two of Z^2 , Z^3 , and Z^4 are each independently $-C(R^{E5})=$ or $-S-$;

m is an integer of 0, 1, or 2;

R^{E1} is hydrogen, deuterium, halo, or C_{1-6} alkyl;

R^{E2} is hydrogen or C_{1-6} alkyl;


each R^{E4} is independently (i) deuterium, cyano, halo, or nitro; (ii) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (iii) $-C(O)R^{1a}$, $-C(O)OR^{1a}$, $-C(O)NR^{1b}R^{1c}$, $-C(O)SR^{1a}$, $-C(NR^{1a})NR^{1b}R^{1c}$, $-C(S)R^{1a}$, $-C(S)OR^{1a}$, $-C(S)NR^{1b}R^{1c}$, $-OR^{1a}$, $-OC(O)R^{1a}$, $-OC(O)OR^{1a}$, $-OC(O)NR^{1b}R^{1c}$, $-OC(O)SR^{1a}$, $-OC(NR^{1a})NR^{1b}R^{1c}$, $-OC(S)R^{1a}$, $-OC(S)OR^{1a}$, $-OC(S)NR^{1b}R^{1c}$, $-OS(O)R^{1a}$, $-OS(O)_2R^{1a}$, $-OS(O)NR^{1b}R^{1c}$, $-OS(O)_2NR^{1b}R^{1c}$, $-NR^{1b}R^{1c}$, $-NR^{1a}C(O)R^{1d}$, $-NR^{1a}C(O)OR^{1d}$, $-NR^{1a}C(O)NR^{1b}R^{1c}$, $-NR^{1a}C(O)SR^{1d}$, $-NR^{1a}C(NR^{1d})NR^{1b}R^{1c}$, $-NR^{1a}C(S)R^{1d}$, $-NR^{1a}C(S)OR^{1d}$, $-NR^{1a}C(S)NR^{1b}R^{1c}$, $-NR^{1a}S(O)R^{1d}$, $-NR^{1a}S(O)_2R^{1d}$, $-NR^{1a}S(O)NR^{1b}R^{1c}$, $-NR^{1a}S(O)_2NR^{1b}R^{1c}$, $-SR^{1a}$, $-S(O)R^{1a}$, $-S(O)_2R^{1a}$, $-S(O)NR^{1b}R^{1c}$, or $-S(O)_2NR^{1b}R^{1c}$;

each R^{E5} is independently hydrogen or R^{E4} ; and

R^{1a} , R^{1b} , R^{1c} , and R^{1d} are each as defined herein;


wherein each alkyl, alkylene, heteroalkyl, heteroalkylene, alkenyl, alkenylene, heteroalkenylene, alkynyl, alkynylene, heteroalkynylene, cycloalkyl, cycloalkylene, aryl, arylene, aralkyl, aralkylene, heteroaryl, heteroarylene, heterocyclyl, and heterocyclylene is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q.

[0097] In certain embodiments, R^E is a moiety having the structure of Formula (EC-II):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein n is an integer of 0, 1, 2, or 3; and A^E , R^{E1} , R^{E2} , R^{E4} , Z , and m are each as defined herein.

[0098] In certain embodiments, R^E is a moiety having the structure of Formula (EC-III):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein A^E , R^{E1} , R^{E2} , R^{E5} , Z , and m are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.

[0099] In certain embodiments, R^E is a moiety having the structure of Formula (EC-IV):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein A^E , R^{E1} , R^{E2} , R^{E5} , Z , and m are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.

[00100] In certain embodiments, R^E is a moiety having the structure of Formula (EC-V):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein A^E , R^{E1} , R^{E2} , R^{E5} , Z , and m are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.

[00101] In certain embodiments, R^E is a moiety having the structure of Formula (EC-VI):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein n is an integer of 0 or 1; and A^E , R^{E1} , R^{E2} , R^{E4} , Z , and m are each as defined herein.

[00102] In certain embodiments, R^E is a moiety having the structure of Formula (EC-VII):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein A^E , R^{E1} , R^{E2} , R^{E5} , Z , and m are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.

[00103] In certain embodiments, R^E is a moiety having the structure of Formula (EC-VIII):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein A^E , R^{E1} , R^{E2} , R^{E5} , Z , and m are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.


[00104] In certain embodiments, R^E is a moiety having the structure of Formula (EC-IX):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof;


wherein n is an integer of 0 or 1; and A^E , R^{E1} , R^{E2} , R^{E4} , Z, and m are each as defined herein.

[00105] In certain embodiments, R^E is a moiety having the structure of Formula (EC-X):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein A^E , R^{E1} , R^{E2} , R^{E5} , Z, and m are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.

[00106] In certain embodiments, R^E is a moiety having the structure of Formula (EC-XI):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein A^E , R^{E1} , R^{E2} , R^{E5} , Z, and m are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.

[00107] In certain embodiments, R^E is a moiety having the structure of Formula (EC-XII):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein n is an integer of 0 or 1; and A^E , R^{E1} , R^{E2} , R^{E4} , Z, and m are each as defined herein.

[00108] In certain embodiments, R^E is a moiety having the structure of Formula (EC-XIII):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein A^E , R^{E1} , R^{E2} , R^{E5} , Z , and m are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.

[00109] In certain embodiments, R^E is a moiety having the structure of Formula (EC-XIV):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein A^E , R^{E1} , R^{E2} , R^{E5} , Z , and m are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.

[00110] In certain embodiments, R^E is a moiety having the structure of Formula (EC-XV):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein R^{E3} is hydrogen, deuterium, halo, or C_{1-6} alkyl, optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q ; and A^E , R^{E1} , R^{E2} , Z^1 , Z^2 , Z^3 , Z^4 , and m are each as defined herein.

[00111] In certain embodiments, R^E is a moiety having the structure of Formula (EC-XVI):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein n is an integer of 0, 1, 2, or 3; and A^E , R^{E1} , R^{E2} , R^{E3} , R^{E4} , and m are each as defined herein.

[00112] In certain embodiments, R^E is a moiety having the structure of Formula (EC-XVII):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein A^E , R^{E1} , R^{E2} , R^{E3} , R^{E5} , and m are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.

[00113] In certain embodiments, R^E is a moiety having the structure of Formula (EC-XVIII):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein A^E , R^{E1} , R^{E2} , R^{E3} , R^{E5} , and m are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.

[00114] In certain embodiments, R^E is a moiety having the structure of Formula (EC-XIX):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein n is an integer of 0 or 1; and A^E , R^{E1} , R^{E2} , R^{E3} , R^{E4} , and m are each as defined herein.

[00115] In certain embodiments, R^E is a moiety having the structure of Formula (EC-XX):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein A^E , R^{E1} , R^{E2} , R^{E3} , R^{E5} , and m are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.

[00116] In certain embodiments, R^E is a moiety having the structure of Formula (EC-XXI):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein A^E , R^{E1} , R^{E2} , R^{E3} , R^{E5} , and m are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.

[00117] In certain embodiments, R^E is a moiety having the structure of Formula (EC-XXII):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein n is an integer of 0 or 1; and A^E , R^{E1} , R^{E2} , R^{E3} , R^{E4} , and m are each as defined herein.

[00118] In certain embodiments, R^E is a moiety having the structure of Formula (EC-XXIII):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein A^E , R^{E1} , R^{E2} , R^{E3} , R^{E5} , and m are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.

[00119] In certain embodiments, R^E is a moiety having the structure of Formula (EC-XXIV):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein A^E , R^{E1} , R^{E2} , R^{E3} , R^{E5} , and m are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.

[00120] In certain embodiments, R^E is a moiety having the structure of Formula (EC-XXV):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein n is an integer of 0 or 1; and A^E , R^{E1} , R^{E2} , R^{E3} , R^{E4} , and m are each as defined herein.

[00121] In certain embodiments, R^E is a moiety having the structure of Formula (EC-XXVI):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein A^E , R^{E1} , R^{E2} , R^{E3} , R^{E5} , and m are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.

[00122] In certain embodiments, R^E is a moiety having the structure of Formula (EC-XXVII):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein A^E , R^{E1} , R^{E2} , R^{E3} , R^{E5} , and m are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.

[00123] In certain embodiments, R^E is a moiety having the structure of Formula (EC-XXVIII):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein:

R^{E6} is (i) hydrogen; (ii) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more, in one embodiment, one, two, or three, substituents Q; or (iii) $-C(O)R^{1a}$, $-C(O)OR^{1a}$, $-C(O)NR^{1b}R^{1c}$, $-C(O)SR^{1a}$, $-C(NR^{1a})NR^{1b}R^{1c}$, $-C(S)R^{1a}$, $-C(S)OR^{1a}$, $-C(S)NR^{1b}R^{1c}$, $-OR^{1a}$, $-OC(O)R^{1a}$, $-OC(O)OR^{1a}$, $-OC(O)NR^{1b}R^{1c}$, $-OC(O)SR^{1a}$, $-OC(NR^{1a})NR^{1b}R^{1c}$, $-OC(S)R^{1a}$, $-OC(S)OR^{1a}$, $-OC(S)NR^{1b}R^{1c}$, $-OS(O)R^{1a}$, $-OS(O)_2R^{1a}$, $-OS(O)NR^{1b}R^{1c}$, $-OS(O)_2NR^{1b}R^{1c}$, $-NR^{1b}R^{1c}$, $-NR^{1a}C(O)R^{1d}$, $-NR^{1a}C(O)OR^{1d}$, $-NR^{1a}C(O)NR^{1b}R^{1c}$, $-NR^{1a}C(O)SR^{1d}$, $-NR^{1a}C(NR^{1d})NR^{1b}R^{1c}$, $-NR^{1a}C(S)R^{1d}$, $-NR^{1a}C(S)OR^{1d}$, $-NR^{1a}C(S)NR^{1b}R^{1c}$, $-NR^{1a}S(O)R^{1d}$, $-NR^{1a}S(O)_2R^{1d}$, $-NR^{1a}S(O)NR^{1b}R^{1c}$, $-NR^{1a}S(O)_2NR^{1b}R^{1c}$, $-S(O)R^{1a}$, $-S(O)_2R^{1a}$, $-S(O)NR^{1b}R^{1c}$, or $-S(O)_2NR^{1b}R^{1c}$;

X^E is $C(R^{E1})$ or N; and


A^E , R^{E1} , R^{E2} , R^{E4} , m, and n are each as defined herein.

[00124] In certain embodiments, R^E is a moiety having the structure of Formula (EC-XXIX):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein A^E , R^{E1} , R^{E2} , R^{E4} , R^{E6} , m, and n are each as defined herein.

[00125] In certain embodiments, R^E is a moiety having the structure of Formula (EC-XXX):




[00126] or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein A^E , R^{E1} , R^{E2} , R^{E4} , R^{E6} , m , and n are each as defined herein.

[00127] In certain embodiments, R^E is a moiety having the structure of Formula (EC-XXXI):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein A^E , R^{E1} , R^{E2} , R^{E4} , R^{E6} , m , and n are each as defined herein.

[00128] In certain embodiments, R^E is a moiety having the structure of Formula (EC-XXXII):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein A^E , R^{E2} , R^{E4} , R^{E6} , m , and n are each as defined herein.

[00129] In certain embodiments, R^E is a moiety having the structure of Formula (EC-XXXIII):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein A^E , R^{E2} , R^{E4} , R^{E6} , m , and n are each as defined herein.

[00130] In certain embodiments, R^E is a moiety having the structure of Formula (EC-XXXIV):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein A^E , R^{E2} , R^{E4} , R^{E6} , m , and n are each as defined herein.

[00131] In certain embodiments, R^E is a moiety having the structure of Formula (EC-XXXV):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein:

Y^E is a bond, C_{1-6} alkylene, $-O-$, $-S-$, $-S(O)-$, $-S(O_2)-$, or $-N(R^{E7})-$;

R^{E7} is hydrogen or C_{1-6} alkyl; and


A^E , R^{E2} , R^{E4} , X^E , m , and n are each as defined herein.

[00132] In certain embodiments, R^E is a moiety having the structure of Formula (EC-XXXVI):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein A^E , R^{E2} , R^{E4} , X^E , m , and n are each as defined herein.

[00133] In certain embodiments, R^E is a moiety having the structure of Formula (EC-XXXVII):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein A^E , R^{E1} , R^{E2} , R^{E4} , m , and n are each as defined herein.

[00134] In certain embodiments, R^E is a moiety having the structure of Formula (EC-XXXVIII):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein A^E , R^{E1} , R^{E2} , R^{E4} , m , and n are each as defined herein.

[00135] In certain embodiments, R^E is a moiety having the structure of Formula (EC-XXXIX):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein A^E , R^{E1} , R^{E2} , R^{E4} , m , and n are each as defined herein.

[00136] In certain embodiments, R^E is a moiety having the structure of Formula (EC-XL):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein A^E , R^{E2} , R^{E4} , m , and n are each as defined herein.

[00137] In certain embodiments, R^E is a moiety having the structure of Formula (EC-XLI):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein A^E , R^{E2} , R^{E4} , m , and n are each as defined herein.


[00138] In certain embodiments, R^E is a moiety having the structure of Formula (EC-XLII):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein A^E , R^{E2} , R^{E4} , m , and n are each as defined herein.


[00139] In certain embodiments, R^E is a moiety having the structure of Formula (EC-

XLIII):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein A^E , R^{E1} , R^{E2} , R^{E4} , R^{E7} , m , and n are each as defined herein.

[00140] In certain embodiments, R^E is a moiety having the structure of Formula (EC-XLIV):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein A^E , R^{E1} , R^{E2} , R^{E4} , R^{E7} , m , and n are each as defined herein.

[00141] In certain embodiments, R^E is a moiety having the structure of Formula (EC-XLV):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein A^E , R^{E1} , R^{E2} , R^{E4} , R^{E7} , m , and n are each as defined herein.

[00142] In certain embodiments, R^E is a moiety of an E3 ubiquitin ligase binder disclosed in US 9,938,302 B2; US 10,336,771 B2; US 10,406,165 B2; US 10,513,515 B2; US 2019/0322682 A1; US 2020/0000814 A1; US 2020/0148663 A1; US 2020/0369679 A1; and WO 2019/173224 A1; the disclosure of each of which is incorporated herein by reference in its entirety. In certain embodiments, R^E is a moiety of an E3 ubiquitin ligase binder disclosed in US 9,938,302 B2, in one embodiment, one of compounds 1 to 57 disclosed therein in cols. 108 to 137, which are incorporated herein by reference in their entireties. In certain embodiments, R^E is a moiety of an E3 ubiquitin ligase binder disclosed in US 10,336,771 B2, in one embodiment, one of compounds 1 to 57 and 64 to 66 disclosed therein in cols. 113 to 161 and 169 to 172, which are incorporated herein by reference in their entireties. In certain embodiments, R^E is a moiety of an E3 ubiquitin ligase binder disclosed in US 10,406,165 B2, in one embodiment, one of compounds 1 to 27 disclosed therein in cols. 40 to 64, which are incorporated herein by reference in their entireties. In certain embodiments, R^E is a moiety of an E3 ubiquitin ligase binder disclosed in US 10,513,515 B2, in one embodiment, one of compounds 1 to 5, 7 to 12, 14 to 16, 19, 23, and 27 disclosed therein in cols. 97 to 104, 106 to 112, 114 to 117, 122, 126, and 132, which are incorporated herein by reference in their entireties. In certain embodiments, R^E is a moiety of an E3 ubiquitin ligase binder disclosed in US 2019/0322682 A1, in one embodiment, one of compounds 1 to 15 disclosed therein on pages 31 to 36, which are incorporated herein by reference in their entireties. In certain embodiments, R^E is a moiety of an E3 ubiquitin ligase binder disclosed in US 2020/0000814 A1, in one embodiment, one of compounds 1 to 21 disclosed therein on pages 26 to 41, which are incorporated herein by reference in their entireties. In certain embodiments, R^E is a moiety of an E3 ubiquitin ligase binder disclosed in US 2020/0148663 A1, in one embodiment, one of compounds 1 to 21 disclosed therein on pages 18 to 34, which are incorporated herein by reference in their entireties. In certain embodiments, R^E is a moiety of an E3 ubiquitin ligase binder disclosed in US 2020/0369679 A1, in one embodiment, one of compounds I-1 to I-106 and II-1 to II-164 disclosed therein on pages 50 to 101, which are incorporated herein by reference in their entireties. In certain embodiments, R^E is a moiety of an E3 ubiquitin ligase binder disclosed in WO 2019/173224 A1, in one embodiment, one of compounds 1 to 3 disclosed therein on pages 62 to 65 and the compounds disclosed therein on page 78, which are incorporated herein by reference in their entireties.

[00143] In certain embodiments, R^E is a moiety of an E3 ubiquitin ligase binder disclosed

in US 2020/0199073 A1, the disclosure of which is incorporated herein by reference in its entirety. In certain embodiments, R^E is a moiety of an E3 ubiquitin ligase binder disclosed in US Application No. US 2020/0199073 A1, in one embodiment, one of compounds 1 to 291 disclosed therein on pages 118 to 193, which are incorporated herein by reference in their entireties.

[00144] In certain embodiments, in any one of Formulae (EC-I) to (EC-XXVII), A^E is a bond, $-O-$, $-N(R^{1b})-$, C_{2-6} alkynylene, heterocyclylene, C_{1-6} heteroalkylene- C_{6-14} arylene, or C_{2-6} alkynylene-heterocyclylene, where each heteroalkylene, alkynylene, arylene, and heterocyclylene is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q;

Z, if present, is $-CH_2-$ or $-C(O)-$;

m is an integer of 0, 1, or 2;

R^{E1} and R^{E2} are each hydrogen; and

R^{E5} , if present, is independently hydrogen or fluoro.

[00145] In certain embodiments, in any one of Formulae (EC-I) to (EC-XXVII), A^E is a bond, $-O-$, $-NH-$, ethynediyl, piperidindiyl, piperazindiyl, (phendiyl)oxymethanediyl, or (piperidindiyl)ethynediyl;

Z, if present, is $-CH_2-$ or $-C(O)-$;

m is an integer of 0, 1, or 2;

R^{E1} and R^{E2} are each hydrogen; and

R^{E5} , if present, is independently hydrogen or fluoro.

[00146] In certain embodiments, in any one of Formulae (EC-I) to (EC-XXVII), A^E is a bond, $-NH-$, piperidin-1,3-diyl, piperidin-1,4-diyl, piperaz-1,4-diyl, (phen-1,4-diyl)oxymethanediyl, or (piperidin-1,4-diyl)ethynediyl;

Z, if present, is $-CH_2-$ or $-C(O)-$;

m is an integer of 0, 1, or 2;

R^{E1} and R^{E2} are each hydrogen; and

R^{E5} , if present, is independently hydrogen or fluoro.

[00147] In one embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA)

to (VA), R^E is a moiety having the structure of Formula (EC-I), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-II), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-III), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-IV), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-V), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-VI), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-VII), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-VIII), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-IX), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an

isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-X), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-XI), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-XII), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-XIII), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In still another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-XIV), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

[00148] In one embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-XV), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-XVI), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-XVII), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the

structure of Formula (EC-XVIII), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-XIX), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-XX), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-XXI), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-XXII), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-XXIII), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-XXIV), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-XXV), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-XXVI), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In


still another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-XXVII), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

[00149] In one embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-XXVIII), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-XXIX), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-XXX), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-XXXI), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-XXXII), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-XXXIII), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In still another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-XXXIV), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

[00150] In one embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-XXXV), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-XXXVI), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-XXXVII), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-XXXVIII), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-XXXIX), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-XL), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-XLI), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-XLII), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-XLIII), or an enantiomer, a mixture of

enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-XLIV), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In still another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EC-XLV), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

[00151] In certain embodiments, R^E is a moiety having the structure of:



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein A^E is as defined herein.

[00152] In one embodiment, in any one of Formulae **EC-1** to **EC-6**, A^E is a bond, $-O-$, $-NH-$, ethynediyl, piperidindiyl, piperazindiyl, (phendiyl)oxymethanediyl, or (piperidindiyl)-ethynediyl. In another embodiment, in any one of Formulae **EC-1** to **EC-6**, A^E is a bond. In yet another embodiment, in any one of Formulae **EC-1** to **EC-6**, A^E is $-O-$. In yet another embodiment, in any one of Formulae **EC-1** to **EC-6**, A^E is $-NH-$. In yet another embodiment, in any one of Formulae **EC-1** to **EC-6**, A^E is ethynediyl. In yet another embodiment, in any one of Formulae **EC-1** to **EC-6**, A^E is piperidindiyl. In yet another embodiment, in any one of Formulae **EC-1** to **EC-6**, A^E is piperazindiyl. In yet another embodiment, in any one of


Formulae **EC-1** to **EC-6**, A^E is (phendiyl)oxymethanediyl. In still another embodiment, in any one of Formulae **EC-1** to **EC-6**, A^E is (piperidindiyl)ethynediyl.


[00153] In one embodiment, in any one of Formulae **EC-1** to **EC-6**, A^E is a bond, –O–, –NH–, ethynediyl, piperidin-1,3-diyl, piperidin-1,4-diyl, piperazin-1,4-diyl, (phen-1,4-diyl)-oxymethanediyl, or (piperidin-1,4-diyl)ethynediyl. In another embodiment, in any one of Formulae **EC-1** to **EC-6**, A^E is piperidin-1,3-diyl. In yet another embodiment, in any one of Formulae **EC-1** to **EC-6**, A^E is piperidin-1,4-diyl. In yet another embodiment, in any one of Formulae **EC-1** to **EC-6**, A^E is piperazin-1,4-diyl. In yet another embodiment, in any one of Formulae **EC-1** to **EC-6**, A^E is (phen-1,4-diyl)oxymethanediyl. In yet another embodiment, in any one of Formulae **EC-1** to **EC-6**, A^E is (piperidin-1,4-diyl)ethynediyl. In still another embodiment, in any one of Formulae **EC-1** to **EC-6**, A^E is 1-(piperidin-1,4-diyl)ethynediyl.

[00154] In one embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-1**, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-2**, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-3**, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-4**, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-5**, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In still another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a

moiety having the structure of Formula **EC-6**, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

[00155] In certain embodiments, R^E is a moiety having the structure of:






or an enantiomer, a mixture of enantiomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

[00156] In one embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-7**, or an enantiomer, a mixture of enantiomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-8**, or an enantiomer, a mixture of enantiomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-9**, or an enantiomer, a mixture of enantiomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-10**, or an enantiomer, a mixture of enantiomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-11**, or an enantiomer, a mixture of enantiomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-12**, or an enantiomer, a mixture of enantiomers, a

tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-13**, or an enantiomer, a mixture of enantiomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-14**, or an enantiomer, a mixture of enantiomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-15**, or an enantiomer, a mixture of enantiomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-16**, or an enantiomer, a mixture of enantiomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-17**, or an enantiomer, a mixture of enantiomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-18**, or an enantiomer, a mixture of enantiomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-19**, or an enantiomer, a mixture of enantiomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-20**, or an enantiomer, a mixture of enantiomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In still another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-21**, or an enantiomer, a mixture of enantiomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

[00157] In certain embodiments, R^E is a moiety having the structure of:



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein A^E is as defined herein.


[00158] In one embodiment, in Formula **EC-22** or **EC-23**, A^E is a bond, —O—, —NH—, ethynediyl, piperidindiyl, piperazindiyl, (phendiyl)oxymethanediyl, or (piperidindiyl)ethynediyl. In another embodiment, in Formula **EC-22** or **EC-23**, A^E is a bond. In yet another embodiment, in Formula **EC-22** or **EC-23**, A^E is —O—. In yet another embodiment, in Formula **EC-22** or **EC-23**, A^E is —NH—. In yet another embodiment, in Formula **EC-22** or **EC-23**, A^E is ethynediyl. In yet another embodiment, in Formula **EC-22** or **EC-23**, A^E is piperidindiyl. In yet another embodiment, in Formula **EC-22** or **EC-23**, A^E is piperazindiyl. In yet another embodiment, in Formula **EC-22** or **EC-23**, A^E is (phendiyl)oxymethanediyl. In still another embodiment, in Formula **EC-22** or **EC-23**, A^E is (piperidindiyl)ethynyl.

[00159] In one embodiment, in Formula **EC-22** or **EC-23**, A^E is a bond, —O—, —NH—, ethynediyl, piperidin-1,3-diyl, piperidin-1,4-diyl, piperazin-1,4-diyl, (phen-1,4-diyl)oxy-methanediyl, or (piperidin-1,4-diyl)ethynediyl. In another embodiment, in Formula **EC-22** or **EC-23**, A^E is piperidin-1,3-diyl. In yet another embodiment, in Formula **EC-22** or **EC-23**, A^E is piperidin-1,4-diyl. In yet another embodiment, in Formula **EC-22** or **EC-23**, A^E is piperazin-1,4-diyl. In yet another embodiment, in Formula **EC-22** or **EC-23**, A^E is (phen-1,4-diyl)oxy-methanediyl. In still another embodiment, in Formula **EC-22** or **EC-23**, A^E is (piperidin-1,4-diyl)ethynediyl.

[00160] In one embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-22**, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of

Formula **EC-23**, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.


[00161] In certain embodiments, R^E is a moiety having the structure of:



or an enantiomer, a mixture of enantiomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

[00162] In one embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-24**, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-25**, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-26**, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In still another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-27**, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.


[00163] In certain embodiments, R^E is a moiety having the structure of:



or an enantiomer, a mixture of enantiomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein A^E is as defined herein.

[00164] In one embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-28**, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-29**, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.


[00165] In certain embodiments, R^E is a moiety having the structure of:



or an enantiomer, a mixture of enantiomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

[00166] In one embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-30**, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-31**, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-32**, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In still another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-33**, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

[00167] In certain embodiments, R^E is a moiety having the structure of:





or an enantiomer, a mixture of enantiomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein A^E is as defined herein.

[00168] In one embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-34**, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of

two or more tautomers, or an isotopic variant thereof. In another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-35**, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-36**, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-37**, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-38**, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In still another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-39**, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

[00169] In certain embodiments, R^E is a moiety having the structure of:






or an enantiomer, a mixture of enantiomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

[00170] In one embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-40**, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-41**, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-42**, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-43**, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-44**, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a


moiety having the structure of Formula **EC-45**, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-46**, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-47**, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-48**, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-48**, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-50**, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In still another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EC-51**, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

[00171] In one embodiment, provided herein is a compound of Formula (IX):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^2 , R^{3a} , R^{3b} , R^{3c} , R^{3d} , R^{3e} , R^{4a} , R^{E1} , R^{E2} , A^E , L , X , Y , Z , Z^1 , Z^2 , Z^3 , Z^4 , a , and m are each as defined herein.

[00172] In another embodiment, provided herein is a compound of Formula (X):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^2 , R^{3a} , R^{3b} , R^{3c} , R^{3d} , R^{3e} , R^{4a} , R^{E1} , R^{E2} , A^E , L , X , Z , and a are each as defined herein.

[00173] In yet another embodiment, provided herein is a compound of Formula (XI):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^{3b} , R^{3c} , A^E , and L are each as defined herein.

[00174] In yet another embodiment, provided herein is a compound of Formula (XII):




or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R¹, R^{3b}, R^{3c}, A^E, and L are each as defined herein.

[00175] In yet another embodiment, provided herein is a compound of Formula (XIII):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R¹, R^{3b}, R^{3c}, and L are each as defined herein.

[00176] In still another embodiment, provided herein is a compound of Formula (XIV):




or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R¹, R^{3b}, R^{3c}, and L are each as defined herein.

[00177] In one embodiment, provided herein is a compound of Formula (XV):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^2 , R^4 , R^{3a} , R^{3b} , R^{3c} , R^{3d} , R^{3e} , R^{E1} , R^{E2} , A^E , L , X , Y , Z , Z^1 , Z^2 , Z^3 , Z^4 , and m are each as defined herein.

[00178] In another embodiment, provided herein is a compound of Formula (XVI):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^2 , R^4 , R^{3a} , R^{3b} , R^{3c} , R^{3d} , R^{3e} , R^{E1} , R^{E2} , A^E , L , X , and Z are each as defined herein.


[00179] In yet another embodiment, provided herein is a compound of Formula (XVII):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more


diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^4 , R^{3b} , R^{3c} , A^E , and L are each as defined herein.

[00180] In yet another embodiment, provided herein is a compound of Formula (XVIII):




or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^4 , R^{3b} , R^{3c} , A^E , and L are each as defined herein.

[00181] In yet another embodiment, provided herein is a compound of Formula (XIX):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^4 , R^{3b} , R^{3c} , and L are each as defined herein.

[00182] In still another embodiment, provided herein is a compound of Formula (XX):




or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R¹, R⁴, R^{3b}, R^{3c}, and L are each as defined herein.

[00183] In one embodiment, provided herein is a compound of Formula (XXI):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R¹, R², R^{3a}, R^{3b}, R^{3c}, R^{3d}, R^{3e}, R^{4a}, R^{E1}, R^{E2}, R^{E4}, A^E, L, X, Y, Z, a, m, and n are each as defined herein.


[00184] In another embodiment, provided herein is a compound of Formula (XXII):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R¹, R², R^{3a}, R^{3b}, R^{3c}, R^{3d}, R^{3e}, R^{4a}, R^{E1}, R^{E2}, R^{E5}, A^E, L, X, Z, and a are each as defined herein. In one


embodiment, R^{E5} is hydrogen or fluoro.

[00185] In yet another embodiment, provided herein is a compound of Formula (XXIII):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^{3b} , R^{3c} , R^{E5} , A^E , and L are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.

[00186] In yet another embodiment, provided herein is a compound of Formula (XXIV):



or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^{3b} , R^{3c} , R^{E5} , A^E , and L are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.


[00187] In yet another embodiment, provided herein is a compound of Formula (XXV):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more


diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^{3b} , R^{3c} , R^{E5} , and L are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.


[00188] In still another embodiment, provided herein is a compound of Formula (XXVI):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^{3b} , R^{3c} , R^{E5} , and L are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.


[00189] In one embodiment, provided herein is a compound of Formula (XXVII):






or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R¹, R^{3b}, R^{3c}, R^{E5}, A^E, and L are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.

[00191] In yet another embodiment, provided herein is a compound of Formula (XXIX):




or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R¹, R^{3b}, R^{3c}, R^{E5}, A^E, and L are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.

[00192] In yet another embodiment, provided herein is a compound of Formula (XXX):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R¹, R^{3b}, R^{3c}, R^{E5}, and L are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.

[00193] In still another embodiment, provided herein is a compound of Formula (XXXI):




or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^{3b} , R^{3c} , R^{E5} , and L are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.

[00194] In one embodiment, provided herein is a compound of Formula (XXXII):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^2 , R^4 , R^{3a} , R^{3b} , R^{3c} , R^{3d} , R^{3e} , R^{E1} , R^{E2} , R^{E4} , A^E , L , X , Y , Z , m , and n are each as defined herein.


[00195] In another embodiment, provided herein is a compound of Formula (XXXIII):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^2 , R^4 , R^{3a} ,


R^{3b} , R^{3c} , R^{3d} , R^{3e} , R^{E1} , R^{E2} , R^{E5} , A^E , L , X , and Z are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.

[00196] In yet another embodiment, provided herein is a compound of Formula (XXXIV):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^4 , R^{3b} , R^{3c} , R^{E5} , A^E , and L are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.

[00197] In yet another embodiment, provided herein is a compound of Formula (XXXV):




or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^4 , R^{3b} , R^{3c} , R^{E5} , A^E , and L are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.

[00198] In yet another embodiment, provided herein is a compound of Formula (XXXVI):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R¹, R⁴, R^{3b}, R^{3c}, R^{E5}, and L are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.

[00199] In still another embodiment, provided herein is a compound of Formula (XXXVII):




or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R¹, R⁴, R^{3b}, R^{3c}, R^{E5}, and L are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.

[00200] In one embodiment, provided herein is a compound of Formula (XXXVIII):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^2 , R^4 , R^{3a} , R^{3b} , R^{3c} , R^{3d} , R^{3e} , R^{E1} , R^{E2} , R^{E5} , A^E , L , X , and Z are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.

[00201] In another embodiment, provided herein is a compound of Formula (XXXIX):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^4 , R^{3b} , R^{3c} , R^{E5} , A^E , and L are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.

[00202] In yet another embodiment, provided herein is a compound of Formula (XL):




or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R¹, R⁴, R^{3b}, R^{3c}, R^{E5}, A^E, and L are each as defined herein.

[00203] In yet another embodiment, provided herein is a compound of Formula (XLI):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R¹, R⁴, R^{3b}, R^{3c}, R^{E5}, and L are each as defined herein.

[00204] In still another embodiment, provided herein is a compound of Formula (XLII):



or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R¹, R⁴, R^{3b}, R^{3c}, R^{E5}, and L are each as defined herein.

[00205] In certain embodiments, in any one of Formulae (IX) to (XLII), R¹ is (i) C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more substituents Q; or (ii) -OR^{1a} or -NR^{1b}R^{1c}; wherein R^{1a}, R^{1b}, and R^{1c} are each as

defined herein. In certain embodiments, in any one of Formulae (IX) to (XLII), R¹ is C₁₋₆ alkyl or C₃₋₁₀ cycloalkyl, each of which is optionally substituted with one or more substituents Q. In certain embodiments, in any one of Formulae (IX) to (XLII), R¹ is C₁₋₆ alkyl, optionally substituted with one or more substituents Q. In certain embodiments, in any one of Formulae (IX) to (XLII), R¹ is methyl or cyclopropylmethyl. In certain embodiments, in any one of Formulae (IX) to (XLII), R¹ is methyl. In certain embodiments, in any one of Formulae (IX) to (XLII), R¹ is C₃₋₁₀ cycloalkyl, optionally substituted with one or more substituents Q. In certain embodiments, in any one of Formulae (IX) to (XLII), R¹ is cyclopropyl.

[00206] In certain embodiments, in any one of Formulae (IX) to (XLII), R^{3b} is C₁₋₆ alkyl, C₁₋₆ heteroalkyl, C₃₋₁₀ cycloalkyl, C₆₋₁₄ aryl, C₇₋₁₅ aralkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more substituents Q. In certain embodiments, in any one of Formulae (IX) to (XLII), R^{3b} is C₁₋₆ alkyl, C₁₋₆ heteroalkyl, or C₃₋₁₀ cycloalkyl, each of which is optionally substituted with one or more substituents Q. In certain embodiments, in any one of Formulae (IX) to (XLII), R^{3b} is C₁₋₆ alkyl, optionally substituted with one or more substituents Q. In certain embodiments, in any one of Formulae (IX) to (XLII), R^{3b} is methyl, ethyl, or cyclopropylmethyl. In certain embodiments, in any one of Formulae (IX) to (XLII), R^{3b} is ethyl. In certain embodiments, in any one of Formulae (IX) to (XLII), R^{3b} is C₃₋₁₀ cycloalkyl, optionally substituted with one or more substituents Q. In certain embodiments, in any one of Formulae (IX) to (XLII), R^{3b} is cyclopropyl.

[00207] In certain embodiments, in any one of Formulae (IX) to (XLII), R^{3c} is C₁₋₆ alkyl, C₁₋₆ heteroalkyl, C₃₋₁₀ cycloalkyl, C₆₋₁₄ aryl, C₇₋₁₅ aralkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more substituents Q. In certain embodiments, in any one of Formulae (IX) to (XLII), R^{3c} is C₁₋₆ alkyl, C₁₋₆ heteroalkyl, or C₃₋₁₀ cycloalkyl, each of which is optionally substituted with one or more substituents Q. In certain embodiments, in any one of Formulae (IX) to (XLII), R^{3c} is C₁₋₆ alkyl, optionally substituted with one or more substituents Q. In certain embodiments, in any one of Formulae (IX) to (XLII), R^{3c} is methyl, ethyl, or cyclopropylmethyl. In certain embodiments, in any one of Formulae (IX) to (XLII), R^{3c} is methyl. In certain embodiments, in any one of Formulae (IX) to (XLII), R^{3c} is C₃₋₁₀ cycloalkyl, optionally substituted with one or more substituents Q. In certain embodiments, in any one of Formulae (IX) to (XLII), R^{3c} is cyclopropyl.


[00208] In certain embodiments, in any one of Formulae (IX) to (XLII), R^{3b} and R^{3c} are each independently C_{1-6} alkyl, optionally substituted with one or more substituents Q. In certain embodiments, in any one of Formulae (IX) to (XLII), R^{3b} and R^{3c} are each independently methyl or ethyl. In certain embodiments, in any one of Formulae (IX) to (XLII), R^{3b} is methyl and R^{3c} is ethyl. In certain embodiments, in any one of Formulae (IX) to (XLII), R^{3b} is ethyl and R^{3c} is methyl.

[00209] In certain embodiments, in any one of Formulae (XV) to (XX) and (XXXII) to (XLII), R^4 is hydrogen, deuterium, halo, $-NR^{1b}R^{1c}$, or $-NR^{1a}C(O)R^{1d}$, wherein R^{1a} , R^{1b} , R^{1c} , and R^{1d} are each as defined herein. In certain embodiments, in any one of Formulae (XV) to (XX) and (XXXII) to (XLII), R^4 is hydrogen. In certain embodiments, in any one of Formulae (XV) to (XX) and (XXXII) to (XLII), R^4 is deuterium. In certain embodiments, in any one of Formulae (XV) to (XX) and (XXXII) to (XLII), R^4 is halo. In certain embodiments, in any one of Formulae (XV) to (XX) and (XXXII) to (XLII), R^4 is $-NR^{1b}R^{1c}$, wherein R^{1b} and R^{1c} are each as defined herein. In certain embodiments, in any one of Formulae (XV) to (XX) and (XXXII) to (XLII), R^4 is $-NH_2$. In certain embodiments, in any one of Formulae (XV) to (XX) and (XXXII) to (XLII), R^4 is $-NR^{1a}C(O)R^{1d}$, wherein R^{1a} and R^{1d} are each as defined herein. In certain embodiments, in any one of Formulae (XV) to (XX) and (XXXII) to (XLII), R^4 is $-NHC(O)R^{1d}$, wherein R^{1d} is C_{1-6} alkyl optionally substituted with one or more substituents Q. In certain embodiments, in any one of Formulae (XV) to (XX) and (XXXII) to (XLII), R^4 is $-NHC(O)CH_3$.

[00210] In certain embodiments, in any one of Formulae (XXII) to (XVIV), (XXVII) to (XXXI), (XXXIII) to (XLII), R^{E5} is hydrogen. In certain embodiments, in any one of Formulae (XXII) to (XVIV), (XXVII) to (XXXI), (XXXIII) to (XLII), R^{E5} is fluoro.


[00211] In one embodiment, in any one of Formulae (IX) to (XLII),
 R^1 is methyl or cyclopropylmethyl;
 R^2 , if present, is hydrogen or deuterium;
 R^{3b} and R^{3c} are each independently methyl or ethyl;
 R^4 , if present, is hydrogen or $-NHC(O)CH_3$;
 R^{E5} , if present, is hydrogen or fluoro; and
X, if present, is $-CH_2-$ or $-C(O)-$.

[00212] In one embodiment, provided herein is a compound of Formula (VIA):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^5 , R^6 , R^{7a} , R^{7b} , R^{7c} , R^{7d} , R^{E1} , R^{E2} , A^E , L , Z , Z^1 , Z^2 , Z^3 , Z^4 , and m are each as defined herein.

[00213] In another embodiment, provided herein is a compound of Formula (VIIA):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^5 , R^6 , R^{7a} , R^{7b} , R^{7c} , R^{7d} , R^{E1} , R^{E2} , A^E , L , and Z are each as defined herein.

[00214] In yet another embodiment, provided herein is a compound of Formula (VIII A):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^5 , R^{7a} , R^{7d} , A^E , and L are each as defined herein.

[00215] In still another embodiment, provided herein is a compound of Formula (IXA):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R⁵, R^{7a}, R^{7d}, and L are each as defined herein.

[00216] In one embodiment, provided herein is a compound of Formula (XA):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R⁵, R⁶, R^{7a}, R^{7b}, R^{7c}, R^{7d}, R^{E1}, R^{E2}, R^{E5}, A^E, L, and Z are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.

[00217] In another embodiment, provided herein is a compound of Formula (XIA):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R⁵, R^{7a}, R^{7d}, R^{E5}, A^E, and L are each as defined herein.

[00218] In yet another embodiment, provided herein is a compound of Formula (XIIA):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^5 , R^{7a} , R^{7d} , R^{E5} , and L are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.

[00219] In one embodiment, provided herein is a compound of Formula (XIIIA):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^5 , R^6 , R^{7a} , R^{7b} , R^{7c} , R^{7d} , R^{E1} , R^{E2} , R^{E5} , A^E , L, and Z are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.


[00220] In another embodiment, provided herein is a compound of Formula (XIVA):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or


a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^5 , R^{7a} , R^{7d} , R^{E5} , A^E , and L are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.

[00221] In yet another embodiment, provided herein is a compound of Formula (XVA):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^5 , R^{7a} , R^{7d} , R^{E5} , and L are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.

[00222] In one embodiment, provided herein is a compound of Formula (XVIA):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^5 , R^6 , R^{7a} , R^{7b} , R^{7c} , R^{7d} , R^{E1} , R^{E2} , A^E , L , Z , Z^1 , Z^2 , Z^3 , Z^4 , and m are each as defined herein.


[00223] In another embodiment, provided herein is a compound of Formula (XVIIA):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or


a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^5 , R^6 , R^{7a} , R^{7b} , R^{7c} , R^{7d} , R^{E1} , R^{E2} , A^E , L , and Z are each as defined herein.

[00224] In yet another embodiment, provided herein is a compound of Formula (XVIII):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R⁵, R^{7a}, R^{7d}, A^E, and L are each as defined herein.

[00225] In still another embodiment, provided herein is a compound of Formula (XIXA):



or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R⁵, R^{7a}, R^{7d}, and L are each as defined herein


[00226] In one embodiment, provided herein is a compound of Formula (XXA):



[00227] or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R⁵, R⁶, R^{7a}, R^{7b}, R^{7c}, R^{7d}, R^{E1}, R^{E2}, R^{E5}, A^E, L, and Z are each as defined herein. In one embodiment,


R^{E5} is hydrogen or fluoro.

[00228] In another embodiment, provided herein is a compound of Formula (XXIA):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R⁵, R^{7a}, R^{7d}, R^{E5}, A^E, and L are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.

[00229] In yet another embodiment, provided herein is a compound of Formula (XXIIA):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R⁵, R^{7a}, R^{7d}, R^{E5}, and L are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.


[00230] In one embodiment, provided herein is a compound of Formula (XXIII A):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R⁵, R⁶, R^{7a}, R^{7b},


R^{7c} , R^{7d} , R^{E1} , R^{E2} , R^{E5} , A^E , L , and Z are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.

[00231] In another embodiment, provided herein is a compound of Formula (XXIVA):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^5 , R^{7a} , R^{7d} , R^{E5} , A^E , and L are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.

[00232] In yet another embodiment, provided herein is a compound of Formula (XXVA):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^5 , R^{7a} , R^{7d} , R^{E5} , and L are each as defined herein. In one embodiment, R^{E5} is hydrogen or fluoro.

[00233] In certain embodiments, in any one of Formulae (VIA) or (XXVA), R^5 is (i) hydrogen or deuterium; (ii) C_{1-6} alkyl, optionally substituted with one or more substituents Q ; or (iii) $-OR^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, in any one of Formulae (VIA) or (XXVA), R^5 is hydrogen or deuterium. In certain embodiments, in any one of Formulae (VIA) or (XXVA), R^5 is C_{1-6} alkyl, optionally substituted with one or more substituents Q . In certain embodiments, in any one of Formulae (VIA) or (XXVA), R^5 is $-OR^{1a}$, wherein R^{1a} is as defined herein. In certain embodiments, in any one of Formulae (VIA) or (XXVA), R^5 is $-OR^{1a}$, wherein R^{1a} is C_{1-6} alkyl optionally substituted with one or more substituents Q . In certain embodiments, in any one of Formulae (VIA) or (XXVA), R^5 is methoxy, difluoromethoxy, trifluoromethoxy, ethoxy, or cyclopropylmethoxy. In certain


embodiments, in any one of Formulae (VIA) or (XXVA), R⁵ is difluoromethoxy or cyclopropylmethoxy.

[00234] In certain embodiments, in any one of Formulae (VIA) or (XXVA), R^{7a} is hydrogen, deuterium, halo, or C₁₋₆ alkyl optionally substituted with one or more substituents Q. In certain embodiments, in any one of Formulae (VIA) or (XXVA), R^{7a} is hydrogen, halo, or C₁₋₆ alkyl optionally substituted with one or more substituents Q. In certain embodiments, in any one of Formulae (VIA) or (XXVA), R^{7a} is hydrogen. In certain embodiments, in any one of Formulae (VIA) or (XXVA), R^{7a} is deuterium. In certain embodiments, in any one of Formulae (VIA) or (XXVA), R^{7a} is halo. In certain embodiments, in any one of Formulae (VIA) or (XXVA), R^{7a} is chloro. In certain embodiments, in any one of Formulae (VIA) or (XXVA), R^{7a} is C₁₋₆ alkyl optionally substituted with one or more substituents Q. In certain embodiments, in any one of Formulae (VIA) or (XXVA), R^{7a} is methyl, optionally substituted with one or more substituents Q. In certain embodiments, in any one of Formulae (VIA) or (XXVA), R^{7a} is trifluoromethyl.

[00235] In certain embodiments, in any one of Formulae (VIA) or (XXVA), R^{7d} is hydrogen, deuterium, halo, or C₁₋₆ alkyl optionally substituted with one or more substituents Q. In certain embodiments, in any one of Formulae (VIA) or (XXVA), R^{7d} is hydrogen, halo, or C₁₋₆ alkyl optionally substituted with one or more substituents Q. In certain embodiments, in any one of Formulae (VIA) or (XXVA), R^{7d} is hydrogen. In certain embodiments, in any one of Formulae (VIA) or (XXVA), R^{7d} is deuterium. In certain embodiments, in any one of Formulae (VIA) or (XXVA), R^{7d} is halo. In certain embodiments, in any one of Formulae (VIA) or (XXVA), R^{7d} is chloro. In certain embodiments, in any one of Formulae (VIA) or (XXVA), R^{7d} is C₁₋₆ alkyl optionally substituted with one or more substituents Q. In certain embodiments, in any one of Formulae (VIA) or (XXVA), R^{7d} is methyl, optionally substituted with one or more substituents Q. In certain embodiments, in any one of Formulae (VIA) or (XXVA), R^{7d} is trifluoromethyl.


[00236] In certain embodiments, in any one of Formulae (XA) to (XVA) and (XXA) to (XXVA), R^{E5} is hydrogen. In certain embodiments, in any one of Formulae (XA) to (XVA) and (XXA) to (XXVA), R^{E5} is fluoro.

[00237] In certain embodiments, R^E is a moiety of an IAP E3 ligand. In certain embodiments, R^E is a moiety of an IAP E3 ligand having the structure of:



or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

[00238] In certain embodiments, R^E is a moiety having the structure of:




or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

[00239] In one embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety of compound **EI-1**, or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety of compound **EI-2**, or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

[00240] In one embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EI-3**, or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

[00241] In certain embodiments, R^E is a moiety of an MDM2 E3 ligand. In certain embodiments, R^E is a moiety of an MDM2 E3 ligand having the structure of:




or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

[00242] In one embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety of compound **EM-1**, or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

[00243] In certain embodiments, R^E is a moiety of a VHL E3 ligand.

[00244] In certain embodiments, R^E has the structure of Formula (EV-I):




or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein:

R^{E6} , R^{E8} , and R^{E9} are each independently hydrogen, deuterium, C_{1-6} alkyl, or C_{3-10} cycloalkyl; and

R^{E7} is hydrogen, deuterium, halo, hydroxyl, $-OC_{1-6}$ alkyl, or $-OC_{3-10}$ cycloalkyl;

wherein each alkyl and cycloalkyl is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q.

[00245] In certain embodiments, R^E has the structure of Formula (EV-II):




or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein:

R^{E10} is $-NHC(O)C_{1-6}$ alkyl, $-NHC(O)C_{3-10}$ cycloalkyl, or heterocyclyl, wherein the alkyl, cycloalkyl, and heterocyclyl are each optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q; and

R^{E6} , R^{E7} , and R^{E8} are each as defined herein.

[00246] In certain embodiments, R^E has the structure of Formula (EV-III):



or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein R^{E6} , R^{E8} , R^{E9} , and R^{E10} are each as defined herein.

[00247] In certain embodiments, in any one of Formulae (EV-I) to (EV-III),

R^{E6} is methyl;

R^{E7} , if present, is hydrogen;

R^{E8} is hydrogen;

R^{E9} , if present, is propyl, butyl, or cyclopropyl; and

R^{E10} , if present, is acetamido, cyclopropamido, or isoindolinyl;

wherein the propyl, butyl, cyclopropyl, acetamido, cyclopropamido, and isoindolinyl are each optionally substituted with cyano, fluoro, or trifluoromethyl.

[00248] In certain embodiments, in any one of Formulae (EV-I) to (EV-III),

R^{E6} is methyl;

R^{E7} , if present, is hydrogen;


R^{E8} is hydrogen;


R^{E9} , if present, is isopropyl, *tert*-butyl, cyclopropyl, 1-fluorocyclopropyl, or 1-trifluoromethylcyclopropyl; and

R^{E10} , if present, is acetamido, cyclopropamido, 1-cyanocyclopropamido, 1-fluorocyclopropamido, or 1-oxoisindolin-2-yl.

[00249] In one embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EV-I), or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EV-II), or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula (EV-III), or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

[00250] In certain embodiments, R^E is a moiety of a VHL E3 ligand having the structure of:






or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

[00251] In one embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety of compound **EV-1**, or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety of compound **EV-2**, or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety of compound **EV-3**, or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety of compound **EV-4**, or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety of compound **EV-5**, or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety of compound **EV-6**, or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In still another


embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety of compound **EV-7**, or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

[00252] In certain embodiments, R^E is a moiety having the structure of:



or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

[00253] In certain embodiments, R^E is a moiety having the structure of:




or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

[00254] In one embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EV-8**, or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EV-9**, or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EV-10**, or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EV-11**, or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EV-12**, or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EV-13**, or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In yet another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a moiety having the structure of Formula **EV-14**, or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof. In still another embodiment, in a compound of any one of Formulae (I) to (VIII) and (IA) to (VA), R^E is a


moiety having the structure of Formula **EV-15**, or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

[00255] In one embodiment, provided herein is a compound of Formula (XLIII):




or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R¹, R², R^{3a}, R^{3b}, R^{3c}, R^{3d}, R^{3e}, R^{4a}, R^{E6}, R^{E7}, R^{E8}, R^{E9}, L, X, Y, and a are each as defined herein.

[00256] In another embodiment, provided herein is a compound of Formula (XLIV):




or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R¹, R^{3b}, R^{3c}, and L are each as defined herein.

[00257] In one embodiment, provided herein is a compound of Formula (XLV):




or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^2 , R^4 , R^{3a} , R^{3b} , R^{3c} , R^{3d} , R^{3e} , R^{E6} , R^{E7} , R^{E8} , R^{E9} , L, X, and Y are each as defined herein.

[00258] In another embodiment, provided herein is a compound of Formula (XLVI):




or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^1 , R^4 , R^{3b} , R^{3c} , and L are each as defined herein.

[00259] In one embodiment, provided herein is a compound of Formula (XXVIA):




or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R^5 , R^6 , R^{7a} , R^{7b} , R^{7c} , R^{7d} , R^{E6} , R^{E7} , R^{E8} , R^{E9} , and L are each as defined herein.

[00260] In another embodiment, provided herein is a compound of Formula (XXVIIA):




or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R⁵, R^{7a}, R^{7d}, and L are each as defined herein.

[00261] In one embodiment, provided herein is a compound of Formula (XXVIII A):



or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R⁵, R⁶, R^{7a}, R^{7b}, R^{7c}, R^{7d}, R^{E6}, R^{E7}, R^{E8}, R^{E9}, and L are each as defined herein.

[00262] In another embodiment, provided herein is a compound of Formula (XXIXA):



or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate,

or prodrug thereof; wherein R^5 , R^{7a} , R^{7d} , and L are each as defined herein.

[00263] In certain embodiments, L is C_{1-20} alkylene, C_{1-20} heteroalkylene, C_{2-20} alkenylene, C_{2-20} heteroalkenylene, C_{2-20} alkynylene, C_{2-20} heteroalkynylene, C_{3-10} cycloalkylene, C_{6-14} arylene, heteroarylene, or heterocyclylene, each of which is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q. In certain embodiments, L is C_{1-20} alkylene, C_{1-20} heteroalkylene, C_{2-20} alkenylene, C_{2-20} heteroalkenylene, C_{2-20} alkynylene, or C_{2-20} heteroalkynylene, each of which is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q. In certain embodiments, L is C_{1-20} alkylene or C_{1-20} heteroalkylene, each of which is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q.

[00264] In certain embodiments, L is C_{1-20} alkylene, optionally substituted with one, two, or three substituents Q. In certain embodiments, L is C_{4-16} alkylene, optionally substituted with one, two, or three substituents Q. In certain embodiments, L is C_{4-12} alkylene, optionally substituted with one, two, or three substituents Q. In certain embodiments, L is C_{1-20} alkylene, optionally substituted with one or two oxo. In certain embodiments, L is C_{4-16} alkylene, optionally substituted with one or two oxo. In certain embodiments, L is C_{4-12} alkylene, optionally substituted with one or two oxo. In certain embodiments, L is $-(CH_2)_p-$, optionally substituted with one or two oxo; wherein p is an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16. In certain embodiments, L is $-(CH_2)_p-$, optionally substituted with one or two oxo; wherein p is an integer of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12. In certain embodiments, L is $-(CH_2)_p-$, optionally substituted with one or two oxo; wherein p is an integer of 5, 6, 7, 8, or 9.

[00265] In certain embodiments, L is C_{1-20} heteroalkylene, optionally substituted with one, two, or three substituents Q. In certain embodiments, L is C_{4-16} heteroalkylene, optionally substituted with one, two, or three substituents Q. In certain embodiments, L is C_{4-12} heteroalkylene, optionally substituted with one, two, or three substituents Q. In certain embodiments, L is C_{1-20} heteroalkylene, optionally substituted with one, two, or three oxo. In certain embodiments, L is C_{4-16} heteroalkylene, optionally substituted with one, two, or three oxo. In certain embodiments, L is C_{4-12} heteroalkylene, optionally substituted with one, two, or three oxo.

[00266] In certain embodiments, L is C₂₋₂₀ heteroalkylene comprising an ethyleneoxy (–CH₂CH₂O–) group, optionally substituted with one or more substituents Q. In certain embodiments, L is C₂₋₁₄ heteroalkylene comprising an ethyleneoxy group, optionally substituted with one or more substituents Q. In certain embodiments, L is C₂₋₁₀ heteroalkylene comprising an ethyleneoxy group, optionally substituted with one or more substituents Q. In certain embodiments, L is C₃₋₂₀ heteroalkylene comprising a propyleneoxy (–CH₂CH₂CH₂O–) group, optionally substituted with one or more substituents Q. In certain embodiments, L is C₃₋₁₄ heteroalkylene comprising a propyleneoxy group, optionally substituted with one or more substituents Q. In certain embodiments, L is C₃₋₁₀ heteroalkylene comprising a propyleneoxy group, optionally substituted with one or more substituents Q.

[00267] In certain embodiments, L is C₁₋₂₀ alkylene, C₁₋₂₀ heteroalkylene, C₂₋₂₀ alkenylene, C₂₋₂₀ heteroalkenylene, C₂₋₂₀ alkynylene, or C₂₋₂₀ heteroalkynylene, wherein one or more methylene groups are each independently replaced by a divalent group, and each divalent group is independently C₃₋₁₀ cycloalkylene, C₆₋₁₄ arylene, heteroarylene, or heterocyclylene; and wherein the alkylene, heteroalkylene, alkenylene, heteroalkenylene, alkynylene, heteroalkynylene, cycloalkylene, arylene, heteroarylene, and heterocyclylene are each optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q. In certain embodiments, L is C₁₋₂₀ alkylene or C₁₋₂₀ heteroalkylene, wherein one or more methylene groups are each independently replaced by a divalent group, and each divalent group is independently C₃₋₁₀ cycloalkylene, C₆₋₁₄ arylene, heteroarylene, or heterocyclylene; and wherein the alkylene, heteroalkylene, cycloalkylene, arylene, heteroarylene, and heterocyclylene are each optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q.

[00268] In certain embodiments, L is C₁₋₂₀ alkylene, wherein one or more methylene groups are each independently replaced by a divalent group, and each divalent group is independently C₃₋₁₀ cycloalkylene, C₆₋₁₄ arylene, heteroarylene, or heterocyclylene; and wherein the alkylene, cycloalkylene, arylene, heteroarylene, and heterocyclylene are each optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q. In certain embodiments, L is C₁₋₂₀ alkylene, wherein one or two methylene groups are each independently replaced by C₃₋₁₀ cycloalkylene; and wherein the alkylene and cycloalkylene are

each optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q. In certain embodiments, L is C₁₋₂₀ alkylene, wherein one or two methylene groups are each independently replaced by C₆₋₁₄ arylene; and wherein the alkylene and arylene are each optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q. In certain embodiments, L is C₁₋₂₀ alkylene, wherein one or two methylene groups are each independently replaced by heteroarylene; and wherein the alkylene and heteroarylene are each optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q. In certain embodiments, L is C₁₋₂₀ alkylene, wherein one or two methylene groups are each independently replaced by heterocyclylene; and wherein the alkylene and heterocyclylene are each optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q. In certain embodiments, L is C₁₋₂₀ alkylene, wherein one, two, or three methylene groups are each independently replaced by a divalent group; wherein each divalent group is independently cyclohexane-1,4-diyl, phen-1,3-diyl, phen-1,4-diyl, 1,2,3-triazol-1,4-diyl, or 2,5-dioxopyrrolidin-1,3-diyl.

[00269] In certain embodiments, L is C₁₋₂₀ alkylene, wherein one or two methylene groups are each independently replaced by a divalent group; wherein each divalent group is independently C₃₋₁₀ cycloalkylene, C₆₋₁₄ arylene, heteroarylene, or heterocyclylene; and wherein the alkylene, cycloalkylene, arylene, heteroarylene, and heterocyclylene are each optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q. In certain embodiments, L is C₁₋₂₀ alkylene, wherein one or two methylene groups are each independently replaced by a divalent group; wherein each divalent group is independently cyclohexanediyl, phendiyl, triazoldiyl, or 2,5-dioxopyrrolidindiyl. In certain embodiments, L is C₁₋₂₀ alkylene, wherein one or two methylene groups are each independently replaced by a divalent group; wherein each divalent group is independently cyclohexane-1,4-diyl, phen-1,3-diyl, phen-1,4-diyl, 1,2,3-triazol-1,4-diyl, or 2,5-dioxopyrrolidin-1,3-diyl.

[00270] In certain embodiments, L is C₁₋₂₀ alkylene, wherein a methylene group is replaced by a divalent group; wherein the divalent group is C₃₋₁₀ cycloalkylene, C₆₋₁₄ arylene, heteroarylene, or heterocyclylene; and wherein the alkylene, cycloalkylene, arylene, heteroarylene, and heterocyclylene are each optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q. In certain embodiments, L is C₁₋₂₀

alkylene, wherein a methylene group is replaced by a divalent group; wherein the divalent group is cyclohexanediyl, phendiyl, triazoldiyl, or 2,5-dioxopyrrolidindiyl. In certain embodiments, L is C₁₋₂₀ alkylene, wherein a methylene group is replaced by a divalent group; wherein each divalent group is independently cyclohexane-1,4-diyl, phen-1,3-diyl, phen-1,4-diyl, 1,2,3-triazol-1,4-diyl, or 2,5-dioxopyrrolidin-1,3-diyl.

[00271] In certain embodiments, L is C₁₋₂₀ heteroalkylene, wherein one or more methylene groups are each independently replaced by a divalent group; wherein each divalent group is independently C₃₋₁₀ cycloalkylene, C₆₋₁₄ arylene, heteroarylene, or heterocyclylene; and wherein the heteroalkylene, cycloalkylene, arylene, heteroarylene, and heterocyclylene are each optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q. In certain embodiments, L is C₁₋₂₀ heteroalkylene, wherein one, two, or three methylene groups are each independently replaced by a divalent group; wherein each divalent group is independently C₃₋₁₀ cycloalkylene, C₆₋₁₄ arylene, heteroarylene, or heterocyclylene; and wherein the heteroalkylene, cycloalkylene, arylene, heteroarylene, and heterocyclylene are each optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q. In certain embodiments, L is C₁₋₂₀ heteroalkylene, wherein one, two, or three methylene groups are each independently replaced by a divalent group; wherein each divalent group is independently cyclohexanediyl, phendiyl, triazoldiyl, or 2,5-dioxopyrrolidindiyl. In certain embodiments, L is C₁₋₂₀ alkylene, wherein one, two, or three methylene groups are each independently replaced by a divalent group; wherein each divalent group is independently cyclohexane-1,4-diyl, phen-1,3-diyl, phen-1,4-diyl, 1,2,3-triazol-1,4-diyl, or 2,5-dioxopyrrolidin-1,3-diyl.

[00272] In certain embodiments, L is C₁₋₂₀ heteroalkylene, wherein one or two methylene groups are each independently replaced by a divalent group; wherein each divalent group is independently C₃₋₁₀ cycloalkylene, C₆₋₁₄ arylene, heteroarylene, or heterocyclylene; and wherein the heteroalkylene, cycloalkylene, arylene, heteroarylene, and heterocyclylene are each optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q. In certain embodiments, L is C₁₋₂₀ heteroalkylene, wherein one or two methylene groups are each independently replaced by a divalent group; wherein each divalent group is independently cyclohexanediyl, phendiyl, triazoldiyl, or 2,5-dioxopyrrolidindiyl. In certain embodiments, L is

C₁₋₂₀ heteroalkylene, wherein one or two methylene groups are each independently replaced by a divalent group; wherein each divalent group is independently cyclohexane-1,4-diyl, phen-1,3-diyl, phen-1,4-diyl, 1,2,3-triazol-1,4-diyl, or 2,5-dioxopyrrolidin-1,3-diyl.

[00273] In certain embodiments, L is C₁₋₂₀ heteroalkylene, wherein a methylene group is replaced by a divalent group; wherein the divalent group is C₃₋₁₀ cycloalkylene, C₆₋₁₄ arylene, heteroarylene, or heterocyclylene; and wherein the heteroalkylene, cycloalkylene, arylene, heteroarylene, and heterocyclylene are each optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q. In certain embodiments, L is C₁₋₂₀ heteroalkylene, wherein a methylene group is replaced by a divalent group; wherein the divalent group is cyclohexanediyl, phendiyl, triazoldiyl, or 2,5-dioxopyrrolidindiyl. In certain embodiments, L is C₁₋₂₀ heteroalkylene, wherein a methylene group is replaced by a divalent group; wherein each divalent group is independently cyclohexane-1,4-diyl, phen-1,3-diyl, phen-1,4-diyl, 1,2,3-triazol-1,4-diyl, or 2,5-dioxopyrrolidin-1,3-diyl.

[00274] In certain embodiments, L is C₁₋₁₅ alkylene-C₃₋₁₀ cycloalkylene, C₁₋₁₅ heteroalkylene-C₃₋₁₀ cycloalkylene, C₁₋₁₅ alkylene-C₆₋₁₄ arylene, C₁₋₁₅ heteroalkylene-C₆₋₁₄ arylene, C₁₋₁₅ alkylene-heteroarylene, C₁₋₁₅ heteroalkylene-heteroarylene, C₁₋₁₅ alkylene-heterocyclylene, C₁₋₁₅ heteroalkylene-heterocyclylene, or heteroarylene-heterocyclylene, where each alkylene, heteroalkylene, cycloalkylene, arylene, heteroarylene, and heterocyclylene is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q. In certain embodiments, L is C₁₋₁₅ alkylene-C₃₋₁₀ cycloalkylene, where the alkylene and cycloalkylene are each optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q. In certain embodiments, L is C₁₋₁₅ heteroalkylene-C₃₋₁₀ cycloalkylene, where the heteroalkylene and cycloalkylene are each optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q. In certain embodiments, L is C₁₋₁₅ alkylene-C₆₋₁₄ arylene, where the alkylene and arylene are each optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q. In certain embodiments, L is C₁₋₁₅ heteroalkylene-C₆₋₁₄ arylene, where the heteroalkylene and arylene are each optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q. In certain embodiments, L is C₁₋₁₅ alkylene-heteroarylene, where the alkylene and heteroarylene are each optionally substituted with one or more, in one embodiment,

one, two, three, or four, substituents Q. In certain embodiments, L is C₁₋₁₅ heteroalkylene-heteroarylene, where the heteroalkylene and heteroarylene are each optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q. In certain embodiments, L is C₁₋₁₅ alkylene-heterocyclylene, where the alkylene and heterocyclylene are each optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q. In certain embodiments, L is C₁₋₁₅ heteroalkylene-heterocyclylene, where the heteroalkylene and heterocyclylene are each optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q. In certain embodiments, L is C₁₋₁₅ heteroarylene-heterocyclylene, where the heteroarylene and heterocyclylene are each optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q.

[00275] In certain embodiments, L has the structure of L¹-L²-L³, wherein:
L¹ is a bond, C₁₋₁₀ alkylene, C₁₋₁₀ heteroalkylene, or heterocyclylene;
L² is C₃₋₁₀ cycloalkylene, C₆₋₁₄ arylene, heteroarylene, or heterocyclylene; and
L³ is C₁₋₁₀ alkylene, C₁₋₁₀ heteroalkylene, heteroarylene, or heterocyclylene;
wherein each alkylene, heteroalkylene, cycloalkylene, arylene, heteroarylene, and heterocyclylene is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q.

[00276] In certain embodiments, L² is C₃₋₁₀ cycloalkylene, optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q. In certain embodiments, L² is monocyclic C₃₋₁₀ cycloalkylene, optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q. In certain embodiments, L² is cyclopentanedyl or cyclohexanedyl, each optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q. In certain embodiments, L² is cyclopentane-1,3-diyl or cyclohexane-1,4-diyl, each optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q.

[00277] In certain embodiments, L² is C₆₋₁₄ arylene, optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q. In certain embodiments, L² is phendiyl, optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q. In certain embodiments, L² is phen-1,4-diyl, optionally substituted with one or

more, in one embodiment, one, two, three, or four, substituents Q.

[00278] In certain embodiments, L^2 is heteroarylene, optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q. In certain embodiments, L^2 is monocyclic heteroarylene, optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q. In certain embodiments, L^2 is 5- or 6-membered heteroarylene, each optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q. In certain embodiments, L^2 is triazoldiyl, optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q. In certain embodiments, L^2 is 1,2,3-triazol-1,4-diyl, optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q.

[00279] In certain embodiments, L^2 is heterocyclylene, optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q. In certain embodiments, L^2 is monocyclic heterocyclylene, optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q. In certain embodiments, L^2 is 5- or 6-membered heterocyclylene, each optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q. In certain embodiments, L^2 is piperidindiyl or piperazindiyl, each optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q. In certain embodiments, L^2 is piperidin-1,3-diyl, piperidin-1,4-diyl, or piperazin-1,4-diyl, each optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q.

[00280] In certain embodiments, L is a linker having the structure of $-Z^L-(R^L-Z^L)_z-$, wherein:

each R^L is independently C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene, C_{3-10} cycloalkylene, C_{6-14} arylene, heteroarylene, or heterocyclylene, each of which is optionally substituted with one or more substituents Q;

each Z^L is independently a bond, $-C(O)-$, $-C(O)O-$, $-C(O)NR^{1b}-$, $-C(O)S-$, $-C(NR^{1a})NR^{1b}-$, $-C(S)-$, $-C(S)O-$, $-C(S)NR^{1b}-$, $-O-$, $-OC(O)O-$, $-OC(O)NR^{1b}-$, $-OC(O)S-$, $-OC(NR^{1a})NR^{1b}-$, $-OC(S)O-$, $-OC(S)NR^{1b}-$, $-OS(O)-$, $-OS(O)_2-$, $-OS(O)NR^{1b}-$, $-OS(O)_2NR^{1b}-$, $-NR^{1b}-$, $-NR^{1a}C(O)NR^{1b}-$, $-NR^{1a}C(O)S-$, $-NR^{1a}C(NR^{1d})NR^{1b}-$,

$-\text{NR}^{1a}\text{C}(\text{S})\text{NR}^{1b}-$, $-\text{NR}^{1a}\text{S}(\text{O})\text{NR}^{1b}-$, $-\text{NR}^{1a}\text{S}(\text{O})_2\text{NR}^{1b}-$, $-\text{S}-$, $-\text{S}(\text{O})-$, $-\text{S}(\text{O})_2-$, $-\text{S}(\text{O})\text{NR}^{1b}-$, or $-\text{S}(\text{O})_2\text{NR}^{1b}-$; where each R^{1a} and R^{1b} is as defined herein; and

z is an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

[00281] In certain embodiments, each R^L is independently C_{1-10} alkylene, C_{2-10} alkynylene, C_{3-10} cycloalkylene, C_{6-14} arylene, heteroarylene, or heterocyclylene, each optionally substituted with one or more substituents Q ; each Z^L is independently a bond, $-\text{C}(\text{O})-$, $-\text{C}(\text{O})\text{NR}^{1b}-$, $-\text{C}(\text{NR}^{1a})\text{NR}^{1b}-$, $-\text{O}-$, $-\text{OC}(\text{O})\text{NR}^{1b}-$, $-\text{NR}^{1b}-$, $-\text{NR}^{1a}\text{C}(\text{O})\text{NR}^{1b}-$, $-\text{NR}^{1a}\text{C}(\text{NR}^{1d})\text{NR}^{1b}-$, $-\text{NR}^{1a}\text{S}(\text{O})\text{NR}^{1b}-$, $-\text{NR}^{1a}\text{S}(\text{O})_2\text{NR}^{1b}-$, $-\text{S}-$, $-\text{S}(\text{O})-$, $-\text{S}(\text{O})_2-$, $-\text{S}(\text{O})\text{NR}^{1b}-$, or $-\text{S}(\text{O})_2\text{NR}^{1b}-$; and z is an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; where each R^{1a} , R^{1b} , and R^{1d} is as defined herein.


[00282] In certain embodiments, each R^L is independently C_{1-10} alkylene, C_{2-10} alkynylene, C_{3-10} cycloalkylene, C_{6-14} arylene, heteroarylene, or heterocyclylene, each optionally substituted with one or more substituents Q ; each Z^L is independently a bond, $-\text{C}(\text{O})-$, $-\text{C}(\text{O})\text{NR}^{1b}-$, $-\text{O}-$, $-\text{OC}(\text{O})\text{NR}^{1b}-$, $-\text{NR}^{1b}-$, $-\text{NR}^{1a}\text{C}(\text{O})\text{NR}^{1b}-$, or $-\text{NR}^{1a}\text{C}(\text{NR}^{1d})\text{NR}^{1b}-$; and z is an integer of 1, 2, 3, 4, 5, 6, 7, or 8; where each R^{1a} and R^{1b} is as defined herein.


[00283] In certain embodiments, each R^L is independently methanediyl, ethanediyl, propanediyl, butanediyl, pentanediyl, hexanediyl, heptanediyl, octanediyl, nonanediyl, decanediyl, undecanediyl, dodecanediyl, tridecanediyl, ethynediyl, cyclobutanediyl, cyclopentanediyl, cyclohexanediyl, cycloheptanediyl, bicyclo[2.2.2]octanediyl, phenediyl, pyrazoldiyl, imidazoldiyl, tetrazoldiyl, pyrimidindiyl, 5,6,7,8,9,10-hexahydrocycloocta[d]-pyridazindiyl, 1,3-dioxandiyl, piperazindiyl, piperidindiyl, or 3,9-diazaspiro[5.5]undecanediyl, each optionally substituted with one or more substituents Q ; each Z^L is independently a bond, $-\text{C}(\text{O})-$, $-\text{C}(\text{O})\text{O}-$, $-\text{C}(\text{O})\text{NH}-$, $-\text{OC}(\text{O})\text{NH}-$, $-\text{O}-$, $-\text{NH}-$, $-\text{N}(\text{CH}_3)-$, or $-\text{NHC}(\text{O})\text{NH}-$; and z is an integer of 1, 2, 3, 4, 5, 6, 7, or 8.

[00284] In certain embodiments, each R^L is independently methanediyl, ethane-1,2-diyl, propane-1,3-diyl, butane-1,4-diyl, pentane-1,5-diyl, hexane-1,6-diyl, heptane-1,7-diyl, octane-1,8-diyl, nonane-1,9-diyl, decane-1,10-diyl, undecane-1,11-diyl, dodecane-1,12-diyl, tridecane-1,13-diyl, ethyne-1,2-diyl, cyclobutane-1,3-diyl, cyclopentane-1,3-diyl, cyclohexane-1,3-diyl, cyclohexane-1,4-diyl, cycloheptane-1,3-diyl, cycloheptane-1,4-diyl, bicyclo[2.2.2]octane-1,4-diyl, phen-1,3-diyl, phen-1,4-diyl, pyrazol-1,3-diyl, pyrazol-1,4-diyl, imidazol-1,4-diyl, 1,2,3-


triazol-1,4-diyl, pyrimidin-2,4-diyl, pyrimidin-2,5-diyl, 5,6,7,8,9,10-hexahydrocycloocta[*d*]-pyridazin-1,7-diyl, pyrazolidin-1,3-diyl, pyrazolidin-1,4-diyl, 1,3-dioxan-2,5-diyl, piperazin-1,4-diyl, piperidin-1,3-diyl, piperidin-1,4-diyl, or 3,9-diazaspiro[5.5]-undecane-3,9-diyl, each optionally substituted with one or more substituents Q; each Z^L is independently a bond, -C(O)-, -C(O)O-, -C(O)NH-, -OC(O)NH-, -O-, -NH-, -N(CH₃)-, or -NHC(O)NH-; and z is an integer of 1, 2, 3, 4, 5, 6, 7, or 8.

[00285] In certain embodiments, L is:








[00286] In certain embodiments, L is:




[00287] In certain embodiments, L is:













[00288] In certain embodiments, L is:

















[00289] In certain embodiments, L is:




















































[00290] In certain embodiments, L is:
















wherein each R^L is independently hydrogen or C_{1-6} alkyl optionally substituted with one or more substituents Q.


[00291] In certain embodiments, L is pentan-1,5-diyl, hexan-1,6-diyl, heptan-1,7-diyl, octan-1,8-diyl, nonan-1,9-diyl, decan-1,10-diyl, undecan-1,11-diyl, piperazin-1,4-diyl,




[00292] In certain embodiments, L is pentan-1,5-diyl, heptan-1,7-diyl, nonan-1,9-diyl,



[00293] In certain embodiments, L is:





[00294] In one embodiment, provided herein is:

N-(6-(7-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)heptyl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide **A1**;

N-(6-(7-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)hept-1-yn-1-yl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide **A2**;

N-(6-(5-(4-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)ethynyl)piperidin-1-yl)-5-oxopentyl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide **A3**;

14-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)-3,6,9,12-tetraoxatetradecan-1-amide **A4**;

N-(6-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)propyl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide **A5**;

12-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)dodecanamide **A6**;

9-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-5-yl)piperidin-1-yl)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)-nonanamide **A7**;

N-(6-(7-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)piperidin-4-yl)heptyl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide **A8**;

3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)ethoxy)-ethoxy)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)propanamide **A9**;

3-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)ethoxy)-ethoxy)ethoxy)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)propanamide **A10**;

3-((4-((2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)ethoxy)-

methyl)benzyl)oxy)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)propanamide **A11**;

9-((4-((5-(2,6-dioxopiperidin-3-yl)-4-oxo-5,6-dihydro-4*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy)benzyl)amino)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)nonanamide **A12**;

9-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)-nonanamide **A13**;

N-(6-(12-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)dodecyl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide **A14**;

9-{1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl]-piperidin-4-yl}-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}nonanamide **A15**;

9-({[4-({[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]oxy}-methyl)phenyl]methyl}amino)-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}nonanamide **A16**;

N-[7-(12-{4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]piperidin-1-yl}dodecyl)-2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl]acetamide **A17**;

4-amino-7-(12-{4-[2-(2,6-Dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]piperidin-1-yl}dodecyl)-2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl)-2,3-dihydro-1*H*-isoindole-1,3-dione **A18**;

10-{4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1*H*-isoindol-5-yl]piperidin-1-yl}-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}decanamide **A19**;

9-(4-{2-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1*H*-isoindol-5-yl]ethynyl}piperidin-1-yl)-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}nonanamide **A20**;

9-{4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1*H*-isoindol-5-yl]piperidin-1-yl}-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-

dioxo-2,3-dihydro-1*H*-isoindol-4-yl}nonanamide **A21**;

8-{4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1*H*-isoindol-5-yl]piperidin-1-yl}-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}octanamide **A22**;

9-{4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1*H*-isoindol-5-yl]-1*H*-1,2,3-triazol-1-yl}-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}nonanamide **A23**;

4-[1-(2-{4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1*H*-isoindol-5-yl]piperidin-1-yl}ethyl)-1*H*-1,2,3-triazol-4-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}butanamide **A24**;

4-[(9-{4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1*H*-isoindol-5-yl]piperidin-1-yl}nonyl)amino]-2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-2,3-dihydro-1*H*-isoindole-1,3-dione **A25**;

9-{4-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1*H*-isoindol-5-yl]piperidin-1-yl}-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}nonanamide **A26**;

4-(10-{4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1*H*-isoindol-5-yl]piperidin-1-yl}decyl)-2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-2,3-dihydro-1*H*-isoindole-1,3-dione **A27**;

2-[4-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1*H*-isoindol-5-yl]piperidin-1-yl}butyl)piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}acetamide **A28**;

6-{4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1*H*-isoindol-5-yl]-[1,4'-bipiperidin]-1'-yl}-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}hexanamide **A29**;

5-{4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1*H*-isoindol-5-yl]-[1,4'-bipiperidin]-1'-yl}-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}pentanamide **A30**;

3-[4-(3-{4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1*H*-isoindol-5-yl]piperidin-1-yl}propyl)piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}propanamide **A31**;

8-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)-octanamide **A32**;

3-(2-(2-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)amino)propoxy)-ethoxy)ethoxy)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)propanamide **A33**;

N-(6-(2-(2-(2-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)amino)-propoxy)-ethoxy)ethoxy)ethyl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide **A34**;

6-(4-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)ethynyl)piperidin-1-yl)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)-6-oxohexanamide **A35**;

8-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)piperidin-1-yl)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)octanamide **A36**;

N-(6-(7-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)piperidin-1-yl)-heptyl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide **A37**;

7-((4-((5-((*S*)-2,6-dioxopiperidin-3-yl)-4-oxo-5,6-dihydro-4*H*-thieno[3,4-*c*]pyrrol-1-yl)-methoxy)benzyl)amino)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)heptanamide **A38**;

5-((4-((5-(2,6-dioxopiperidin-3-yl)-4-oxo-5,6-dihydro-4*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy)benzyl)amino)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)pentanamide **A39**;

2-{4-[(4-{[5-(2,6-dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]methoxy}phenyl)methyl]morpholin-2-yl}-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isindol-4-yl}acetamide **A40**;

3-[2-(2-{[(4-{[5-(2,6-dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]methoxy}phenyl)methyl]amino}ethoxy)ethoxy]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isindol-4-yl}propanamide **A41**;

4-[4-(2-{[(4-{[5-(2,6-dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-

1-yl]methoxy}phenyl)methyl]amino}ethyl)phenyl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}butanamide **A42**;

11-[(4-{[5-(2,6-dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]methoxy}phenyl)methyl]amino}-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}undecanamide **A43**;

4-[(9-{[(4-{[5-(2,6-dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]methoxy}phenyl)methyl]amino}nonyl)amino]-2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-2,3-dihydro-1*H*-isoindole-1,3-dione **A44**;

4-[4-(2-{[(4-{[5-(2,6-dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]methoxy}phenyl)methyl]amino}ethyl)piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}butanamide **A45**;

11-[(4-{[5-(2,6-dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]-methoxy}phenyl)methyl](methyl)amino}-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}undecanamide **A46**;

8-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)octanamide **A47**;

4-[1-(2-{[(4-{[5-(2,6-dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]methoxy}phenyl)methyl]amino}ethyl)-1*H*-1,2,3-triazol-4-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}butanamide **A48**;

4-(10-{[(4-{[5-(2,6-dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]methoxy}phenyl)methyl]amino}decyl)-2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-2,3-dihydro-1*H*-isoindole-1,3-dione **A49**;

4-[(9-{[(4-{[5-(2,6-dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]methoxy}phenyl)methyl]amino}nonyl)oxy]-2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-2,3-dihydro-1*H*-isoindole-1,3-dione **A50**;

4-({2-[4-(4-{[(4-{[5-(2,6-dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]methoxy}phenyl)methyl]amino}butyl)phenyl]ethyl}amino)-2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-2,3-dihydro-1*H*-isoindole-1,3-dione **A51**;

4-[(11-{[(4-{[5-(2,6-dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-

yl]methoxy}phenyl)methyl]amino}undecyl)amino]-2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-2,3-dihydro-1*H*-isoindole-1,3-dione **A52**;

4-({4-[4-(2-{[(4-{[5-(2,6-dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]methoxy}phenyl)methyl]amino}ethyl)phenyl]butyl}amino)-2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-2,3-dihydro-1*H*-isoindole-1,3-dione **A53**;

9-[4-(2-{[5-(2,6-dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]methoxy}acetyl)piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}nonanamide **A54**;

4-[4-(2-{[(4-{[5-(2,6-dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]methoxy}phenyl)methyl](methyl)amino}ethyl)phenyl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}butanamide **A55**;

11-(4-{[5-(2,6-dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]methoxy}phenyl)-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}undecanamide **A56**;

11-(4-{[5-(2,6-dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]methoxy}phenyl)-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}undecanamide **A57**;

8-(4-((5-(2,6-dioxopiperidin-3-yl)-4-oxo-5,6-dihydro-4*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy)phenyl)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)octanamide **A58**; or

N-(6-(7-(4-((5-(2,6-dioxopiperidin-3-yl)-4-oxo-5,6-dihydro-4*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy)phenyl)heptyl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide **A59**;

or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[00295] In another embodiment, provided herein is:

*N*¹-(2-((*S*)-1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)-*N*¹⁰-((*S*)-1-((2*S*,4*R*)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)-pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)decanediamide **A60**;

(2*S*,4*R*)-1-[(2*S*)-2-(13-{7-acetamido-2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-

methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-5-yl}tridecanamido)-3,3-dimethylbutanoyl]-4-hydroxy-*N*-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide **A61**;

(2*S*,4*R*)-1-[(2*S*)-2-(11-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}undecanamido)-3,3-dimethylbutanoyl]-4-hydroxy-*N*-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide **A62**;

(2*S*,4*R*)-1-[(2*S*)-2-(2-{4-[4-({2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}carbamoyl)butyl]piperazin-1-yl}acetamido)-3,3-dimethylbutanoyl]-4-hydroxy-*N*-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide **A63**;

N-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}-*N'*-[(2*S*)-1-[(2*S*,4*R*)-4-hydroxy-2-({[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]dodecanediamide **A64**;

(2*S*,4*R*)-1-[(2*S*)-2-{[9-({2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}carbamoyl)nonyl]amino}-3,3-dimethylbutanoyl]-4-hydroxy-*N*-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide **A65**;

(2*S*,4*R*)-1-[(2*S*)-2-(5-{4-[2-({2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl]amino)acetyl]piperazin-1-yl}pentanamido)-3,3-dimethylbutanoyl]-4-hydroxy-*N*-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide **A66**;

N-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}-*N'*-[(2*S*)-1-[(2*S*,4*R*)-4-hydroxy-2-({[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]octanediamide **A67**;

(2*S*,4*R*)-1-[(2*S*)-2-(2-{4-[4-({2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}carbamoyl)butyl]piperidin-1-yl}acetamido)-3,3-dimethylbutanoyl]-4-hydroxy-*N*-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide **A68**;

(2*S*,4*R*)-1-[(2*S*)-2-{[10-({2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}amino)decyl]amino}-3,3-dimethyl-

butanoyl]-4-hydroxy-*N*-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide **A69**;

(2*S*,4*R*)-1-[(2*S*)-2-{6-[4-(2-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}ethyl)piperidin-1-yl]hexanamido}-3,3-dimethylbutanoyl]-4-hydroxy-*N*-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide **A70**;

(2*S*,4*R*)-1-[(2*S*)-2-(5-{1-[2-({2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}amino)acetyl]piperidin-4-yl}pentanamido)-3,3-dimethylbutanoyl]-4-hydroxy-*N*-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide **A71**;

(2*S*,4*R*)-1-((*S*)-2-((8-((2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)amino)-8-oxooctyl)amino)-3,3-dimethylbutanoyl]-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide **A72**;

(2*S*,4*R*)-1-((*S*)-2-((7-(7-acetamido-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-5-yl)heptyl)amino)-3,3-dimethylbutanoyl]-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide **A73**;

(2*S*,4*R*)-1-[(2*S*)-2-acetamido-3,3-dimethylbutanoyl]-*N*-[(2-{[8-({2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl)-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl]-carbonyl)octyl]oxy}-4-(4-methyl-1,3-thiazol-5-yl)phenyl)methyl]-4-hydroxypyrrolidine-2-carboxamide **A74**;

(2*S*,4*R*)-1-[(2*S*)-2-acetamido-3,3-dimethylbutanoyl]-*N*-[(2-{[10-({2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl)-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl]-carbonyl)decyl]oxy}-4-(4-methyl-1,3-thiazol-5-yl)phenyl)methyl]-4-hydroxypyrrolidine-2-carboxamide **A75**; or

(2*S*,4*R*)-1-[(2*S*)-2-acetamido-3,3-dimethylbutanoyl]-*N*-[(2-{[6-({2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl)-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl]-carbonyl)hexyl]oxy}-4-(4-methyl-1,3-thiazol-5-yl)phenyl)methyl]-4-hydroxypyrrolidine-2-carboxamide **A76**;

or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[00296] In yet another embodiment, provided herein is:

8-[4-([3-(2,6-dioxopiperidin-3-yl)-1-methyl-1*H*-indazol-6-yl]carbamoyl)-methyl]piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}octanamide **A77**;

6-[4-([3-(2,6-dioxopiperidin-3-yl)-1-methyl-1*H*-indazol-6-yl]carbamoyl)-methyl]piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}hexanamide **A78**;

10-[4-([3-(2,6-dioxopiperidin-3-yl)-1-methyl-1*H*-indazol-6-yl]carbamoyl)-methyl]piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}decanamide **A79**;

8-[4-([3-(2,6-dioxopiperidin-3-yl)-1-methyl-1*H*-indazol-7-yl]carbamoyl)-methyl]piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}octanamide **A80**;

10-[4-([3-(2,6-dioxopiperidin-3-yl)-1-methyl-1*H*-indazol-7-yl]carbamoyl)-methyl]piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}decanamide **A81**; or

6-[4-([3-(2,6-dioxopiperidin-3-yl)-1-methyl-1*H*-indazol-7-yl]carbamoyl)-methyl]piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}hexanamide **A82**;

or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[00297] In yet another embodiment, provided herein is:

6-[4-([4-(2,6-dioxopiperidin-3-yl)phenyl]carbamoyl)methyl]piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}hexanamide **A83**;

8-[4-([4-(2,6-dioxopiperidin-3-yl)phenyl]carbamoyl)methyl]piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}octanamide **A84**;

8-[4-([3-(2,6-dioxopiperidin-3-yl)phenyl]carbamoyl)methyl]piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-

isoindol-4-yl}octanamide **A85**;

10-[4-({[4-(2,6-dioxopiperidin-3-yl)phenyl]carbamoyl}methyl)piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}decanamide **A86**;

6-[4-({[3-(2,6-dioxopiperidin-3-yl)phenyl]carbamoyl}methyl)piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}hexanamide **A87**; or

10-[4-({[3-(2,6-dioxopiperidin-3-yl)phenyl]carbamoyl}methyl)piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}decanamide **A88**;

or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[00298] In yet another embodiment, provided herein is:

N-{6-[12-({3-[(2,6-dioxopiperidin-3-yl)amino]phenyl}amino)dodecyl]-2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}acetamide **A89**;

4-amino-6-[12-({3-[(2,6-dioxopiperidin-3-yl)amino]phenyl}amino)dodecyl]-2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-2,3-dihydro-1*H*-isoindole-1,3-dione **A90**;

9-({3-[(2,6-dioxopiperidin-3-yl)amino]phenyl}amino)-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}nonanamide **A91**; or

6-{4-[(3-[(2,6-dioxopiperidin-3-yl)amino]phenyl]carbamoyl)methyl]piperazin-1-yl}-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}hexanamide **A92**;

or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[00299] In yet another embodiment, provided herein is:

N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-(4-(2-(2,6-dioxo-piperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)heptyl)oxy)benzamide **B1**;

N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((5-(4-((2-(2,6-dioxo-piperidin-3-yl)-1-oxoisindolin-4-yl)ethynyl)piperidin-1-yl)-5-oxopentyl)oxy)benzamide **B2**;

N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-(4-(2-(2,6-dioxo-piperidin-3-yl)-6-fluoro-1-oxoisindolin-5-yl)piperidin-1-yl)heptyl)oxy)benzamide **B3**;

N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((9-(4-(2-(2,6-dioxo-piperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)nonyl)oxy)benzamide **B4**;

N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((5-(4-(2-(2,6-dioxo-piperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)pentyl)oxy)benzamide **B5**;

N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)heptyl)oxy)benzamide **B6**;

N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((12-(4-(2-(2,6-dioxo-piperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)dodecyl)oxy)benzamide **B7**;

N-(3,5-dichloropyridin-4-yl)-3-(difluoromethoxy)-4-(2-(2-(2-(2-((2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)ethoxy)benzamide **B8**;

3-(cyclopropylmethoxy)-*N*-(3,5-dichloropyridin-4-yl)-4-(2-(2-(2-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)amino)propoxy)ethoxy)ethoxy)ethoxy)benzamide **B9**;

3-(cyclopropylmethoxy)-*N*-(3,5-dichloropyridin-4-yl)-4-((7-(4-(2-(2,6-dioxo-piperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)heptyl)oxy)benzamide **B10**;

N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)propoxy)benzamide **B11**;

3-(cyclopropylmethoxy)-*N*-(3,5-dichloropyridin-4-yl)-4-((9-(4-(2-(2,6-dioxo-piperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)nonyl)oxy)benzamide **B12**;

3-((9-(4-(2-(1-acetamido-1-oxopropan-2-yl)-6-fluoro-1-oxoisindolin-4-yl)-piperidin-1-yl)nonyl)oxy)-*N*-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide **B13**;

N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-(1-(2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxoisindolin-4-yl)piperidin-4-yl)heptyl)oxy)benzamide **B14**;

N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-(2-{4-[2-(2,6-dioxo-piperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1*H*-isoindol-5-yl]piperidin-1-yl}ethoxy)benzamide **B15**;

N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-(2-(2-(2-(3-((2-(2,6-dioxo-piperidin-3-yl)-1-oxoisindolin-4-yl)amino)propoxy)ethoxy)ethoxy)ethoxy)benzamide **B16**;

N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-(4-(2-(2,6-dioxo-piperidin-3-yl)-1-oxoisindolin-4-yl)piperidin-1-yl)heptyl)oxy)benzamide **B17**;

N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-((4-((5-(2,6-dioxo-piperidin-3-yl)-4-oxo-5,6-dihydro-4*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy)benzyl)amino)heptyl)-oxy)benzamide **B18**; or

N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-(4-((5-(2,6-dioxo-piperidin-3-yl)-4-oxo-5,6-dihydro-4*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy)phenyl)heptyl)oxy)-benzamide **B19**;

or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[00300] In yet another embodiment, provided herein is:

(2*S*,4*R*)-1-((*S*)-2-(9-(5-((3,5-dichloropyridin-4-yl)carbamoyl)-2-(difluoromethoxy)phenoxy)nonanamido)-3,3-dimethylbutanoyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide **B20**;

(2*S*,4*R*)-1-((*S*)-2-(11-(5-((3,5-dichloropyridin-4-yl)carbamoyl)-2-(difluoromethoxy)phenoxy)undecanamido)-3,3-dimethylbutanoyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide **B21**;

(2*S*,4*R*)-1-((*S*)-2-(9-(2-(cyclopropylmethoxy)-5-((3,5-dichloropyridin-4-yl)-carbamoyl)phenoxy)nonanamido)-3,3-dimethylbutanoyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide **B22**; or

(2*S*,4*R*)-1-((*S*)-2-((7-(5-((3,5-dichloropyridin-4-yl)carbamoyl)-2-(difluoromethoxy)-phenoxy)heptyl)amino)-3,3-dimethylbutanoyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)-pyrrolidine-2-carboxamide **B23**;

or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[00301] In still another embodiment, provided herein is:

N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-(2-(4-(2-((3-((2,6-dioxopiperidin-3-yl)amino)phenyl)amino)-2-oxoethyl)piperazin-1-yl)ethoxy)benzamide **B24**; or

N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-(4-(4-(2-((3-((2,6-dioxopiperidin-3-yl)amino)phenyl)amino)-2-oxoethyl)piperazin-1-yl)butoxy)benzamide **B25**;

or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[00302] In certain embodiments, a compound provided herein is not any one of 8-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)octanamide; *N*-(6-(7-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)heptyl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide; 3-(2-(2-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)amino)propoxy)ethoxy)ethoxy)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)propenamide; *N*-(6-(2-(2-(2-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)amino)propoxy)ethoxy)ethoxy)ethyl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide; 6-(4-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)ethynyl)piperidin-1-yl)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)-6-oxohexanamide; *N*-(6-(5-(4-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)ethynyl)piperidin-1-yl)-5-oxopentyl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide; 8-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)piperidin-1-yl)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)octanamide; *N*-(6-(7-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)piperidin-1-yl)heptyl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide; 8-(4-((5-(2,6-dioxopiperidin-3-yl)-4-oxo-5,6-dihydro-4*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy)phenyl)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)octanamide; *N*-(6-(7-(4-((5-(2,6-dioxopiperidin-3-yl)-4-oxo-5,6-dihydro-4*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy)phenyl)heptyl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide; (2*S*,4*R*)-1-((*S*)-2-((8-((2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)amino)-8-oxooctyl)amino)-3,3-dimethylbutanoyl)-4-hydroxy-*N*-(4-(4-methyl-

thiazol-5-yl)benzyl)pyrrolidine-2-carboxamide; and (2*S*,4*R*)-1-((*S*)-2-((7-(7-acetamido-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-5-yl)heptyl)amino)-3,3-dimethylbutanoyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide.

[00303] In certain embodiments, a compound provided herein is not any one of 3-(cyclopropylmethoxy)-*N*-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-*N*-(7-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)heptyl)benzamide; *N*-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)heptyl)oxy)benzamide; 3-(cyclopropylmethoxy)-*N*-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-*N*-(2-(2-(2-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)amino)propoxy)ethoxy)ethoxy)ethyl)benzamide; *N*-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-(2-(2-(2-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)amino)propoxy)ethoxy)ethoxy)ethoxy)benzamide; 3-(cyclopropylmethoxy)-*N*-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-*N*-(5-(4-((2-(2,6-dioxopiperidin-3-yl)-1-oxo-isindolin-4-yl)ethynyl)piperidin-1-yl)-5-oxopentyl)benzamide; *N*-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((5-(4-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)ethynyl)-piperidin-1-yl)-5-oxopentyl)oxy)benzamide; 3-(cyclopropylmethoxy)-*N*-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-*N*-(7-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)piperidin-1-yl)heptyl)benzamide; *N*-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)piperidin-1-yl)heptyl)oxy)benzamide; 3-(cyclopropylmethoxy)-*N*-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-*N*-(7-(4-((5-(2,6-dioxopiperidin-3-yl)-4-oxo-5,6-dihydro-4*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy)phenyl)heptyl)benzamide; *N*-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-(4-((5-(2,6-dioxopiperidin-3-yl)-4-oxo-5,6-dihydro-4*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy)phenyl)heptyl)oxy)benzamide; (2*S*,4*R*)-1-((*S*)-2-((7-(3-(cyclopropylmethoxy)-*N*-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamido)heptyl)-amino)-3,3-dimethylbutanoyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide; and (2*S*,4*R*)-1-((*S*)-2-((7-(5-((3,5-dichloropyridin-4-yl)carbamoyl)-2-(difluoromethoxy)phenoxy)heptyl)amino)-3,3-dimethylbutanoyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide.

[00304] In certain embodiments, a compound provided herein is deuterium-enriched. In certain embodiments, a compound provided herein is carbon-13 enriched. In certain

embodiments, a compound provided herein is carbon-14 enriched. In certain embodiments, a compound provided herein contains one or more less prevalent isotopes for other elements, including, but not limited to, ^{15}N for nitrogen; ^{17}O or ^{18}O for oxygen, and ^{34}S , ^{35}S , or ^{36}S for sulfur.

[00305] In certain embodiments, a compound provided herein has an isotopic enrichment factor of no less than about 5, no less than about 10, no less than about 20, no less than about 50, no less than about 100, no less than about 200, no less than about 500, no less than about 1,000, no less than about 2,000, no less than about 5,000, or no less than about 10,000. In any events, however, an isotopic enrichment factor for a specified isotope is no greater than the maximum isotopic enrichment factor for the specified isotope, which is the isotopic enrichment factor when a compound at a given position is 100% enriched with the specified isotope. Thus, the maximum isotopic enrichment factor is different for different isotopes. The maximum isotopic enrichment factor is 6,410 for deuterium and 90 for carbon-13.

[00306] In certain embodiments, a compound provided herein has a deuterium enrichment factor of no less than about 64 (about 1% deuterium enrichment), no less than about 130 (about 2% deuterium enrichment), no less than about 320 (about 5% deuterium enrichment), no less than about 640 (about 10% deuterium enrichment), no less than about 1,300 (about 20% deuterium enrichment), no less than about 3,200 (about 50% deuterium enrichment), no less than about 4,800 (about 75% deuterium enrichment), no less than about 5,130 (about 80% deuterium enrichment), no less than about 5,450 (about 85% deuterium enrichment), no less than about 5,770 (about 90% deuterium enrichment), no less than about 6,090 (about 95% deuterium enrichment), no less than about 6,220 (about 97% deuterium enrichment), no less than about 6,280 (about 98% deuterium enrichment), no less than about 6,350 (about 99% deuterium enrichment), or no less than about 6,380 (about 99.5% deuterium enrichment). The deuterium enrichment can be determined using conventional analytical methods known to one of ordinary skill in the art, including mass spectrometry and nuclear magnetic resonance spectroscopy. In certain embodiments, at least one of the atoms of a compound provided herein, as specified as deuterium-enriched, has deuterium enrichment of no less than about 50%, no less than about 70%, no less than about 80%, no less than about 90%, or no less than about 98%.

[00307] In certain embodiments, a compound provided herein is isolated or purified. In certain embodiments, a compound provided herein has a purity of at least about 90%, at least about 95%, at least about 98%, at least about 99%, or at least about 99.5% by weight.

[00308] The compounds provided herein are intended to encompass all possible stereoisomers unless a particular stereochemistry is specified. Where a compound provided herein contains an alkenyl group, the compound may exist as one or mixture of geometric *cis/trans* (or *Z/E*) isomers. Where structural isomers are interconvertible, the compound may exist as a single tautomer or a mixture of tautomers. This can take the form of proton tautomerism in the compound that contains, for example, an imino, keto, or oxime group; or so-called valence tautomerism in the compound that contains an aromatic moiety. It follows that a single compound may exhibit more than one type of isomerism.

[00309] A compound provided herein can be enantiomerically pure, such as a single enantiomer or a single diastereomer, or be stereoisomeric mixtures, such as a mixture of enantiomers, *e.g.*, a racemic mixture of two enantiomers; or a mixture of two or more diastereomers. As such, one of ordinary skill in the art will recognize that administration of a compound in its (*R*) form is equivalent, for the compound that undergoes epimerization *in vivo*, to administration of the compound in its (*S*) form. Conventional techniques for the preparation/isolation of individual enantiomers include synthesis from a suitable optically pure precursor, asymmetric synthesis from achiral starting materials, or resolution of an enantiomeric mixture, for example, chiral chromatography, recrystallization, resolution, diastereomeric salt formation, or derivatization into diastereomeric adducts followed by separation.

[00310] When a compound provided herein contains an acidic or basic moiety, it can also be provided as a pharmaceutically acceptable salt. *See*, Berge *et al.*, *J. Pharm. Sci.* **1977**, *66*, 1-19; *Handbook of Pharmaceutical Salts: Properties, Selection, and Use*, 2nd ed.; Stahl and Wermuth Eds.; John Wiley & Sons, 2011. In certain embodiments, a pharmaceutically acceptable salt of a compound provided herein is a solvate. In certain embodiments, a pharmaceutically acceptable salt of a compound provided herein is a hydrate.

[00311] Suitable acids for use in the preparation of pharmaceutically acceptable salts of a compound provided herein include, but are not limited to, acetic acid, 2,2-dichloroacetic acid,

acylated amino acids, adipic acid, alginic acid, ascorbic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, boric acid, (+)-camphoric acid, camphorsulfonic acid, (+)-(1*S*)-camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, cinnamic acid, citric acid, cyclamic acid, cyclohexanesulfamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxy-ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, D-gluconic acid, D-glucuronic acid, L-glutamic acid, α -oxoglutaric acid, glycolic acid, hippuric acid, hydrobromic acid, hydrochloric acid, hydroiodic acid, (+)-L-lactic acid, ($\pm$)-DL-lactic acid, lactobionic acid, lauric acid, maleic acid, (-)-L-malic acid, malonic acid, ($\pm$)-DL-mandelic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, nitric acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, perchloric acid, phosphoric acid, L-pyroglutamic acid, saccharic acid, salicylic acid, 4-amino-salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, (+)-L-tartaric acid, thiocyanic acid, *p*-toluenesulfonic acid, undecylenic acid, and valeric acid.

[00312] Suitable bases for use in the preparation of pharmaceutically acceptable salts of a compound provided herein include, but are not limited to, inorganic bases, such as magnesium hydroxide, calcium hydroxide, potassium hydroxide, zinc hydroxide, and sodium hydroxide; and organic bases, such as primary, secondary, tertiary, and quaternary, aliphatic and aromatic amines, including, but not limited to, L-arginine, benethamine, benzathine, choline, deanol, diethanolamine, diethylamine, dimethylamine, dipropylamine, diisopropylamine, 2-(diethylamino)-ethanol, ethanolamine, ethylamine, ethylenediamine, isopropylamine, *N*-methyl-glucamine, hydrabamine, 1*H*-imidazole, L-lysine, morpholine, 4-(2-hydroxyethyl)-morpholine, methylamine, piperidine, piperazine, propylamine, pyrrolidine, 1-(2-hydroxyethyl)-pyrrolidine, pyridine, quinuclidine, quinoline, isoquinoline, triethanolamine, trimethylamine, triethylamine, *N*-methyl-D-glucamine, 2-amino-2-(hydroxymethyl)-1,3-propanediol, and tromethamine.

[00313] A compound provided herein may also be provided as a prodrug, which is a functional derivative of the compound and is readily convertible into the parent compound *in vivo*. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent compound. They may, for instance, be bioavailable by oral administration whereas the parent compound is not. The prodrug may also have enhanced solubility in

pharmaceutical compositions over the parent compound. A prodrug may be converted into the parent drug by various mechanisms, including enzymatic processes and metabolic hydrolysis.

Pharmaceutical Compositions

[00314] In one embodiment, provided herein is a pharmaceutical composition, comprising a compound provided herein, *e.g.*, a compound of Formula (I) or (IA), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and a pharmaceutically acceptable excipient.

[00315] The pharmaceutical composition provided herein can be formulated in various dosage forms, including, but not limited to, dosage forms for oral, parenteral, and topical administration. The pharmaceutical composition can also be formulated as modified release dosage forms, including delayed-, extended-, prolonged-, sustained-, pulsatile-, controlled-, accelerated-, fast-, targeted-, programmed-release, and gastric retention dosage forms. These dosage forms can be prepared according to conventional methods and techniques known to those skilled in the art. *See, e.g., Remington: The Science and Practice of Pharmacy, supra; Modified-Release Drug Delivery Technology*, 2nd ed.; Rathbone *et al.*, Eds.; Drugs and the Pharmaceutical Sciences 184; CRC Press: Boca Raton, FL, 2008.

[00316] In one embodiment, the pharmaceutical composition provided herein is formulated in a dosage form for oral administration. In another embodiment, the pharmaceutical composition provided herein is formulated in a dosage form for parenteral administration. In yet another embodiment, the pharmaceutical composition provided herein is formulated in a dosage form for intravenous administration. In yet another embodiment, the pharmaceutical composition provided herein is formulated in a dosage form for intramuscular administration. In yet another embodiment, the pharmaceutical composition provided herein is formulated in a dosage form for subcutaneous administration. In still another embodiment, the pharmaceutical composition provided herein is formulated in a dosage form for topical administration.

[00317] The pharmaceutical composition provided herein can be provided in a unit-dosage form or multiple-dosage form. A unit-dosage form, as used herein, refers to physically discrete a

unit suitable for administration to a subject, and packaged individually as is known in the art. Each unit-dose contains a predetermined quantity of an active ingredient(s) (*e.g.*, a compound provided herein) sufficient to produce the desired therapeutic effect, in association with the required pharmaceutical excipient(s). Examples of a unit-dosage form include, but are not limited to, an ampoule, syringe, and individually packaged tablet and capsule. A unit-dosage form may be administered in fractions or multiples thereof. A multiple-dosage form is a plurality of identical unit-dosage forms packaged in a single container to be administered in a segregated unit-dosage form. Examples of a multiple-dosage form include, are not limited to, a vial, bottle of tablets or capsules, or bottle of pints or gallons.

[00318] The pharmaceutical composition provided herein can be administered at once or multiple times at intervals of time. It is understood that the precise dosage and duration of treatment may vary with the age, weight, and condition of the subject being treated, and may be determined empirically using known testing protocols or by extrapolation from *in vivo* or *in vitro* test or diagnostic data. It is further understood that for any particular individual, specific dosage regimens should be adjusted over time according to the subject's need and the professional judgment of the person administering or supervising the administration of the pharmaceutical composition.

A. Oral Administration

[00319] The pharmaceutical composition provided herein for oral administration can be provided in solid, semisolid, or liquid dosage forms for oral administration. As used herein, oral administration also includes buccal, lingual, and sublingual administration. Suitable oral dosage forms include, but are not limited to, tablets, fastmelts, chewable tablets, capsules, pills, strips, troches, lozenges, pastilles, cachets, pellets, medicated chewing gum, bulk powders, effervescent or non-effervescent powders or granules, oral mists, solutions, emulsions, suspensions, wafers, sprinkles, elixirs, and syrups. In addition to the active ingredient(s), the pharmaceutical composition can contain one or more pharmaceutically acceptable carriers or excipients, including, but not limited to, binders, fillers, diluents, disintegrants, wetting agents, lubricants, glidants, coloring agents, dye-migration inhibitors, sweetening agents, flavoring agents, emulsifying agents, suspending and dispersing agents, preservatives, solvents, non-aqueous

liquids, organic acids, and sources of carbon dioxide.

[00320] Binders or granulators impart cohesiveness to a tablet to ensure the tablet remaining intact after compression. Suitable binders or granulators include, but are not limited to, starches, such as corn starch, potato starch, and pre-gelatinized starch (*e.g.*, STARCH 1500®); gelatin; sugars, such as sucrose, glucose, dextrose, molasses, and lactose; natural and synthetic gums, such as acacia, alginic acid, alginates, extract of Irish moss, Panwar gum, Ghatti gum, mucilage of isabgol husks, carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone (PVP), VEEGUM®, larch arabinogalactan, powdered tragacanth, and guar gum; celluloses, such as ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose, methyl cellulose, hydroxyethylcellulose (HEC), hydroxypropylcellulose (HPC), hydroxypropyl methyl cellulose (HPMC); and microcrystalline celluloses, such as AVICEL® PH-101, AVICEL® PH-103, AVICEL® PH-105, and AVICEL® RC-581. Suitable fillers include, but are not limited to, talc, calcium carbonate, microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, and pre-gelatinized starch. The amount of a binder or filler in the pharmaceutical composition provided herein varies upon the type of formulation, and is readily discernible to those of ordinary skill in the art. The binder or filler may be present from about 50 to about 99% by weight in the pharmaceutical composition provided herein.

[00321] Suitable diluents include, but are not limited to, dicalcium phosphate, calcium sulfate, lactose, sorbitol, sucrose, inositol, cellulose, kaolin, mannitol, sodium chloride, dry starch, and powdered sugar. Certain diluents, such as mannitol, lactose, sorbitol, sucrose, and inositol, when present in sufficient quantity, can impart properties to some compressed tablets that permit disintegration in the mouth by chewing. Such compressed tablets can be used as chewable tablets. The amount of a diluent in the pharmaceutical composition provided herein varies upon the type of formulation, and is readily discernible to those of ordinary skill in the art.

[00322] Suitable disintegrants include, but are not limited to, agar; bentonite; celluloses, such as methylcellulose and carboxymethylcellulose; wood products; natural sponge; cation-exchange resins; alginic acid; gums, such as guar gum and VEEGUM® HV; citrus pulp; cross-linked celluloses, such as croscarmellose; cross-linked polymers, such as crospovidone; cross-

linked starches; calcium carbonate; microcrystalline cellulose, such as sodium starch glycolate; polacrillin potassium; starches, such as corn starch, potato starch, tapioca starch, and pre-gelatinized starch; clays; and algins. The amount of a disintegrant in the pharmaceutical composition provided herein varies upon the type of formulation, and is readily discernible to those of ordinary skill in the art. The pharmaceutical composition provided herein may contain from about 0.5 to about 15% or from about 1 to about 5% by weight of a disintegrant.

[00323] Suitable lubricants include, but are not limited to, calcium stearate; magnesium stearate; mineral oil; light mineral oil; glycerin; sorbitol; mannitol; glycols, such as glycerol behenate and polyethylene glycol (PEG); stearic acid; sodium lauryl sulfate; talc; hydrogenated vegetable oil, such as peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil; zinc stearate; ethyl oleate; ethyl laureate; agar; starch; lycopodium; and silica or silica gels, such as AEROSIL[®] 200 and CAB-O-SIL[®]. The amount of a lubricant in the pharmaceutical composition provided herein varies upon the type of formulation, and is readily discernible to those of ordinary skill in the art. The pharmaceutical compositions provided herein may contain about 0.1 to about 5% by weight of a lubricant.

[00324] Suitable glidants include, but are not limited to, colloidal silicon dioxide, CAB-O-SIL[®], and asbestos-free talc. Suitable coloring agents include, but are not limited to, any of the approved, certified, water soluble FD&C dyes, and water insoluble FD&C dyes suspended on alumina hydrate, and color lakes. A color lake is a combination by adsorption of a water-soluble dye to a hydrous oxide of a heavy metal, resulting in an insoluble form of the dye. Suitable flavoring agents include, but are not limited to, natural flavors extracted from plants, such as fruits, and synthetic blends of compounds which produce a pleasant taste sensation, such as peppermint and methyl salicylate. Suitable sweetening agents include, but are not limited to, sucrose, lactose, mannitol, syrups, glycerin, and artificial sweeteners, such as saccharin and aspartame. Suitable emulsifying agents include, but are not limited to, gelatin, acacia, tragacanth, bentonite, and surfactants, such as polyoxyethylene sorbitan monooleate (TWEEN[®] 20), polyoxyethylene sorbitan monooleate 80 (TWEEN[®] 80), and triethanolamine oleate. Suitable suspending and dispersing agents include, but are not limited to, sodium carboxymethylcellulose, pectin, tragacanth, VEEGUM[®], acacia, sodium carboxymethylcellulose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone. Suitable

preservatives include, but are not limited to, glycerin, methyl and propylparaben, benzoic acid, and sodium benzoate and alcohol. Suitable wetting agents include, but are not limited to, propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate, and polyoxyethylene lauryl ether. Suitable solvents include, but are not limited to, glycerin, sorbitol, ethyl alcohol, and syrup. Suitable non-aqueous liquids utilized in emulsions include, but are not limited to, mineral oil and cottonseed oil. Suitable organic acids include, but are not limited to, citric and tartaric acid. Suitable sources of carbon dioxide include, but are not limited to, sodium bicarbonate and sodium carbonate.

[00325] It should be understood that many carriers and excipients may serve several functions, even within the same formulation.

[00326] The pharmaceutical composition provided herein for oral administration can be provided as compressed tablets, tablet triturates, chewable lozenges, rapidly dissolving tablets, multiple compressed tablets, or enteric-coating tablets, sugar-coated, or film-coated tablets. Enteric-coated tablets are compressed tablets coated with substances that resist the action of stomach acid but dissolve or disintegrate in the intestine, thus protecting the active ingredient(s) from the acidic environment of the stomach. Enteric-coatings include, but are not limited to, fatty acids, fats, phenyl salicylate, waxes, shellac, ammoniated shellac, and cellulose acetate phthalates. Sugar-coated tablets are compressed tablets surrounded by a sugar coating, which may be beneficial in covering up objectionable tastes or odors and in protecting the tablets from oxidation. Film-coated tablets are compressed tablets that are covered with a thin layer or film of a water-soluble material. Film coatings include, but are not limited to, hydroxyethylcellulose, sodium carboxymethylcellulose, polyethylene glycol 4000, and cellulose acetate phthalate. Film coating imparts the same general characteristics as sugar coating. Multiple compressed tablets are compressed tablets made by more than one compression cycle, including layered tablets, and press-coated or dry-coated tablets.

[00327] The tablet dosage forms can be prepared from an active ingredient(s) in powdered, crystalline, or granular forms, alone or in combination with one or more carriers or excipients described herein, including binders, disintegrants, controlled-release polymers, lubricants, diluents, and/or colorants. Flavoring and sweetening agents are especially useful in

the formation of chewable tablets and lozenges.

[00328] The pharmaceutical composition provided herein for oral administration can be provided as soft or hard capsules, which can be made from gelatin, methylcellulose, starch, or calcium alginate. The hard gelatin capsule, also known as the dry-filled capsule (DFC), consists of two sections, one slipping over the other, thus completely enclosing the active ingredient(s). The soft elastic capsule (SEC) is a soft, globular shell, such as a gelatin shell, which is plasticized by the addition of glycerin, sorbitol, or a similar polyol. The soft gelatin shells may contain a preservative to prevent the growth of microorganisms. Suitable preservatives are those as described herein, including methyl- and propyl-parabens, and sorbic acid. The liquid, semisolid, and solid dosage forms provided herein may be encapsulated in a capsule. Suitable liquid and semisolid dosage forms include solutions and suspensions in propylene carbonate, vegetable oils, or triglycerides. Capsules containing such solutions can be prepared as described in U.S. Pat. Nos. 4,328,245; 4,409,239; and 4,410,545. The capsules may also be coated as known by those of skill in the art in order to modify or sustain dissolution of the active ingredient(s).

[00329] The pharmaceutical composition provided herein for oral administration can be provided in liquid and semisolid dosage forms, including emulsions, solutions, suspensions, elixirs, and syrups. An emulsion is a two-phase system, in which one liquid is dispersed in the form of small globules throughout another liquid, which can be oil-in-water or water-in-oil. Emulsions may include a pharmaceutically acceptable non-aqueous liquid or solvent, emulsifying agent, and preservative. Suspensions may include a pharmaceutically acceptable suspending agent and preservative. Aqueous alcoholic solutions may include a pharmaceutically acceptable acetal, such as a di(lower alkyl) acetal of a lower alkyl aldehyde, *e.g.*, acetaldehyde diethyl acetal; and a water-miscible solvent having one or more hydroxyl groups, such as propylene glycol and ethanol. Elixirs are clear, sweetened, and hydroalcoholic solutions. Syrups are concentrated aqueous solutions of a sugar, for example, sucrose, and may also contain a preservative. For a liquid dosage form, for example, a solution in a polyethylene glycol may be diluted with a sufficient quantity of a pharmaceutically acceptable liquid carrier, *e.g.*, water, to be measured conveniently for administration.

[00330] Other useful liquid and semisolid dosage forms include, but are not limited to, those containing an active ingredient(s), and a dialkylated mono- or poly-alkylene glycol, including, 1,2-dimethoxymethane, diglyme, triglyme, tetraglyme, polyethylene glycol-350-dimethyl ether, polyethylene glycol-550-dimethyl ether, polyethylene glycol-750-dimethyl ether, wherein 350, 550, and 750 refer to the approximate average molecular weight of the polyethylene glycol. These dosage forms can further comprise one or more antioxidants, such as butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), propyl gallate, vitamin E, hydroquinone, hydroxycoumarins, ethanolamine, lecithin, cephalin, ascorbic acid, malic acid, sorbitol, phosphoric acid, bisulfite, sodium metabisulfite, thiodipropionic acid and its esters, and dithiocarbamates.

[00331] The pharmaceutical composition provided herein for oral administration can be also provided in the forms of liposomes, micelles, microspheres, or nanosystems. Micellar dosage forms can be prepared as described in U.S. Pat. No. 6,350,458.

[00332] The pharmaceutical composition provided herein for oral administration can be provided as non-effervescent or effervescent, granules and powders, to be reconstituted into a liquid dosage form. Pharmaceutically acceptable carriers and excipients used in the non-effervescent granules or powders may include diluents, sweeteners, and wetting agents. Pharmaceutically acceptable carriers and excipients used in the effervescent granules or powders may include organic acids and a source of carbon dioxide.

[00333] Coloring and flavoring agents can be used in all of the dosage forms described herein.

[00334] The pharmaceutical composition provided herein for oral administration can be formulated as immediate or modified release dosage forms, including delayed-, sustained, pulsed-, controlled, targeted-, and programmed-release forms.

B. Parenteral Administration

[00335] The pharmaceutical composition provided herein can be administered parenterally by injection, infusion, or implantation, for local or systemic administration. Parenteral administration, as used herein, include intravenous, intraarterial, intraperitoneal, intrathecal,

intraventricular, intraurethral, intrasternal, intracranial, intramuscular, intrasynovial, intravesical, and subcutaneous administration.

[00336] The pharmaceutical composition provided herein for parenteral administration can be formulated in any dosage forms that are suitable for parenteral administration, including, but not limited to, solutions, suspensions, emulsions, micelles, liposomes, microspheres, nanosystems, and solid forms suitable for solutions or suspensions in liquid prior to injection. Such dosage forms can be prepared according to conventional methods known to those skilled in the art of pharmaceutical science. *See, e.g., Remington: The Science and Practice of Pharmacy, supra.*

[00337] The pharmaceutical composition provided herein for parenteral administration can include one or more pharmaceutically acceptable carriers and excipients, including, but not limited to, aqueous vehicles, water-miscible vehicles, non-aqueous vehicles, antimicrobial agents or preservatives against the growth of microorganisms, stabilizers, solubility enhancers, isotonic agents, buffering agents, antioxidants, local anesthetics, suspending and dispersing agents, wetting or emulsifying agents, complexing agents, sequestering or chelating agents, cryoprotectants, lyoprotectants, thickening agents, pH adjusting agents, and inert gases.

[00338] Suitable aqueous vehicles include, but are not limited to, water, saline, physiological saline or phosphate buffered saline (PBS), sodium chloride injection, Ringer's injection, isotonic dextrose injection, sterile water injection, dextrose and lactated Ringer's injection. Suitable non-aqueous vehicles include, but are not limited to, fixed oils of vegetable origin, castor oil, corn oil, cottonseed oil, olive oil, peanut oil, peppermint oil, safflower oil, sesame oil, soybean oil, hydrogenated vegetable oils, hydrogenated soybean oil, and medium-chain triglycerides of coconut oil, and palm seed oil. Suitable water-miscible vehicles include, but are not limited to, ethanol, 1,3-butanediol, liquid polyethylene glycol (*e.g.*, polyethylene glycol 300 and polyethylene glycol 400), propylene glycol, glycerin, *N*-methyl-2-pyrrolidone, *N,N*-dimethylacetamide, and dimethyl sulfoxide.

[00339] Suitable antimicrobial agents or preservatives include, but are not limited to, phenols, cresols, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl *p*-hydroxybenzoates, thimerosal, benzalkonium chloride (*e.g.*, benzethonium chloride), methyl-

and propyl-parabens, and sorbic acid. Suitable isotonic agents include, but are not limited to, sodium chloride, glycerin, and dextrose. Suitable buffering agents include, but are not limited to, phosphate and citrate. Suitable antioxidants include those described herein, such as bisulfite and sodium metabisulfite. Suitable local anesthetics include, but are not limited to, procaine hydrochloride. Suitable suspending and dispersing agents include those described herein, such as sodium carboxymethylcellulose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone. Suitable emulsifying agents include those described herein, such as polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monooleate 80, and triethanolamine oleate. Suitable sequestering or chelating agents include, but are not limited to, EDTA. Suitable pH adjusting agents include, but are not limited to, sodium hydroxide, hydrochloric acid, citric acid, and lactic acid. Suitable complexing agents include, but are not limited to, cyclodextrins, including α -cyclodextrin, β -cyclodextrin, hydroxypropyl- β -cyclodextrin, sulfobutylether- β -cyclodextrin, and sulfobutylether 7- β -cyclodextrin (CAPTISOL[®]).

[00340] When the pharmaceutical composition provided herein is formulated for multiple dosage administration, multiple dosage parenteral formulations must contain an antimicrobial agent at bacteriostatic or fungistatic concentrations. All parenteral formulations must be sterile, as known and practiced in the art.

[00341] In one embodiment, the pharmaceutical composition for parenteral administration is provided as a ready-to-use sterile solution. In another embodiment, the pharmaceutical composition is provided as a sterile dry soluble product, including a lyophilized powder and hypodermic tablet, to be reconstituted with a vehicle prior to use. In yet another embodiment, the pharmaceutical composition is provided as a ready-to-use sterile suspension. In yet another embodiment, the pharmaceutical composition is provided as a sterile dry insoluble product to be reconstituted with a vehicle prior to use. In still another embodiment, the pharmaceutical composition is provided as a ready-to-use sterile emulsion.

[00342] The pharmaceutical composition provided herein for parenteral administration can be formulated as immediate or modified release dosage forms, including delayed-, sustained, pulsed-, controlled, targeted-, and programmed-release forms.

[00343] The pharmaceutical composition provided herein for parenteral administration can

be formulated as a suspension, solid, semi-solid, or thixotropic liquid, for administration as an implanted depot. In one embodiment, the pharmaceutical composition provided herein are dispersed in a solid inner matrix, which is surrounded by an outer polymeric membrane that is insoluble in body fluids but allows the active ingredient(s) in the pharmaceutical composition to diffuse through.

[00344] Suitable inner matrixes include, but are not limited to, polymethylmethacrylate, polybutylmethacrylate, plasticized or unplasticized polyvinylchloride, plasticized nylon, plasticized polyethylene terephthalate, natural rubber, polyisoprene, polyisobutylene, polybutadiene, polyethylene, ethylene-vinyl acetate copolymers, silicone rubbers, polydimethylsiloxanes, silicone carbonate copolymers, hydrophilic polymers (such as hydrogels of esters of acrylic and methacrylic acid), collagen, cross-linked polyvinyl alcohol, and cross-linked partially hydrolyzed polyvinyl acetate.

[00345] Suitable outer polymeric membranes include, but are not limited to, polyethylene, polypropylene, ethylene/propylene copolymers, ethylene/ethyl acrylate copolymers, ethylene/vinyl acetate copolymers, silicone rubbers, polydimethylsiloxanes, neoprene rubber, chlorinated polyethylene, polyvinylchloride, vinyl chloride copolymers with vinyl acetate, vinylidene chloride, ethylene and propylene, ionomer polyethylene terephthalate, butyl rubber epichlorohydrin rubbers, ethylene/vinyl alcohol copolymer, ethylene/vinyl acetate/vinyl alcohol terpolymer, and ethylene/vinyloxyethanol copolymer.

C. Topical Administration

[00346] The pharmaceutical composition provided herein can be administered topically to the skin, orifices, or mucosa. The topical administration, as used herein, includes (intra)dermal, conjunctival, intracorneal, intraocular, ophthalmic, auricular, transdermal, nasal, vaginal, urethral, respiratory, and rectal administration.

[00347] The pharmaceutical composition provided herein can be formulated in any dosage forms that are suitable for topical administration for local or systemic effect, including, but not limited to, emulsions, solutions, suspensions, creams, gels, hydrogels, ointments, dusting powders, dressings, elixirs, lotions, suspensions, tinctures, pastes, foams, films, aerosols,

irrigations, sprays, suppositories, bandages, and dermal patches. The topical formulations of the pharmaceutical composition provided herein can also comprise liposomes, micelles, microspheres, and nanosystems.

[00348] Pharmaceutically acceptable carriers and excipients suitable for use in the topical formulations include, but are not limited to, aqueous vehicles, water-miscible vehicles, non-aqueous vehicles, antimicrobial agents or preservatives against the growth of microorganisms, stabilizers, solubility enhancers, isotonic agents, buffering agents, antioxidants, local anesthetics, suspending and dispersing agents, wetting or emulsifying agents, complexing agents, sequestering or chelating agents, penetration enhancers, cryoprotectants, lyoprotectants, thickening agents, and inert gases.

[00349] The pharmaceutical composition can also be administered topically by electroporation, iontophoresis, phonophoresis, sonophoresis, or microneedle or needle-free injection, such as POWDERJECT™ and BIOJECT™.

[00350] The pharmaceutical composition provided herein can be provided in the forms of ointments, creams, and gels. Suitable ointment vehicles include oleaginous or hydrocarbon vehicles, including lard, benzoinated lard, olive oil, cottonseed oil, and other oils, white petrolatum; emulsifiable or absorption vehicles, such as hydrophilic petrolatum, hydroxystearin sulfate, and anhydrous lanolin; water-removable vehicles, such as hydrophilic ointment; water-soluble ointment vehicles, including polyethylene glycols of varying molecular weight; emulsion vehicles, either water-in-oil (W/O) emulsions or oil-in-water (O/W) emulsions, including cetyl alcohol, glyceryl monostearate, lanolin, and stearic acid. *See, e.g., Remington: The Science and Practice of Pharmacy, supra.* These vehicles are emollient but generally require addition of antioxidants and preservatives.

[00351] Suitable cream base can be oil-in-water or water-in-oil. Suitable cream vehicles may be water-washable, and contain an oil phase, an emulsifier, and an aqueous phase. The oil phase is also called the “internal” phase, which is generally comprised of petrolatum and a fatty alcohol such as cetyl or stearyl alcohol. The aqueous phase usually, although not necessarily, exceeds the oil phase in volume, and generally contains a humectant. The emulsifier in a cream formulation may be a nonionic, anionic, cationic, or amphoteric surfactant.

[00352] Gels are semisolid, suspension-type systems. Single-phase gels contain organic macromolecules distributed substantially uniformly throughout the liquid carrier. Suitable gelling agents include, but are not limited to, crosslinked acrylic acid polymers, such as carbomers, carboxypolyalkylenes, and CARBOPOL®; hydrophilic polymers, such as polyethylene oxides, polyoxyethylene-polyoxypropylene copolymers, and polyvinylalcohol; cellulosic polymers, such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, and methylcellulose; gums, such as tragacanth and xanthan gum; sodium alginate; and gelatin. In order to prepare a uniform gel, dispersing agents such as alcohol or glycerin can be added, or the gelling agent can be dispersed by trituration, mechanical mixing, and/or stirring.

[00353] The pharmaceutical composition provided herein can be administered rectally, urethrally, vaginally, or perivaginally in the forms of suppositories, pessaries, bougies, poultices or cataplasm, pastes, powders, dressings, creams, plasters, contraceptives, ointments, solutions, emulsions, suspensions, tampons, gels, foams, sprays, or enemas. These dosage forms can be manufactured using conventional processes as described in *Remington: The Science and Practice of Pharmacy, supra*.

[00354] Rectal, urethral, and vaginal suppositories are solid bodies for insertion into body orifices, which are solid at ordinary temperatures but melt or soften at body temperature to release the active ingredient(s) inside the orifices. Pharmaceutically acceptable carriers utilized in rectal and vaginal suppositories include bases or vehicles, such as stiffening agents, which produce a melting point in the proximity of body temperature, when formulated with an active ingredient(s); and antioxidants as described herein, including bisulfite and sodium metabisulfite. Suitable vehicles include, but are not limited to, cocoa butter (theobroma oil), glycerin-gelatin, carbowax (polyoxyethylene glycol), spermaceti, paraffin, white and yellow wax, and appropriate mixtures of mono-, di- and triglycerides of fatty acids, and hydrogels, such as polyvinyl alcohol, hydroxyethyl methacrylate, and polyacrylic acid. Combinations of the various vehicles can also be used. Rectal and vaginal suppositories may be prepared by compressing or molding. The typical weight of a rectal and vaginal suppository is about 2 to about 3 g.

[00355] The pharmaceutical composition provided herein can be administered

ophthalmically in the forms of solutions, suspensions, ointments, emulsions, gel-forming solutions, powders for solutions, gels, ocular inserts, and implants.

[00356] The pharmaceutical composition provided herein can be administered intranasally or by inhalation to the respiratory tract. The pharmaceutical composition can be provided in the form of an aerosol or solution for delivery using a pressurized container, pump, spray, atomizer, such as an atomizer using electrohydrodynamics to produce a fine mist, or nebulizer, alone or in combination with a suitable propellant, such as 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane. The pharmaceutical composition can also be provided as a dry powder for insufflation, alone or in combination with an inert carrier such as lactose or phospholipids; and nasal drops. For intranasal use, the powder can comprise a bioadhesive agent, including chitosan or cyclodextrin.

[00357] Solutions or suspensions for use in a pressurized container, pump, spray, atomizer, or nebulizer can be formulated to contain ethanol, aqueous ethanol, or a suitable alternative agent for dispersing, solubilizing, or extending release of an active ingredient(s); a propellant as solvent; and/or a surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid.

[00358] The pharmaceutical composition provided herein can be micronized to a size suitable for delivery by inhalation, such as about 50 micrometers or less, or about 10 micrometers or less. Particles of such sizes can be prepared using a comminuting method known to those skilled in the art, such as spiral jet milling, fluid bed jet milling, supercritical fluid processing to form nanoparticles, high pressure homogenization, or spray drying.

[00359] Capsules, blisters, and cartridges for use in an inhaler or insufflator can be formulated to contain a powder mix of the pharmaceutical composition provided herein; a suitable powder base, such as lactose or starch; and a performance modifier, such as *L*-leucine, mannitol, or magnesium stearate. The lactose may be anhydrous or in the form of the monohydrate. Other suitable excipients or carriers include, but are not limited to, dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose, and trehalose. The pharmaceutical composition provided herein for inhaled/intranasal administration can further comprise a suitable flavor, such as menthol and levomenthol; and/or sweeteners, such as saccharin and saccharin

sodium.

[00360] The pharmaceutical composition provided herein for topical administration can be formulated to be immediate release or modified release, including delayed-, sustained-, pulsed-, controlled-, targeted, and programmed release.

D. Modified Release

[00361] The pharmaceutical composition provided herein can be formulated as a modified release dosage form. As used herein, the term “modified release” refers to a dosage form in which the rate or place of release of an active ingredient(s) is different from that of an immediate dosage form when administered by the same route. Modified release dosage forms include, but are not limited to, delayed-, extended-, prolonged-, sustained-, pulsatile-, controlled-, accelerated- and fast-, targeted-, programmed-release, and gastric retention dosage forms. The pharmaceutical composition in modified release dosage forms can be prepared using a variety of modified release devices and methods known to those skilled in the art, including, but not limited to, matrix-controlled release devices, osmotic controlled release devices, multiparticulate controlled release devices, ion-exchange resins, enteric coatings, multilayered coatings, microspheres, liposomes, and combinations thereof. The release rate of the active ingredient(s) can also be modified by varying the particle sizes and polymorphism of the active ingredient(s).

1. Matrix Controlled Release Devices

[00362] The pharmaceutical composition provided herein in a modified release dosage form can be fabricated using a matrix-controlled release device known to those skilled in the art. *See, e.g., Takada et al. in Encyclopedia of Controlled Drug Delivery*, Mathiowitz Ed.; Wiley, 1999; Vol. 2.

[00363] In certain embodiments, the pharmaceutical composition provided herein in a modified release dosage form is formulated using an erodible matrix device, which is water-swellaable, erodible, or soluble polymers, including, but not limited to, synthetic polymers, and naturally occurring polymers and derivatives, such as polysaccharides and proteins.

[00364] Materials useful in forming an erodible matrix include, but are not limited to,

chitin, chitosan, dextran, and pullulan; gum agar, gum arabic, gum karaya, locust bean gum, gum tragacanth, carrageenans, gum Ghatti, guar gum, xanthan gum, and scleroglucan; starches, such as dextrin and maltodextrin; hydrophilic colloids, such as pectin; phosphatides, such as lecithin; alginates; propylene glycol alginate; gelatin; collagen; cellulose, such as ethyl cellulose (EC), methylethyl cellulose (MEC), carboxymethyl cellulose (CMC), CMEC, hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC), cellulose acetate (CA), cellulose propionate (CP), cellulose butyrate (CB), cellulose acetate butyrate (CAB), CAP, CAT, hydroxypropyl methyl cellulose (HPMC), HPMCP, HPMCAS, hydroxypropyl methyl cellulose acetate trimellitate (HPMCAT), and ethyl hydroxyethyl cellulose (EHEC); polyvinyl pyrrolidone; polyvinyl alcohol; polyvinyl acetate; glycerol fatty acid esters; polyacrylamide; polyacrylic acid; copolymers of ethacrylic acid or methacrylic acid (EUDRAGIT®); poly(2-hydroxyethyl-methacrylate); polylactides; copolymers of L-glutamic acid and ethyl-L-glutamate; degradable lactic acid-glycolic acid copolymers; poly-D-(-)-3-hydroxybutyric acid; and other acrylic acid derivatives, such as homopolymers and copolymers of butylmethacrylate, methyl methacrylate, ethyl methacrylate, ethylacrylate, (2-dimethylaminoethyl)methacrylate, and (trimethylaminoethyl)methacrylate chloride.

[00365] In certain embodiments, the pharmaceutical composition provided herein is formulated with a non-erodible matrix device. The active ingredient(s) is dissolved or dispersed in an inert matrix and is released primarily by diffusion through the inert matrix once administered. Materials suitable for use as a non-erodible matrix device include, but are not limited to, insoluble plastics, such as polyethylene, polypropylene, polyisoprene, polyisobutylene, polybutadiene, polymethylmethacrylate, polybutylmethacrylate, chlorinated polyethylene, polyvinylchloride, methyl acrylate-methyl methacrylate copolymers, ethylene-vinyl acetate copolymers, ethylene/propylene copolymers, ethylene/ethyl acrylate copolymers, vinyl chloride copolymers with vinyl acetate, vinylidene chloride, ethylene and propylene, ionomer polyethylene terephthalate, butyl rubbers, epichlorohydrin rubbers, ethylene/vinyl alcohol copolymer, ethylene/vinyl acetate/vinyl alcohol terpolymer, ethylene/vinylalcohol copolymer, polyvinyl chloride, plasticized nylon, plasticized polyethylene terephthalate, natural rubber, silicone rubbers, polydimethylsiloxanes, and silicone carbonate copolymers; hydrophilic polymers, such as ethyl cellulose, cellulose acetate, crospovidone, and cross-linked partially hydrolyzed polyvinyl acetate; and fatty compounds, such as carnauba wax, microcrystalline wax,

and triglycerides.

[00366] In a matrix-controlled release system, the desired release kinetics can be controlled, for example, *via* the polymer type employed, the polymer viscosity, the particle sizes of the polymer and/or the active ingredient(s), the ratio of the active ingredient(s) versus the polymer, and other excipients or carriers in the compositions.

[00367] The pharmaceutical composition provided herein in a modified release dosage form can be prepared by methods known to those skilled in the art, including direct compression, dry or wet granulation followed by compression, and melt-granulation followed by compression.

2. Osmotic Controlled Release Devices

[00368] The pharmaceutical composition provided herein in a modified release dosage form can be fabricated using an osmotic controlled release device, including, but not limited to, one-chamber system, two-chamber system, asymmetric membrane technology (AMT), and extruding core system (ECS). In general, such devices have at least two components: (a) a core which contains an active ingredient; and (b) a semipermeable membrane with at least one delivery port, which encapsulates the core. The semipermeable membrane controls the influx of water to the core from an aqueous environment of use so as to cause drug release by extrusion through the delivery port(s).

[00369] In addition to the active ingredient(s), the core of the osmotic device optionally includes an osmotic agent, which creates a driving force for transport of water from the environment of use into the core of the device. One class of osmotic agents is water-swelling hydrophilic polymers, which are also referred to as “osmopolymers” and “hydrogels.” Suitable water-swelling hydrophilic polymers as osmotic agents include, but are not limited to, hydrophilic vinyl and acrylic polymers, polysaccharides such as calcium alginate, polyethylene oxide (PEO), polyethylene glycol (PEG), polypropylene glycol (PPG), poly(2-hydroxyethyl methacrylate), poly(acrylic) acid, poly(methacrylic) acid, polyvinylpyrrolidone (PVP), crosslinked PVP, polyvinyl alcohol (PVA), PVA/PVP copolymers, PVA/PVP copolymers with hydrophobic monomers such as methyl methacrylate and vinyl acetate, hydrophilic polyurethanes containing large PEO blocks, sodium croscarmellose, carrageenan, hydroxyethyl

cellulose (HEC), hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), carboxymethyl cellulose (CMC) and carboxyethyl, cellulose (CEC), sodium alginate, polycarbophil, gelatin, xanthan gum, and sodium starch glycolate.

[00370] The other class of osmotic agents is osmogens, which are capable of imbibing water to affect an osmotic pressure gradient across the barrier of the surrounding coating. Suitable osmogens include, but are not limited to, inorganic salts, such as magnesium sulfate, magnesium chloride, calcium chloride, sodium chloride, lithium chloride, potassium sulfate, potassium phosphates, sodium carbonate, sodium sulfite, lithium sulfate, potassium chloride, and sodium sulfate; sugars, such as dextrose, fructose, glucose, inositol, lactose, maltose, mannitol, raffinose, sorbitol, sucrose, trehalose, and xylitol; organic acids, such as ascorbic acid, benzoic acid, fumaric acid, citric acid, maleic acid, sebacic acid, sorbic acid, adipic acid, edetic acid, glutamic acid, p-toluenesulfonic acid, succinic acid, and tartaric acid; urea; and mixtures thereof.

[00371] Osmotic agents of different dissolution rates can be employed to influence how rapidly the active ingredient(s) is initially delivered from the dosage form. For example, amorphous sugars, such as MANNOGEM™ EZ can be used to provide faster delivery during the first couple of hours to promptly produce the desired therapeutic effect, and gradually and continually release of the remaining amount to maintain the desired level of therapeutic or prophylactic effect over an extended period of time. In this case, the active ingredient(s) is released at such a rate to replace the amount of the active ingredient metabolized and excreted.

[00372] The core can also include a wide variety of other excipients and carriers as described herein to enhance the performance of the dosage form or to promote stability or processing.

[00373] Materials useful in forming the semipermeable membrane include various grades of acrylics, vinyls, ethers, polyamides, polyesters, and cellulosic derivatives that are water-permeable and water-insoluble at physiologically relevant pHs or are susceptible to being rendered water-insoluble by chemical alteration, such as crosslinking. Examples of suitable polymers useful in forming the coating, include plasticized, unplasticized, and reinforced cellulose acetate (CA), cellulose diacetate, cellulose triacetate, CA propionate, cellulose nitrate, cellulose acetate butyrate (CAB), CA ethyl carbamate, CAP, CA methyl carbamate, CA

succinate, cellulose acetate trimellitate (CAT), CA dimethylaminoacetate, CA ethyl carbonate, CA chloroacetate, CA ethyl oxalate, CA methyl sulfonate, CA butyl sulfonate, CA p-toluene sulfonate, agar acetate, amylose triacetate, beta glucan acetate, beta glucan triacetate, acetaldehyde dimethyl acetate, triacetate of locust bean gum, hydroxylated ethylene-vinylacetate, EC, PEG, PPG, PEG/PPG copolymers, PVP, HEC, HPC, CMC, CMEC, HPMC, HPMCP, HPMCAS, HPMCAT, poly(acrylic) acids and esters and poly-(methacrylic) acids and esters and copolymers thereof, starch, dextran, dextrin, chitosan, collagen, gelatin, polyalkenes, polyethers, polysulfones, polyethersulfones, polystyrenes, polyvinyl halides, polyvinyl esters and ethers, natural waxes, and synthetic waxes.

[00374] Semipermeable membrane can also be a hydrophobic microporous membrane, wherein the pores are substantially filled with a gas and are not wetted by the aqueous medium but are permeable to water vapor, as disclosed in U.S. Pat. No. 5,798,119. Such hydrophobic but water-vapor permeable membrane are typically composed of hydrophobic polymers such as polyalkenes, polyethylene, polypropylene, polytetrafluoroethylene, polyacrylic acid derivatives, polyethers, polysulfones, polyethersulfones, polystyrenes, polyvinyl halides, polyvinylidene fluoride, polyvinyl esters and ethers, natural waxes, and synthetic waxes.

[00375] The delivery port(s) on the semipermeable membrane can be formed post-coating by mechanical or laser drilling. Delivery port(s) can also be formed in situ by erosion of a plug of water-soluble material or by rupture of a thinner portion of the membrane over an indentation in the core. In addition, delivery ports can be formed during coating process, as in the case of asymmetric membrane coatings of the type disclosed in U.S. Pat. Nos. 5,612,059 and 5,698,220.

[00376] The total amount of the active ingredient(s) released and the release rate can substantially be modulated *via* the thickness and porosity of the semipermeable membrane, the composition of the core, and the number, size, and position of the delivery ports.

[00377] The pharmaceutical composition in an osmotic controlled-release dosage form can further comprise additional conventional excipients or carriers as described herein to promote performance or processing of the formulation.

[00378] The osmotic controlled-release dosage forms can be prepared according to

conventional methods and techniques known to those skilled in the art. *See, e.g., Remington: The Science and Practice of Pharmacy, supra*; Santus and Baker, *J. Controlled Release*, **1995**, 35, 1-21; Verma *et al.*, *Drug Dev. Ind. Pharm.*, **2000**, 26, 695-708; Verma *et al.*, *J. Controlled Release*, **2002**, 79, 7-27.

[00379] In certain embodiments, the pharmaceutical composition provided herein is formulated as an AMT controlled-release dosage form, which comprises an asymmetric osmotic membrane that coats a core comprising the active ingredient(s) and other pharmaceutically acceptable excipients or carriers. *See, e.g., U.S. Pat. No. 5,612,059 and WO 2002/17918*. The AMT controlled-release dosage forms can be prepared according to conventional methods and techniques known to those skilled in the art, including direct compression, dry granulation, wet granulation, and a dip-coating method.

[00380] In certain embodiments, the pharmaceutical composition provided herein is formulated as an ESC controlled-release dosage form, which comprises an osmotic membrane that coats a core comprising the active ingredient(s), a hydroxyethyl cellulose, and other pharmaceutically acceptable excipients or carriers.

3. Multiparticulate Controlled Release Devices

[00381] The pharmaceutical composition provided herein in a modified release dosage form can be fabricated as a multiparticulate controlled release device, which comprises a multiplicity of particles, granules, or pellets, ranging from about 10 μm to about 3 mm, about 50 μm to about 2.5 mm, or from about 100 μm to about 1 mm in diameter. Such multiparticulates can be made by the processes known to those skilled in the art, including wet-and dry-granulation, extrusion/spheronization, roller-compaction, melt-congealing, and by spray-coating seed cores. *See, e.g., Multiparticulate Oral Drug Delivery*; Ghebre-Sellassie Eds.; Drugs and the Pharmaceutical Sciences 65; CRC Press: 1994; and *Pharmaceutical Palletization Technology*; Ghebre-Sellassie Eds.; Drugs and the Pharmaceutical Sciences 37; CRC Press: 1989.

[00382] Other excipients or carriers as described herein can be blended with the pharmaceutical composition to aid in processing and forming the multiparticulates. The resulting particles can themselves constitute the multiparticulate device or can be coated by

various film-forming materials, such as enteric polymers, water-swellaable, and water-soluble polymers. The multiparticulates can be further processed as a capsule or a tablet.

4. Targeted Delivery

[00383] The pharmaceutical composition provided herein can also be formulated to be targeted to a particular tissue, receptor, or other area of the body of the subject to be treated, including liposome-, resealed erythrocyte-, and antibody-based delivery systems. Examples include, but are not limited to, those disclosed in U.S. Pat. Nos. 6,316,652; 6,274,552; 6,271,359; 6,253,872; 6,139,865; 6,131,570; 6,120,751; 6,071,495; 6,060,082; 6,048,736; 6,039,975; 6,004,534; 5,985,307; 5,972,366; 5,900,252; 5,840,674; 5,759,542; and 5,709,874.

Methods of Use

[00384] In one embodiment, provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a disorder, disease, or condition mediated by a PDE4 in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of a compound provided herein, *e.g.*, a compound of Formula (I) or (IA), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[00385] In certain embodiments, the disorder, disease, or condition is mediated by a PDE4A. In certain embodiments, the disorder, disease, or condition is mediated by a PDE4B. In certain embodiments, the disorder, disease, or condition is mediated by a PDE4C. In certain embodiments, the disorder, disease, or condition is mediated by a PDE4D. In certain embodiments, the disorder, disease, or condition is mediated by a PDE4D short isoform.

[00386] In certain embodiments, the disorder, disease, or condition mediated by a PDE4 is an inflammatory disease.

[00387] In another embodiment, provided herein is a method of treating, preventing, or ameliorating one or more symptoms of an inflammatory disease in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of a compound

provided herein, *e.g.*, a compound of Formula (I) or (IA), or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[00388] In certain embodiments, the inflammatory disease is arthritis, ankylosing spondylitis, osteoarthritis, rheumatoid arthritis, Behcet's disease, an inflammatory bowel disease, Crohn's disease, ulcerative colitis, psoriasis, psoriatic arthritis, atopic dermatitis, contact dermatitis, or COPD. In certain embodiments, the inflammatory disease is psoriasis. In some embodiments, the inflammatory disease is psoriatic arthritis. In certain embodiments, the inflammatory disease is atopic dermatitis. In certain embodiments, the inflammatory disease is contact dermatitis.

[00389] In certain embodiments, the subject is a mammal. In certain embodiments, the subject is a human.

[00390] In certain embodiments, the therapeutically effective amount of a compound provided herein is ranging from about 0.1 to about 100 mg/kg/day, from about 0.1 to about 50 mg/kg/day, from about 0.1 to about 60 mg/kg/day, from about 0.1 to about 50 mg/kg/day, from about 0.1 to about 25 mg/kg/day, from about 0.1 to about 20 mg/kg/day, from about 0.1 to about 15 mg/kg/day, from about 0.1 to about 10 mg/kg/day, or from about 0.1 to about 5 mg/kg/day. In one embodiment, the therapeutically effective amount of a compound provided herein is ranging from about 0.1 to about 100 mg/kg/day. In another embodiment, the therapeutically effective amount of a compound provided herein is ranging from about 0.1 to about 50 mg/kg/day. In yet another embodiment, the therapeutically effective amount of a compound provided herein is ranging from about 0.1 to about 60 mg/kg/day. In yet another embodiment, the therapeutically effective amount of a compound provided herein is ranging from about 0.1 to about 50 mg/kg/day. In yet another embodiment, the therapeutically effective amount of a compound provided herein is ranging from about 0.1 to about 25 mg/kg/day. In yet another embodiment, the therapeutically effective amount of a compound provided herein is ranging from about 0.1 to about 20 mg/kg/day. In yet another embodiment, the therapeutically effective amount of a compound provided herein is ranging from about 0.1 to about 15 mg/kg/day. In yet

another embodiment, the therapeutically effective amount of a compound provided herein is ranging from about 0.1 to about 10 mg/kg/day. In still another embodiment, the therapeutically effective amount of a compound provided herein is ranging from about 0.1 to about 5 mg/kg/day.

[00391] It is understood that the administered dose can also be expressed in units other than mg/kg/day. For example, doses for parenteral administration can be expressed as mg/m²/day. One of ordinary skill in the art would readily know how to convert doses from mg/kg/day to mg/m²/day to given either the height or weight of a subject or both. For example, a dose of 1 mg/m²/day for a 65 kg human is approximately equal to 58 mg/kg/day.

[00392] Depending on the disorder, disease, or condition to be treated and the subject's condition, a compound provided herein may be administered by oral, parenteral (*e.g.*, intramuscular, intraperitoneal, intravenous, CIV, intracisternal injection or infusion, subcutaneous injection, or implant), inhalation, nasal, vaginal, rectal, sublingual, or topical (*e.g.*, transdermal or local) routes of administration. A compound provided herein may be formulated in suitable dosage unit with a pharmaceutically acceptable excipient, carrier, adjuvant, or vehicle, appropriate for each route of administration.

[00393] In one embodiment, a compound provided herein is administered orally. In another embodiment, a compound provided herein is administered parenterally. In yet another embodiment, a compound provided herein is administered intravenously. In yet another embodiment, a compound provided herein is administered intramuscularly. In yet another embodiment, a compound provided herein is administered subcutaneously. In still another embodiment, a compound provided herein is administered topically.

[00394] A compound provided herein can be delivered as a single dose such as, *e.g.*, a single bolus injection, or oral tablets or pills; or over time such as, *e.g.*, continuous infusion over time or divided bolus doses over time. A compound provided herein can be administered repetitively if necessary, for example, until the subject experiences stable disease or regression, or until the patient experiences disease progression or unacceptable toxicity.

[00395] A compound provided herein can be administered once daily (QD) or divided into multiple daily doses such as twice daily (BID), and three times daily (TID). In addition, the

administration can be continuous, *i.e.*, every day, or intermittently. The term “intermittent” or “intermittently” as used herein is intended to mean stopping and starting at either regular or irregular intervals. For example, intermittent administration of a compound provided herein is administration for one to six days per week, administration in cycles (*e.g.*, daily administration for two to eight consecutive weeks, then a rest period with no administration for up to one week), or administration on alternate days.

[00396] In certain embodiments, a compound provided herein is cyclically administered to a subject. Cycling therapy involves the administration of an active agent for a period of time, followed by a rest for a period of time, and repeating this sequential administration. Cycling therapy can reduce the development of resistance to one or more of the therapies, avoid or reduce the side effects of one of the therapies, and/or improves the efficacy of the treatment.

[00397] A compound provided herein can also be combined or used in combination with other therapeutic agents useful in the treatment and/or prevention of a condition, disorder, or disease described herein.

[00398] As used herein, the term “in combination” includes the use of more than one therapy (*e.g.*, one or more prophylactic and/or therapeutic agents). However, the use of the term “in combination” does not restrict the order in which therapies (*e.g.*, prophylactic and/or therapeutic agents) are administered to a subject with a disease or disorder. A first therapy (*e.g.*, a prophylactic or therapeutic agent such as a compound provided herein) can be administered prior to (*e.g.*, 5 minutes, 15 minutes, 50 minutes, 65 minutes, 1 hour, 2 hours, 6 hours, 6 hours, 12 hours, 26 hours, 68 hours, 72 hours, 96 hours, 1 week, 2 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks before), concomitantly with, or subsequent to (*e.g.*, 5 minutes, 15 minutes, 50 minutes, 65 minutes, 1 hour, 2 hours, 6 hours, 12 hours, 26 hours, 68 hours, 72 hours, 96 hours, 1 week, 2 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after) the administration of a second therapy (*e.g.*, a prophylactic or therapeutic agent) to the subject. Triple therapy is also contemplated herein.

[00399] The route of administration of a compound provided herein is independent of the route of administration of a second therapy. In one embodiment, a compound provided herein is administered orally. In another embodiment, a compound provided herein is administered

topically. Thus, in accordance with these embodiments, a compound provided herein is administered orally or topically, and the second therapy can be administered orally, parenterally, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, *via* inhalation, vaginally, intraocularly, *via* local delivery by catheter or stent, subcutaneously, intraadiposally, intraarticularly, intrathecally, or in a slow release dosage form. In one embodiment, a compound provided herein and a second therapy are administered by the same mode of administration, orally or topically. In another embodiment, a compound provided herein is administered by one mode of administration, *e.g.*, topically, whereas the second agent (an anticancer agent) is administered by another mode of administration, *e.g.*, orally.

[00400] In one embodiment, provided herein is a method of inhibiting the activity of a PDE4, comprising contacting the PDE4 with an effective amount of a compound of Formula (I) or (IA), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[00401] In one embodiment, provided herein is a method of inducing degradation of a PDE4, comprising contacting the PDE4 with an effective amount of a compound of Formula (I) or (IA), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[00402] In certain embodiments, the PDE4 is a PDE4A. In certain embodiments, the PDE4 is a PDE4B. In certain embodiments, the PDE4 is a PDE4C. In certain embodiments, the PDE4 is a PDE4D. In certain embodiments, the PDE4 is a PDE4D. In certain embodiments, the PDE4 is a PDE4D short isoform.

[00403] A compound provided herein can also be provided as an article of manufacture using packaging materials well known to those of skill in the art. *See, e.g.*, U.S. Pat. Nos. 5,525,907; 5,052,558; and 5,055,252. Examples of pharmaceutical packaging materials include, but are not limited to, blister packs, bottles, tubes, inhalers, pumps, bags, vials, containers, syringes, and any packaging material suitable for a selected formulation and intended mode of

administration and treatment.

[00404] In certain embodiments, provided herein is a kit which, when used by a medical practitioner, can simplify the administration of an appropriate amount of a compound provided herein as an active ingredient to a subject. In certain embodiments, the kit provided herein includes a container and a dosage form of a compound provided herein.

[00405] Kits provided herein can further include devices that are used to administer the active ingredients. Examples of such devices include, but are not limited to, syringes, needle-less injectors drip bags, patches, and inhalers. The kits provided herein can also include condoms for administration of the active ingredients.

[00406] Kits provided herein can further include pharmaceutically acceptable vehicles that can be used to administer one or more active ingredients. For example, if an active ingredient is provided in a solid form that must be reconstituted for parenteral administration, the kit can comprise a sealed container of a suitable vehicle in which the active ingredient can be dissolved to form a particulate-free sterile solution that is suitable for parenteral administration. Examples of pharmaceutically acceptable vehicles include, but are not limited to: aqueous vehicles, including, but not limited to, water for injection USP, sodium chloride injection, Ringer's injection, dextrose injection, dextrose and sodium chloride injection, and lactated Ringer's injection; water-miscible vehicles, including, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and non-aqueous vehicles, including, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.

[00407] The disclosure will be further understood by the following non-limiting examples.

EXAMPLES


[00408] As used herein, the symbols and conventions used in these processes, schemes and examples, regardless of whether a particular abbreviation is specifically defined, are consistent with those used in the contemporary scientific literature, for example, the Journal of the American Chemical Society, the Journal of Medicinal Chemistry, or the Journal of Biological Chemistry. Specifically, but without limitation, the following abbreviations may be used in the examples and throughout the specification: g (grams); mg (milligrams); mL (milliliters); μ L


(microliters); mM (millimolar); μ M (micromolar); mmol (millimoles); h (hour or hours); min (minute or minutes); ACN (acetonitrile); AcOH (acetic acid); DCM (dichloromethane); DMF (dimethylformamide); DMSO (dimethyl sulfoxide); EtOH (ethanol); MeOH (methanol); EtOAc (ethyl acetate); PE (petroleum ether); THF (tetrahydrofuran); Ac₂O (acetic anhydride); CDI (1,1'-carbonyldiimidazole); DIBAL-H (diisobutylaluminum hydride); DIPEA (*N,N*-diisopropylethylamine); HATU (1-(bis(dimethylamino)methylene)-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxide hexafluorophosphate); HOBt (1-hydroxybenzotriazole); TEA (triethylamine); TFA (trifluoroacetic acid); HPLC (high-performance liquid chromatography); MS (mass spectrometry); NMR (nuclear magnetic resonance); and TLC (thin-layer chromatography).

[00409] For all of the following examples, standard work-up and purification methods known to those skilled in the art can be utilized. Unless otherwise indicated, all temperatures are expressed in °C (degrees Centigrade). All reactions are conducted at room temperature unless otherwise specified. Synthetic methodologies illustrated herein are intended to exemplify the applicable chemistry through the use of specific examples and are not indicative of the scope of the disclosure.

Example 1

Synthesis of *N*-(6-(7-(4-(2-(2,6-Dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)heptyl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide **A1** and *N*-(6-(7-(4-(2-(2,6-Dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)hept-1-yn-1-yl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide **A2**





[00410] To a solution of 2-methyl-3-nitrobenzoic acid (5.00 g, 27.6 mmol) in H₂SO₄ (25 mL) at 60 °C was added *N*-iodosuccinimide (7.458 g, 33.1 mmol) in portions. The mixture was stirred at 60 °C for 2 h and then poured into 150 g of ice. The mixture was filtered, washed with water and petroleum ether, and concentrated to afford 5-iodo-2-methyl-3-nitrobenzoic acid (8.302 g) in 98% yield. MS (ESI) *m/z*: 306.2 [M-H]⁻.

[00411] To a suspension of 5-iodo-2-methyl-3-nitrobenzoic acid (3.0 g, 10 mmol) in water (78 mL) was added NaOH (2M solution, 5.2 mL, 2.6 mmol), followed by addition of KMnO₄ (6.32 g, 40 mmol) at 60 °C. After refluxed overnight, the mixture was cooled to 80 °C, filtered, and washed with hot water. The filtrate was acidified to pH 1 with conc. HCl, filtered, and concentrated to afford 5-iodo-3-nitrophthalic acid (5.2 g) in a quantitative yield. MS (ESI) *m/z*: 335.9 [M-H]⁻.

[00412] A solution of 5-iodo-3-nitrophthalic acid (5.2 g, 10 mmol) in acetic anhydride (20 mL) was heated to 140 °C and stirred for 3 h. The mixture was concentrated to give 6-iodo-4-nitroisobenzofuran-1,3-dione (5.0 g, crude).

[00413] To a solution of 6-iodo-4-nitroisobenzofuran-1,3-dione (5.0 g, crude) in acetic acid (20 mL) was added (*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethanamine (4.1 g, 15 mmol). After stirred at 60 °C for 3 h, the mixture was concentrated and water/EtOH (4:1) was added. The resulting solid was collected by filtration and washed with petroleum ether to afford (*S*)-2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-6-iodo-4-nitroisindoline-1,3-dione (2.3 g) in 40% yield. MS (ESI) *m/z*: 574.9 [M+H]⁺.

[00414] To a solution of (*S*)-2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-6-iodo-4-nitroisindoline-1,3-dione (2.3 g, 4 mmol) in EtOH (40 mL) and water (20 mL) were

added NH₄Cl (1.08 g, 20 mmol) and iron powder (1.12 g, 20 mmol). After refluxed for 1 h, the mixture was filtered through celite, washed with ethyl acetate, concentrated, and purified using silica gel eluting with methanol in dichloromethane from 0% to 5% to give (*S*)-4-amino-2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-6-iodoisindoline-1,3-dione (1.366 g) in 63% yield. MS (ESI) *m/z*: 562.2 [M+NH₄]⁺.


[00415] To a solution of (*S*)-4-amino-2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-6-iodoisindoline-1,3-dione (1.366 g, 2.5 mmol) in dichloromethane (10 mL) were added triethylamine (0.7 mL, 5 mmol) and acetyl chloride (234 mg, 3 mmol) at 0 °C. The mixture was stirred at room temperature for 3 h and then concentrated. The residue was purified using silica gel eluting with ethyl acetate in petroleum ether from 50% to 85% to give (*S*)-*N*-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-6-iodo-1,3-dioxoisindolin-4-yl)-acetamide (700 mg) in 48% yield. MS (ESI) *m/z*: 587.5 [M+H]⁺.

[00416] To a solution of (*S*)-*N*-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-6-iodo-1,3-dioxoisindolin-4-yl)acetamide (450 mg, 0.77 mmol) and 3-(6-fluoro-4-(1-(hept-6-yn-1-yl)piperidin-4-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione (828 mg, 1.89 mmol) in *N,N*-dimethylformamide (10 mL) were added Pd(PPh₃)₂Cl₂ (112 mg, 0.16 mmol), CuI (30 mg, 0.16 mmol), and triethylamine (191 mg, 1.89 mmol) under N₂. After the mixture was stirred at 80 °C for 5 h, 1N HCl was added and the mixture was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated. The residue was purified using silica gel eluting with methanol in dichloromethane from 3% to 10% and further purified using prep-HPLC to afford *N*-(6-(7-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)hept-1-yn-1-yl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide **A2** (45 mg) in 7% yield. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.02 (s, 1H), 9.70 (s, 1H), 8.44 (s, 1H), 7.49 (s, 1H), 7.36 (d, *J* = 8.8 Hz, 2H), 7.06 (s, 1H), 6.98-6.90 (m, 2H), 5.79-5.73 (m, 1H), 5.14 (dd, *J* = 4.4, 12.4 Hz, 1H), 4.53-4.28 (m, 3H), 4.17-4.12 (m, 1H), 4.01 (q, *J* = 7.6 Hz, 2H), 3.73 (s, 3H), 3.01 (s, 3H), 2.97-2.54 (m, 2H), 2.67-2.54 (m, 2H), 2.43-2.32 (m, 2H), 2.19 (s, 3H), 2.03-1.95 (m, 3H), 1.80-1.73 (m, 4H), 1.65-1.45 (m, 6H), 1.32 (t, *J* = 6.0 Hz, 3H), 1.26-1.21 (m, 4H); MS (ESI) *m/z*: 898.3 [M+H]⁺.

[00417] To a solution of *N*-(6-(7-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)hept-1-yn-1-yl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide (50 mg, 0.06 mmol) in THF (3 mL) and MeOH (3 mL) was added Pd/C (5 mg, 0.04 mmol). After stirred under H₂ for 20 h, the mixture was filtered and washed with ethyl acetate. The filtrate was concentrated and the residue was purified using prep-HPLC to afford *N*-(6-(7-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)heptyl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide **A1** (12 mg) in 24% yield. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.01 (s, 1H), 9.64 (s, 1H), 8.28 (s, 1H), 7.46-7.31 (m, 3H), 7.06 (s, 1H), 6.98-6.90 (m, 2H), 5.76 (dd, *J* = 4.0, 10.4 Hz, 1H), 5.13 (dd, *J* = 5.2, 13.2 Hz, 1H), 4.52-4.31 (m, 3H), 4.15-4.10 (m, 1H), 4.01 (q, *J* = 6.8 Hz, 2H), 3.73 (s, 3H), 3.01 (s, 3H), 2.96-2.89 (m, 3H), 2.76-2.65 (m, 2H), 2.64-2.54 (m, 2H), 2.46-2.39 (m, 1H), 2.29-2.21 (m, 2H), 2.18 (s, 3H), 2.06-1.86 (m, 4H), 1.78-1.64 (m, 4H), 1.63-1.52 (m, 2H), 1.46-1.36 (m, 2H), 1.35-1.18 (m, 8H); MS (ESI) *m/z*: 902.3 [M+H]⁺.

Example 2

Synthesis of *N*-(6-(5-(4-((2-(2,6-Dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)ethynyl)piperidin-1-yl)-5-oxopentyl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide **A3**



[00418] To a solution of pent-4-ynoic acid (1.0 g, 10.20 mmol) in methanol (15 mL) was added H₂SO₄ (1.0 g, 10.20 mmol). After stirred at 70 °C for 16 h, the reaction was quenched by NaHCO₃ (aq.) (10 mL) and the reaction mixture was extracted with ethyl acetate. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated. The residue was purified using silica gel eluting with petroleum ether/ethyl acetate (20:1) to give methyl pent-4-ynoate (464 mg) in 46% yield.

[00419] To a solution of methyl pent-4-ynoate (191 mg, 1.7 mmol) in tetrahydrofuran (20 mL) were added (*S*)-*N*-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-6-iodo-1,3-dioxoisindolin-4-yl)acetamide (400 mg, 0.68 mmol), CuI (26 mg, 0.14 mmol), triethylamine (206 mg, 2.04 mmol), and Pd(PPh₃)₂Cl₂ (98 mg, 0.14 mmol). The mixture was stirred at 70 °C under N₂ atmosphere for 16 h and then concentrated. The residue was diluted with H₂O and extracted with ethyl acetate. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated. The residue was purified using prep-TLC eluting with DCM/MeOH (20:1) to give (*S*)-methyl 5-(7-acetamido-2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-5-yl)pent-4-ynoate (212 mg) in 55% yield. MS (ESI) *m/z*: 571.2 [M+H]⁺.

[00420] To a solution of (*S*)-methyl 5-(7-acetamido-2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-5-yl)pent-4-ynoate (212 mg, 0.37 mmol) in MeOH (10 mL) was added Pd/C (212 mg). After stirred under H₂ atmosphere for 16 h, the mixture was filtered and washed with dichloromethane. The combined filtrates were concentrated. The residue was purified using prep-TLC eluting with DCM/MeOH (20:1) to give (*S*)-methyl 5-(7-acetamido-2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-5-yl)pentanoate (199 mg) in 94% yield. MS (ESI) *m/z*: 575.2 [M+H]⁺.


[00421] To a solution of (*S*)-methyl 5-(7-acetamido-2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-5-yl)pentanoate (118 mg, 0.206 mmol) in tetrahydrofuran (10 mL) was added potassium trimethylsilanolate (79 mg, 0.618 mmol). The mixture was stirred at 0 °C for 3 h and then concentrated to afford (*S*)-5-(7-acetamido-2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-5-yl)pentanoic acid. MS (ESI) *m/z*: 561.2 [M+H]⁺.

[00422] To a solution of *tert*-butyl 4-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)ethynyl)piperidine-1-carboxylate (89 mg, 0.197 mmol) in dichloromethane (8 mL) was added HCl-ethyl acetate (2 mL). The mixture was stirred for 1 h and then concentrated to give 3-(1-oxo-4-(piperidin-4-ylethynyl)isindolin-2-yl)piperidine-2,6-dione HCl salt (75 mg), which was dissolved in *N,N*-dimethylformamide (1 mL). *N,N*-Diisopropylethylamine (76 mg, 0.591 mmol) was then added, followed by addition of a solution of (*S*)-5-(7-acetamido-2-(1-(3-ethoxy-4-

methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-5-yl)pentanoic acid (solution, 0.206 mmol), HOBt (40 mg, 0.296 mmol), and EDCI·HCl (57 mg, 0.296 mmol). After stirred overnight, the mixture was diluted with H₂O and extracted with ethyl acetate. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated. The residue was purified using prep-TLC eluting with dichloromethane/methanol (10:1) and further purified using prep-HPLC to give *N*-(6-(5-(4-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)ethynyl)piperidin-1-yl)-5-oxopentyl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide **A3** (6.6 mg) in 4% yield. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.00 (s, 1H), 9.66 (s, 1H), 8.29 (s, 1H), 7.73 (d, *J* = 7.2 Hz, 1H), 7.66 (d, *J* = 7.6 Hz, 1H), 7.54 (d, *J* = 7.6 Hz, 1H), 7.45 (s, 1H), 7.07 (s, 1H), 6.97-6.93 (m, 2H), 5.77 (dd, *J* = 4.4, 10.4 Hz, 1H), 5.13 (dd, *J* = 4.4, 12.8 Hz, 1H), 4.49-4.31 (m, 4H), 4.15-4.11 (m, 1H), 4.02 (q, *J* = 7.2 Hz, 2H), 3.89-3.84 (m, 2H), 3.74 (s, 3H), 3.72-3.57 (m, 2H), 3.22-3.17 (m, 1H), 3.02 (s, 3H), 2.97-2.90 (m, 1H), 2.75 (t, *J* = 6.8 Hz, 2H), 2.63-2.59 (m, 2H), 2.36-2.33 (m, 2H), 2.18 (s, 3H), 2.04-1.98 (m, 2H), 1.89-1.81 (m, 2H), 1.64-1.59 (m, 2H), 1.56-1.49 (m, 2H), 1.33 (t, *J* = 7.2 Hz, 2H); MS (ESI) *m/z*: 894.3[M+H]⁺.

Example 3

Synthesis of 14-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)-3,6,9,12-tetraoxatetradecan-1-amide **A4**




[00423] To a stirred solution of 2,2-dimethyl-4-oxo-3,8,11,14,17-pentaoxa-5-azanonadecan-19-oic acid (300 mg, 0.85 mmol) in dichloromethane (10 mL) were added oxalyl chloride (130 mg, 1.02 mmol) and 1 drop of *N,N*-dimethylformamide. The mixture was stirred for 2 h and then concentrated to give *tert*-butyl (14-chloro-14-oxo-3,6,9,12-tetraoxatetradecyl)carbamate (300 mg, crude).

[00424] To a stirred solution of *tert*-butyl (14-chloro-14-oxo-3,6,9,12-tetraoxatetradecyl)-carbamate (0.85 mmol) in tetrahydrofuran (10 mL) was added (*S*)-4-amino-2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)isoindoline-1,3-dione (120 mg, 0.287 mmol). The mixture was stirred overnight and then concentrated. The residue was purified using prep-TLC eluting with dichloromethane/methanol (20:1) to give (*S*)-14-amino-*N*-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)-3,6,9,12-tetraoxatetradecan-1-amide (90 mg) in 48% yield. MS (ESI) m/z : 652.2 $[M+H]^+$.

[00425] To a stirred solution of (*S*)-14-amino-*N*-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)-3,6,9,12-tetraoxatetradecan-1-amide (90 mg, 0.14 mmol) and 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (41 mg, 0.15 mmol) in 1-methyl-2-pyrrolidinone (3 mL) was added ethyldiisopropylamine (54 mg, 0.42 mmol). The mixture was stirred at 150 °C for 1 h under microwave. Water was added and the mixture was extracted with dichloromethane. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified using prep-HPLC to give 14-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)-3,6,9,12-tetraoxatetradecan-1-amide **A4** (9.8 mg) in 8% yield. ^1H NMR (400 MHz, DMSO- d_6) δ 11.09 (s, 1H), 10.35 (s, 1H), 8.67 (d, $J = 8.8$ Hz, 1H), 7.81 (t, $J = 8.0$ Hz, 1H), 7.58-7.52 (m, 2H), 7.10-7.08 (m, 2H), 7.02-6.91 (m, 3H), 6.56 (t, $J = 5.2$ Hz, 1H), 5.78 (dd, $J = 4.0, 10.4$ Hz, 1H), 5.04 (dd, $J = 5.2, 12.4$ Hz, 1H), 4.35-4.12 (m, 4H), 4.01 (q, $J = 7.2$ Hz, 2H), 3.76-3.72 (m, 5H), 3.68-3.64 (m, 2H), 3.58-3.55 (m, 2H), 3.54-3.52 (m, 2H), 3.49-3.46 (m, 8H), 3.01 (s, 3H), 2.88-2.82 (m, 1H), 2.60-2.53 (m, 2H), 2.04-1.99 (m, 1H), 1.31 (t, $J = 7.2$ Hz, 3H); MS (ESI) m/z : 908.2 $[M+H]^+$.

Example 4

Synthesis of *N*-(6-(3-(4-(2-(2,6-Dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)propyl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide **A5**




[00426] To a solution of (*S*)-*N*-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-6-iodo-1,3-dioxoisindolin-4-yl)acetamide (100 mg, 0.17 mmol) and 3-(6-fluoro-1-oxo-4-(1-(prop-2-yn-1-yl)piperidin-4-yl)isindolin-2-yl)piperidine-2,6-dione (130 mg, 0.34 mmol) in 5 mL of THF were added Pd(PPh₃)₂Cl₂ (24 mg, 0.034 mmol), CuI (6.5 mg, 0.034 mmol), and triethylamine (52 mg, 0.51 mmol) under N₂. After stirred at 70 °C for 3 h, the mixture was concentrated and purified using prep-TLC eluting with ethyl acetate to afford *N*-(6-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)prop-1-yn-1-yl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide (95 mg) in 66% yield. MS (ESI) *m/z*: 842.2 [M+H]⁺.

[00427] To a mixture of *N*-(6-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)prop-1-yn-1-yl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide (95 mg, 0.11 mmol) in 2 mL of THF was added Pd/C (10 mg). After stirred under H₂ for 48 h, the mixture was filtered and washed with ethyl acetate. The filtrate was concentrated and the residue purified using prep-HPLC to afford *N*-(6-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)propyl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide **A5** (31 mg) in 32% yield. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.01 (s, 1H), 9.64 (s, 1H), 8.28 (s, 1H), 7.47 (s, 1H), 7.40 (dd, *J* = 2.0, 11.2 Hz, 1H), 7.34 (dd, *J* = 2.0, 7.2 Hz, 1H), 7.06 (s, 1H), 6.98-6.90 (m, 2H), 5.75 (dd, *J* = 4.4, 10.4 Hz, 1H), 5.13 (dd, *J* = 4.8, 13.2 Hz, 1H), 4.52-4.33 (m, 3H), 4.15-4.09 (m, 1H), 4.01(q, *J* = 6.8 Hz, 2H), 3.73 (s, 3H), 3.01 (s, 3H), 2.96-2.89 (m, 3H), 2.76-2.65 (m, 2H), 2.64-2.54 (m, 2H), 2.46-2.39 (m, 1H), 2.29-2.21 (m, 2H), 2.18 (s, 3H), 2.06-1.86 (m, 3H), 1.78-1.64 (m, 4H), 1.63-1.52 (m, 2H), 1.32 (t, *J* = 6.8 Hz, 3H); MS (ESI) *m/z*: 846.1 [M+H]⁺.

Example 5

Synthesis of 12-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)dodecanamide **A6**



[00428] To a stirred solution of 12-aminododecanoic acid (1 g, 4.65 mmol) in 2N sodium hydroxide (15 mL) at 0 °C was added benzyl chloroformate (951 mg, 5.58 mmol) in 2N sodium hydroxide (15 mL). After stirred at 0 °C for 2 h, the mixture was diluted with H₂O and extracted with methyl *tert*-butyl ether. The aqueous layer was acidified to pH 3-4 with 1N hydrochloric acid and extracted with methyl *tert*-butyl ether. The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to give 12-(((benzyloxy)carbonyl)-amino)dodecanoic acid (700 mg) in 43% yield. MS (ESI) *m/z*: 350.2 [M+H]⁺.

[00429] To a stirred solution of 12-(((benzyloxy)carbonyl)amino)dodecanoic acid (700 mg, 2 mmol) in toluene (7 mL) was added thionyl chloride (1.19 g, 10 mmol). The mixture was stirred at 100 °C for 2 h and then concentrated to give benzyl (12-chloro-12-oxododecyl)carbamate (1.2 g, crude).

[00430] To a stirred solution of benzyl (12-chloro-12-oxododecyl)carbamate (1.2 g, 2 mmol) in tetrahydrofuran (4 mL) were added (*S*)-4-amino-2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)isoindoline-1,3-dione (418 mg, 1 mmol) and triethylamine (4 mL). The mixture was stirred for 3 days and then concentrated. The residue was purified using silica gel eluting with ethyl acetate in petroleum ether from 0 to 50% to give (*S*)-benzyl (12-((2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)amino)-12-oxododecyl)-carbamate (441 mg) in 59% yield. MS (ESI) *m/z*: 750.2 [M+H]⁺.


[00431] To a stirred solution of (*S*)-benzyl (12-((2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)amino)-12-oxododecyl)carbamate (441 mg, 0.59

mmol) in methanol (9 mL) and dichloromethane (1 mL) was added Pd/C (200 mg). After stirred overnight under hydrogen, the mixture was filtered and the filtrate was concentrated to give (*S*)-12-amino-*N*-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)dodecanamide (350 mg) in 96% yield. MS (ESI) m/z : 616.2 $[M+H]^+$.

[00432] To a stirred solution of (*S*)-12-amino-*N*-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)dodecanamide (180 mg, 0.29 mmol) in *N,N*-dimethylformamide (3 mL) were added 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisindoline-1,3-dione (96 mg, 0.35 mmol) and *N,N*-diisopropylethylamine (112 mg, 0.87 mmol). After stirred at 150 °C for 1 h under microwave, the mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified using prep-TLC eluting with petroleum ether/ethyl acetate (1:2) and further purified using prep-HPLC to give 12-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)dodecanamide **A6** (27.3 mg). ^1H NMR (400 MHz, DMSO- d_6) δ 11.11 (s, 1H), 9.66 (s, 1H), 8.48 (d, J = 8.4 Hz, 1H), 7.79 (t, J = 7.6 Hz, 1H), 7.59-7.55 (m, 2H), 7.10-7.06 (m, 2H), 7.03-6.99 (m, 2H), 6.94 (d, J = 8.0 Hz, 1H), 6.51 (t, J = 5.2 Hz, 1H), 5.80 (dd, J = 3.6, 10.0 Hz, 1H), 5.06 (dd, J = 5.2, 12.8 Hz, 1H), 4.39-4.34 (m, 1H), 4.16 (dd, J = 3.6, 14.4 Hz, 1H), 4.01 (q, J = 6.8 Hz, 2H), 3.74 (s, 3H), 3.29-3.26 (m, 2H), 3.03 (s, 3H), 2.93-2.86 (m, 1H), 2.63-2.55 (m, 2H), 2.48-2.45 (m, 2H), 2.08-2.02 (m, 1H), 1.63-1.54 (m, 4H), 1.35-1.25 (m, 17H); MS (ESI) m/z : 872.4 $[M+H]^+$.

Example 6

Synthesis of 9-(4-(2-(2,6-Dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-5-yl)piperidin-1-yl)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)-nonanamide **A7**



[00433] To a solution of 9-methoxy-9-oxononanoic acid (800 mg, 3.95 mmol) in dichloromethane (15 mL) was added oxalyl chloride (753 mg, 5.93 mmol), followed by addition DMF (1 drop). The mixture was stirred for 2 h and then concentrated to give methyl 9-chloro-9-oxononanoate (869 mg, crude).

[00434] To a solution of (*S*)-4-amino-2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)isoindoline-1,3-dione (823 mg, 1.97 mmol) in pyridine (10 mL) at 0 °C was added methyl 9-chloro-9-oxononanoate (869 mg, 3.95 mmol, crude). The mixture was stirred at room temperature overnight and then concentrated. The residue was purified using silica gel eluting with ethyl acetate in petroleum ether from 10% to 50% to give (*S*)-methyl 9-((2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)amino)-9-oxononanoate (659 mg) in 56% yield. MS (ESI) m/z : 603.2 [M+H]⁺.


[00435] To a solution of (*S*)-methyl 9-((2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)amino)-9-oxononanoate (659 mg, 1.09 mmol) in toluene (15 mL) at -70 °C under N₂ was added DIBAL-H (2.19 mL, 1 M in THF). After stirred at this temperature for 30 min, the reaction was quenched with sat. NH₄Cl (5 mL) and the reaction mixture was extracted with ethyl acetate. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated to give (*S*)-*N*-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)-9-oxononanamide (218 mg) in 35% yield. MS (ESI) m/z : 573.2[M+H]⁺.

[00436] To a solution of (*S*)-*N*-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)-9-oxononanamide (218 mg, 0.13 mmol) in DCM/methanol (8 mL/2 mL) were added 3-(6-fluoro-1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione (62 mg, 0.18 mmol) and *N,N*-diisopropylethylamine (23 mg, 0.18 mmol), followed by addition of NaBH₃CN (16 mg, 0.266 mmol). The mixture was stirred overnight and then concentrated. The residue was purified using silica gel eluting with methanol in dichloromethane from 0% to 10% and further purified using prep-HPLC to give 9-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-5-yl)piperidin-1-yl)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)nonanamide **A7** (43.4 mg) in 36% yield. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.99 (s, 1H), 9.67 (s, 1H), 8.46 (d, *J* = 8.4 Hz, 1H), 7.78 (t, *J* = 8.0 Hz, 1H), 7.59

(d, $J = 5.6$ Hz, 1H), 7.56 (d, $J = 7.6$ Hz, 1H), 7.46 (d, $J = 8.8$ Hz, 1H), 7.08 (d, $J = 1.6$ Hz, 1H), 6.99-6.92 (m, 2H), 5.77 (dd, $J = 4.4, 10.4$ Hz, 1H), 5.11 (dd, $J = 4.8, 13.2$ Hz, 1H), 4.43-4.26 (m, 3H), 4.15 (dd, $J = 4.4, 14.4$ Hz, 1H), 4.02 (q, $J = 6.8$ Hz, 2H), 3.73 (s, 3H), 3.01 (s, 3H), 2.97-2.84 (m, 4H), 2.61-2.57 (m, 1H), 2.47-2.45 (m, 2H), 2.41-2.36 (m, 1H), 2.27 (t, $J = 6.8$ Hz, 2H), 2.01-1.90 (m, 3H), 1.71-1.61 (m, 6H), 1.44-1.41 (m, 2H), 1.34-1.30 (m, 12H); MS (ESI) m/z : 902.4 $[M+H]^+$.

Example 7

Synthesis of *N*-(6-(7-(1-(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)piperidin-4-yl)-heptyl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide **A8**



[00437] To a stirred solution of 5-bromopentan-1-ol (10.0 g, 59.88 mmol) in DCM (100 mL) were added *p*-toluenesulfonic acid (1.5 g, 5.99 mmol) and a solution of 3,4-dihydro-2*H*-pyran (7.5 g, 89.82 mmol) in tetrahydrofuran (50 mL) at 0 °C. After stirred at room temperature overnight, the mixture was diluted with water and extracted with dichloromethane. The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified using silica gel eluting with petroleum ether/ethyl acetate (100:1) to give 2-((5-bromopentyl)oxy)tetrahydro-2*H*-pyran (11.0 g) in 73% yield. ^1H NMR (400 MHz, CDCl_3) δ 5.30 (s, 1H), 4.96-4.94 (m, 2H), 3.90-3.85 (m, 2H), 3.55-3.49 (m, 2H), 1.89-1.73 (m, 5H), 1.64-1.48 (m, 8H).

[00438] To a stirred solution of 4-methylpyridine (6.2 g, 66.0 mmol) in tetrahydrofuran (100 mL) was added 2.5M *n*-BuLi in tetrahydrofuran (31.7 mL, 79.2 mmol) at -60 °C dropwise. The mixture was stirred at room temperature for 1.5 hours. 2-((5-Bromopentyl)oxy)tetrahydro-2*H*-pyran (11.0 g, 44.0 mmol) in tetrahydrofuran (50 mL) was added at -60 °C. The reaction was stirred at room temperature overnight and then quenched with sat. NH_4Cl (aq.) (100 mL).

The reaction mixture was extracted with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified using silica gel eluting with petroleum ether/ethyl acetate (20:1) to give 4-(6-((tetrahydro-2H-pyran-2-yl)oxy)hexyl)pyridine (9.5 g) in 82% yield. MS (ESI) m/z : 264.2 $[M+H]^+$.

[00439] To a stirred solution of 4-(6-((tetrahydro-2H-pyran-2-yl)oxy)hexyl)pyridine (9.5 g, 36.1 mmol) in ethyl acetate (100 mL) was added HCl/EtOAc (20 mL). The mixture was stirred overnight and then filtered. The filter cake was washed with ethyl acetate. The solid was dried under vacuum to give 6-(pyridin-4-yl)hexan-1-ol hydrochloride (6.0 g) in 78% yield. MS (ESI) m/z : 180.2 $[M+H]^+$.

[00440] To a stirred solution of 6-(pyridin-4-yl)hexan-1-ol hydrochloride (6.0 g, 27.78 mmol) in ethanol (180 mL) was added platinum dioxide (600 mg) under nitrogen. The mixture was degassed and backfilled with hydrogen. The mixture was stirred overnight under nitrogen and then filtered. The filtrate was concentrated to give 6-(piperidin-4-yl)hexan-1-ol hydrochloride (6.2 g) in a quantitative yield. MS (ESI) m/z : 186.2 $[M+H]^+$.

[00441] To a stirred solution of 6-(piperidin-4-yl)hexan-1-ol hydrochloride (6.2 g, 27.9 mmol) in tetrahydrofuran/water (1:1 80 mL) were added triethylamine (5.6 g, 55.9 mmol) and di-*tert*-butyl dicarbonate (9.1 g, 41.9 mmol). The mixture was stirred for 3 h and then extracted with ethyl acetate. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated. The residue was purified using silica gel eluting with petroleum ether/ethyl acetate (20:1) to give *tert*-butyl 4-(6-hydroxyhexyl)piperidine-1-carboxylate (7.2 g) in 90% yield. ¹H NMR (400 MHz, CDCl₃) δ 4.02 (s, 2H), 3.60 (t, J = 6.4 Hz, 2H), 2.63 (t, J = 12.0 Hz, 2H), 1.77 (s, 1H), 1.62-1.49 (m, 4H), 1.42 (s, 9H), 1.36-1.16 (m, 8H), 1.07-0.98 (m, 2H).

[00442] To a stirred solution of *tert*-butyl 4-(6-hydroxyhexyl)piperidine-1-carboxylate (2 g, 7.02 mmol) in dichloromethane (40 mL) was added Dess-Martin reagent (3.57 g, 8.42 mmol). After stirred for 3 h, the mixture was filtered and washed with dichloromethane. The filtrate was concentrated and the residue was purified using silica gel eluting with methanol in dichloromethane from 0% to 10% to give *tert*-butyl 4-(6-oxohexyl)piperidine-1-carboxylate (1.6 g) in 81% yield. ¹H NMR (400 MHz, CDCl₃) δ 9.80 (s, 1H), 4.10 (s, 2H), 2.70 (t, J = 16.4 Hz, 2H), 2.46 (t, J = 9.6 Hz, 2H), 1.69-1.64 (m, 4H), 1.49 (s, 9H), 1.36-1.25 (m, 7H), 1.16-1.07 (m,

2H).

[00443] To a stirred solution of *tert*-butyl 4-(6-oxohexyl)piperidine-1-carboxylate (1.6 g, 5.65 mmol) and potassium carbonate (1.56 g, 11.31 mmol) in methanol (30 mL) was added dimethyl (1-diazo-2-oxopropyl)phosphonate (1.14 g, 5.94 mmol). The mixture was stirred overnight and then diluted with water (50 mL). The organic solvent was removed under vacuum. The aqueous phase was extracted with petroleum ether. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated to give *tert*-butyl 4-(hept-6-yn-1-yl)piperidine-1-carboxylate (1.2 g) in 76% yield. ¹H NMR (400 MHz, CDCl₃) δ 4.10 (s, 2H), 2.70-2.63 (m, 2H), 2.18 (m, 2H), 1.94 (t, *J* = 2.4 Hz, 1H), 1.65-1.49 (m, 5H), 1.46 (s, 9H), 1.42-1.21 (m, 6H), 1.11-1.04 (m, 2H).

[00444] To a stirred solution of (*S*)-*N*-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-6-iodo-1,3-dioxoisindolin-4-yl)acetamide (1 g, crude), *tert*-butyl 4-(hept-6-yn-1-yl)piperidine-1-carboxylate (953 mg, 3.41 mmol), and triethylamine (517 mg, 5.12 mmol) in tetrahydrofuran (15 mL) were added cuprous iodide (65 mg, 0.341 mmol) and Pd(PPh₃)Cl₂ (240 mg, 0.34 mmol) under nitrogen. The mixture was degassed and backfilled with nitrogen. After stirred at 70 °C for 4 h, the mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated. The residue was purified using silica gel eluting with PE/EtOAc (5:1) to give (*S*)-*tert*-butyl 4-(7-(7-acetamido-2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-5-yl)hept-6-yn-1-yl)piperidine-1-carboxylate (520 mg). MS (ESI) *m/z*: 638.3 [M+H]⁺.

[00445] To a stirred solution of (*S*)-*tert*-butyl 4-(7-(7-acetamido-2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-5-yl)hept-6-yn-1-yl)piperidine-1-carboxylate (520 mg, 0.706 mmol) in MeOH (20 mL) was added Pd/C (100 mg) under nitrogen. The mixture was degassed and backfilled with hydrogen. The mixture was stirred overnight and then filtered. The filtrate was concentrated to give (*S*)-*tert*-butyl 4-(7-(7-acetamido-2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-5-yl)heptyl)piperidine-1-carboxylate (470 mg) in 83% yield. MS (ESI) *m/z*: 642.4 [M+H]⁺.


[00446] To a stirred solution of (*S*)-*tert*-butyl 4-(7-(7-acetamido-2-(1-(3-ethoxy-4-

methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-5-yl)heptyl)piperidine-1-carboxylate (50 mg, 0.068 mmol) in dichloromethane (1.5 mL) was added trifluoroacetic acid (0.5 mL). The mixture was stirred for 1 h and then concentrated. The residue was dissolved in tetrahydrofuran (2 mL) and then potassium carbonate (19 mg, 0.14 mmol) was added. The mixture was stirred for 10 min and then concentrated. The residue was purified using silica gel eluting with dichloromethane/methanol (20:1) and further purified using prep-HPLC to afford (*S*)-*N*-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxo-6-(7-(piperidin-4-yl)heptyl)isoindolin-4-yl)acetamide (43 mg) in a quantitative yield. MS (ESI) *m/z*: 642.4 [M+H]⁺.

[00447] To a stirred solution of (*S*)-*N*-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxo-6-(7-(piperidin-4-yl)heptyl)isoindolin-4-yl)acetamide (43 mg, 0.067 mmol) and DIPEA (22 mg, 0.168 mmol) in *N*-methylpyrrolidone (2 mL) was added 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (6) (22 mg, 0.081 mmol) under nitrogen. After heated at 150 °C under microwave for 2.5 h, the mixture was poured into ethyl acetate (25 mL) and then washed with 1M LiCl aqueous solution. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated. The residue was purified using silica gel eluting with methanol in dichloromethane from 0% to 10% and further purified using prep-HPLC to afford *N*-(6-(7-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)piperidin-4-yl)heptyl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide (15.5 mg) **A8** in 26% yield. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.08 (s, 1H), 9.64 (s, 1H), 8.28 (s, 1H), 7.66 (t, *J* = 7.6 Hz, 1H), 7.43 (s, 1H), 7.33-7.30 (m, 2H), 7.06 (s, 1H), 6.96-6.91 (m, 2H), 5.75 (dd, *J* = 10.8 Hz, 4.4 Hz, 1H), 5.08 (dd, *J* = 12.8 Hz, 5.2 Hz, 1H), 4.34-4.30 (m, 1H), 4.15-4.11 (m, 1H), 4.01 (q, *J* = 6.8 Hz, 2H), 3.73 (s, 3H), 3.67 (d, *J* = 12.4 Hz, 2H), 3.01 (s, 3H), 2.86-2.80 (m, 3H), 2.73-2.70 (m, 2H), 2.54-2.50 (m, 2H), 2.17 (s, 3H), 2.03-1.98 (m, 2H), 1.74 (d, *J* = 12.0 Hz, 2H), 1.60-1.57 (m, 2H), 1.33-1.30 (m, 15H); MS (ESI) *m/z*: 898.4 [M+H]⁺.

Example 8

Synthesis of 3-(2-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)-ethoxy)ethoxy)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)propanamide **A9**



[00448] To a stirred solution of *tert*-butyl (2-(2-hydroxyethoxy)ethyl)carbamate (2 g, 9.76 mmol) in toluene (20 mL) were added ethyl acrylate (2.928 g, 29.28 mmol) and cesium carbonate (6.344 g, 19.52 mmol). After stirred at 50 °C overnight, the mixture was concentrated, diluted with H₂O, and extracted with ethyl acetate. The combined organic layers were concentrated. The residue was purified using silica gel eluting with ethyl acetate in petroleum ether from 0 to 50% to give ethyl 2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatetradecan-14-oate (948 mg) in 32% yield.

[00449] To a stirred solution of ethyl 2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatetradecan-14-oate (948 mg, 3.11 mmol) in tetrahydrofuran (8 mL), methanol (2 mL), and H₂O (2 mL) at 0 °C was added lithium hydroxide (266 mg, 6.22 mmol). After stirred at room temperature overnight, the mixture was concentrated, diluted with H₂O, and extracted with methyl *tert*-butyl ether. The aqueous phase was acidified to pH 5-6 with 1N hydrochloric acid and extracted with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated to give 2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatetradecan-14-oic acid (644 mg) in 74% yield. MS (ESI) *m/z*: 275 [M-H]⁺.

[00450] To a stirred solution of 2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatetradecan-14-oic acid (644 mg, 2.32 mmol) in dichloromethane (8 mL) at 0 °C were added oxalyl chloride (359 mg, 2.78 mmol) and 1 drop of *N,N*-dimethylformamide. The mixture was stirred at room temperature for 1 h and then concentrated to give *tert*-butyl (2-(2-(3-chloro-3-oxopropoxy)ethoxy)ethyl)carbamate (650 mg, crude).


[00451] To a stirred solution of *tert*-butyl (2-(2-(3-chloro-3-oxopropoxy)ethoxy)ethyl)carbamate (2.32 mmol, crude) in tetrahydrofuran (3 mL) was added (*S*)-4-amino-2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)isoindoline-1,3-dione (388 mg, 0.93 mmol). The mixture was stirred overnight and then concentrated. The residue was purified using prep-TLC

eluting with dichloromethane/methanol (10:1) to give (*S*)-14-amino-*N*-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)-3,6,9,12-tetraoxatetradecan-1-amide (35 mg) in 7% yield. MS (ESI) m/z : 578.2 $[M+H]^+$.

[00452] To a stirred solution of ((*S*)-14-amino-*N*-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)-3,6,9,12-tetraoxatetradecan-1-amide (35 mg, 0.06 mmol) and 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisindoline-1,3-dione (33 mg, 0.12 mmol) in *N,N*-dimethylformamide (3 mL) was added *N,N*-diisopropylethylamine (23 mg, 0.18 mmol). The mixture was stirred at 150 °C for 1 h under microwave. Water was added and the mixture was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified using prep-TLC eluting with ethyl acetate to give 3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)ethoxy)ethoxy)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)propanamide **A9** (16.3 mg) in 33% yield. ^1H NMR (400 MHz, DMSO- d_6) δ 11.08 (s, 1H), 9.87 (s, 1H), 8.52 (d, J = 8.4 Hz, 1H), 7.75 (t, J = 7.6 Hz, 1H), 7.53-7.48 (m, 2H), 7.10-7.05 (m, 1H), 6.99-6.97 (m, 3H), 6.92 (d, J = 8.0 Hz, 1H), 6.53 (t, J = 5.6 Hz, 1H), 5.77 (dd, J = 4.4, 10.8 Hz, 1H), 5.03 (dd, J = 5.2, 12.4 Hz, 1H), 4.36-4.30 (m, 1H), 4.14 (dd, J = 4.4, 14.8 Hz, 1H), 4.01 (q, J = 6.4 Hz, 2H), 3.76-3.75 (m, 2H), 3.72 (s, 3H), 3.61-3.57 (m, 6H), 3.01 (s, 3H), 2.91-2.82 (m, 1H), 2.69-2.65 (m, 2H), 2.59-2.55 (m, 1H), 2.45-2.43 (m, 2H), 2.05-1.98 (m, 2H), 1.31 (t, J = 6.8 Hz, 3H); MS (ESI) m/z : 834.3 $[M+H]^+$.

Example 9

Synthesis of 7-(((4-((5-((*S*)-2,6-Dioxopiperidin-3-yl)-4-oxo-5,6-dihydro-4*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy)benzyl)amino)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)heptanamide **A38**



[00453] To a stirred solution of 7-(((benzyloxy)carbonyl)amino)heptanoic acid (500 mg,

1.79 mmol) in toluene (10 mL) was added thionyl chloride (1.1 g, 9.24 mmol). The mixture was stirred at 100 °C for 2 h and then concentrated to give benzyl (7-chloro-7-oxoheptyl)carbamate (crude).

[00454] To a stirred solution of benzyl (7-chloro-7-oxoheptyl)carbamate (1.79 mmol) in tetrahydrofuran (10 mL) was added (*S*)-4-amino-2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)isoindoline-1,3-dione (375 mg, 0.9 mmol). The mixture was stirred for 3 days and then concentrated. The residue was purified using silica gel eluting with ethyl acetate in petroleum ether from 20% to 50% to give (*S*)-benzyl (7-((2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)amino)-7-oxoheptyl)carbamate (565 mg) in 93% yield. MS (ESI) *m/z*: 680.2 [M+H]⁺.


[00455] To a stirred solution of (*S*)-benzyl (7-((2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)amino)-7-oxoheptyl)carbamate (200 mg, 0.29 mmol) in methanol (5 mL) was added 10% Pd/C (200 mg). After stirred at room temperature overnight under hydrogen, the mixture was filtered and the filtrate was concentrated to give (*S*)-7-amino-*N*-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)heptanamide (135 mg) in 84% yield. MS (ESI) *m/z*: 546.2 [M+H]⁺.

[00456] To a stirred solution of (*S*)-7-amino-*N*-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)heptanamide (135 mg, 0.25 mmol) and (*S*)-4-((5-(2,6-dioxopiperidin-3-yl)-4-oxo-5,6-dihydro-4*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy)-benzaldehyde (95 mg, 0.25 mmol) in dichloromethane (4 mL) and methanol (1 mL) were added sodium cyanoborohydride (32 mg, 0.5 mmol) and acetic acid (2 drops). The mixture was stirred overnight then concentrated. The residue was purified using prep-TLC (DCM/methanol (10:1) and further purified using prep-HPLC to give 7-(((4-((5-((*S*)-2,6-dioxopiperidin-3-yl)-4-oxo-5,6-dihydro-4*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy)benzyl)amino)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)heptanamide **A38** (8.0 mg). ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.99 (s, 1H), 9.66 (s, 1H), 8.66 (brs, 2H), 8.46 (d, *J* = 8.4 Hz, 1H), 8.03 (s, 1H), 7.79 (t, *J* = 8.0 Hz, 1H), 7.57 (d, *J* = 7.2 Hz, 1H), 7.42 (d, *J* = 8.8 Hz, 2H), 7.12-7.07 (m, 3H), 7.00-6.92 (m, 2H), 5.77 (dd, *J* = 4.0, 10.4 Hz, 1H), 5.34 (s, 2H), 5.02 (dd, *J* = 4.8, 13.2 Hz, 1H), 4.38-4.30 (m, 2H), 4.24-4.12 (m, 2H), 4.07 (t, *J* = 4.8 Hz, 2H), 4.01 (q, *J* = 6.4

Hz, 2H), 3.73 (s, 3H), 3.01 (s, 3H), 2.97-2.85 (m, 3H), 2.67-2.53 (m, 1H), 2.49-2.46 (m, 2H), 2.38-2.28 (m, 1H), 2.02-1.97 (m, 1H), 1.66-1.58 (m, 4H), 1.38-1.30 (m, 7H); MS (ESI) m/z : 914.2 $[M+H]^+$.

Example 10

Synthesis of 5-((4-((5-(2,6-Dioxopiperidin-3-yl)-4-oxo-5,6-dihydro-4*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy)benzyl)amino)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)pentanamide **A39**



[00457] To a stirred solution of 5-bromopentanoic acid (300 mg, 1.66 mmol) in toluene (6 mL) was added thionyl chloride (988 mg, 8.3 mmol). The mixture was stirred at 100 °C for 2 h and then concentrated to give 5-bromopentanoyl chloride (320 mg, crude).

[00458] To a stirred solution of 5-bromopentanoyl chloride (1.66 mmol, crude) in tetrahydrofuran (10 mL) was added (*S*)-4-amino-2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)isoindoline-1,3-dione (150 mg, 0.36 mmol). The mixture was stirred overnight and then concentrated. The residue was purified using prep-TLC eluting with petroleum/ethyl acetate (1:1) to give (*S*)-5-bromo-*N*-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)pentanamide (200 mg) in 96% yield. MS (ESI) m/z : 581.2 $[M+H]^+$, 598.2 $[M+NH_4]^+$.

[00459] To a stirred solution of (*S*)-5-bromo-*N*-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)pentanamide (200 mg, 0.34 mmol) in *N,N*-dimethylformamide (4 mL) were added sodium azide (45 mg, 0.68 mmol) and potassium iodide (6 mg, 0.034 mmol). After stirred at 55 °C overnight, the reaction was quenched with water and the reaction mixture was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give (*S*)-5-azido-*N*-


(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)-pentanamide (120 mg, crude). MS (ESI) m/z : 561.2 $[M+NH_4]^+$.

[00460] To a stirred solution of (*S*)-5-azido-*N*-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)pentanamide (0.34 mmol, crude) in tetrahydrofuran (10 mL) and water (0.5 mL) was added triphenylphosphine (135 mg, 0.52 mmol). The mixture was stirred overnight and then concentrated. The residue was purified using prep-TLC eluting with dichloromethane/methanol (10:1) to give (*S*)-5-amino-*N*-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)pentanamide (70 mg) in 39% yield. MS (ESI) m/z : 518.2 $[M+H]^+$.

[00461] To a stirred solution of (*S*)-5-amino-*N*-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)pentanamide (70 mg, 0.135 mmol) and 4-((5-(2,6-dioxopiperidin-3-yl)-4-oxo-5,6-dihydro-4*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy)benzaldehyde (52 mg, 0.135 mmol) in dichloromethane (4 mL) and methanol (1 mL) were added sodium cyanoborohydride (26 mg, 0.41 mmol) and acetic acid (1 drop). The mixture was stirred overnight and then concentrated. The residue was purified using prep-HPLC to give 5-((4-((5-(2,6-dioxopiperidin-3-yl)-4-oxo-5,6-dihydro-4*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy)benzyl)-amino)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)pentanamide **A39** (49.9 mg) in 42% yield. ^1H NMR (400 MHz, DMSO- d_6) δ 9.67 (s, 1H), 8.46 (d, J = 8.4 Hz, 1H), 8.00 (s, 1H), 7.79 (t, J = 8.0 Hz, 1H), 7.56 (d, J = 7.2 Hz, 1H), 7.25 (d, J = 8.4 Hz, 2H), 7.07 (s, 1H), 6.98-6.91 (m, 4H), 5.77 (dd, J = 4.0, 10.4 Hz, 1H), 5.27 (s, 2H), 5.01 (dd, J = 4.8, 13.2 Hz, 1H), 4.36-4.31 (m, 2H), 4.24-4.11 (m, 2H), 4.01 (q, J = 6.8 Hz, 2H), 3.72 (s, 3H), 3.64 (s, 2H), 3.18 (s, 3H), 2.89-2.83 (m, 1H), 2.60-2.53 (m, 3H), 2.46 (t, J = 7.2 Hz, 2H), 2.35-2.31 (m, 1H), 2.01-1.96 (m, 1H), 1.66-1.61 (m, 2H), 1.52-1.47 (m, 2H), 1.31 (t, J = 7.2 Hz, 3H); MS (ESI) m/z : 886.3 $[M+H]^+$.

Example 11

Synthesis of *N*¹-(2-((*S*)-1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)-*N*¹⁰-((*S*)-1-((2*S*,4*R*)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)-carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)decanediamide **A60**



[00462] To a stirred solution of 10-(*tert*-butoxy)-10-oxodecanoic acid (370 mg, 1.43 mmol) in dichloromethane (10 mL) were added oxalyl chloride (182 mg, 1.43 mmol) and 2 drops of *N,N*-dimethylformamide. The mixture was stirred at 0 °C for 2 h and then concentrated to give *tert*-butyl 10-chloro-10-oxodecanoate (350 mg, crude).

[00463] To a stirred solution of *tert*-butyl 10-chloro-10-oxodecanoate (1.43 mmol) in tetrahydrofuran (10 mL) was added (*S*)-4-amino-2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)isoindoline-1,3-dione (200 mg, 0.47 mmol). The mixture was stirred for 2 days and then concentrated. The residue was purified using silica gel eluting with ethyl acetate in petroleum ether from 20% to 50% to give (*S*)-*tert*-butyl 10-((2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)amino)-10-oxodecanoate (207 mg) in 43% yield. MS (ESI) m/z : 659.3 $[M+H]^+$.


[00464] To a stirred solution of (*S*)-*tert*-butyl 10-((2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)amino)-10-oxodecanoate (100 mg, 0.15 mmol) in dichloromethane (4 mL) was added trifluoroacetic acid (1 mL). The mixture was stirred for 1 h and then concentrated to give (*S*)-10-((2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)amino)-10-oxodecanoic acid. MS (ESI) m/z : 603.2 $[M+H]^+$.

[00465] To a stirred solution of (*S*)-10-((2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)amino)-10-oxodecanoic acid (91 mg, 0.15 mmol) in *N,N*-dimethylformamide (3 mL) was added (2*S*,4*R*)-1-((*S*)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (64.5 mg, 0.35 mmol), followed by addition of ethyldiisopropylamine (59 mg, 0.45 mmol), 1-hydroxybenzotriazole (31 mg, 0.22 mmol), and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (44 mg, 0.22 mmol). The mixture was stirred overnight and then concentrated. The residue was purified using prep-HPLC to give *N*¹-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-

1,3-dioxoisindolin-4-yl)-*N*¹⁰-(((*S*)-1-(((2*S*,4*R*)-4-hydroxy-2-(((4-(4-methylthiazol-5-yl)benzyl)-carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)decanediamide **A60** (31.8 mg) in 20% yield. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.66 (s, 1H), 8.98 (s, 1H), 8.56 (t, *J* = 6.0 Hz, 1H), 8.46 (d, *J* = 8.4 Hz, 1H), 7.85-7.76 (m, 2H), 7.56 (d, *J* = 7.2 Hz, 1H), 7.43-7.37 (m, 4H), 7.08-7.07 (m, 1H), 6.99-6.92 (m, 2H), 5.77 (dd, *J* = 4.0, 10.4 Hz, 1H), 5.11 (d, *J* = 3.6 Hz, 1H), 4.54 (d, *J* = 9.6 Hz, 1H), 4.46-4.12 (m, 6H), 4.02 (q, *J* = 6.8 Hz, 2H), 3.73 (s, 3H), 3.68-3.62 (m, 2H), 3.01 (s, 3H), 2.47-2.44 (m, 5H), 2.29-2.22 (m, 1H), 2.13-2.10 (m, 1H), 2.02-2.00 (m, 1H), 1.93-1.86 (m, 1H), 1.62-1.44 (m, 4H), 1.33-1.25 (m, 11H), 0.92 (s, 9H); MS (ESI) *m/z*: 1015.4 [*M*+*H*]⁺.


[00466] The following compounds were prepared similarly according to the synthetic procedures or methodologies exemplified herein.

[00467] 3-(2-(2-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)ethoxy)-ethoxy)ethoxy)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)propanamide **A10**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.09 (s, 1H), 9.86 (s, 1H), 8.53 (d, *J* = 8.4 Hz, 1H), 7.78 (t, *J* = 8.0 Hz, 1H), 7.56-7.52 (m, 2H), 7.09-7.07 (m, 2H), 7.02-6.92 (m, 3H), 6.56 (t, *J* = 6.0 Hz, 1H), 5.78 (dd, *J* = 4.0, 10.4 Hz, 1H), 5.05 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.37-4.31 (m, 1H), 4.17-4.12 (m, 1H), 4.01 (q, *J* = 7.2 Hz, 2H), 3.72-3.71 (m, 5H), 3.56-3.55 (m, 6H), 3.49 (s, 4H), 3.43-3.40 (m, 2H), 3.01 (s, 3H), 2.89-2.84 (m, 1H), 2.69 (t, *J* = 6.0 Hz, 2H), 2.61-2.53 (m, 2H), 2.04-2.01 (m, 1H), 1.31 (t, *J* = 6.8 Hz, 3H); MS (ESI) *m/z*: 878.3 [M+H]⁺.




[00468] 3-(((4-((2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)ethoxy)-methyl)benzyl)oxy)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)propanamide **A11**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.09 (s, 1H), 9.90 (s, 1H), 8.52 (d, *J* = 8.0 Hz, 1H), 7.79 (t, *J* = 8.0 Hz, 1H), 7.58-7.53 (m, 2H), 7.29-7.23 (m, 4H), 7.13-7.08 (m, 2H), 7.03 (d, *J* = 7.2 Hz, 1H), 6.98-6.91 (m, 2H), 6.64 (t, *J* = 6.0 Hz, 1H), 5.78 (dd,

$J = 4.4, 10.4$ Hz, 1H), 5.06 (dd, $J = 5.2, 12.8$ Hz, 1H), 4.53 (s, 2H), 4.48 (s, 2H), 4.36-4.30 (m, 1H), 4.16-4.12 (m, 1H), 3.99 (q, $J = 6.4$ Hz, 2H), 3.74-3.72 (m, 5H), 3.61-3.58 (m, 2H), 3.51-3.47 (m, 2H), 3.00 (s, 3H), 2.88-2.85 (m, 1H), 2.74 (t, $J = 6.0$ Hz, 2H), 2.61-2.53 (m, 2H), 2.04-2.01 (m, 1H), 1.29 (t, $J = 7.2$ Hz, 3H); MS (ESI) m/z : 910.3 $[M+H]^+$.




[00469] 9-((4-((5-(2,6-Dioxopiperidin-3-yl)-4-oxo-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)methoxy)benzyl)amino)-N-(2-((S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)nonanamide **A12**. ^1H NMR (400 MHz, DMSO- d_6) δ 9.66 (s, 1H), 8.46 (d, $J = 8.4$ Hz, 1H), 8.00 (s, 1H), 7.78 (t, $J = 8.0$ Hz, 1H), 7.56 (d, $J = 7.6$ Hz, 1H), 7.22 (d, $J = 8.0$ Hz, 2H), 7.07 (s, 1H), 6.98-6.91 (m, 4H), 5.78-5.75 (m, 1H), 5.27 (s, 2H), 5.01 (dd, $J = 4.8, 13.2$ Hz, 1H), 4.36-4.30 (m, 2H), 4.23-4.11 (m, 2H), 4.01 (q, $J = 7.2$ Hz, 2H), 3.72 (s, 3H), 3.58 (s, 2H), 3.04 (s, 3H), 2.91-2.85 (m, 1H), 2.60-2.54 (m, 1H), 2.47-2.40 (m, 4H), 2.35-2.31 (m, 1H), 2.00-1.96 (m, 2H), 1.62-1.58 (m, 2H), 1.40-1.35 (m, 2H), 1.33-1.29 (m, 6H), 1.28-1.24 (m, 5H); MS (ESI) m/z : 942.4 $[M+H]^+$.




[00470] 9-(4-(2-(2,6-Dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)-N-(2-((S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)nonanamide **A13**. ^1H NMR (400 MHz, DMSO- d_6) δ 11.00 (s, 1H), 9.68 (s, 1H), 8.46 (d, $J = 8.4$ Hz, 1H), 7.79 (t, $J = 8.0$ Hz, 1H), 7.56 (d, $J = 7.2$ Hz, 1H), 7.39-7.34 (m, 2H), 7.08 (s, 1H), 6.99-6.92 (m, 2H), 5.78 (dd, $J = 4.0, 10.4$ Hz, 1H), 5.13 (dd, $J = 5.2, 13.2$ Hz, 1H), 4.52-4.31 (m,

3H), 4.14 (dd, $J = 4.0, 14.0$ Hz, 1H), 4.02 (q, $J = 6.8$ Hz, 2H), 3.73 (s, 3H), 3.01 (s, 3H), 2.95-2.87 (m, 3H), 2.63-2.58 (m, 2H), 2.47-2.45 (m, 2H), 2.26 (t, $J = 6.4$ Hz, 2H), 2.03-1.91 (m, 3H), 1.71-1.61 (m, 6H), 1.47-1.41 (m, 2H), 1.34-1.30 (m, 12H); MS (ESI) m/z : 902.4 $[M+H]^+$.




[00471] *N*-(6-(12-(4-(2-(2,6-Dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)dodecyl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide **A14**. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 11.02 (s, 1H), 9.65 (s, 1H), 8.28 (s, 1H), 7.43-7.35 (m, 3H), 7.07 (s, 1H), 6.97-6.95 (m, 2H), 5.77 (d, $J = 10.4$ Hz, 1H), 5.16-5.13 (m, 1H), 4.54-4.33 (m, 3H), 4.15-4.12 (m, 1H), 4.03-4.01 (m, 2H), 3.75-3.70 (m, 4H), 3.02-2.88 (m, 7H), 2.76-2.69 (m, 2H), 2.64-2.59 (m, 2H), 2.45-2.38 (m, 1H), 2.31-2.30 (m, 2H), 2.21-2.18 (m, 3H), 2.08-2.00 (m, 4H), 1.81-1.75 (m, 4H), 1.58 (s, 2H), 1.48-1.41 (m, 2H), 1.33-1.25 (m, 16H); MS (ESI) m/z : 972.5 $[M+H]^+$.




[00472] 9-{1-[2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1*H*-isindol-4-yl]piperidin-4-yl}-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isindol-4-yl}nonanamide **A15**. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 11.08 (s, 1H), 9.67 (s, 1H), 8.48 (d, $J = 8.0$ Hz, 1H), 7.78 (t, $J = 7.6$ Hz, 1H), 7.66 (t, $J = 7.2$ Hz, 1H), 7.56 (d, $J = 6.8$ Hz, 1H), 7.31-7.29 (m, 2H), 7.08 (s, 1H), 6.98-6.92 (m, 2H), 5.78 (dd, $J = 4.4, 10.4$ Hz, 1H), 5.10-5.06 (m, 1H), 4.37-4.31 (m, 1H), 4.16-4.11 (m, 1H), 4.02 (d, $J = 6.8$ Hz, 2H),

3.73 (s, 3H), 3.67-3.64 (m, 2H), 3.01 (s, 3H), 2.87-2.78(m, 3H), 2.61-2.57 (m, 1H), 2.54 (s, 3H), 2.07-1.97 (m, 1H), 1.73-1.62 (m, 4H), 1.31-1.27 (m, 18H); MS (ESI) m/z : 898.4 $[M+H]^+$.




[00473] 9-([4-([2-(2,6-Dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]oxy)-methyl]phenyl)methyl}amino)-*N*-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl-ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}nonanamide **A16**. ^1H NMR (400 MHz, DMSO- d_6) δ 10.96 (brs, 1H), 9.66 (s, 1H), 8.45 (d, J = 8.4 Hz, 1H), 7.78 (t, J = 8.0 Hz, 1H), 7.56 (d, J = 6.8 Hz, 1H), 7.48 (d, J = 8.0 Hz, 1H), 7.45-7.40 (m, 2H), 7.34-7.30 (m, 4H), 7.07 (s, 1H), 6.98-6.91 (m, 2H), 5.77 (dd, J = 4.0, 10.4 Hz, 1H), 5.21 (s, 2H), 5.10 (dd, J = 4.8, 13.6 Hz, 1H), 4.42-4.22 (m, 4H), 4.01 (q, J = 7.2 Hz, 2H), 3.72 (s, 3H), 3.67 (s, 2H), 3.01 (s, 3H), 2.93-2.87 (m, 1H), 2.58-2.54 (m, 1H), 2.47-2.43 (m, 5H), 2.00-1.96 (m, 1H), 1.62-1.58 (m, 2H), 1.42-1.39 (m, 2H), 1.33-1.26 (m, 11H); MS (ESI) m/z : 936.4 $[M+H]^+$.




[00474] *N*-[7-(12-{4-[2-(2,6-Dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1H-isoindol-4-yl]piperidin-1-yl}dodecyl)-2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl-ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]acetamide **A17**. ^1H NMR (400 MHz, DMSO- d_6) δ 11.00 (s, 1H), 9.27 (s, 1H), 8.27 (s, 1H), 7.42 (s, 1H), 7.41-7.34 (m, 2H), 7.06 (s, 1H), 6.98-6.92 (m, 2H), 5.76 (dd, J = 4.0, 10.4 Hz, 1H), 5.13 (dd, J = 5.2, 13.2 Hz, 1H), 4.52-4.31 (m, 3H), 4.14-4.10 (m, 1H), 4.01 (q, J = 7.2 Hz, 2H), 3.73 (s, 3H), 3.01 (s, 3H), 2.96-2.88

(m, 3H), 2.70 (t, $J = 7.6$ Hz, 2H), 2.62-2.58 (m, 2H), 2.45-2.41 (m, 1H), 2.26 (t, $J = 7.2$ Hz, 2H), 2.17 (s, 3H), 2.03-1.88 (m, 4H), 1.74-1.70 (m, 3H), 1.59-1.56 (m, 2H), 1.43-1.40 (m, 2H), 1.32 (t, $J = 6.8$ Hz, 3H), 1.29-1.24 (m, 16H); MS (ESI) m/z : 972.5 $[M+H]^+$.




[00475] 4-Amino-7-(12-{4-[2-(2,6-Dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1H-isoindol-4-yl]piperidin-1-yl}dodecyl)-2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]-2,3-dihydro-1H-isoindole-1,3-dione **A18**. ^1H NMR (400 MHz, DMSO- d_6) δ 11.00 (s, 1H), 7.40-7.34 (m, 2H), 7.06 (s, 1H), 6.96-6.92 (m, 2H), 6.81 (s, 1H), 6.78 (s, 1H), 6.39 (s, 2H), 5.70 (dd, $J = 4.0, 10.4$ Hz, 1H), 5.13 (dd, $J = 5.2, 13.2$ Hz, 1H), 4.52-4.31 (m, 3H), 4.08-4.03 (m, 1H), 4.00 (q, $J = 6.4$ Hz, 2H), 3.72 (s, 3H), 2.99 (s, 3H), 2.96-2.91 (m, 3H), 2.62-2.54 (m, 4H), 2.54-2.41 (m, 1H), 2.28-2.24 (m, 2H), 2.03-1.92 (m, 4H), 1.73-1.70 (m, 3H), 1.55-1.52 (m, 2H), 1.45-1.40 (m, 3H), 1.31 (t, $J = 7.2$ Hz, 3H), 1.29-1.24 (m, 16H); MS (ESI) m/z : 930.5 $[M+H]^+$.




[00476] 10-{4-[2-(2,6-Dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1H-isoindol-5-yl]piperidin-1-yl}-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}decanamide **A19**. ^1H NMR (400 MHz, DMSO- d_6) δ 10.98 (s, 1H), 9.66 (s, 1H), 8.46 (d, $J = 8.4$ Hz, 1H), 7.79 (t, $J = 7.6$ Hz, 1H), 7.61-7.55 (m, 2H), 7.45 (d, $J = 9.2$ Hz, 1H), 7.10-7.05 (m, 1H), 6.99-6.92 (m, 2H), 5.77 (dd, $J = 4.0, 10.4$ Hz, 1H),

5.10 (dd, $J = 4.8, 13.2$ Hz, 1H), 4.43-4.26 (m, 3H), 4.14 (dd, $J = 4.4, 14.4$ Hz, 1H), 4.02 (q, $J = 7.2$ Hz, 2H), 3.73 (s, 3H), 3.01 (s, 3H), 2.97-2.94 (m, 2H), 2.90-2.84 (m, 1H), 2.67-2.57 (m, 3H), 2.47-2.45 (m, 1H), 2.40-2.36 (m, 1H), 2.29-2.25 (m, 2H), 2.03-1.95 (m, 3H), 1.78-1.67 (m, 4H), 1.64-1.58 (m, 2H), 1.45-1.40 (m, 2H), 1.34-1.25 (m, 13H); MS (ESI) m/z : 916.6 $[M+H]^+$.




[00477] 9-(4-{2-[2-(2,6-Dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1H-isoinдол-5-yl]ethynyl}piperidin-1-yl)-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl-ethyl]-1,3-dioxo-2,3-dihydro-1H-isoinдол-4-yl}nonanamide **A20**. ^1H NMR (400 MHz, DMSO- d_6) δ 11.00 (s, br, 1H), 9.66 (s, 1H), 8.46 (d, $J = 8.4$ Hz, 1H), 7.79 (t, $J = 7.6$ Hz, 1H), 7.72 (d, $J = 6.0$ Hz, 1H), 7.58-7.55 (m, 2H), 7.08-7.06 (m, 1H), 6.99-6.92 (m, 2H), 5.78 (dd, $J = 4.0, 10.4$ Hz, 1H), 5.11 (dd, $J = 4.8, 13.2$ Hz, 1H), 4.44-4.28 (m, 3H), 4.14 (dd, $J = 4.0, 14.0$ Hz, 1H), 4.02 (q, $J = 6.8$ Hz, 2H), 3.73 (s, 3H), 3.01 (s, 3H), 2.95-2.86 (m, 2H), 2.75-2.65 (m, 3H), 2.62-2.58 (m, 2H), 2.48-2.45 (m, 2H), 2.25-2.21 (m, 2H), 2.16-2.11 (m, 1H), 2.03-1.97 (m, 1H), 1.88-1.84 (m, 2H), 1.67-1.56 (m, 4H), 1.46-1.36 (m, 2H), 1.34-1.25 (m, 11H); MS (ESI) m/z : 926.5 $[M+H]^+$.




[00478] 9-{4-[2-(2,6-Dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1H-isoinдол-5-yl]piperidin-1-yl}-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl-ethyl]-1,3-dioxo-2,3-dihydro-1H-isoinдол-4-yl}nonanamide **A21**. ^1H NMR (400 MHz, DMSO- d_6) δ 11.06 (s, 1H), 9.66 (s, 1H), 8.47 (d, $J = 8.8$ Hz, 1H), 7.78 (t, $J = 7.6$ Hz, 1H), 7.64 (d, $J = 8.8$ Hz, 1H), 7.57 (d, $J = 7.2$ Hz, 1H), 7.27 (s, 1H), 7.21 (dd, $J = 2.0, 10.4$ Hz, 1H), 7.08 (s, 1H), 6.99-6.91 (m,

2H), 5.78 (dd, $J = 4.4, 10.4$ Hz, 1H), 5.06 (dd, $J = 5.6, 12.8$ Hz, 1H), 4.37-4.30 (m, 1H), 4.16-4.12 (m, 1H), 4.04-3.98 (m, 4H), 3.73 (s, 3H), 3.00 (s, 3H), 2.93-2.83 (m, 3H), 2.67-2.50 (m, 1H), 2.50-2.44 (m, 3H), 2.02-1.99 (m, 1H), 1.72-1.69 (m, 2H), 1.63-1.60 (m, 2H), 1.47-1.46 (m, 1H), 1.33-1.10 (m, 17H); MS (ESI) m/z : 898.6 $[M+H]^+$.




[00479] 8-{4-[2-(2,6-Dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1H-isoindol-5-yl]piperidin-1-yl}-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl-ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}octanamide **A22**. ^1H NMR (400 MHz, DMSO- d_6) δ 10.98 (s, 1H), 9.67 (s, 1H), 8.47 (d, $J = 8.4$ Hz, 1H), 7.79 (t, $J = 8.4$ Hz, 1H), 7.60-7.53 (m, 2H), 7.45 (d, $J = 9.2$ Hz, 1H), 7.08 (s, 1H), 6.99-6.92 (m, 2H), 5.77 (dd, $J = 4.4, 10.4$ Hz, 1H), 5.10 (dd, $J = 5.2, 13.2$ Hz, 1H), 4.43-4.12 (m, 4H), 4.02 (q, $J = 6.8$ Hz, 2H), 3.73 (s, 3H), 3.01 (s, 3H), 2.96-2.94 (m, 2H), 2.87-2.83 (m, 2H), 2.67-2.61 (m, 1H), 2.60-2.57 (m, 2H), 2.50-2.43 (m, 2H), 2.41-2.36 (m, 1H), 2.32-2.29 (m, 1H), 2.27 (t, $J = 7.2$ Hz, 2H), 2.01-1.91 (m, 4H), 1.88 (s, 2H), 1.70-1.62 (m, 6H), 1.45-1.42 (m, 2H), 1.33-1.30 (m, 3H); MS (ESI) m/z : 888.7 $[M+H]^+$.




[00480] 9-{4-[2-(2,6-Dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1H-isoindol-5-yl]-1H-1,2,3-triazol-1-yl}-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl-ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}nonanamide **A23**. ^1H NMR (400 MHz, DMSO- d_6) δ 11.00 (s, 1H), 9.65 (s, 1H), 8.56 (d, $J = 4.0$ Hz, 1H), 8.45 (d, $J = 8.4$ Hz, 1H), 8.37 (d, $J = 6.0$ Hz, 1H), 7.78 (d, $J = 8.0$ Hz, 1H), 7.66 (d, $J = 9.6$ Hz, 1H), 7.55 (d, $J = 7.2$ Hz, 1H), 7.07 (s, 1H), 6.98-

6.91 (m, 2H), 5.77 (dd, $J = 4.4, 10.4$ Hz, 1H), 5.13 (dd, $J = 4.8, 12.8$ Hz, 1H), 4.54-4.30 (m, 5H), 4.16-4.12 (m, 1H), 4.01 (q, $J = 6.8$ Hz, 2H), 3.72 (s, 3H), 3.00 (s, 3H), 2.98-2.97 (m, 1H), 2.63-2.60 (m, 1H), 2.47-2.39 (m, 3H), 2.02-2.01 (m, 1H), 1.90-1.87 (m, 2H), 1.62-1.59 (m, 2H), 1.32-1.29 (m, 11H); MS (ESI) m/z : 886.5 $[M+H]^+$.




[00481] 4-[1-(2-{4-[2-(2,6-Dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1H-isoinдол-5-yl]piperidin-1-yl}ethyl)-1H-1,2,3-triazol-4-yl]-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1H-isoinдол-4-yl}butanamide **A24**. ^1H NMR (400 MHz, DMSO- d_6) δ 10.99 (s, 1H), 9.67 (s, 1H), 9.67 (s, 1H), 8.45 (d, $J = 8.4$ Hz, 1H), 7.91 (s, 1H), 7.78 (t, $J = 8.0$ Hz, 1H), 7.59-7.53 (m, 2H), 7.44 (d, $J = 9.2$ Hz, 1H), 7.10-7.05 (m, 1H), 6.99-6.92 (m, 2H), 5.78 (dd, $J = 4.0, 10.4$ Hz, 1H), 5.10 (dd, $J = 4.8, 13.2$ Hz, 1H), 4.45 (t, $J = 6.4$ Hz, 1H), 4.40-4.23 (m, 3H), 4.14 (dd, $J = 4.4, 14.4$ Hz, 1H), 4.01 (q, $J = 6.8$ Hz, 2H), 3.73 (s, 3H), 3.01 (s, 3H), 2.98-2.90 (m, 2H), 2.88-2.82 (m, 1H), 2.78 (t, $J = 6.4$ Hz, 2H), 2.72 (t, $J = 7.2$ Hz, 2H), 2.64-2.52 (m, 4H), 2.41-2.32 (m, 1H), 2.16-2.11 (m, 2H), 2.03-1.93 (m, 3H), 1.77-1.63 (m, 4H), 1.31 (t, $J = 6.8$ Hz, 3H); MS (ESI) m/z : 927.4 $[M+H]^+$.




[00482] 4-[(9-{4-[2-(2,6-Dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1H-isoinдол-5-yl]piperidin-1-yl}nonyl)amino]-2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl]-2,3-dihydro-1H-isoinдол-1,3-dione **A25**. ^1H NMR (400 MHz, DMSO- d_6) δ 11.01 (s, 1H), 9.91 (s, br, 1H), 7.58-7.53 (m, 3H), 7.07-7.05 (m, 2H), 7.00 (d, $J = 7.2$ Hz, 1H), 6.94-6.93 (m, 2H), 6.53 (t, $J = 5.6$ Hz, 1H), 5.73 (dd, $J = 4.4, 10.8$ Hz, 1H), 5.13 (dd, $J = 5.6, 13.6$ Hz, 1H), 4.49-4.31 (m, 3H), 4.11-4.07 (m, 1H), 4.02 (q, $J = 6.8$ Hz, 2H), 3.74 (s, 3H), 3.59 (d, $J = 11.2$


Hz, 2H), 3.28-3.26 (m, 4H), 3.11-2.84 (m, 6H), 2.64-2.59 (m, 1H), 2.42-2.34 (m, 1H), 2.04-1.99 (m, 5H), 1.71-1.70 (m, 2H), 1.59-1.57 (m, 2H), 1.48-1.46 (m, 1H), 1.34-1.32 (m, 13H); MS (ESI) m/z : 888.6 $[M+H]^+$.




[00483] 9-[4-[2-(2,6-Dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]piperidin-1-yl]-N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl-ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]nonanamide **A26**. ^1H NMR (400 MHz, DMSO- d_6) δ 10.98 (s, 1H), 9.67 (s, 1H), 8.47 (d, J = 8.0 Hz, 1H), 7.79 (t, J = 7.2 Hz, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.56 (d, J = 7.2 Hz, 1H), 7.49-7.45 (m, 1H), 7.38 (d, J = 8.0 Hz, 1H), 7.10-7.05 (m, 1H), 6.99-6.91 (m, 2H), 5.77 (dd, J = 4.0, 10.0 Hz, 1H), 5.09 (dd, J = 5.2, 13.2 Hz, 1H), 4.44-4.26 (m, 3H), 4.14 (dd, J = 4.4, 14.4 Hz, 1H), 4.01 (d, J = 7.2 Hz, 2H), 3.73 (s, 3H), 3.01 (s, 3H), 2.94-2.87 (m, 2H), 2.62-2.56 (m, 4H), 2.45-2.41 (m, 2H), 2.05-1.91 (m, 4H), 1.77-1.61 (m, 5H), 1.47-1.42 (m, 2H), 1.35-1.30 (m, 13H); MS (ESI) m/z : 884.4 $[M+H]^+$.




[00484] 4-(10-[4-[2-(2,6-Dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1H-isoindol-5-yl]piperidin-1-yl]decyl)-2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl-ethyl]-2,3-dihydro-1H-isoindole-1,3-dione **A27**. ^1H NMR (400 MHz, DMSO- d_6) δ 11.00 (s, 1H), 9.53 (s, 1H), 7.76-7.70 (m, 2H), 7.67-7.64 (m, 1H), 7.55-7.52 (m, 2H), 7.10-7.09 (m, 1H), 6.98-6.92 (m, 2H), 5.78 (dd, J = 4.4, 10.0 Hz, 1H), 5.12 (dd, J = 5.2, 13.6 Hz, 1H), 4.47-4.30 (m, 3H), 4.13 (dd, J = 4.4, 14.4 Hz, 1H), 4.02 (q, J = 6.8 Hz, 2H), 3.73 (s, 3H), 3.60-3.56 (m, 2H), 3.06-2.99 (m, 7H), 2.64-2.56 (m, 3H), 2.43-2.39 (m, 1H), 2.07-1.99 (m, 3H), 1.69-1.44 (m, 6H), 1.33-1.25 (m, 17H); MS (ESI) m/z : 887.7 $[M+H]^+$.




[00485] 2-[4-(4-{4-[2-(2,6-Dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1*H*-isoindol-5-yl]piperidin-1-yl}butyl)piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl-ethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}acetamide **A28**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.08 (s, 1H), 10.99 (s, 1H), 8.74 (d, *J* = 8.4 Hz, 1H), 7.81 (t, *J* = 8.0 Hz, 1H), 7.61 (d, *J* = 6.4 Hz, 1H), 7.55 (d, *J* = 7.2 Hz, 1H), 7.46 (d, *J* = 9.2 Hz, 1H), 7.13-7.09 (m, 1H), 7.03-6.98 (m, 1H), 6.94-6.90 (m, 1H), 5.78 (dd, *J* = 4.0, 10.0 Hz, 1H), 5.10 (dd, *J* = 4.8, 13.2 Hz, 1H), 4.43-4.26 (m, 3H), 4.17-4.13 (m, 1H), 4.02 (q, *J* = 6.8 Hz, 2H), 3.73 (s, 3H), 3.21-3.19 (m, 2H), 3.01-2.92 (m, 6H), 2.90-2.86 (m, 2H), 2.64-2.57 (m, 6H), 2.37-2.30 (m, 6H), 2.04-1.97 (m, 4H), 1.79-1.69 (m, 4H), 1.52-1.45 (m, 4H), 1.33 (t, *J* = 7.2 Hz, 3H); MS (ESI) *m/z*: 944.5 [M+H]⁺.




[00486] 6-[4-[2-(2,6-Dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1*H*-isoindol-5-yl]-[1,4'-bipiperidin]-1'-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl-ethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}hexanamide **A29**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.99 (s, 1H), 9.67 (s, 1H), 8.48 (d, *J* = 8.4 Hz, 1H), 7.80 (t, *J* = 7.6 Hz, 1H), 7.40-7.33 (m, 2H), 7.09 (s, 1H), 6.97-6.92 (m, 2H), 5.77 (dd, *J* = 4.4, 10.4 Hz, 1H), 5.13 (dd, *J* = 5.6, 13.2 Hz, 1H), 4.43-4.26 (m, 3H), 4.16-4.13 (m, 1H), 4.01 (q, *J* = 7.2 Hz, 2H), 3.73 (s, 3H), 3.11 (s, 3H), 3.09-2.82 (m, 5H), 2.67-2.61 (m, 2H), 2.38-2.25 (m, 5H), 2.01-1.99 (m, 3H), 1.84-1.63 (m, 10H), 1.48-1.41 (m, 3H), 1.30-1.26 (m, 6H); MS (ESI) *m/z*: 943.7 [M+H]⁺.




[00487] 5-[4-[2-(2,6-Dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1*H*-isoindol-5-yl]-[1,4'-bipiperidin]-1'-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl-ethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}pentanamide **A30**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.99 (s, 1H), 9.67 (s, 1H), 8.47 (d, *J* = 4.0 Hz, 1H), 7.80 (t, *J* = 4.0 Hz, 1H), 7.58-7.56 (m, 2H), 7.47-7.44 (m, 1H), 7.09 (s, 1H), 6.97-6.92 (m, 2H), 5.77 (d, *J* = 2.0 Hz, 1H), 5.09 (d, *J* = 9.4 Hz, 1H), 4.43-4.26 (m, 3H), 4.16-4.13 (m, 1H), 4.02-4.01 (m, 2H), 3.73 (s, 3H), 3.11 (s, 3H), 3.09-2.82 (m, 7H), 2.67-2.61 (m, 2H), 2.38-2.25 (m, 5H), 2.01-1.99 (m, 2H), 1.89-1.87 (m, 2H), 1.84-1.63 (m, 8H), 1.48-1.41 (m, 4H), 1.30-1.26 (m, 3H); MS (ESI) *m/z*: 929.6 [M+H]⁺.




[00488] 3-[4-(3-{4-[2-(2,6-Dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1*H*-isoindol-5-yl]piperidin-1-yl}propyl)piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl-ethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}propanamide **A31**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.99 (s, 1H), 10.74 (s, 1H), 10.06 (s, 1H), 8.42 (d, *J* = 8.0 Hz, 1H), 7.82 (t, *J* = 7.6 Hz, 1H), 7.61 (d, *J* = 7.2 Hz, 1H), 7.53 (d, *J* = 9.2 Hz, 2H), 7.07 (s, 1H), 6.99-6.93 (m, 2H), 5.79 (dd, *J* = 4.0, 10.4 Hz, 1H), 5.11 (dd, *J* = 5.2, 13.2 Hz, 1H), 4.48-4.30 (m, 3H), 4.17-4.13 (m, 1H), 4.01 (q, *J* = 6.8 Hz, 2H), 3.73 (s, 3H), 3.62-3.58 (m, 8H), 3.28-3.18 (m, 10H), 3.03 (s, 3H), 2.96-2.86 (m, 1H), 2.67-2.58 (m, 2H), 2.37-2.32 (m, 2H), 2.21-2.18 (m, 4H), 2.02-1.99 (m, 4H), 1.32 (t, *J* = 6.8 Hz, 3H); MS (ESI) *m/z*: 944.7 [M+H]⁺.




[00489] 2-{4-[(4-{[5-(2,6-Dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]methoxy}phenyl)methyl]morpholin-2-yl}-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl-ethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}acetamide **A40**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.00 (s, 1H), 10.09-10.06 (m, 1H), 8.56-8.54 (m, 1H), 8.02 (s, 1H), 7.78 (t, *J* = 8.0 Hz, 1H), 7.55 (d, *J* = 6.8 Hz, 1H), 7.48 (d, *J* = 8.0 Hz, 1H), 7.23 (d, *J* = 8.0 Hz, 2H), 7.09 (s, 1H), 6.99-6.92 (m, 4H), 5.77 (dd, *J* = 4.0, 10.0 Hz, 1H), 5.28 (s, 2H), 5.03 (dd, *J* = 5.2, 13.2 Hz, 1H), 4.37-4.34 (m, 2H), 4.24-4.13 (m, 2H), 4.01 (q, *J* = 7.2 Hz, 2H), 3.90-3.86 (m, 2H), 3.72 (s, 3H), 3.57 (t, *J* = 11.2 Hz, 1H), 3.41 (s, 2H), 3.00 (s, 3H), 2.92-2.84 (m, 1H), 2.76-2.74 (m, 1H), 2.62-2.57 (m, 4H), 2.36-2.31 (m, 1H), 2.07-2.06 (m, 1H), 1.99-1.97 (m, 1H), 1.88-1.83 (m, 1H), 1.30 (t, *J* = 6.8 Hz, 3H); MS (ESI) *m/z*: 914.4 [M+H]⁺.




[00490] 3-[2-(2-{[(4-{[5-(2,6-Dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]methoxy}phenyl)methyl]amino}ethoxy)ethoxy]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl-ethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}propanamide **A41**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.87 (s, 1H), 8.52 (d, *J* = 8.4 Hz, 1H), 8.01 (s, 1H), 7.78 (t, *J* = 8.0 Hz, 1H), 7.55 (d, *J* = 7.2 Hz, 1H), 7.18 (d, *J* = 8.8 Hz, 2H), 7.09-7.05 (m, 1H), 6.99-6.96 (m, 1H), 6.95-6.90 (m, 3H), 5.77 (dd, *J* = 4.4, 10.4 Hz, 1H), 5.26 (s, 2H), 5.02 (dd, *J* = 4.8, 13.2 Hz, 1H), 4.39-4.13 (m, 4H), 4.01 (q, *J* = 7.2 Hz, 2H), 3.76-3.72 (m, 5H), 3.59-3.56 (m, 4H), 3.53-3.51 (m, 2H), 3.42-3.39 (m, 4H), 3.01 (s, 3H), 2.70-2.67 (m, 2H), 2.60-2.53 (m, 3H), 2.35-2.32 (m, 1H), 2.01-1.97 (m, 2H), 1.31 (t, *J* = 6.8 Hz, 3H); MS (ESI) *m/z*: 946.4 [M+H]⁺.




[00491] 4-[4-(2-{{[(4-{{[5-(2,6-Dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]methoxy}phenyl)methyl]amino}ethyl)phenyl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}butanamide **A42**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.67 (s, 1H), 8.43 (d, *J* = 8.8 Hz, 1H), 8.01 (s, 1H), 7.78 (t, *J* = 7.6 Hz, 1H), 7.56 (d, *J* = 7.6 Hz, 1H), 7.23 (d, *J* = 8.0 Hz, 2H), 7.13-7.08 (m, 5H), 6.99-6.92 (m, 4H), 5.79-5.75 (m, 1H), 5.27 (s, 2H), 5.02 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.36-4.12 (m, 4H), 4.01 (q, *J* = 7.2 Hz, 2H), 3.73 (s, 3H), 3.66 (s, 2H), 3.01 (s, 3H), 2.93-2.84 (m, 1H), 2.67 (s, 4H), 2.62-2.51 (m, 3H), 2.50-2.45 (m, 2H), 2.36-2.31 (m, 1H), 2.03-1.93 (m, 3H), 1.30 (t, *J* = 7.2 Hz, 3H); MS (ESI) *m/z*: 976.4 [M+H]⁺.




[00492] 11-{{[(4-{{[5-(2,6-Dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]methoxy}phenyl)methyl]amino}-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}undecanamide **A43**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.99 (s, 1H), 9.66 (s, 1H), 8.61 (s, 2H), 8.46 (d, *J* = 8.4 Hz, 1H), 8.03 (s, 1H), 7.80 (t, *J* = 7.6 Hz, 1H), 7.57 (d, *J* = 7.2 Hz, 1H), 7.42 (d, *J* = 8.8 Hz, 1H), 7.11-7.08 (m, 3H), 6.99-6.93 (m, 2H), 5.78 (dd, *J* = 4.0, 10.4 Hz, 1H), 5.35 (s, 2H), 5.03 (dd, *J* = 4.8, 12.8 Hz, 1H), 4.39-4.31 (m, 2H), 4.26-4.22 (m, 1H), 4.15-3.99 (m, 5H), 3.74 (s, 3H), 3.02 (s, 3H), 2.94-2.78 (m, 3H), 2.62-2.55 (m, 2H), 2.48-2.25 (m, 2H), 2.04-1.93 (m, 1H), 1.64-1.52 (m, 4H), 1.38-1.26 (m, 15H); MS (ESI) *m/z*: 970.4 [M+H]⁺.




[00493] 4-[(9-[[[4-[[5-(2,6-Dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]methoxy}phenyl)methyl]amino}nonyl)amino]-2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl]-2,3-dihydro-1*H*-isoindole-1,3-dione **A44**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.01 (s, 1H), 7.53 (t, *J* = 8.4 Hz, 1H), 7.25 (d, *J* = 8.0 Hz, 2H), 7.05-7.03 (m, 2H), 6.98-6.96 (m, 3H), 6.92 (s, 2H), 6.52-6.49 (m, 1H), 5.71 (dd, *J* = 3.6, 10.0 Hz, 1H), 5.28 (s, 2H), 5.01 (dd, *J* = 5.2, 13.2 Hz, 1H), 4.38-4.32 (m, 2H), 4.24-4.19 (m, 1H), 4.09-4.05 (m, 2H), 4.03-3.97 (m, 3H), 3.73 (s, 3H), 3.26-3.23 (m, 2H), 2.99 (s, 3H), 2.92-2.95 (m, 1H), 2.57-2.53 (m, 1H), 2.03-1.97 (m, 3H), 1.60-1.53 (m, 3H), 1.45-1.39 (m, 3H), 1.33-1.24 (m, 14H); MS (ESI) *m/z*: 928.4 [M+H]⁺.



[00494] 4-[4-(2-[[[4-[[5-(2,6-Dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]methoxy}phenyl)methyl]amino}ethyl)piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}butanamide **A45**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.64 (s, 1H), 8.48 (d, *J* = 8.4 Hz, 1H), 8.00 (s, 1H), 7.79 (t, *J* = 7.6 Hz, 1H), 7.55 (d, *J* = 7.2 Hz, 1H), 7.22-7.18 (m, 2H), 7.07 (s, 1H), 6.98-6.91 (m, 4H), 5.76 (dd, *J* = 4.4, 10.8 Hz, 1H), 5.72 (s, 2H), 5.01 (dd, *J* = 5.6, 13.2 Hz, 1H), 4.36-4.31 (m, 2H), 4.23-4.11 (m, 2H), 4.00 (q, *J* = 7.2 Hz, 2H), 3.72 (s, 3H), 3.58 (s, 2H), 3.00 (s, 3H), 2.93-2.84 (m, 1H), 2.59-2.55 (m, 1H), 2.47-2.43 (m, 5H), 2.38-2.22 (m, 13H), 2.03-1.95 (m, 2H), 1.79-1.72 (m, 2H), 1.31 (t, *J* = 6.8 Hz, 3H); MS (ESI) *m/z*: 984.4 [M+H]⁺.




[00495] 11-[[4-[[5-(2,6-Dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]methoxy}phenyl)methyl](methylamino)-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}undecanamide **A46**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.98 (s, 1H), 9.84 (s, 1H), 9.66 (s, 1H), 8.46 (d, *J* = 8.4 Hz, 1H), 8.03 (s, 1H), 7.79 (t, *J* = 7.6 Hz, 1H), 7.57 (d, *J* = 7.6 Hz, 1H), 7.51-7.41 (m, 1H), 7.11-7.07 (m, 3H), 6.99-6.92 (m, 2H), 5.77 (dd, *J* = 4.0, 10.4 Hz, 1H), 5.34 (s, 2H), 5.03 (dd, *J* = 4.8, 12.8 Hz, 1H), 4.38-4.31 (m, 3H), 4.24-4.13 (m, 3H), 4.02 (q, *J* = 6.8 Hz, 2H), 3.73 (s, 3H), 3.01 (s, 3H), 2.93-2.85 (m, 2H), 2.65-2.56 (m, 4H), 2.46-2.44 (m, 2H), 2.03-1.99 (m, 1H), 1.68-1.58 (m, 4H), 1.33-1.25 (m, 17H); MS (ESI) *m/z*: 984.4 [*M*+*H*]⁺.




[00496] 8-(4-(2-(2,6-Dioxopiperidin-3-yl)-6-fluoro-1-oxoisoindol-4-yl)piperidin-1-yl)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindol-4-yl)octanamide **A47**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.98 (s, 1H), 9.81 (s, br, 1H), 9.65 (s, 1H), 8.46 (d, *J* = 8.4 Hz, 1H), 8.04 (s, 1H), 7.79 (t, *J* = 7.6 Hz, 1H), 7.56 (d, *J* = 7.2 Hz, 1H), 7.44 (d, *J* = 8.4 Hz, 2H), 7.13 (d, *J* = 8.4 Hz, 2H), 7.07 (d, *J* = 2.0 Hz, 1H), 6.99-6.92 (m, 2H), 5.77 (dd, *J* = 4.0, 10.4 Hz, 1H), 5.35 (s, 2H), 5.02 (dd, *J* = 5.2, 13.2 Hz, 1H), 4.38-4.12 (m, 6H), 4.04-3.97 (m, 3H), 3.73 (s, 3H), 3.65-3.52 (m, 2H), 3.30-3.19 (m, 3H), 3.01 (s, 3H), 2.97-2.85 (m, 1H), 2.78-2.73 (m, 1H), 2.61-2.51 (m, 1H), 2.46-2.44 (m, 2H), 2.35-2.31 (m, 1H), 2.01-1.97 (m, 1H), 1.62-1.59 (m, 2H), 1.41-1.37 (m, 2H), 1.34-1.24 (m, 9H); MS (ESI) *m/z*: 984.4


[M+H]⁺.




[00497] 4-[1-(2-{{[(4-{{[5-(2,6-Dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]methoxy}phenyl)methyl]amino}ethyl)-1*H*-1,2,3-triazol-4-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl-ethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}]butanamide **A48**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.97 (s, 1H), 9.68 (s, 1H), 8.45 (d, *J* = 8.0 Hz, 1H), 7.99 (s, 1H), 7.86 (s, 1H), 7.78 (t, *J* = 7.6 Hz, 1H), 7.56 (d, *J* = 7.2 Hz, 1H), 7.26-7.15 (m, 2H), 7.07 (s, 1H), 7.01-6.89 (m, 4H), 5.77 (dd, *J* = 3.2, 10.0 Hz, 1H), 5.25 (s, 2H), 5.01 (dd, *J* = 4.8, 12.8 Hz, 1H), 4.37-4.31 (m, 4H), 4.22-4.12 (m, 2H), 4.03-3.98 (m, 2H), 3.73 (s, 4H), 3.61 (s, 3H), 3.01 (s, 3H), 2.93-2.83 (m, 3H), 2.71-2.67 (m, 2H), 2.64-2.58 (m, 1H), 2.03-2.02 (m, 4H), 1.31 (t, *J* = 6.8 Hz, 3H); MS (ESI) *m/z*: 967.4 [M+H]⁺.




[00498] 4-(10-{{[(4-{{[5-(2,6-Dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]methoxy}phenyl)methyl]amino}decyl)-2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl-ethyl]-2,3-dihydro-1*H*-isoindole-1,3-dione **A49**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.00 (s, 1H), 7.73-7.63 (m, 3H), 7.24-7.21 (m, 2H), 7.09 (d, *J* = 2.0 Hz, 1H), 6.97-6.91 (m, 4H), 5.76 (dd, *J* = 4.4, 10.0 Hz, 1H), 5.27 (s, 2H), 5.01 (dd, *J* = 5.2, 13.6 Hz, 1H), 4.38-4.32 (m, 2H), 4.23-4.09 (m, 2H), 4.01 (q, *J* = 6.8 Hz, 2H), 3.72 (s, 3H), 3.59 (s, 2H), 3.03-2.98 (m, 5H), 2.93-2.85 (m, 1H), 2.60-2.55 (m, 1H), 2.44-2.40 (m, 2H), 2.35-2.31 (m, 1H), 1.99-1.96 (m, 1H), 1.58-1.53 (m, 2H), 1.39-1.21 (m, 17H); MS (ESI) *m/z*: 927.6 [M+H]⁺.




[00499] 4-[(9-[[[4-[[5-(2,6-Dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]methoxy}phenyl)methyl]amino}nonyl)oxy]-2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl]-2,3-dihydro-1*H*-isoindole-1,3-dione **A50**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.00 (s, 1H), 7.77-7.73 (m, 1H), 7.47-7.37 (m, 2H), 7.23 (d, *J* = 8.4 Hz, 2H), 7.05 (s, 1H), 6.96-6.90 (m, 4H), 5.73 (dd, *J* = 4.0, 10.4 Hz, 1H), 5.27 (s, 2H), 5.01 (dd, *J* = 5.2, 13.2 Hz, 1H), 4.37-4.31 (m, 2H), 4.23-4.06 (m, 4H), 4.01 (q, *J* = 6.8 Hz, 2H), 3.72 (s, 3H), 3.59 (s, 2H), 2.99 (s, 3H), 2.88-2.85 (m, 1H), 2.59-2.55 (m, 1H), 2.44-2.21 (m, 2H), 2.34-2.32 (m, 1H), 1.99-1.95 (m, 1H), 1.76-1.72 (m, 2H), 1.32-1.22 (m, 15H); MS (ESI) *m/z*: 929.5 [M+H]⁺.




[00500] 4-({2-[4-(4-[[[4-[[5-(2,6-Dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]methoxy}phenyl)methyl]amino}butyl)phenyl]ethyl}amino)-2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl]-2,3-dihydro-1*H*-isoindole-1,3-dione **A51**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.00 (d, *J* = 3.6 Hz, 1H), 7.54-7.51 (m, 1H), 7.24-7.17 (m, 4H), 7.12-7.03 (m, 4H), 6.97-6.92 (m, 5H), 6.60-6.57 (m, 1H), 5.71 (dd, *J* = 4.0, 10.4 Hz, 1H), 5.27-5.26 (m, 2H), 5.01 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.36-4.20 (m, 3H), 4.10-4.05 (m, 1H), 4.01 (q, *J* = 6.8 Hz, 2H), 3.72 (s, 3H), 3.59-3.47 (m, 4H), 2.99 (s, 3H), 2.88-2.82 (m, 3H), 2.78-2.72 (m, 1H), 2.69-2.56 (m, 2H), 2.42-2.29 (m, 4H), 1.99-1.96 (m, 2H), 1.67-1.62 (m, 1H), 1.57-1.54 (m, 1H), 1.44-1.39 (m, 1H), 1.32 (t, *J* = 6.4 Hz, 3H); MS (ESI) *m/z*: 962.6 [M+H]⁺.




[00501] 4-[(11-[(4-[(5-(2,6-Dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy}phenyl)methyl]amino}undecyl)amino]-2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-2,3-dihydro-1*H*-isoindole-1,3-dione **A52**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.97 (s, 1H), 8.85 (s, 2H), 8.02 (s, 1H), 7.55-7.52 (m, 1H), 7.46 (d, *J* = 6.8 Hz, 1H), 7.10-6.92 (m, 7H), 6.51 (t, *J* = 5.6 Hz, 1H), 5.72 (dd, *J* = 4.0, 10.4 Hz, 1H), 5.34 (s, 2H), 5.03 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.38-4.21 (m, 3H), 4.10-3.97 (m, 5H), 3.72 (s, 3H), 3.27-3.22 (m, 2H), 3.00 (s, 3H), 2.89-2.82 (m, 3H), 2.60-2.56 (m, 1H), 2.35-2.32 (m, 1H), 2.00-1.96 (m, 1H), 1.57-1.54 (m, 4H), 1.33-1.24 (m, 17H); MS (ESI) *m/z*: 956.2 [*M*+*H*]⁺.




[00502] 4-({4-[4-(2-[(4-[(5-(2,6-Dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy}phenyl)methyl]amino}ethyl)phenyl]butyl}amino)-2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-2,3-dihydro-1*H*-isoindole-1,3-dione **A53**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.01(s, 1H), 7.51 (t, *J* = 8.4 Hz, 1H), 7.22 (d, *J* = 8.4 Hz, 2H), 7.12-7.01 (m, 6H), 6.97-6.92 (m, 5H), 6.55 (t, *J* = 6.0 Hz, 1H), 5.71 (dd, *J* = 4.4, 10.8 Hz, 1H), 5.27 (s, 2H), 5.01 (dd, *J* = 5.2, 13.2 Hz, 1H), 4.37-4.31 (m, 2H), 4.24-4.20 (m, 1H), 4.08 (dd, *J* = 4.0, 14.4 Hz, 1H), 4.01 (q, *J* = 6.8 Hz, 2H), 3.72 (s, 3H), 3.63 (s, 2H), 2.99 (s, 3H), 2.93-2.85 (m, 1H), 2.67-2.66 (m, 5H), 2.58-2.55 (m, 1H), 2.33-2.31 (m, 4H), 2.01-1.96 (m, 2H), 1.62-1.55 (m, 4H), 1.22 (t, *J* = 6.8 Hz, 3H); MS (ESI) *m/z*: 962.1 [*M*+*H*]⁺.




[00503] 9-[4-(2-{[5-(2,6-Dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]methoxy}acetyl)piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}nonanamide **A54**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.97 (s, 1H), 9.66 (s, 1H), 8.47 (d, *J* = 8.4 Hz, 1H), 7.99 (s, 1H), 7.79 (t, *J* = 7.6 Hz, 1H), 7.55 (d, *J* = 7.6 Hz, 1H), 7.08 (s, 1H), 7.00-6.92 (m, 2H), 5.78 (dd, *J* = 4.0 Hz, 10.0 Hz, 1H), 5.02 (dd, *J* = 5.2 Hz, 13.2 Hz, 1H), 4.68 (s, 2H), 4.40-4.30 (m, 2H), 4.21 (s, 2H), 4.21-4.12 (m, 2H), 4.02 (q, *J* = 6.8 Hz, 2H), 3.73 (s, 3H), 3.45-3.38 (m, 4H), 3.01 (s, 3H), 2.95-2.82 (m, 1H), 2.63-2.54 (m, 1H), 2.46 (t, *J* = 7.2 Hz, 2H), 2.38-2.18 (m, 7H), 2.04-1.93 (m, 1H), 1.66-1.56 (m, 2H), 1.46-1.36 (m, 2H), 1.36-1.23 (m, 11H); MS (ESI) *m/z*: 963.5 [*M*+*H*]⁺.




[00504] 4-[4-(2-{[(4-{[5-(2,6-Dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]methoxy}phenyl)methyl](methyl)amino}ethyl)phenyl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}butanamide **A55**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.97 (s, 1H), 9.67 (s, 1H), 8.43 (d, *J* = 8.4 Hz, 1H), 8.14 (s, 1H), 8.01 (s, 1H), 7.78 (t, *J* = 7.6 Hz, 1H), 7.56 (d, *J* = 7.2 Hz, 1H), 7.20-7.07 (m, 7H), 6.97-6.92 (m, 4H), 5.77 (dd, *J* = 4.4, 10.4 Hz, 1H), 5.27 (s, 2H), 5.01 (dd, *J* = 4.8, 13.2 Hz, 1H), 4.37-4.31 (m, 2H), 4.23-4.11 (m, 2H), 4.01 (q, *J* = 6.8 Hz, 2H), 3.73 (s, 3H), 3.47 (s, 2H), 3.00 (s, 3H), 2.93-2.84 (m, 1H), 2.72-2.67 (m, 2H), 2.63-2.59 (m, 2H), 2.47-2.45 (m, 2H), 2.38-2.24 (m, 3H), 2.16 (s, 3H), 1.99-1.89 (m, 4H), 1.30 (t, *J* = 6.8 Hz, 3H); MS (ESI) *m/z*: 990.3 [*M*+*H*]⁺.




[00505] 11-(4-{[5-(2,6-Dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]methoxy}phenyl)-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl-ethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}undecanamide **A56**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.73 (s, 1H), 8.45 (d, *J* = 8.4 Hz, 1H), 8.28 (s, 1H), 8.01 (s, 1H), 7.79 (t, *J* = 7.6 Hz, 1H), 7.58 (d, *J* = 7.2 Hz, 1H), 7.26 (d, *J* = 8.4 Hz, 2H), 7.18 (*J* = 8.0 Hz, 2H), 7.11-7.08 (m, 3H), 6.99-6.92 (m, 4H), 5.78 (dd, *J* = 4.0, 10.4 Hz, 1H), 5.29 (s, 2H), 5.02 (dd, *J* = 5.2, 13.2 Hz, 1H), 4.37-4.31 (m, 2H), 4.24-4.12 (m, 3H), 4.01 (q, *J* = 6.8 Hz, 2H), 3.73 (s, 4H), 3.01 (s, 3H), 2.93-2.84 (m, 3H), 2.80-2.70 (m, 7H), 2.60-2.56 (m, 2H), 2.36-2.31 (m, 1H), 2.01-1.97 (m, 1H), 1.31 (t, *J* = 6.8 Hz, 3H); MS (ESI) *m/z*: 963.5 [M+H]⁺.




[00506] 11-(4-{[5-(2,6-Dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]methoxy}phenyl)-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl-ethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}undecanamide **A57**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.94 (s, 1H), 9.65 (s, 1H), 9.32 (s, 1H), 8.47 (d, *J* = 8.4 Hz, 1H), 7.80-7.74 (m, 2H), 7.56 (d, *J* = 6.8 Hz, 1H), 7.08-7.07 (m, 1H), 6.98-6.91 (m, 3H), 6.87-6.85 (m, 1H), 6.71-6.63 (m, 1H), 5.77 (dd, *J* = 4.4, 10.4 Hz, 1H), 4.98 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.36-4.30 (m, 1H), 4.16-3.95 (m, 7H), 3.72 (s, 3H), 3.00 (s, 3H), 2.87-2.83 (m, 1H), 2.58-2.50 (m, 1H), 2.50-2.39 (m, 3H), 2.25-2.17 (m, 2H), 2.00-1.93 (m, 1H), 1.62-1.59 (m, 2H), 1.46-1.45 (m, 2H), 1.33-1.23 (m, 15H); MS (ESI) *m/z*: 941.5 [M+H]⁺.




[00507] (2*S*,4*R*)-1-[(2*S*)-2-(13-{7-Acetamido-2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isoinдол-5-yl)tridecanamido)-3,3-dimethylbutanoyl]-4-hydroxy-*N*-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide **A61**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.62 (s, 1H), 8.97 (s, 1H), 8.54 (t, *J* = 5.6 Hz, 1H), 8.27 (s, 1H), 7.82 (d, *J* = 9.2 Hz, 1H), 7.41-7.36 (m, 5H), 7.06 (s, 1H), 6.97-6.91 (m, 2H), 5.76 (dd, *J* = 3.6, 10.4 Hz, 1H), 5.11 (d, *J* = 3.2 Hz, 1H), 4.54-4.10 (m, 7H), 4.02 (q, *J* = 7.2 Hz, 2H), 3.73 (s, 3H), 3.66-3.64 (m, 2H), 3.01 (s, 3H), 2.71-2.67 (m, 2H), 2.44 (s, 3H), 2.30-2.20 (m, 1H), 2.17 (s, 3H), 2.14-1.86 (m, 4H), 1.57-1.55 (m, 2H), 1.46-1.34 (m, 2H), 1.31-1.22 (m, 18H), 0.93 (s, 9H); MS (ESI) *m/z*: 1085.6 [M+H]⁺.




[00508] (2*S*,4*R*)-1-[(2*S*)-2-(11-{2-[(1*S*)-1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isoinдол-4-yl)undecanamido)-3,3-dimethylbutanoyl]-4-hydroxy-*N*-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide **A62**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.97 (s, 1H), 8.55 (t, *J* = 6.0 Hz, 1H), 7.81 (d, *J* = 9.2 Hz, 1H), 7.74-7.63 (m, 3H), 7.46-7.32 (m, 4H), 7.09-7.08 (m, 1H), 6.97-6.91 (m, 2H), 5.76 (dd, *J* = 4.4, 10.4 Hz, 1H), 5.11 (d, *J* = 3.6 Hz, 1H), 4.53 (d, *J* = 9.6 Hz, 1H), 4.45-4.32 (m, 4H), 4.24-4.10 (m, 2H), 4.01 (q, *J* = 6.8 Hz, 2H), 3.72 (s, 3H), 3.68-3.61 (m, 2H), 3.03-2.96 (m, 5H), 2.44 (s, 3H), 2.38-2.21 (m, 2H), 2.12-2.00 (m, 2H), 1.56-1.42 (m, 4H), 1.32-1.16 (m, 15H), 0.92 (s, 9H); MS (ESI) *m/z*: 1000.5 [M+H]⁺.




[00509] (2*S*,4*R*)-1-[(2*S*)-2-(2-{4-[4-({2-[(1*S*)-1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}carbonyl)butyl]piperazin-1-yl}acetamido)-3,3-dimethylbutanoyl]-4-hydroxy-*N*-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}-pyrrolidine-2-carboxamide **A63**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.65 (s, 1H), 8.98-8.97 (m, 1H), 8.59 (t, *J* = 6.0 Hz, 1H), 8.46 (d, *J* = 8.4 Hz, 1H), 7.81-7.75 (m, 2H), 7.56 (d, *J* = 7.2 Hz, 1H), 7.44-7.38 (m, 4H), 7.08 (d, *J* = 2.0 Hz, 1H), 6.99-6.92 (m, 2H), 5.77 (dd, *J* = 4.0, 10.4 Hz, 1H), 5.13 (d, *J* = 3.6 Hz, 1H), 4.50-4.23 (m, 6H), 4.14 (dd, *J* = 4.4, 18.8 Hz, 1H), 4.02 (q, *J* = 7.2 Hz, 2H), 3.73 (s, 3H), 3.68-3.58 (m, 2H), 3.03-2.87 (m, 5H), 2.48-2.26 (m, 14H), 2.08-1.87 (m, 3H), 1.64-1.57 (m, 2H), 1.50-1.43 (m, 2H), 1.31 (t, *J* = 6.8 Hz, 3H), 0.93 (s, 9H); MS (ESI) *m/z*: 1057.6 [M+H]⁺.




[00510] *N*-{2-[(1*S*)-1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}-*N'*-[(2*S*)-1-[(2*S*,4*R*)-4-hydroxy-2-({[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}carbonyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]dodecanediamide **A64**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.66 (s, 1H), 8.97 (s, 1H), 8.56 (t, *J* = 6.0 Hz, 1H), 8.47 (d, *J* = 8.0 Hz, 1H), 7.83-7.77 (m, 2H), 7.57 (d, *J* = 7.2 Hz, 1H), 7.43-7.37 (m, 4H), 7.08 (s, 1H), 6.99-6.92 (m, 2H), 5.76 (dd, *J* = 4.4, 10.4 Hz, 1H), 5.11 (d, *J* = 3.6 Hz, 1H), 4.55 (d, *J* = 9.6 Hz, 1H), 4.45-4.40 (m, 2H), 4.37-4.30 (m, 2H), 4.24-4.12 (m, 2H), 4.04-3.99 (m, 2H), 3.73 (s, 3H), 3.69-3.62 (m, 2H), 3.01 (s, 3H), 2.51-2.44 (m, 4H), 2.29-2.21 (m, 1H), 2.13-1.88 (m, 4H), 1.63-1.52 (m, 2H), 1.20-1.39 (m, 2H), 1.33-1.24 (m, 15H), 0.92 (s, 9H); MS (ESI) *m/z*: 1044.7 [M+H]⁺.




[00511] (2*S*,4*R*)-1-[(2*S*)-2-{[9-({2-[(1*S*)-1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isoinдол-4-yl}carbamoyl)nonyl]amino}-3,3-dimethylbutanoyl]-4-hydroxy-*N*-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide **A65**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.65 (s, 1H), 8.97 (s, 1H), 8.54 (t, *J* = 6.0 Hz, 1H), 8.46 (d, *J* = 8.8 Hz, 1H), 7.81-7.77 (m, 1H), 7.59-7.52 (m, 1H), 7.46-7.33 (m, 4H), 7.10-7.05 (m, 1H), 7.00-6.90 (m, 2H), 5.77 (dd, *J* = 4.4, 10.4 Hz, 1H), 5.05-5.00 (m, 1H), 4.54-4.49 (m, 1H), 4.42-4.22 (m, 5H), 4.16-4.11 (m, 1H), 4.06-3.97 (m, 3H), 3.73 (s, 3H), 3.59-3.56 (m, 1H), 3.01 (s, 3H), 2.64-2.54 (m, 2H), 2.47-2.45 (m, 2H), 2.44 (s, 3H), 2.30-2.23 (m, 1H), 2.03-1.91 (m, 2H), 1.66-1.55 (m, 2H), 1.39-1.24 (m, 15H), 0.90 (s, 9H); MS (ESI) *m/z*: 1003.5 [M+H]⁺.



[00512] (2*S*,4*R*)-1-[(2*S*)-2-(5-{4-[2-({2-[(1*S*)-1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isoinдол-4-yl}amino)acetyl]piperazin-1-yl}pentan-amido)-3,3-dimethylbutanoyl]-4-hydroxy-*N*-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide **A66**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.97 (s, 1H), 8.54 (t, *J* = 6.0 Hz, 1H), 7.84 (d, *J* = 6.0 Hz, 1H), 7.56 (t, *J* = 7.2 Hz, 1H), 7.45-7.37 (m, 4 H), 7.11-7.01 (m, 4H), 6.94-6.91 (m, 2H), 5.72 (dd, *J* = 8.0, 10.4 Hz, 1H), 5.11 (d, *J* = 3.6 Hz, 1H), 4.55 (d, *J* = 9.2 Hz, 1H), 4.46-4.30 (m, 4H), 4.21 (dd, *J* = 10.4, 16.0 Hz, 1 H), 4.14 (d, *J* = 4.0 Hz, 2H), 4.07 (t, *J* = 6.8 Hz, 2H), 4.03-3.98 (m, 2H), 3.72 (s, 3H), 3.67-3.60 (m, 2H), 3.50-3.42 (m, 4H), 3.00 (s, 3H), 2.44 (s, 3H), 2.37-2.20 (m, 7H), 2.17-2.10 (m, 1H), 2.02-1.82 (m, 2H), 1.39-1.33 (m, 4H), 1.31 (t, *J* = 6.8 Hz, 3H), 0.94 (s, 9H); MS (ESI) *m/z*: 1057.6 [M+H]⁺.




[00513] *N*-{2-[(1*S*)-1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonyl-ethyl]-1,3-dioxo-2,3-dihydro-1*H*-isindol-4-yl}-*N'*-[(2*S*)-1-[(2*S*,4*R*)-4-hydroxy-2-({[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]octanediamide **A67**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.66 (s, 1H), 8.98 (s, 1H), 8.56 (t, *J* = 6.0 Hz, 1H), 8.48 (*J* = 8.4 Hz, 1H), 7.86-7.77 (m, 2H), 7.57 (d, *J* = 7.2 Hz, 1H), 7.43-7.37 (m, 4H), 7.08 (s, 1H), 6.99-6.92 (m, 2H), 5.76 (dd, *J* = 4.4, 10.4 Hz, 1H), 4.56 (d, *J* = 9.2 Hz, 1H), 4.46-4.40 (m, 2H), 4.37-4.31 (m, 2H), 4.24-4.12 (m, 2H), 4.04-3.99 (m, 2H), 3.73 (s, 3H), 3.69-3.62 (m, 2H), 3.01 (s, 3H), 2.47-2.43 (m, 5H), 2.33-2.23 (m, 1H), 2.15-2.08 (m, 1H), 1.93-1.87 (m, 1H), 1.76-1.74 (m, 1H), 1.62-1.44 (m, 4H), 1.37-1.30 (m, 8H), 0.93 (s, 9H); MS (ESI) *m/z*: 987.7 [M+H]⁺.




[00514] (2*S*,4*R*)-1-[(2*S*)-2-(2-{4-[4-({2-[(1*S*)-1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonyl-ethyl]-1,3-dioxo-2,3-dihydro-1*H*-isindol-4-yl}carbamoyl)butyl]piperidin-1-yl}acetamido)-3,3-dimethylbutanoyl]-4-hydroxy-*N*-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}-pyrrolidine-2-carboxamide **A68**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.65 (s, 1H), 8.96 (s, 1H), 8.58 (t, *J* = 6.0 Hz, 1H), 8.46 (d, *J* = 8.4 Hz, 1H), 7.78 (t, *J* = 7.6 Hz, 2H), 7.65 (d, *J* = 6.8 Hz, 1H), 7.45-7.36 (m, 4H), 7.07 (d, *J* = 1.6 Hz, 1H), 6.98-6.91 (m, 2H), 5.77 (dd, *J* = 4.4 Hz, 10.4 Hz, 1H), 5.12 (d, *J* = 3.6 Hz, 1H), 4.52-4.23 (m, 6H), 4.14 (dd, *J* = 4.4 Hz, 14.4 Hz, 1H), 4.01 (q, *J* = 6.8 Hz, 2H), 3.72 (s, 3H), 3.67-3.56 (m, 2H), 3.00 (s, 3H), 2.96-2.64 (m, 4H), 2.47-2.45 (m, 2H), 2.43 (s, 3H), 2.16-1.93 (m, 4H), 1.90-1.88 (m, 1H), 1.73-1.49 (m, 4H), 1.33-1.15 (m,

10H), 0.93 (s, 9H); MS (ESI) m/z : 1058.2 $[M+H]^+$.




[00515] (2*S*,4*R*)-1-[(2*S*)-2-{[10-({2-[(1*S*)-1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl]amino)decyl]amino}-3,3-dimethylbutanoyl]-4-hydroxy-*N*-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide **A69**. ^1H NMR (400 MHz, DMSO- d_6) δ 8.98 (s, 1H), 8.56 (t, J = 5.2 Hz, 1H), 7.54 (t, J = 7.6 Hz, 1H), 7.44-7.35 (m, 4H), 7.06-7.03 (m, 2H), 6.97 (d, J = 7.2 Hz, 1H), 6.73 (s, 2H), 6.51 (t, J = 5.6 Hz, 1H), 5.71 (dd, J = 4.0, 10.0 Hz, 1H), 5.03 (brs, 1H), 4.53 (t, J = 8.0 Hz, 1H), 4.43-4.21 (m, 4H), 4.08 (dd, J = 3.6, 14.0 Hz, 1H), 4.03-3.98 (m, 2H), 3.73 (s, 3H), 3.63-3.53 (m, 2H), 3.29-3.25 (m, 4H), 3.00 (s, 3H), 2.44 (s, 3H), 2.33-2.28 (m, 1H), 2.08-1.97 (m, 1H), 1.58-1.53 (m, 2H), 1.35-1.24 (m, 17H), 1.18-1.09 (m, 2H), 0.92 (s, 9H); MS (ESI) m/z : 987.6 $[M+H]^+$.




[00516] (2*S*,4*R*)-1-[(2*S*)-2-{6-[4-(2-{2-[(1*S*)-1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}piperidin-1-yl)]hexanamido}-3,3-dimethylbutanoyl]-4-hydroxy-*N*-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide **A70**. ^1H NMR (400 MHz, DMSO- d_6) δ 9.90 (s, 1H), 9.01 (s, 1H), 8.57 (t, J = 6.0 Hz, 1H), 7.87 (d, J = 9.6 Hz, 1H), 7.76-7.68 (m, 3H), 7.44-7.34 (m, 4H), 7.24 (s, 1H), 6.97-6.92 (m, 2H), 5.78 (dd, J = 4.4, 10.4 Hz, 1H), 4.55 (d, J = 9.6 Hz, 1H), 4.46-4.35 (m, 5H), 4.20-4.15 (m, 1H), 4.13 (q, J = 4.4 Hz, 2H), 3.73 (s, 3H), 3.69-3.61 (m, 2H), 3.44-3.41 (m, 2H), 3.05-3.03 (m, 2H), 3.00 (s, 3H), 2.93-2.80 (m, 2H), 2.78-2.75 (m, 2H), 2.46 (s, 3H), 2.32-2.28 (m, 1H), 2.24-2.21 (m, 1H), 2.17-2.01 (m, 1H), 1.88-1.84 (m, 3H), 1.67-1.52 (m, 2H), 1.51-1.34 (m, 6H),

1.33 (s, 3H), 1.31 (t, $J = 6.8$ Hz, 3H), 0.93 (s, 9H); MS (ESI) m/z : 1041.3 $[M+H]^+$.




[00517] (2*S*,4*R*)-1-[(2*S*)-2-(5-{1-[2-({2-[(1*S*)-1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isoinдол-4-yl}amino)acetyl]piperidin-4-yl}pentan-amido)-3,3-dimethylbutanoyl]-4-hydroxy-*N*-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}-pyrrolidine-2-carboxamide **A71**. ^1H NMR (400 MHz, DMSO- d_6) δ 8.99 (s, 1H), 8.57 (d, $J = 4.4$ Hz, 1H), 7.88 (d, $J = 9.2$ Hz, 1H), 7.57 (t, $J = 7.2$ Hz, 1H), 7.47-7.35 (m, 4H), 7.22-6.89 (m, 6H), 5.74 (dd, $J = 4.0, 10.8$ Hz, 1H), 5.15 (s, 1H), 4.57 (d, $J = 9.2$ Hz, 1H), 4.48-4.32 (m, 5H), 4.23 (dd, $J = 5.2$ Hz, 16.0 Hz, 1H), 4.17-3.95 (m, 5H), 3.87 (d, $J = 12$ Hz, 1H), 3.74 (s, 3H), 3.70-3.64 (m, 2H), 3.08-2.96 (m, 4H), 2.63 (t, $J = 12.4$ Hz, 1H), 2.45 (s, 3H), 2.34-2.23 (m, 1H), 2.16-1.86 (m, 4H), 1.77-1.63 (m, 2H), 1.57-1.38 (m, 3H), 1.34-1.24 (m, 8H), 0.95 (s, 9 H); MS (ESI) m/z : 1056.2 $[M+H]^+$.




[00518] (2*S*,4*R*)-1-[(2*S*)-2-Acetamido-3,3-dimethylbutanoyl]-*N*-[(2-{[8-({2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isoinдол-4-yl}-carbamoyl)octyl]oxy}-4-(4-methyl-1,3-thiazol-5-yl)phenyl)methyl]-4-hydroxypyrrolidine-2-carboxamide **A74**. ^1H NMR (400 MHz, DMSO- d_6) δ 9.66 (s, 1H), 8.97 (s, 1H), 8.48-8.44 (m, 2H), 7.94 (d, $J = 9.6$ Hz, 1H), 7.78 (t, $J = 8.0$ Hz, 1H), 7.56 (d, $J = 7.2$ Hz, 1H), 7.46 (d, $J = 8.0$ Hz, 1H), 7.08 (s, 1H), 6.99-6.89 (m, 4H), 5.77 (dd, $J = 4.0, 10.0$ Hz, 1H), 5.11 (d, $J = 3.6$ Hz, 1H), 4.55-4.44 (m, 2H), 4.37-4.29 (m, 3H), 4.16-4.12 (m, 2H), 4.04-3.99 (m, 4H), 3.73 (s, 3H),

3.64 (s, 2H), 3.00 (s, 3H), 2.49-2.45 (m, 5H), 2.03-2.01 (m, 1H), 1.95-1.91 (m, 1H), 1.86 (s, 3H), 1.76-1.67 (m, 2H), 1.63-1.61 (m, 2H), 1.45-1.44 (m, 2H), 1.34-1.24 (m, 9H), 0.91 (s, 9H); MS (ESI) m/z : 1045.6 $[M+H]^+$.




[00519] (2*S*,4*R*)-1-[(2*S*)-2-Acetamido-3,3-dimethylbutanoyl]-*N*-[(2-{[10-({2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl]-carbamoyl)decyl]oxy}-4-(4-methyl-1,3-thiazol-5-yl)phenyl)methyl]-4-hydroxypyrrolidine-2-carboxamide **A75**. ^1H NMR (400 MHz, DMSO- d_6) δ 9.65 (s, 1H), 8.97 (s, 1H), 8.48-8.41 (m, 2H), 7.94 (d, J = 9.6 Hz, 1H), 7.78 (t, J = 8.0 Hz, 1H), 7.56 (d, J = 7.2 Hz, 1H), 7.46 (d, J = 8.0 Hz, 1H), 7.08 (s, 1H), 6.98-6.89 (m, 4H), 5.77 (dd, J = 4.0, 10.0 Hz, 1H), 5.11 (d, J = 3.6 Hz, 1H), 4.55-4.44 (m, 2H), 4.37-4.29 (m, 3H), 4.16-4.12 (m, 2H), 4.04-3.99 (m, 4H), 3.73 (s, 3H), 3.64 (s, 2H), 3.00 (s, 3H), 2.49-2.45 (m, 5H), 2.03-2.01 (m, 1H), 1.95-1.91 (m, 1H), 1.86 (s, 3H), 1.76-1.67 (m, 2H), 1.63-1.61 (m, 2H), 1.45-1.44 (m, 2H), 1.34-1.24 (m, 13H), 0.91 (s, 9H); MS (ESI) m/z : 1075.7 $[M+H]^+$.




[00520] (2*S*,4*R*)-1-[(2*S*)-2-Acetamido-3,3-dimethylbutanoyl]-*N*-[(2-{[6-({2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl]-


carbamoyl)hexyl]oxy}-4-(4-methyl-1,3-thiazol-5-yl)phenyl)methyl]-4-hydroxypyrrolidine-2-carboxamide **A76**. ^1H NMR (400 MHz, DMSO- d_6) δ 9.67 (s, 1H), 8.97 (s, 1H), 8.48-8.43 (m, 2H), 7.94 (d, J = 9.6 Hz, 1H), 7.78 (t, J = 8.0 Hz, 1H), 7.56 (d, J = 7.2 Hz, 1H), 7.46 (d, J = 8.0 Hz, 1H), 7.07 (s, 1H), 6.98-6.89 (m, 4H), 5.77 (dd, J = 4.0, 10.0 Hz, 1H), 5.11 (d, J = 3.6, 1H), 4.55-4.44 (m, 2H), 4.37-4.29 (m, 3H), 4.16-4.12 (m, 2H), 4.04-3.99 (m, 4H), 3.73 (s, 3H), 3.64 (s, 2H), 3.00 (s, 3H), 2.50-2.45 (m, 5H), 2.05-2.01 (m, 1H), 1.93-1.90 (m, 1H), 1.89 (s, 3H), 1.79-1.75 (m, 2H), 1.68-1.64 (m, 2H), 1.51-1.46 (m, 2H), 1.43-1.41 (m, 2H), 1.34-1.24 (m, 3H), 0.91 (s, 9H); MS (ESI) m/z : 1017.5 $[\text{M}+\text{H}]^+$.




[00521] 8-[4-([3-(2,6-Dioxopiperidin-3-yl)-1-methyl-1*H*-indazol-6-yl]carbamoyl)-methyl]piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}octanamide **A77**. ^1H NMR (400 MHz, DMSO- d_6) δ 10.87 (s, 1H), 9.83 (s, 1H), 9.66 (s, 1H), 8.47 (d, J = 8.0 Hz, 1H), 8.04 (s, 1H), 7.79 (t, J = 7.2 Hz, 1H), 7.63 (d, J = 8.8 Hz, 1H), 7.56 (d, J = 7.6 Hz, 1H), 7.17 (dd, J = 1.6, 8.8 Hz, 1H), 7.08 (d, J = 2.0 Hz, 1H), 6.99-6.92 (m, 2H), 5.77 (dd, J = 4.0, 10.4 Hz, 1H), 4.37-4.30 (m, 2H), 4.17-4.12 (m, 1H), 4.01 (q, J = 6.8 Hz, 2H), 3.92 (s, 3H), 3.73 (s, 3H), 3.14 (s, 2H), 3.01 (s, 3H), 2.67-2.61 (m, 2H), 2.46-2.44 (m, 4H), 2.41-2.26 (m, 4H), 2.35-2.31 (m, 2H), 2.26 (t, J = 7.2 Hz, 2H), 2.20-2.16 (m, 1H), 2.03-1.97 (m, 1H), 1.63-1.60 (m, 2H), 1.43-1.39 (m, 2H), 1.34-1.34 (m, 9H); MS (ESI) m/z : 927.5 $[\text{M}+\text{H}]^+$.




[00522] 6-[4-([3-(2,6-Dioxopiperidin-3-yl)-1-methyl-1*H*-indazol-6-yl]carbamoyl)-methyl]piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl-ethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}hexanamide **A78**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.88 (s, 1H), 9.84 (s, 1H), 9.67 (s, 1H), 8.47 (d, *J* = 8.4 Hz, 1H), 8.04 (s, 1H), 7.79 (t, *J* = 7.6 Hz, 1H), 7.63 (d, *J* = 8.8 Hz, 1H), 7.56 (d, *J* = 6.8 Hz, 1H), 7.19 (dd, *J* = 1.2, 8.8 Hz, 1H), 7.07 (d, *J* = 2.0 Hz, 1H), 6.97-6.92 (m, 2H), 5.77 (dd, *J* = 4.0, 10.4 Hz, 1H), 4.37-4.30 (m, 2H), 4.17-4.12 (m, 1H), 4.01 (q, *J* = 6.8 Hz, 2H), 3.92 (s, 3H), 3.73 (s, 3H), 3.14 (s, 2H), 3.01 (s, 3H), 2.67-2.61 (m, 2H), 2.48-2.39 (m, 6H), 2.35-2.26 (m, 4H), 2.20-2.15 (m, 1H), 2.03-1.99 (m, 1H), 1.66-1.62 (m, 2H), 1.48-1.44 (m, 2H), 1.37-1.28 (m, 7H); MS (ESI) *m/z*: 899.4 [M+H]⁺.




[00523] 10-[4-([3-(2,6-Dioxopiperidin-3-yl)-1-methyl-1*H*-indazol-6-yl]carbamoyl)-methyl]piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl-ethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}decanamide **A79**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.88 (s, 1H), 9.84 (s, 1H), 9.66 (s, 1H), 8.46 (d, *J* = 8.4 Hz, 1H), 8.04 (s, 1H), 7.79 (t, *J* = 7.6 Hz, 1H), 7.63 (d, *J* = 8.4 Hz, 1H), 7.56 (d, *J* = 7.2 Hz, 1H), 7.20-7.18 (m, 1H), 7.08-7.07 (m, 1H), 6.99-6.92 (m, 2H), 5.77 (dd, *J* = 4.0, 10.4 Hz, 1H), 4.37-4.30 (m, 2H), 4.17-4.12 (m, 1H), 4.02 (q, *J* = 6.8 Hz, 2H), 3.92 (s, 3H), 3.73 (s, 3H), 3.15 (s, 2H), 3.01 (s, 3H), 2.67-2.61 (m, 2H), 2.46-2.44 (m, 6H), 2.42-2.32 (m, 2H), 2.28-2.23 (m, 2H), 2.20-2.15 (m, 1H), 2.03-1.97 (m, 1H), 1.63-1.60 (m, 2H), 1.43-1.37 (m, 2H), 1.33-1.26 (m, 15H); MS (ESI) *m/z*: 955.5 [M+H]⁺.




[00524] 8-[4-([3-(2,6-Dioxopiperidin-3-yl)-1-methyl-1*H*-indazol-7-yl]carbamoyl)-methyl]piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}octanamide **A80**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.89 (s, 1H), 9.82 (s, 1H), 9.66 (s, 1H), 8.46 (d, *J* = 8.8 Hz, 1H), 7.79 (t, *J* = 7.6 Hz, 1H), 7.58-7.55 (m, 2H), 7.31-7.29 (m, 1H), 7.09-7.05 (m, 2H), 6.98-6.92 (m, 2H), 5.76 (dd, *J* = 4.8, 10.4 Hz, 1H), 4.39-4.35 (m, 2H), 4.16-4.13 (m, 1H), 4.10 (s, 3H), 4.02 (q, *J* = 6.8 Hz, 2H), 3.73 (s, 3H), 3.28 (s, 5H), 3.21-3.17 (m, 2H), 3.00 (s, 3H), 2.69-2.58 (m, 5H), 2.46-2.43 (m, 3H), 2.40-2.35 (m, 3H), 2.18-2.15 (m, 1H), 1.63-1.60 (m, 2H), 1.46-1.40 (m, 2H), 1.33-1.30 (m, 8H); MS (ESI) *m/z*: 927.6 [M+H]⁺.



[00525] 10-[4-([3-(2,6-Dioxopiperidin-3-yl)-1-methyl-1*H*-indazol-7-yl]carbamoyl)-methyl]piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}decanamide **A81**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.89 (s, 1H), 9.82 (s, 1H), 9.66 (s, 1H), 8.46 (d, *J* = 8.4 Hz, 1H), 7.78 (t, *J* = 7.6 Hz, 1H), 7.58-7.55 (m, 2H), 7.32-7.30 (m, 1H), 7.09-7.05 (m, 2H), 6.98-6.91 (m, 2H), 5.76 (dd, *J* = 4.4, 10.4 Hz, 1H), 4.39-4.30 (m, 2H), 4.16-4.13 (m, 1H), 4.10 (s, 3H), 4.02 (q, *J* = 6.8 Hz, 2H), 3.73 (s, 3H), 3.28 (s, 5H), 3.18 (s, 2H), 3.00 (s, 3H), 2.66-2.58 (m, 5H), 2.46-2.43 (m, 3H), 2.39-2.32 (m, 3H), 2.18-2.17 (m, 1H), 1.63-1.60 (m, 2H), 1.43-1.40 (m, 2H), 1.33-1.26 (m, 12H); MS (ESI) *m/z*: 955.3 [M+H]⁺.




[00526] 6-[4-([3-(2,6-Dioxopiperidin-3-yl)-1-methyl-1*H*-indazol-7-yl]carbamoyl)-methyl]piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}hexanamide **A82**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.90 (s, 1H), 10.33 (s, br, 1H), 9.69 (s, 1H), 8.46 (d, *J* = 8.8 Hz, 1H), 7.80 (t, *J* = 8.0 Hz, 1H), 7.64-7.56 (m, 2H), 7.23-7.21 (m, 1H), 7.12-7.07 (m, 2H), 6.99-6.94 (m, 2H), 5.78 (dd, *J* = 4.0, 10.4 Hz, 1H), 4.41-4.31 (m, 2H), 4.17-4.12 (m, 1H), 4.09 (s, 3H), 4.02 (q, *J* = 7.2 Hz, 2H), 3.73 (s, 3H), 3.60-3.55 (m, 2H), 3.26-3.10 (m, 8H), 3.01 (s, 3H), 2.73-2.62 (m, 3H), 2.52-2.50 (m, 1H), 2.43-2.12 (m, 3H), 2.03-1.95 (m, 1H), 1.75-1.60 (m, 4H), 1.42-1.23 (m, 5H); MS (ESI) *m/z*: 899.1 [M+H]⁺.




[00527] 6-[4-([4-(2,6-Dioxopiperidin-3-yl)phenyl]carbamoyl)methyl]piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}hexanamide **A83**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.80 (s, 1H), 9.67 (s, 1H), 9.64 (s, 1H), 8.46 (d, *J* = 8.4 Hz, 1H), 7.79 (t, *J* = 7.2 Hz, 1H), 7.57-7.55 (m, 3H), 7.15 (d, *J* = 8.0 Hz, 2H), 7.08 (s, 1H), 6.99-6.92 (m, 2H), 5.77 (dd, *J* = 4.4, 10.8 Hz, 1H), 4.37-4.30 (m, 1H), 4.17-4.12 (m, 1H), 4.02 (q, *J* = 6.8 Hz, 2H), 3.80 (dd, *J* = 4.8, 11.2 Hz, 1H), 3.73 (s, 3H), 3.08 (s, 2H), 3.01 (s, 3H), 2.67-2.64 (m, 1H), 2.47-2.41 (m, 11H), 2.33-2.26 (m, 3H), 2.19-2.15 (m, 1H), 2.04-1.99 (m, 2H), 1.65-1.62 (m, 2H), 1.47-1.44 (m, 2H), 1.32 (t, *J* = 6.8 Hz, 3H), 1.25-1.23 (m,


2H); MS (ESI) m/z : 845.4 $[M+H]^+$.




[00528] 8-[4-({[4-(2,6-Dioxopiperidin-3-yl)phenyl]carbamoyl}methyl)piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl-ethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}octanamide **A84**. ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 10.80 (s, 1H), 9.66 (s, 1H), 9.63 (s, 1H), 8.46 (d, $J = 8.4$ Hz, 1H), 7.79 (t, $J = 7.2$ Hz, 1H), 7.57-7.55 (m, 3H), 7.15 (d, $J = 8.4$ Hz, 2H), 7.08 (s, 1H), 6.99-6.92 (m, 2H), 5.77 (dd, $J = 4.4, 10.4$ Hz, 1H), 4.37-4.30 (m, 1H), 4.17-4.12 (m, 1H), 4.02 (q, $J = 6.8$ Hz, 2H), 3.80 (dd, $J = 4.8, 11.2$ Hz, 1H), 3.73 (s, 3H), 3.08 (s, 2H), 3.01 (s, 3H), 2.67-2.62 (m, 1H), 2.48-2.44 (m, 9H), 2.40-2.37 (m, 4H), 2.24 (t, $J = 7.2$ Hz, 2H), 2.18-2.15 (m, 1H), 2.04-1.99 (m, 1H), 1.63-1.60 (m, 2H), 1.42-1.40 (m, 2H), 1.32 (t, $J = 6.8$ Hz, 3H), 1.28-1.23 (m, 4H); MS (ESI) m/z : 873.6 $[M+H]^+$.




[00529] 8-[4-({[3-(2,6-Dioxopiperidin-3-yl)phenyl]carbamoyl}methyl)piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl-ethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}octanamide **A85**. ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 10.83 (s, 1H), 9.66 (s, 1H), 9.64 (s, 1H), 8.46 (d, $J = 8.4$ Hz, 1H), 7.78 (t, $J = 7.6$ Hz, 1H), 7.56-7.53 (m, 3H), 7.26 (t, $J = 8.0$ Hz, 1H), 7.07 (s, 1H), 6.99-6.91 (m, 3H), 5.77 (dd, $J = 4.0, 10.0$ Hz, 1H), 4.36-4.30 (m, 1H), 4.16-4.11 (m, 1H), 4.02 (q, $J = 7.2$ Hz, 2H), 3.85-3.81 (m, 1H), 3.73 (s, 3H), 3.07 (s, 2H), 3.00 (s, 3H), 2.69-2.66 (m, 1H), 2.52-2.50 (m, 1H), 2.49-2.44 (m, 5H), 2.38-2.32 (m, 4H), 2.30-1.96 (m, 5H), 1.63-1.58 (m, 2H), 1.41-1.36 (m, 2H), 1.33-1.30 (m, 9H); MS (ESI) m/z : 873.6 $[M+H]^+$.




[00530] 10-[4-({[4-(2,6-Dioxopiperidin-3-yl)phenyl]carbonyl}methyl)piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}decanamide **A86**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.80 (s, 1H), 9.66 (s, 1H), 9.63 (s, 1H), 8.46 (d, *J* = 8.0 Hz, 1H), 7.79 (t, *J* = 8.0 Hz, 1H), 7.57-7.55 (m, 3H), 7.15 (d, *J* = 8.8 Hz, 2H), 7.08 (s, 1H), 6.99-6.92 (m, 2H), 5.77 (dd, *J* = 4.0, 10.0 Hz, 1H), 4.37-4.30 (m, 1H), 4.17-4.13 (m, 1H), 4.02 (q, *J* = 6.8 Hz, 2H), 3.80 (dd, *J* = 8.0, 11.6 Hz, 1H), 3.73 (s, 3H), 3.08 (s, 2H), 3.01 (s, 3H), 2.67-2.61 (m, 1H), 2.48-2.44 (m, 8H), 2.40-2.32 (m, 4H), 2.23 (t, *J* = 7.2 Hz, 2H), 2.18-2.13 (m, 1H), 2.03-1.99 (m, 1H), 1.63-1.60 (m, 2H), 1.40-1.36 (m, 2H), 1.32 (t, *J* = 7.2 Hz, 3H), 1.28-1.23 (m, 9H); MS (ESI) *m/z*: 901.7 [M+H]⁺.




[00531] 6-[4-({[3-(2,6-Dioxopiperidin-3-yl)phenyl]carbonyl}methyl)piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}hexanamide **A87**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.84 (s, br, 1H), 9.66 (d, *J* = 6.8 Hz, 2H), 8.46 (d, *J* = 8.4 Hz, 1H), 7.79 (t, *J* = 7.6 Hz, 1H), 7.57-7.51 (m, 3H), 7.26 (t, *J* = 8.0 Hz, 1H), 7.08-7.07 (m, 1H), 6.98-6.91 (m, 3H), 5.77 (dd, *J* = 4.0, 10.4 Hz, 1H), 4.36-4.30 (m, 1H), 4.16-4.12 (m, 1H), 4.01 (q, *J* = 6.8 Hz, 2H), 3.83 (dd, *J* = 4.8, 11.2 Hz, 1H), 3.72 (s, 3H), 3.07 (s, 2H), 3.00 (s, 3H), 2.68-2.62 (m, 2H), 2.47-2.40 (m, 7H), 2.30-2.25 (m, 2H), 2.16-2.04 (m, 3H), 1.66-1.58 (m, 2H), 1.46-1.30 (m, 9H); MS (ESI) *m/z*: 845.4 [M+H]⁺.




[00532] 10-[4-({[3-(2,6-Dioxopiperidin-3-yl)phenyl]carbamoyl}methyl)piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}decanamide **A88**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.83 (s, 1H), 9.65 (d, *J* = 6.4 Hz, 2H), 8.46 (d, *J* = 8.4 Hz, 1H), 7.79 (t, *J* = 7.6 Hz, 1H), 7.56-7.53 (m, 3H), 7.26 (t, *J* = 8.0 Hz, 1H), 7.08-7.07 (m, 1H), 6.98-6.91 (m, 3H), 5.77 (dd, *J* = 4.8, 10.4 Hz, 1H), 4.36-4.30 (m, 1H), 4.16-4.11 (m, 1H), 4.02 (q, *J* = 7.2 Hz, 2H), 3.83 (dd, *J* = 5.2, 11.2 Hz, 1H), 3.73 (s, 3H), 3.07 (s, 2H), 3.00 (s, 3H), 2.67-2.62 (m, 2H), 2.49-2.38 (m, 9H), 2.33-2.32 (m, 1H), 2.22 (t, *J* = 7.2 Hz, 2H), 2.16-2.05 (m, 2H), 1.63-1.59 (m, 2H), 1.39-1.25 (m, 15H); MS (ESI) *m/z*: 901.6 [M+H]⁺.




[00533] *N*-{6-[12-({[3-[(2,6-Dioxopiperidin-3-yl)amino]phenyl]amino)dodecyl]-2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}acetamide **A89**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.77 (s, br, 1H), 9.65 (s, 1H), 8.29 (s, 1H), 7.44 (s, 1H), 7.08 (d, *J* = 3.2 Hz, 1H), 7.00-6.94 (m, 2H), 6.78 (t, *J* = 8.4 Hz, 1H), 5.92-5.87 (m, 3H), 5.78 (dd, *J* = 4.0, 10.4 Hz, 1H), 5.45 (d, *J* = 7.2 Hz, 1H), 5.17 (t, *J* = 4.8 Hz, 1H), 4.39-4.33 (m, 1H), 4.24-4.19 (m, 1H), 4.16-4.12 (m, 1H), 4.03 (q, *J* = 7.2 Hz, 2H), 3.75 (s, 3H), 3.03 (s, 3H), 2.95-2.91 (m, 2H), 2.75-2.70 (m, 3H), 2.63-2.56 (m, 1H), 2.20 (s, 3H), 2.15-2.12 (m, 1H), 1.88-1.85 (m, 1H), 1.61-1.50 (m, 4H), 1.34 (t, *J* = 6.8 Hz, 3H), 1.29-1.25 (m, 16H); MS (ESI) *m/z*: 846.6 [M+H]⁺.




[00534] 4-Amino-6-[12-({3-[(2,6-dioxopiperidin-3-yl)amino]phenyl}amino)dodecyl]-2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl]-2,3-dihydro-1*H*-isoindole-1,3-dione **A90**. ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 10.77 (s, 1H), 7.08 (s, 1H), 6.94 (s, 2H), 6.84 (s, 1H), 6.80-6.76 (m, 2H), 6.40 (s, 2H), 5.92-5.87 (m, 3H), 5.72 (dd, $J = 4.4, 10.4$ Hz, 1H), 5.45 (d, $J = 7.2$ Hz, 1H), 5.17 (t, $J = 4.8$ Hz, 1H), 4.40-4.34 (m, 1H), 4.23-4.20 (m, 1H), 4.10-4.05 (m, 1H), 4.02 (q, $J = 7.2$ Hz, 2H), 3.75 (s, 3H), 3.01 (s, 3H), 2.95-2.91 (m, 2H), 2.74-2.70 (m, 1H), 2.62-2.56 (m, 1H), 2.14-2.09 (m, 1H), 2.03-1.99 (m, 1H), 1.90-1.85 (m, 1H), 1.60-1.50 (m, 5H), 1.34 (t, $J = 6.8$ Hz, 3H), 1.29-1.25 (m, 16H); MS (ESI) m/z : 804.5 $[\text{M}+\text{H}]^+$.



[00535] 9-({3-[(2,6-Dioxopiperidin-3-yl)amino]phenyl}amino)-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}nonanamide **A91**. ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 10.75 (s, 1H), 9.66 (s, 1H), 8.46 (d, $J = 8.4$ Hz, 1H), 7.79 (t, $J = 7.6$ Hz, 1H), 7.56 (d, $J = 6.8$ Hz, 1H), 7.12-7.05 (m, 1H), 6.99-6.92 (m, 2H), 6.76 (t, $J = 8.0$ Hz, 1H), 5.93-5.75 (m, 4H), 5.43 (d, $J = 7.2$ Hz, 1H), 5.20-5.11 (m, 1H), 4.38-4.31 (m, 1H), 4.20-4.13 (m, 2H), 4.04-3.99 (m, 3H), 3.73 (s, 3H), 3.01 (s, 3H), 2.94-2.89 (m, 2H), 2.74-2.70 (m, 1H), 2.61-2.58 (m, 1H), 2.45-2.43 (m, 1H), 2.13-2.08 (m, 1H), 2.03-1.99 (m, 1H), 1.67-1.58 (m, 2H), 1.53-1.47 (m, 2H), 1.34-1.27 (m, 11H); MS (ESI) m/z : 776.5 $[\text{M}+\text{H}]^+$.




[00536] 6-{4-[(3-[(2,6-Dioxopiperidin-3-yl)amino]phenyl)carbonyl)methyl]piperazin-1-yl}-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}hexanamide **A92**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.77 (s, 1H), 9.67 (s, 1H), 9.36 (s, 1H), 8.47 (d, *J* = 8.4 Hz, 1H), 7.79 (t, *J* = 7.6 Hz, 1H), 7.56 (d, *J* = 7.2 Hz, 1H), 7.10-7.06 (m, 1H), 7.01-6.96 (m, 3H), 6.94-6.91 (m, 1H), 6.80 (d, *J* = 8.0 Hz, 1H), 6.39 (d, *J* = 8.0 Hz, 1H), 5.86 (d, *J* = 7.6 Hz, 1H), 5.77 (dd, *J* = 4.0, 10.0 Hz, 1H), 4.37-4.23 (m, 2H), 4.14 (dd, *J* = 4.0, 14.4 Hz, 1H), 4.02 (q, *J* = 7.2 Hz, 2H), 3.73 (s, 3H), 3.05 (s, 2H), 3.01 (s, 3H), 2.75-2.69 (m, 1H), 2.48-2.33 (m, 11H), 2.30-2.23 (m, 2H), 2.13-2.06 (m, 1H), 1.89-1.85 (m, 1H), 1.67-1.60 (m, 2H), 1.50-1.40 (m, 2H), 1.36-1.30 (m, 5H); MS (ESI) *m/z*: 860.2 [M+H]⁺.




[00537] The following compounds are prepared similarly according to the synthetic procedures or methodologies exemplified herein.


[00538] 8-(4-(2-(2,6-Dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)-N-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)octanamide **A32**.




[00539] 3-(2-(2-(3-((2-(2,6-Dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)amino)propoxy)-ethoxy)ethoxy)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)propanamide **A33**.




[00540] *N*-(6-(2-(2-(2-(3-((2-(2,6-Dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)amino)propoxy)-ethoxy)ethoxy)ethyl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide **A34**.




[00541] 6-(4-((2-(2,6-Dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)ethynyl)piperidin-1-yl)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)-6-oxohexanamide **A35**.




[00542] 8-(4-(2-(2,6-Dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)piperidin-1-yl)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)octanamide **A36**.




[00543] *N*-(6-(7-(4-(2-(2,6-Dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)piperidin-1-yl)heptyl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide **A37**.




[00544] 8-(4-((5-(2,6-Dioxopiperidin-3-yl)-4-oxo-5,6-dihydro-4*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy)phenyl)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)octanamide **A58**.




[00545] *N*-(6-(7-(4-((5-(2,6-Dioxopiperidin-3-yl)-4-oxo-5,6-dihydro-4*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy)phenyl)heptyl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide **A59**.



[00546] (2*S*,4*R*)-1-((*S*)-2-((8-((2-((*S*)-1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)-ethyl)-1,3-dioxoisindolin-4-yl)amino)-8-oxooctyl)amino)-3,3-dimethylbutanoyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide **A72**.




[00547] (2*S*,4*R*)-1-((*S*)-2-((7-(7-Acetamido-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-5-yl)heptyl)amino)-3,3-dimethylbutanoyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide **A73**.



Example 12

Synthesis of *N*-(3,5-Dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)heptyl)oxy)benzamide **B1**



[00548] To a solution of methyl 4-(difluoromethoxy)-3-hydroxybenzaldehyde (1.0 g, 5.32 mmol) in ACN (14 mL) were added K_2CO_3 (2.20 g, 15.96 mmol) and 7-iodo-*N*-methoxy-*N*-methylheptanamide (2.39 g, 7.92 mmol). After stirred at 80 °C for 2 h, the mixture was diluted with H_2O and extracted with EtOAc. The combined organic layers were dried over anhydrous Na_2SO_4 , filtered, and concentrated. The residue was purified using silica gel with ethyl acetate in petroleum ether from 0% to 50% to give 7-(2-(difluoromethoxy)-5-formylphenoxy)-*N*-methoxy-*N*-methylheptanamide (1.8 g) in 94% yield. MS (ESI) m/z : 360.3 $[M+H]^+$.

[00549] To a solution of 7-(2-(difluoromethoxy)-5-formylphenoxy)-*N*-methoxy-*N*-methylheptanamide (1.8 g, 5.01 mmol) in acetic acid (40 mL) were added sulfamic acid (1.46 g, 15.04 mmol) and a solution of sodium chlorite (1.36 g, 15.04 mmol) in H_2O (13 mL) dropwise. After stirred at 35 °C for 2 h, the mixture was diluted with H_2O and filtered to give 4-(difluoromethoxy)-3-((7-(methoxy(methyl)amino)-7-oxoheptyl)oxy)benzoic acid (1.88 g) in 90% yield. MS (ESI) m/z : 376.3 $[M+H]^+$.

[00550] To a solution of 4-(difluoromethoxy)-3-((7-(methoxy(methyl)amino)-7-

oxoheptyl)oxy)benzoic acid (500 mg, 1.333 mmol) in dichloromethane (8 mL) in 0 °C were added oxalyl chloride (250 mg, 2.00 mmol) and DMF (1 drop). After stirred at room temperature for 1 h, the mixture was concentrated to give 4-(difluoromethoxy)-3-((7-(methoxy(methyl)amino)-7-oxoheptyl)oxy)benzoyl chloride (crude).

[00551] To a solution of 3,5-dichloropyridin-4-amine (464 mg, 2.67 mmol) in tetrahydrofuran (6 mL) in 0 °C was added sodium hydride (64 mg, 2.67 mmol). After the mixture was stirred at 0 °C for 30 min, *N*-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-(methoxy(methyl)amino)-7-oxoheptyl)oxy)benzamide (524 mg, 1.33 mmol) was added. After stirred at room temperature for 2 h, the mixture was diluted with H₂O and extracted with ethyl acetate. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated. The residue was purified using silica gel eluting with ethyl acetate in petroleum ether from 0% to 40% to give *N*-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-(methoxy(methyl)amino)-7-oxoheptyl)oxy)benzamide (254 mg) in 37% yield. MS (ESI) *m/z*: 520.1 [M+H]⁺.


[00552] To a solution of *N*-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-(methoxy(methyl)amino)-7-oxoheptyl)oxy)benzamide (50 mg, 0.096 mmol) in tetrahydrofuran (3 mL) at -78 °C under nitrogen was added lithium aluminum hydride (0.14 mL, 1M in tetrahydrofuran) dropwise. After stirred at this temperature for 1 h, the reaction was quenched with ammonium chloride (5 mL) and the reaction mixture was extracted with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated to give *N*-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-oxoheptyl)oxy)benzamide (40 mg, crude). MS (ESI) *m/z*: 461.1[M+H]⁺.

[00553] To a solution of 3-(6-fluoro-1-oxo-4-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione (42 mg, 0.010 mmol) in dichloromethane/methanol (4 mL/1 mL) was added *N,N*-diisopropylethylamine (12 mg, 0.10 mmol) at 0 °C, followed by addition of *N*-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-oxoheptyl)oxy)benzamide (40 mg, crude, 0.10 mmol), NaBH₃CN (12 mg, 0.19 mmol), and acetic acid (1 drop). The mixture was stirred at room temperature overnight and then concentrated. The residue was purified using prep-HPLC eluting with water (0.1% TFA) in ACN (0.1% TFA) at a gradient of 95 to 5% to give *N*-(3,5-

dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)heptyl)oxy)benzamide **B1** (17.2 mg) in 23% yield. ^1H NMR (400 MHz, DMSO- d_6) δ 11.00 (s, 1H), 10.66 (brs, 1H), 8.77 (s, 2H), 7.73 (d, $J = 2.0$ Hz, 1H), 7.66 (dd, $J = 2.0, 8.4$ Hz, 1H), 7.40-7.07 (m, 4H), 5.14 (dd, $J = 4.8, 13.2$ Hz, 1H), 4.53-4.32 (m, 2H), 4.13 (t, $J = 6.4$ Hz, 2H), 3.52-3.49 (m, 2H), 3.01-2.88 (m, 3H), 2.62-2.58 (m, 2H), 2.45-2.35 (m, 2H), 2.07-1.99 (m, 3H), 1.81-1.70 (m, 5H), 1.51-1.27 (m, 8H); MS (ESI) m/z : 790.3 $[\text{M}+\text{H}]^+$.

Example 13

Synthesis of *N*-(3,5-Dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((5-(4-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)ethynyl)piperidin-1-yl)-5-oxopentyl)oxy)benzamide **B2**



[00554] A solution of 3-(benzyloxy)-*N*-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-benzamide (110 mg, 0.271 mmol) in trifluoroacetic acid (6 mL) was stirred at 80 °C for 1 h and then concentrated to give *N*-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-hydroxy-benzamide (crude). MS (ESI) m/z : 349.0 $[\text{M}+\text{H}]^+$.

[00555] To a solution of *N*-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-hydroxy-benzamide (94 mg, 0.270 mmol) in acetonitrile (5 mL) were added potassium carbonate (112 mg, 0.810 mmol) and methyl 5-bromopentanoate (47 mg, 0.243 mmol). After heated at 80 °C overnight, the mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were dried over anhydrous Na_2SO_4 , filtered, and concentrated. The residue was purified using prep-TLC eluting with petroleum ether/ethyl acetate (3:1) to give methyl 5-(5-((3,5-dichloropyridin-4-yl)carbamoyl)-2-(difluoromethoxy)phenoxy)pentanoate (75 mg) in 60% yield. MS (ESI) m/z : 463.1 $[\text{M}+\text{H}]^+$.


[00556] To a solution of methyl 5-(5-((3,5-dichloropyridin-4-yl)carbamoyl)-2-(difluoromethoxy)phenoxy)pentanoate (75 mg, 0.162 mmol) in methanol (4 mL),

tetrahydrofuran (2 mL), and water (1 mL) was added lithium hydroxide (14 mg, 0.325 mmol). After stirred for 12 h, the mixture was neutralized to pH 6 with 1N HCl and then extracted with ethyl acetate. The combined organic layers were concentrated to give 5-(5-((3,5-dichloropyridin-4-yl)carbamoyl)-2-(difluoromethoxy)phenoxy)pentanoic acid (72 mg) in 99% yield. MS (ESI) m/z : 449.2 $[M+H]^+$.

[00557] To a solution of 5-(5-((3,5-dichloropyridin-4-yl)carbamoyl)-2-(difluoromethoxy)phenoxy)pentanoic acid (72 mg, 0.162 mmol) in *N,N*-dimethylformamide (5 mL) were added HATU (93 mg, 0.243 mmol), 3-(1-oxo-4-(piperidin-4-ylethynyl)isoindolin-2-yl)piperidine-2,6-dione (57 mg, 0.62 mmol), and ethyldiisopropylamine (63 mg, 0.486 mmol). The mixture was stirred overnight and then concentrated. The residue was purified using prep-HPLC to give *N*-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((5-(4-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)ethynyl)piperidin-1-yl)-5-oxopentyl)oxy)benzamide **B2** (36.9 mg) in 29% yield. ^1H NMR (400 MHz, DMSO- d_6) δ 10.98 (s, 1H), 10.63 (s, 1H), 8.74 (s, 2H), 7.72-7.70 (m, 2H), 7.66-7.63 (m, 2H), 7.53 (t, $J = 7.6$ Hz, 1H), 7.38-7.01 (m, 2H), 5.12 (dd, $J = 5.2, 13.6$ Hz, 1H), 4.47-4.29 (m, 2H), 4.15 (t, $J = 6.4$, 2H), 3.90-3.87 (m, 1H), 3.73-3.69 (m, 1H), 3.29 (s, 2H), 3.22-3.16 (m, 1H), 2.99-2.86 (m, 2H), 2.66-2.57 (m, 1H), 2.45-2.38 (m, 3H), 2.07-1.95 (m, 2H), 1.71-1.66 (m, 2H), 1.23 (s, 4H); MS (ESI) m/z : 782.2 $[M+H]^+$.

Example 14

Synthesis of *N*-(3,5-Dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-5-yl)piperidin-1-yl)heptyl)oxy)benzamide **B3**



[00558] To a solution of *N*-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-(methoxy(methyl)amino)-7-oxoheptyl)oxy)benzamide (80 mg, 0.154 mmol) in tetrahydrofuran (5 mL) at -78 °C under nitrogen was added lithium aluminum hydride (0.23 mL, 1 M in tetrahydrofuran) dropwise. After stirred at this temperature for 1 h, the reaction was quenched


with ammonium chloride (5 mL) and the reaction mixture was extracted with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated to give *N*-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-oxoheptyl)oxy)benzamide (71 mg, crude). MS (ESI) m/z : 461.1[M+H]⁺.

[00559] To a solution of *tert*-butyl 4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-5-yl)piperidine-1-carboxylate (60 mg, 0.135 mmol) in dichloromethane (3 mL) was added trifluoroacetic acid (1 mL). The mixture was stirred for 1 h and then concentrated. The residue was co-evaporated with toluene to give 3-(6-fluoro-1-oxo-5-(piperidin-4-yl)isindolin-2-yl)piperidine-2,6-dione (47 mg, crude). MS (ESI) m/z : 346.1 [M+H]⁺.

[00560] To a solution of 3-(6-fluoro-1-oxo-5-(piperidin-4-yl)isindolin-2-yl)piperidine-2,6-dione (47 mg, 0.135 mmol) in dichloromethane (4 mL) and methanol (1 mL) at 0 °C was added *N,N*-diisopropylethylamine (35 mg, 0.27 mmol), followed by addition of *N*-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-oxoheptyl)oxy)benzamide (71 mg, crude, 0.154 mmol), NaBH₃CN (17 mg, 0.27 mmol), and acetic acid (1 drop). The mixture was stirred at room temperature for 8 h and then concentrated. The residue was purified using silica gel eluting with methanol in dichloromethane from 0% to 10% to give *N*-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-5-yl)piperidin-1-yl)heptyl)oxy)benzamide **B3** (28.0 mg) in 26.4% yield. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.99 (s, 1H), 10.66 (s, 1H), 8.76 (s, 2H), 7.72 (d, *J* = 2.0 Hz, 1H), 7.65 (dd, *J* = 1.6, 8.0 Hz, 1H), 7.61 (d, *J* = 6.4 Hz, 1H), 7.46 (d, *J* = 9.2 Hz, 1H), 7.38-7.01 (m, 2H), 5.10 (dd, *J* = 4.8, 12.8 Hz, 1H), 4.32-4.26 (m, 2H), 4.13 (t, *J* = 6.4 Hz, 2H), 2.99-2.96 (m, 2H), 2.94-2.83 (m, 2H), 2.67-2.58 (m, 1H), 2.43-2.36 (m, 1H), 2.36-2.28 (m, 3H), 2.03-1.98 (m, 3H), 1.79-1.72 (m, 6H), 1.48-1.44 (m, 4H), 1.38-1.29 (m, 4H); MS (ESI) m/z : 790.3 [M+H]⁺.

Example 15

Synthesis of *N*-(3,5-Dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-((4-((5-(2,6-dioxopiperidin-3-yl)-4-oxo-5,6-dihydro-4*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy)benzyl)amino)heptyl)-oxy)benzamide **B18**



[00561] To a solution of *tert*-butyl 5-amino-4-(1-(hydroxymethyl)-4-oxo-4*H*-thieno[3,4-*c*]pyrrol-5(6*H*)-yl)-5-oxopentanoate (650 mg, 1.84 mmol) in dichloromethane (20 mL) at 0 °C was added triethylamine (371 mg, 3.68 mmol), followed by addition of methanesulfonyl chloride (420 mg, 3.68 mmol). The mixture was stirred overnight and then concentrated. The residue was purified using silica gel eluting with ethyl acetate in petroleum ether from 10% to 70% to give *tert*-butyl 5-amino-4-(1-(chloromethyl)-4-oxo-4*H*-thieno[3,4-*c*]pyrrol-5(6*H*)-yl)-5-oxopentanoate (458 mg) in 67% yield. MS (ESI) *m/z*: 373.1 [M+H]⁺.

[00562] To a solution of *tert*-butyl 5-amino-4-(1-(chloromethyl)-4-oxo-4*H*-thieno[3,4-*c*]pyrrol-5(6*H*)-yl)-5-oxopentanoate (423 mg, 1.14 mmol) in *N,N*-dimethylformamide (20 mL) were added *tert*-butyl 4-hydroxybenzylcarbamate (304 mg, 1.36 mmol) and potassium carbonate (314 mg, 2.28 mmol). After heated at 80 °C for 2 h, the mixture was diluted with H₂O and extracted with ethyl acetate. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated. The residue was purified using silica gel eluting with ethyl acetate in petroleum ether from 10% to 80% to give *tert*-butyl 5-amino-4-(1-((4-(((*tert*-butoxycarbonyl)-amino)methyl)-phenoxy)methyl)-4-oxo-4*H*-thieno[3,4-*c*]pyrrol-5(6*H*)-yl)-5-oxopentanoate (576 mg) in 91% yield. MS (ESI) *m/z*: 560.2 [M+H]⁺.

[00563] To a solution of *tert*-butyl 5-amino-4-(1-((4-(((*tert*-butoxycarbonyl)-amino)methyl)phenoxy)methyl)-4-oxo-4*H*-thieno[3,4-*c*]pyrrol-5(6*H*)-yl)-5-oxopentanoate (576 mg, 1.03 mmol) in tetrahydrofuran/H₂O (15 mL/15 mL) was added LiOH·H₂O (46 mg, 1.03 mmol). The mixture was stirred overnight and then concentrated. The residue was acidified to pH 5 with 2N HCl and then extracted with dichloromethane/methanol (10:1). The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated to give 5-amino-4-(1-((4-(((*tert*-butoxycarbonyl)-amino)methyl)phenoxy)methyl)-4-oxo-4*H*-thieno[3,4-*c*]pyrrol-5(6*H*)-yl)-5-oxopentanoic acid (359 mg) in 69% yield. MS (ESI) *m/z*: 504.2 [M+H]⁺.

[00564] To a solution of 5-amino-4-(1-((4-(((*tert*-butoxycarbonyl)amino)methyl)-phenoxy)methyl)-4-oxo-4*H*-thieno[3,4-*c*]pyrrol-5(6*H*)-yl)-5-oxopentanoic acid (359 mg, 0.714 mmol) in acetonitrile (20 mL) was added 1,1'-carbonyldiimidazole (346 mg, 2.14 mmol). The mixture was stirred at 95 °C for 4 h. The resulting solid was filtered and dried under vacuum to give *tert*-butyl 4-((5-(2,6-dioxopiperidin-3-yl)-4-oxo-5,6-dihydro-4*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy)-benzylcarbamate (197 mg). The filtrate was concentrated and the residue was purified using silica gel eluting with ethyl acetate in petroleum ether from 10% to 70% to give additional *tert*-butyl 4-((5-(2,6-dioxopiperidin-3-yl)-4-oxo-5,6-dihydro-4*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy)benzylcarbamate (108 mg). The combined total of the desired product was 305 mg (88% yield). MS (ESI) *m/z*: 486.2 [M+H]⁺.

[00565] To a solution of *tert*-butyl 4-((5-(2,6-dioxopiperidin-3-yl)-4-oxo-5,6-dihydro-4*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy)benzylcarbamate (44 mg, 0.091 mmol) in dichloromethane (4 mL) was added trifluoroacetic acid (1 mL). The mixture was stirred for 1 h and then concentrated to give 3-(1-((4-(aminomethyl)phenoxy)methyl)-4-oxo-4*H*-thieno[3,4-*c*]pyrrol-5(6*H*)-yl)piperidine-2,6-dione (35 mg, crude). MS (ESI) *m/z*: 386.1[M+H]⁺.


[00566] To a solution of *N*-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-(methoxy(methyl)amino)-7-oxoheptyl)oxy)benzamide (80 mg, 0.15 mmol) in tetrahydrofuran (5 mL) at -70 °C under N₂ was added LiAlH₄ (0.31 mL, 1 M in THF). After stirred at this temperature for 30 min, the reaction was quenched with sat. NH₄Cl (5 mL) and the reaction mixture was extracted with ethyl acetate. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated to give *N*-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-oxoheptyl)oxy)benzamide (75 mg, crude). MS (ESI) *m/z*: 461.1 [M+H]⁺.

[00567] To a solution of *N*-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-oxoheptyl)oxy)benzamide (54 mg, 0.12 mmol) in dichloromethane/methanol (4 mL/1 mL) were added 3-(1-((4-(aminomethyl)phenoxy)methyl)-4-oxo-4*H*-thieno[3,4-*c*]pyrrol-5(6*H*)-yl)piperidine-2,6-dione (35 mg, crude) and *N,N*-diisopropylethylamine (12 mg, 0.09 mmol), followed by addition of NaBH₃CN (18 mg, 0.27 mmol). The mixture was stirred overnight and then concentrated. The residue was purified using silica gel eluting with methanol in

dichloromethane from 0% to 10% and further purified using prep-HPLC to give *N*-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-((4-((5-(2,6-dioxopiperidin-3-yl)-4-oxo-5,6-dihydro-4*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy)benzyl)-amino)heptyl)oxy)benzamide **B18** (21.7 mg) in 28.9% yield. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.70 (s, 2H), 8.01 (s, 1H), 7.72 (d, *J* = 1.6 Hz, 1H), 7.65 (dd, *J* = 2.0, 8.8 Hz, 1H), 7.35-7.32 (m, 1H), 7.26-7.24 (m, 2H), 7.17 (s, 1H), 6.98-6.95 (m, 2H), 5.28 (s, 2H), 5.01 (dd, *J* = 5.3, 13.2 Hz, 1H), 4.37-4.20 (m, 2H), 4.10 (t, *J* = 6.4 Hz, 2H), 3.64 (s, 2H), 3.52-3.48 (m, 2H), 2.93-2.84 (m, 1H), 2.60-2.55 (m, 2H), 2.39-2.29 (m, 1H), 2.00-1.95 (m, 1H), 1.79-1.73 (m, 2H), 1.45-1.41 (m, 4H), 1.32-1.31 (m, 4H); MS (ESI) *m/z*: 832.2 [M+H]⁺.

Example 16

Synthesis of (2*S*,4*R*)-1-((*S*)-2-(9-(5-((3,5-Dichloropyridin-4-yl)carbamoyl)-2-(difluoromethoxy)phenoxy)nonanamido)-3,3-dimethylbutanoyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide **B20**



[00568] To a solution of 4-(difluoromethoxy)-3-hydroxybenzaldehyde (150 mg, 0.79 mmol) in acetonitrile (10 mL) were added methyl 9-bromononanoate (260 mg, 1.02 mmol) and potassium carbonate (330 mg, 2.3 mmol). After stirred at 80 °C overnight, the reaction was quenched with ammonium chloride (10 mL) and the reaction mixture was extracted with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated to give methyl 9-(2-(difluoromethoxy)-5-formylphenoxy)nonanoate (217 mg, crude). MS (ESI) *m/z*: 359.1[M+H]⁺.

[00569] To a solution of methyl 9-(2-(difluoromethoxy)-5-formylphenoxy)nonanoate (200 mg, 0.55 mmol) in acetic acid (10 mL) and water (10 mL) at 0 °C were added sulfamic acid (150 mg, 1.66 mmol) and sodium hypochlorite (162 mg, 1.67 mmol). After stirred at 0 °C for 30 min, the mixture was diluted with water and extracted with ethyl acetate. The combined organic

layers were dried over anhydrous sodium sulfate, filtered, and concentrated to give 4-(difluoromethoxy)-3-((9-methoxy-9-oxononyl)oxy)benzoic acid (210 mg) in 89% yield. MS (ESI) m/z : 375.2 $[M+H]^+$.

[00570] To a solution of 4-(difluoromethoxy)-3-((9-methoxy-9-oxononyl)oxy)benzoic acid (100 mg, 0.27 mmol) in dichloromethane (10 mL) at 0 °C were added oxalyl chloride (51 mg, 0.41 mmol) and *N,N*-dimethylformamide (1 drop). The mixture was stirred at 0 °C for 3 h and then concentrated to give methyl 9-(5-(chlorocarbonyl)-2-(difluoromethoxy)phenoxy)-nonanoate (crude).

[00571] To a solution of 3,5-dichloropyridin-4-amine (65 mg, 0.41 mmol) in *N,N*-dimethylformamide (5 mL) at 0 °C was added NaH (21 mg, 0.54 mmol). After the mixture was stirred at this temperature for 30 min, a solution of methyl 9-(5-(chlorocarbonyl)-2-(difluoromethoxy)phenoxy)nonanoate (crude) in *N,N*-dimethylformamide (5 mL) was added. The reaction was stirred at 0 °C overnight and then quenched with water. The reaction mixture was extracted with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated to give methyl 9-(5-((3,5-dichloropyridin-4-yl)carbamoyl)-2-(difluoromethoxy)phenoxy)nonanoate (50 mg, crude). MS (ESI) m/z : 519.2 $[M+H]^+$.


[00572] To a solution of methyl 9-(5-((3,5-dichloropyridin-4-yl)carbamoyl)-2-(difluoromethoxy)phenoxy)nonanoate (50 mg, 0.096 mmol) in tetrahydrofuran (5 mL) and water (5 mL) was added lithium hydroxide monohydrate (7.8 mg, 0.19 mmol). After stirred for 8 h, the mixture was acidified to pH 5 with 2N HCl and extracted with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated to give 9-(5-((3,5-dichloropyridin-4-yl)carbamoyl)-2-(difluoromethoxy)phenoxy)nonanoic acid (37 mg, crude). MS (ESI) m/z : 504.1 $[M+H]^+$.

[00573] To a solution of 9-(5-((3,5-dichloropyridin-4-yl)carbamoyl)-2-(difluoromethoxy)-phenoxy)nonanoic acid (37 mg, 0.073 mmol) in *N,N*-dimethylformamide (10 mL) at room temperature were added (2*S*,4*R*)-1-((*S*)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (34.2 mg, 0.073 mmol), *N,N*-diisopropylethylamine (28.3 mg, 0.219 mmol), HOBt (19.7 mg, 0.146 mmol), and EDCI·HCl

(28.1 mg, 0.146 mmol). After stirred overnight, the mixture was diluted with H₂O and extracted with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified using prep-HPLC to give (2*S*,4*R*)-1-((*S*)-2-(9-(5-((3,5-dichloropyridin-4-yl)carbamoyl)-2-(difluoromethoxy)phenoxy)nonanamido)-3,3-dimethylbutanoyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide **B20** (12 mg). ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.66 (s, 1H), 8.98 (s, 1H), 8.76 (s, 2H), 8.56 (t, *J* = 5.2 Hz, 1H), 7.84 (d, *J* = 9.2 Hz, 1H), 7.71 (s, 1H), 7.65 (d, *J* = 7.6 Hz, 1H), 7.42-7.36 (m, 5H), 7.18 (t, *J* = 74.0 Hz, 1H), 5.13 (d, *J* = 3.6 Hz, 1H), 4.53 (d, *J* = 9.6 Hz, 1H), 4.46-4.40 (m, 2H), 4.34 (s, 1H), 4.24-4.19 (m, 1H), 4.11 (t, *J* = 6.0 Hz, 2H), 3.68-3.62 (m, 2H), 2.44 (s, 3H), 2.29-2.22 (m, 1H), 2.14-2.08 (m, 1H), 2.05-1.99 (m, 1H), 1.92-1.86 (m, 1H), 1.78-1.73 (m, 2H), 1.53-1.43 (m, 4H), 1.29-1.23 (m, 6H), 0.92 (s, 9H); MS (ESI) *m/z*: 917.3[M+H]⁺.

Example 17

Synthesis of (2*S*,4*R*)-1-((*S*)-2-(11-(5-((3,5-Dichloropyridin-4-yl)carbamoyl)-2-(difluoromethoxy)phenoxy)undecanamido)-3,3-dimethylbutanoyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide **B21**



[00574] A solution of 3-(benzyloxy)-*N*-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-benzamide (120 mg, 0.274 mmol) in trifluoroacetic acid (6 mL) was heated at 80 °C for 1 h and then concentrated to give *N*-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-hydroxy-benzamide (crude). MS (ESI) *m/z*: 349.0 [M+H]⁺.

[00575] To a solution of *N*-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-hydroxy-benzamide (95 mg, 0.273 mmol) in acetonitrile (6 mL) were added potassium carbonate (113 mg, 0.819 mmol) and *tert*-butyl 11-bromoundecanoate (96 mg, 0.30 mmol). After heated at 80 °C overnight, the mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were concentrated. The residue was purified using silica gel eluting with ethyl

acetate in petroleum from 0% to 20% to give *tert*-butyl 11-(5-((3,5-dichloropyridin-4-yl)-carbamoyl)-2-(difluoromethoxy)phenoxy)undecanoate (86 mg) in 54% yield. MS (ESI) m/z : 533.2 [M-56+H]⁺.


[00576] To a solution of *tert*-butyl 11-(5-((3,5-dichloropyridin-4-yl)carbamoyl)-2-(difluoromethoxy)phenoxy)undecanoate (86 mg, 0.146 mmol) in dichloromethane (6 mL) was trifluoroacetic acid (2 mL). The mixture was stirred for 12 h and then concentrated to give 11-(5-((3,5-dichloropyridin-4-yl)carbamoyl)-2-(difluoromethoxy)phenoxy)undecanoic acid (70 mg, crude). MS (ESI) m/z : 533.2 [M+H]⁺.

[00577] To a solution of 11-(5-((3,5-dichloropyridin-4-yl)carbamoyl)-2-(difluoromethoxy)phenoxy)undecanoic acid (77.8 mg, 0.146 mmol) in *N,N*-dimethylformamide (6 mL) were added ethyldiisopropylamine (57 mg, 0.438 mmol), (2*S*,4*R*)-1-((*S*)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (68 mg, 0.146 mmol), 1-hydroxybenzotriazole (30 mg, 0.219 mmol), and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (42 mg, 0.219 mmol). The mixture was stirred overnight and then concentrated. The residue was purified using prep-TLC eluting with DCM/methanol (15:1) and further purified using prep-HPLC to give (2*S*,4*R*)-1-((*S*)-2-(11-(5-((3,5-dichloropyridin-4-yl)carbamoyl)-2-(difluoromethoxy)phenoxy)undecanamido)-3,3-dimethylbutanoyl)-4-hydroxy-*N*-(4-(4-methyl-thiazol-5-yl)benzyl)pyrrolidine-2-carboxamide **B21** (30.3 mg) in 22% yield. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.64 (s, 1H), 8.97 (s, 1H), 8.76 (s, 2H), 8.54 (t, J = 5.6 Hz, 1H), 7.83 (d, J = 10.0 Hz, 1H), 7.72 (s, 1H), 7.66 (d, J = 8.0 Hz, 1H), 7.42-6.99 (m, 6H), 5.11 (d, J = 3.6 Hz, 1H), 4.54 (d, J = 8.8 Hz, 1H), 4.52-4.12 (m, 4H), 4.11 (t, J = 6.4 Hz, 2H), 3.65 (s, 2H), 2.44 (s, 3H), 2.27-2.23 (m, 1H), 2.13-1.89 (m, 3H), 1.77-1.74 (m, 2H), 1.47-1.41 (m, 4H), 1.25-1.23 (m, 10H), 0.92 (s, 9H); MS (ESI) m/z : 945.1 [1/2M+H]⁺, 473.3 [1/2M+H]⁺.


[00578] The following compounds were prepared similarly according to the synthetic procedures or methodologies exemplified herein.

[00579] *N*-(3,5-Dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((9-(4-(2-(2,6-dioxo-piperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)nonyl)oxy)benzamide **B4**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.05 (s, 1H), 10.73 (s, 1H), 10.32 (s, 1H), 8.77 (s, 2H), 7.75 (d, J = 1.6 Hz, 1H), 7.67 (dd, J = 1.6, 8.0 Hz, 1H), 7.43 (dd, J = 1.6, 7.6 Hz, 1H), 7.39-7.02 (m, 3H), 5.17


(dd, $J = 5.2, 13.2$ Hz, 1H), 4.58-4.35 (m, 2H), 4.13 (t, $J = 6.4$ Hz, 2H), 3.60-3.50 (m, 2H), 3.07-2.89 (m, 6H), 2.67-2.57 (m, 1H), 2.39-2.33 (m, 1H), 2.07-1.96 (m, 5H), 1.81-1.69 (m, 4H), 1.47-1.44 (m, 2H), 1.33-1.29 (m, 8H); MS (ESI) m/z : 819.7 $[M+H]^+$.




[00580] *N*-(3,5-Dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((5-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)pentyl)oxy)benzamide **B5**. ^1H NMR (400 MHz, DMSO- d_6) δ 11.05 (s, 1H), 10.67 (s, 1H), 9.18 (s, 1H), 8.77 (s, 2H), 7.73-7.68 (m, 2H), 7.45-7.37 (m, 2H), 7.31-6.95 (m, 2H), 5.17 (dd, $J = 5.2, 13.2$ Hz, 1H), 4.56-4.40 (m, 2H), 4.17 (t, $J = 6.4$ Hz, 2H), 3.62 (d, $J = 10.4$ Hz, 2H), 3.15-3.10 (m, 2H), 3.04-2.93 (m, 4H), 2.66-2.61 (m, 1H), 2.35-2.27 (m, 1H), 2.06-2.03 (m, 3H), 1.89-1.74 (m, 6H), 1.54-1.47 (m, 2H); MS (ESI) m/z : 764.2 $[M+H]^+$.




[00581] *N*-(3,5-Dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)heptyl)oxy)benzamide **B6**. ^1H NMR (400 MHz, DMSO- d_6) δ 11.02 (s, 1H), 10.72 (brs, 1H), 8.77 (s, 2H), 7.74 (s, 1H), 7.67 (d, $J = 7.6$ Hz, 1H), 7.41-7.00 (m, 4H), 5.15 (dd, $J = 3.6, 12$ Hz, 1H), 4.54-4.33 (m, 2H), 4.17-4.07 (m, 2H), 3.03-2.90 (m, 3H), 2.64-2.60 (m, 2H), 2.47-2.43 (m, 1H), 2.36-2.24 (m, 2H), 2.09-1.92 (m, 4H), 1.85-1.63 (m, 6H), 1.54-1.45 (m, 4H), 1.44-1.27 (m, 14H); MS (ESI) m/z : 718.2 $[M+H]^+$.




[00582] *N*-(3,5-Dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((12-(4-(2-(2,6-dioxo-piperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)dodecyl)oxy)benzamide **B7**. ^1H NMR (400 MHz, DMSO- d_6) δ 11.02 (s, 1H), 10.72 (brs, 1H), 8.77 (s, 2H), 7.74 (s, 1H), 7.67 (d, $J = 7.6$ Hz, 1H), 7.41-7.00 (m, 4H), 5.15 (dd, $J = 3.6, 12$ Hz, 1H), 4.54-4.33 (m, 2H), 4.17-4.07 (m, 2H), 3.03-2.90 (m, 3H), 2.64-2.60 (m, 2H), 2.47-2.43 (m, 1H), 2.36-2.24 (m, 2H), 2.09-1.92 (m, 4H), 1.85-1.63 (m, 6H), 1.54-1.45 (m, 4H), 1.44-1.27 (m, 14H); MS (ESI) m/z : 860.3 $[\text{M}+\text{H}]^+$.




[00583] *N*-(3,5-Dichloropyridin-4-yl)-3-(difluoromethoxy)-4-(2-(2-(2-(2-((2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)ethoxy)benzamide **B8**. ^1H NMR (400 MHz, DMSO- d_6) δ 11.08 (s, 1H), 10.66 (s, 1H), 8.76 (s, 2H), 7.76 (s, 1H), 7.67 (d, $J = 8.4$ Hz, 1H), 7.57 (t, $J = 8.0$ Hz, 1H), 7.37 (t, $J = 10.4$ Hz, 1H), 7.21 (s, 1H), 7.12 (d, $J = 8.4$ Hz, 1H), 7.03 (d, $J = 6.8$ Hz, 1H), 6.59 (t, $J = 5.6$ Hz, 1H), 5.05 (dd, $J = 5.2, 12.8$ Hz, 1H), 4.28-4.22 (m, 2H), 3.79-3.76 (m, 2H), 3.63-3.58 (m, 4H), 3.56-3.51 (m, 6H), 3.46-3.44 (m, 2H), 2.91-2.84 (m, 1H), 2.60-2.54 (m, 2H), 2.03-1.96 (m, 1H); MS (ESI) m/z : 780.1 $[\text{M}+\text{H}]^+$.



[00584] 3-(Cyclopropylmethoxy)-*N*-(3,5-dichloropyridin-4-yl)-4-(2-(2-(2-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)amino)propoxy)ethoxy)ethoxy)ethoxy)benzamide **B9**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.09 (s, 1H), 10.41 (s, 1H), 8.74 (s, 2H), 7.64 (dd, *J* = 2.0, 8.4 Hz, 1H), 7.57 (t, *J* = 7.6 Hz, 1H), 7.41-7.39 (m, 1H), 7.13 (d, *J* = 8.8 Hz, 2H), 7.03 (d, *J* = 7.6 Hz, 1H), 6.60 (t, *J* = 5.2 Hz, 1H), 5.23 (dd, *J* = 4.8, 12.4 Hz, 1H), 4.74-4.71 (m, 1H), 4.17 (t, *J* = 3.6 Hz, 2H), 3.77 (t, *J* = 4.4 Hz, 2H), 3.64-3.62 (m, 4H), 3.57-3.55 (m, 5H), 3.48-3.43 (m, 4H), 2.92-2.84 (m, 1H), 2.60-2.56 (m, 1H), 2.45-2.39 (m, 2H), 2.10-1.99 (m, 3H), 1.78-1.75 (m, 1H), 1.66-1.59 (m, 1H); MS (ESI) *m/z*: 784.2 [M+H]⁺.




[00585] 3-(Cyclopropylmethoxy)-*N*-(3,5-dichloropyridin-4-yl)-4-((7-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)heptyl)oxy)benzamide **B10**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.00 (s, 1H), 11.14 (s, 1H), 8.74 (s, 2H), 7.65 (d, *J* = 8.4 Hz, 1H), 7.41-7.34 (m, 3H), 7.12 (d, *J* = 8.4 Hz, 1H), 5.13 (dd, *J* = 4.8, 12.8 Hz, 1H), 4.73 (t, *J* = 7.2 Hz, 1H), 4.52-4.32 (m, 2H), 4.07 (t, *J* = 6.4 Hz, 2H), 2.99-2.87 (m, 2H), 2.60-2.52 (m, 2H), 2.43 (d, *J* = 8.4 Hz, 2H), 2.30 (t, *J* = 6.8 Hz, 2H), 2.10-1.91 (m, 4H), 1.80-1.63 (m, 6H), 1.47-1.24 (m, 13H); MS (ESI) *m/z*: 794.3 [M+H]⁺.




[00586] *N*-(3,5-Dichloropyridin-4-yl)-4-(difluoromethoxy)-3-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)propoxy)benzamide **B11**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.01 (s, 1H), 10.69 (s, 1H), 8.77 (s, 2H), 7.77 (s, 1H), 7.68 (d, *J* = 8.4 Hz, 1H), 7.41-7.04 (m, 4H), 5.14 (dd, *J* = 4.8, 13.2 Hz, 1H), 4.54-4.32 (m, 2H), 4.21 (s, 2H), 3.03-


2.88 (m, 3H), 2.67-2.58 (m, 2H), 2.50-2.32 (m, 3H), 2.03-1.99 (m, 5H), 1.89-1.79 (m, 4H); MS (ESI) m/z : 734.2 $[M+H]^+$.




[00587] 3-(Cyclopropylmethoxy)-*N*-(3,5-dichloropyridin-4-yl)-4-((9-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)nonyl)oxy)benzamide **B12**. ^1H NMR (400 MHz, DMSO- d_6) δ 11.05 (s, 1H), 10.41 (s, 1H), 9.32 (s, 1H), 8.75 (s, 2H), 7.65 (d, $J = 8.4$ Hz, 1H), 7.44-7.41 (m, 2H), 7.31 (d, $J = 10.4$ Hz, 1H), 7.12 (d, $J = 8.8$ Hz, 1H), 5.17 (dd, $J = 4.8, 13.2$ Hz, 1H), 4.75-4.71 (m, 1H), 4.55-4.35 (m, 2H), 4.06 (t, $J = 6.0$ Hz, 2H), 3.60 (d, $J = 10.4$ Hz, 2H), 3.08-2.90 (m, 6H), 2.65-2.61 (m, 1H), 2.46-2.32 (m, 3H), 2.09-1.93 (m, 7H), 1.83-1.76 (m, 3H), 1.67-1.61 (m, 3H), 1.47-1.45 (m, 2H), 1.36-1.33 (m, 8H); MS (ESI) m/z : 822.3 $[M+H]^+$.




[00588] 3-((9-(4-(2-(1-Acetamido-1-oxopropan-2-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)nonyl)oxy)-*N*-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide **B13**. ^1H NMR (400 MHz, DMSO- d_6) δ 11.88 (s, 1H), 10.60 (brs, 1H), 8.75 (s, 2H), 7.72 (s, 1H), 7.65 (d, $J = 7.6$ Hz, 1H), 7.42-7.00 (m, 4H), 5.05 (d, $J = 7.2$ Hz, 1H), 4.68-4.58 (m, 2H), 4.21-4.05 (m, 2H), 2.94 (d, $J = 8.8$ Hz, 2H), 2.69-2.67 (m, 1H), 2.34-2.30 (m, 2H), 2.20 (s, 3H), 2.06-1.93 (m, 3H), 1.85-1.66 (m, 5H), 1.54-1.52 (m, 3H), 1.45-1.40 (m, 5H), 1.30-1.26 (m, 8H); MS (ESI) m/z : 820.3 $[M+H]^+$.



[00589] *N*-(3,5-Dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-(1-(2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxoisindolin-4-yl)piperidin-4-yl)heptyl)oxy)benzamide **B14**. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 11.07 (s, 1H), 10.65 (s, 1H), 8.76 (s, 2H), 7.72 (s, 1H), 7.68-7.64 (m, 2H), 7.37-7.00 (m, 4H), 5.09 (dd, $J = 5.2, 12.8$ Hz, 1H), 4.12 (t, $J = 6.4$ Hz, 2H), 2.86-2.80 (m, 3H), 2.60-2.56 (m, 1H), 2.02-1.98 (m, 2H), 1.79-1.73 (m, 4H), 1.45-1.27 (m, 16H); MS (ESI) m/z : 786.2 $[\text{M}+\text{H}]^+$.




[00590] *N*-(3,5-Dichloropyridin-4-yl)-4-(difluoromethoxy)-3-(2-{4-[2-(2,6-dioxo-piperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1H-isindol-5-yl]piperidin-1-yl}ethoxy)benzamide **B15**. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 11.00 (s, 1H), 10.72 (s, 1H), 9.63 (s, br, 1H), 8.78 (s, 2H), 7.80-7.76 (m, 2H), 7.56-7.52 (m, 2H), 7.47-7.29 (m, 2H), 5.11 (dd, $J = 4.8, 14.0$ Hz, 1H), 4.56-4.54 (m, 2H), 4.34-4.30 (m, 2H), 3.76-3.64 (m, 4H), 3.26-3.24 (m, 3H), 2.96-2.87 (m, 1H), 2.67-2.55 (m, 1H), 2.42-2.39 (m, 1H), 2.03-1.99 (m, 5H); MS (ESI) m/z : 720.2 $[\text{M}+\text{H}]^+$.




[00591] (2*S*,4*R*)-1-((*S*)-2-(9-(2-(Cyclopropylmethoxy)-5-((3,5-dichloropyridin-4-


yl)carbamoyl)phenoxy)nonanamido)-3,3-dimethylbutanoyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide **B22**. ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 10.37 (s, 1H), 8.95 (s, 1H), 8.71 (s, 2H), 8.53 (s, 1H), 7.82 (d, $J = 8.4$ Hz, 1H), 7.62 (d, $J = 7.6$ Hz, 1H), 7.40-7.37 (m, 5H), 7.08 (d, $J = 8.8$ Hz, 1H), 5.10 (s, 1H), 4.71-4.68 (m, 1H), 4.52 (d, $J = 9.2$ Hz, 1H), 4.42-4.38 (m, 2H), 4.33 (s, 1H), 4.19 (dd, $J = 4.0$ Hz, 15.6 Hz, 1H), 4.02-3.63 (m, 2H), 3.33 (s, 2H), 2.48-2.42 (m, 5H), 2.26-2.28 (m, 1H), 2.10-2.08 (m, 4H), 2.04-2.02 (m, 1H), 1.88-1.86 (m, 3H), 1.76-1.72 (m, 1H), 1.64-1.59 (m, 4H), 1.48-1.40 (m, 7H), 1.25 (s, 9H); MS (ESI) m/z : 924.2 $[\text{M}+\text{H}]^+$.



[00592] *N*-(3,5-Dichloropyridin-4-yl)-4-(difluoromethoxy)-3-(2-(4-(2-((3-((2,6-dioxopiperidin-3-yl)amino)phenyl)amino)-2-oxoethyl)piperazin-1-yl)ethoxy)benzamide **B24**. ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 10.76 (s, 1H), 10.64 (s, 1H), 9.37 (s, 1H), 8.76 (s, 2H), 7.78 (d, $J = 1.6$ Hz, 1H), 7.67-7.65 (m, 1H), 7.36 (d, $J = 8.4$ Hz, 1H), 7.28-6.79 (m, 4H), 6.38 (d, $J = 9.2$ Hz, 1H), 5.86 (d, $J = 7.6$ Hz, 1H), 4.27-4.24 (m, 3H), 3.29 (s, 2H), 3.05 (s, 2H), 2.78-2.71 (m, 3H), 2.60-2.54 (m, 5H), 2.49-2.38 (m, 1H), 2.10-2.07 (m, 1H), 1.98-1.86 (m, 2H); MS (ESI) m/z : 720.2 $[\text{M}+\text{H}]^+$.




[00593] *N*-(3,5-Dichloropyridin-4-yl)-4-(difluoromethoxy)-3-(4-(4-(2-((3-((2,6-dioxopiperidin-3-yl)amino)phenyl)amino)-2-oxoethyl)piperazin-1-yl)butoxy)benzamide **B25**. ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 10.77 (s, 1H), 10.64 (s, 1H), 9.36 (s, 1H), 8.76 (s, 2H), 7.72-7.64 (m, 2H), 7.37-6.97 (m, 4H), 6.80 (d, $J = 8.0$ Hz, 1H), 6.39 (d, $J = 9.2$ Hz, 1H), 5.87 (d, $J = 8.0$ Hz, 1H), 4.29-4.23 (m, 1H), 4.15 (t, $J = 6.0$ Hz, 2H), 3.22-3.20 (m, 2H), 3.05 (s, 2H), 2.73-2.69 (m, 1H), 2.61-2.55 (m, 2H), 2.38-2.36 (m, 7H), 2.11-2.07 (m, 2H), 1.90-1.82 (m, 2H), 1.62-1.58 (m, 2H); MS (ESI) m/z : 748.2 $[\text{M}+\text{H}]^+$.




[00594] The following compounds are prepared similarly according to the synthetic procedures or methodologies exemplified herein.


[00595] *N*-(3,5-Dichloropyridin-4-yl)-4-(difluoromethoxy)-3-(2-(2-(2-(3-((2-(2,6-dioxo-1,2,3,4-tetrahydropyridin-3-yl)-1-oxoisoindolin-4-yl)amino)propoxy)ethoxy)ethoxy)ethoxy)benzamide **B16**.




[00596] *N*-(3,5-Dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-(4-(2-(2,6-dioxo-1,2,3,4-tetrahydropyridin-3-yl)-1-oxoisoindolin-4-yl)piperidin-1-yl)heptyl)oxy)benzamide **B17**.



[00597] *N*-(3,5-Dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-(4-((5-(2,6-dioxo-1,2,3,4-tetrahydropyridin-3-yl)-4-oxo-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)methoxy)phenyl)heptyl)oxy)benzamide **B19**.



[00598] (2*S*,4*R*)-1-((*S*)-2-((7-(5-((3,5-Dichloropyridin-4-yl)carbamoyl)-2-(difluoromethoxy)-phenoxy)heptyl)amino)-3,3-dimethylbutanoyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)-pyrrolidine-2-carboxamide **B23**.



Example B1. Cell-based TNF- α Inhibition Assay

[00599] Frozen primary blood mononuclear cells (PBMCs) were quick thawed, washed once with RPMI 1640 media supplemented with 10% fetal bovine serum, 1% penicillin, and 1% streptomycin, and plated in a 96 well plate at 200,000 cells per well. The cells were pretreated with DMSO only as a control or a compound for 1 h, and then induced with LPS (lipopolysaccharide) (100 ng/mL) for 18-24 h. The supernatant was analyzed for TNF- α using the Meso Scale assay. Compound activity was determined as a percentage of the stimulated DMSO control. The results are summarized in Table 1, where A represents a percent inhibition value $\geq 60\%$; B represents a percent inhibition value $< 60\%$ and $\geq 40\%$; C represents a percent inhibition value $< 40\%$ and $\geq 20\%$; and D represents a single percent inhibition value $< 20\%$.

TABLE 1. TNF- α Inhibition

Compound No.	Compound Concentration	
	0.1 μ M	1 μ M
A1	A	A
A2	A	A
A3	A	A
A4	A	A
A5	A	A
A6	A	A
A7	A	A
A8	A	A
A9	A	A
A10	D	D
A11	A	A
A12	A	A
A13	A	A

Compound No.	Compound Concentration	
	0.1 μ M	1 μ M
A14	A	A
A15	B	A
A16	A	A
A17	A	A
A18	A	A
A19	A	A
A20	A	A
A21	A	A
A22	A	A
A23	A	A
A24	A	A
A25	A	A
A26	A	A
A27	A	A
A28	B	A
A29	B	A
A38	A	A
A39	A	A
A40	A	A
A41	B	A
A42	A	A
A43	A	A
A44	A	A
A45	A	A
A46	A	A
A47	A	A
A48	B	A
A49	A	A
A50	A	A
A51	A	A
A60	A	A
A61	A	A
A62	A	A
A63	A	A
A64	A	A
A65	A	A
A66	B	A
A74	A	A
A75	A	A
A76	B	A
A77	A	A
A78	A	A
A79	A	A

Compound No.	Compound Concentration	
	0.1 μ M	1 μ M
A83	A	A
A84	A	A
A85	A	A
A86	A	A
A87	A	A
A88	A	A
A89	A	A
A90	A	A
A91	A	A
B1	D	D
B2	A	A
B3	A	A
B4	A	A
B5	A	A
B6	A	A
B7	A	A
B8	A	A
B9	A	A
B10	C	A
B11	A	A
B12	C	A
B13	A	A
B14	A	A
B15	A	A
B18	A	A
B20	A	A
B21	A	A
B22	D	C
B24	A	A
B25	A	A

Example B2. Protein Degradation Assay

[00600] A549 cells were grown in RPMI 1640 media supplemented with 10% fetal bovine serum, streptomycin, and penicillin. The cells were plated in 6-well plates at 300,000 cells/well in the growth media. After overnight incubation, the cells were treated with DMSO (control) or a compound at predetermined concentrations (*e.g.*, 10 nM, 100 nM, 1 μ M, 3 μ M, or 10 μ M) for 24 h at 37 °C under 5% CO₂. Whole cell extracts were prepared using an immunoprecipitation (IP) lysis buffer. The cells were washed once in PBS, and the cell pellets were resuspended in the IP lysis buffer and incubated for 15 min on ice. Cells debris was removed by centrifugation

and the cleared whole cell lysates were transferred to new tubes for further analysis.


[00601] For a western blot analysis, the whole cell protein extracts were separated on 4-12% SDS-polyacrylamide gels, transferred to nitrocellulose, and probed with primary antibodies. Membranes were subsequently washed and probed with IRDYE[®] secondary antibodies. The signals were detected using an ODYSSEY[®] Imaging System. The antibodies used in the assay included anti-PDE4B antibody; anti-PDE4D antibodies (top, bottom, and short isoform); β -actin mouse monoclonal antibody; IRDYE[®] 680RD goat anti-rabbit antibody; and IRDYE[®] 800CW goat anti-mouse antibody. The compounds provided herein are PDE4 protein degraders. For example, compounds **A1, A4, A6, A8, A9, A10, A12 to A15, A19 to A22, A40 to A44, A60, B1 to B3, B6, B7, B9 to B11, B14, B15, B20, B21, B24, and B25** were determined to be able to degrade PDE4B as high as about 70% relative to DMSO; and compounds **A1 to A4, A7 to A22, A38 to A44, A60, A61, A89, B1 to B10, B14, B18, B20, B21, B24, and B25** were determined to be able to degrade PDE4D, in particular, PDE4D short isoform, as high as about 95% relative to DMSO; whereas apremilast did not degrade the PDE4D under the same conditions.

* * * * *

[00602] The examples set forth above are provided to give those of ordinary skill in the art with a complete disclosure and description of how to make and use the claimed embodiments and are not intended to limit the scope of what is disclosed herein. Modifications that are obvious to persons of skill in the art are intended to be within the scope of the following claims. All publications, patents, and patent applications cited in this specification are incorporated herein by reference as if each such publication, patent or patent application were specifically and individually indicated to be incorporated herein by reference.

What is claimed is:

1. A compound of Formula (I):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:

L is a linker;

X is $-\text{CH}_2-$ or $-\text{C}(\text{O})-$;

Y is C_{1-6} alkylene or C_{3-10} cycloalkylene;

R^{E} is an E3 ubiquitin ligase binding moiety;

R^1 is (i) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (ii) $-\text{OR}^{1a}$ or $-\text{NR}^{1b}\text{R}^{1c}$;

R^2 is hydrogen or deuterium;

R^{3a} , R^{3d} , and R^{3e} are each independently (i) hydrogen, deuterium, cyano, halo, or nitro; (ii) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (iii) $-\text{C}(\text{O})\text{R}^{1a}$, $-\text{C}(\text{O})\text{OR}^{1a}$, $-\text{C}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{C}(\text{O})\text{SR}^{1a}$, $-\text{C}(\text{NR}^{1a})\text{NR}^{1b}\text{R}^{1c}$, $-\text{C}(\text{S})\text{R}^{1a}$, $-\text{C}(\text{S})\text{OR}^{1a}$, $-\text{C}(\text{S})\text{NR}^{1b}\text{R}^{1c}$, $-\text{OR}^{1a}$, $-\text{OC}(\text{O})\text{R}^{1a}$, $-\text{OC}(\text{O})\text{OR}^{1a}$, $-\text{OC}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{OC}(\text{O})\text{SR}^{1a}$, $-\text{OC}(\text{NR}^{1a})\text{NR}^{1b}\text{R}^{1c}$, $-\text{OC}(\text{S})\text{R}^{1a}$, $-\text{OC}(\text{S})\text{OR}^{1a}$, $-\text{OC}(\text{S})\text{NR}^{1b}\text{R}^{1c}$, $-\text{OS}(\text{O})\text{R}^{1a}$, $-\text{OS}(\text{O})_2\text{R}^{1a}$, $-\text{OS}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{OS}(\text{O})_2\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{C}(\text{O})\text{R}^{1d}$, $-\text{NR}^{1a}\text{C}(\text{O})\text{OR}^{1d}$, $-\text{NR}^{1a}\text{C}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{C}(\text{O})\text{SR}^{1d}$, $-\text{NR}^{1a}\text{C}(\text{NR}^{1d})\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{C}(\text{S})\text{R}^{1d}$, $-\text{NR}^{1a}\text{C}(\text{S})\text{OR}^{1d}$, $-\text{NR}^{1a}\text{C}(\text{S})\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{S}(\text{O})\text{R}^{1d}$, $-\text{NR}^{1a}\text{S}(\text{O})_2\text{R}^{1d}$, $-\text{NR}^{1a}\text{S}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, $-\text{NR}^{1a}\text{S}(\text{O})_2\text{NR}^{1b}\text{R}^{1c}$, $-\text{SR}^{1a}$, $-\text{S}(\text{O})\text{R}^{1a}$, $-\text{S}(\text{O})_2\text{R}^{1a}$, $-\text{S}(\text{O})\text{NR}^{1b}\text{R}^{1c}$, or $-\text{S}(\text{O})_2\text{NR}^{1b}\text{R}^{1c}$;

R^{3b} and R^{3c} are each independently C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl;

each R^{4a} is independently (i) deuterium, cyano, halo, or nitro; (ii) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or

heterocyclyl; or (iii) $-C(O)R^{1a}$, $-C(O)OR^{1a}$, $-C(O)NR^{1b}R^{1c}$, $-C(O)SR^{1a}$, $-C(NR^{1a})NR^{1b}R^{1c}$, $-C(S)R^{1a}$, $-C(S)OR^{1a}$, $-C(S)NR^{1b}R^{1c}$, $-OR^{1a}$, $-OC(O)R^{1a}$, $-OC(O)OR^{1a}$, $-OC(O)NR^{1b}R^{1c}$, $-OC(O)SR^{1a}$, $-OC(NR^{1a})NR^{1b}R^{1c}$, $-OC(S)R^{1a}$, $-OC(S)OR^{1a}$, $-OC(S)NR^{1b}R^{1c}$, $-OS(O)R^{1a}$, $-OS(O)_2R^{1a}$, $-OS(O)NR^{1b}R^{1c}$, $-OS(O)_2NR^{1b}R^{1c}$, $-NR^{1b}R^{1c}$, $-NR^{1a}C(O)R^{1d}$, $-NR^{1a}C(O)OR^{1d}$, $-NR^{1a}C(O)NR^{1b}R^{1c}$, $-NR^{1a}C(O)SR^{1d}$, $-NR^{1a}C(NR^{1d})NR^{1b}R^{1c}$, $-NR^{1a}C(S)R^{1d}$, $-NR^{1a}C(S)OR^{1d}$, $-NR^{1a}C(S)NR^{1b}R^{1c}$, $-NR^{1a}S(O)R^{1d}$, $-NR^{1a}S(O)_2R^{1d}$, $-NR^{1a}S(O)NR^{1b}R^{1c}$, $-NR^{1a}S(O)_2NR^{1b}R^{1c}$, $-SR^{1a}$, $-S(O)R^{1a}$, $-S(O)_2R^{1a}$, $-S(O)NR^{1b}R^{1c}$, or $-S(O)_2NR^{1b}R^{1c}$; and R^4 is hydrogen or R^{4a} ;

each R^{1a} , R^{1b} , R^{1c} , and R^{1d} is independently hydrogen, deuterium, C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; and

a is an integer of 0, 1, 2, 3, or 4;

wherein each alkyl, alkylene, heteroalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylene, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q, wherein each Q is independently selected from: (a) deuterium, cyano, halo, imino, nitro, and oxo; (b) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, and heterocyclyl, each of which is further optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a ; and (c) $-C(O)R^a$, $-C(O)OR^a$, $-C(O)NR^bR^c$, $-C(O)SR^a$, $-C(NR^a)NR^bR^c$, $-C(S)R^a$, $-C(S)OR^a$, $-C(S)NR^bR^c$, $-OR^a$, $-OC(O)R^a$, $-OC(O)OR^a$, $-OC(O)NR^bR^c$, $-OC(O)SR^a$, $-OC(NR^a)NR^bR^c$, $-OC(S)R^a$, $-OC(S)OR^a$, $-OC(S)NR^bR^c$, $-OP(O)(OR^a)OR^d$, $-OS(O)R^a$, $-OS(O)_2R^a$, $-OS(O)NR^bR^c$, $-OS(O)_2NR^bR^c$, $-NR^bR^c$, $-NR^aC(O)R^d$, $-NR^aC(O)OR^d$, $-NR^aC(O)NR^bR^c$, $-NR^aC(O)SR^d$, $-NR^aC(NR^d)NR^bR^c$, $-NR^aC(S)R^d$, $-NR^aC(S)OR^d$, $-NR^aC(S)NR^bR^c$, $-NR^aS(O)R^d$, $-NR^aS(O)_2R^d$, $-NR^aS(O)NR^bR^c$, $-NR^aS(O)_2NR^bR^c$, $-SR^a$, $-S(O)R^a$, $-S(O)_2R^a$, $-S(O)NR^bR^c$, and $-S(O)_2NR^bR^c$, wherein each R^a , R^b , R^c , and R^d is independently (i) hydrogen or deuterium; (ii) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a ; or (iii) R^b and R^c together with the N atom to which they are attached form heterocyclyl, optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a ;

wherein each Q^a is independently selected from: (a) deuterium, cyano, halo, nitro,

imino, and oxo; (b) C₁₋₆ alkyl, C₁₋₆ heteroalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, C₆₋₁₄ aryl, C₇₋₁₅ aralkyl, heteroaryl, and heterocyclyl; and (c) $-\text{C}(\text{O})\text{R}^e$, $-\text{C}(\text{O})\text{OR}^e$, $-\text{C}(\text{O})\text{NR}^f\text{R}^g$, $-\text{C}(\text{O})\text{SR}^e$, $-\text{C}(\text{NR}^e)\text{NR}^f\text{R}^g$, $-\text{C}(\text{S})\text{R}^e$, $-\text{C}(\text{S})\text{OR}^e$, $-\text{C}(\text{S})\text{NR}^f\text{R}^g$, $-\text{OR}^e$, $-\text{OC}(\text{O})\text{R}^e$, $-\text{OC}(\text{O})\text{OR}^e$, $-\text{OC}(\text{O})\text{NR}^f\text{R}^g$, $-\text{OC}(\text{O})\text{SR}^e$, $-\text{OC}(\text{NR}^e)\text{NR}^f\text{R}^g$, $-\text{OC}(\text{S})\text{R}^e$, $-\text{OC}(\text{S})\text{OR}^e$, $-\text{OC}(\text{S})\text{NR}^f\text{R}^g$, $-\text{OP}(\text{O})(\text{OR}^f)\text{OR}^g$, $-\text{OS}(\text{O})\text{R}^e$, $-\text{OS}(\text{O})_2\text{R}^e$, $-\text{OS}(\text{O})\text{NR}^f\text{R}^g$, $-\text{OS}(\text{O})_2\text{NR}^f\text{R}^g$, $-\text{NR}^f\text{R}^g$, $-\text{NR}^e\text{C}(\text{O})\text{R}^h$, $-\text{NR}^e\text{C}(\text{O})\text{OR}^f$, $-\text{NR}^e\text{C}(\text{O})\text{NR}^f\text{R}^g$, $-\text{NR}^e\text{C}(\text{O})\text{SR}^f$, $-\text{NR}^e\text{C}(\text{NR}^h)\text{NR}^f\text{R}^g$, $-\text{NR}^e\text{C}(\text{S})\text{R}^h$, $-\text{NR}^e\text{C}(\text{S})\text{OR}^f$, $-\text{NR}^e\text{C}(\text{S})\text{NR}^f\text{R}^g$, $-\text{NR}^e\text{S}(\text{O})\text{R}^h$, $-\text{NR}^e\text{S}(\text{O})_2\text{R}^h$, $-\text{NR}^e\text{S}(\text{O})\text{NR}^f\text{R}^g$, $-\text{NR}^e\text{S}(\text{O})_2\text{NR}^f\text{R}^g$, $-\text{SR}^e$, $-\text{S}(\text{O})\text{R}^e$, $-\text{S}(\text{O})_2\text{R}^e$, $-\text{S}(\text{O})\text{NR}^f\text{R}^g$, and $-\text{S}(\text{O})_2\text{NR}^f\text{R}^g$; wherein each R^e, R^f, R^g, and R^h is independently (i) hydrogen or deuterium; (ii) C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, C₆₋₁₄ aryl, C₇₋₁₅ aralkyl, heteroaryl, or heterocyclyl; or (iii) R^f and R^g together with the N atom to which they are attached form heterocyclyl.


2. The compound of claim 1, wherein Y is C₁₋₆ alkylene, optionally substituted with one or more substituents Q.

3. The compound of claim 1 or 2, wherein R^{3a} is hydrogen.

4. The compound of any one of claims 1 to 3, wherein R^{3d} is hydrogen.


5. The compound of any one of claims 1 to 4, wherein R^{3e} is hydrogen.

6. The compound of any one of claims 1 to 5, having the structure of Formula (IV):



or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

7. The compound of any one of claims 1 to 5, having the structure of Formula (VI):




or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

8. The compound of any one of claims 1 to 7, wherein R^E is a moiety of a cereblon (CRBN) E3 ligand, an inhibitors-of-apoptosis protein (IAP) E3 ligand, a mouse double minute 2 homolog (MDM2) E3 ligand, or a von Hippel-Lindau (VHL) E3 ligand.

9. The compound of any one of claims 1 to 8, wherein R^E is a moiety of a cereblon (CRBN) E3 ligand.

10. The compound of any one of claims 1 to 9, wherein R^E is a moiety having the structure of Formula (EC-I):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein:

A^E is a bond, $-O-$, $-N(R^{1b})-$, $-S-$, C_{1-6} alkylene, C_{1-6} heteroalkylene, C_{2-6} alkenylene, C_{2-6} heteroalkenylene, C_{2-6} alkynylene, C_{2-6} heteroalkynylene, C_{3-10} cycloalkylene, C_{6-14} arylene, C_{7-15} aralkylene, heteroarylene, heterocyclylene, C_{1-6} heteroalkylene- C_{6-14} arylene, or C_{2-6} alkynylene-heterocyclylene;

Z is $-CH_2-$ or $-C(O)-$;

one of Z^1 , Z^2 , Z^3 , and Z^4 is $-C=$ and the remaining three of Z^1 , Z^2 , Z^3 , and Z^4 are each independently $-C(R^{E5})=$; or Z^1 is a bond, one of Z^2 , Z^3 , and Z^4 is $-C=$, and the remaining

two of Z^2 , Z^3 , and Z^4 are each independently $-C(R^{E5})=$ or $-S-$;

m is an integer of 0, 1, or 2;


R^{E1} is hydrogen, deuterium, halo, or C_{1-6} alkyl;

R^{E2} is hydrogen or C_{1-6} alkyl; and

each R^{E4} is independently (i) deuterium, cyano, halo, or nitro; (ii) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (iii) $-C(O)R^{1a}$, $-C(O)OR^{1a}$, $-C(O)NR^{1b}R^{1c}$, $-C(O)SR^{1a}$, $-C(NR^{1a})NR^{1b}R^{1c}$, $-C(S)R^{1a}$, $-C(S)OR^{1a}$, $-C(S)NR^{1b}R^{1c}$, $-OR^{1a}$, $-OC(O)R^{1a}$, $-OC(O)OR^{1a}$, $-OC(O)NR^{1b}R^{1c}$, $-OC(O)SR^{1a}$, $-OC(NR^{1a})NR^{1b}R^{1c}$, $-OC(S)R^{1a}$, $-OC(S)OR^{1a}$, $-OC(S)NR^{1b}R^{1c}$, $-OS(O)R^{1a}$, $-OS(O)_2R^{1a}$, $-OS(O)NR^{1b}R^{1c}$, $-OS(O)_2NR^{1b}R^{1c}$, $-NR^{1b}R^{1c}$, $-NR^{1a}C(O)R^{1d}$, $-NR^{1a}C(O)OR^{1d}$, $-NR^{1a}C(O)NR^{1b}R^{1c}$, $-NR^{1a}C(O)SR^{1d}$, $-NR^{1a}C(NR^{1d})NR^{1b}R^{1c}$, $-NR^{1a}C(S)R^{1d}$, $-NR^{1a}C(S)OR^{1d}$, $-NR^{1a}C(S)NR^{1b}R^{1c}$, $-NR^{1a}S(O)R^{1d}$, $-NR^{1a}S(O)_2R^{1d}$, $-NR^{1a}S(O)NR^{1b}R^{1c}$, $-NR^{1a}S(O)_2NR^{1b}R^{1c}$, $-SR^{1a}$, $-S(O)R^{1a}$, $-S(O)_2R^{1a}$, $-S(O)NR^{1b}R^{1c}$, or $-S(O)_2NR^{1b}R^{1c}$; and each R^{E5} is independently hydrogen or R^{E4} ;

wherein each alkyl, alkylene, heteroalkyl, heteroalkylene, alkenyl, alkenylene, heteroalkenylene, alkynyl, alkynylene, heteroalkynylene, cycloalkyl, cycloalkylene, aryl, arylene, aralkyl, aralkylene, heteroaryl, heteroarylene, heterocyclyl, and heterocyclylene is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q.


11. The compound of claim 10, having the structure of Formula (IX):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.


12. The compound of claim 10 or 11, wherein m is an integer of 1.

13. The compound of any one of claims 10 to 12, wherein Z^1 is a bond.
14. The compound of any one of claims 10 to 13, wherein Z^2 is S.
15. The compound of any one of claims 10 to 13, wherein Z^3 is S.
16. The compound of any one of claims 10 to 13, wherein Z^4 is S.
17. The compound of claim 11 or 15, having the structure of Formula (X):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

18. The compound of claim 11, having the structure of Formula (XXI):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

19. The compound of claim 11 or 18, having the structure of Formula (XXII):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

20. The compound of claim 11 or 18, having the structure of Formula (XXVII):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

21. The compound of any one of claims 1 to 20, wherein X is $-\text{CH}_2-$.
22. The compound of any one of claims 1 to 20, wherein X is $-\text{C}(\text{O})-$.
23. The compound of any one of claims 1 to 22, wherein R^2 is hydrogen.
24. The compound of any one of claims 10 to 23, wherein Z is $-\text{CH}_2-$.
25. The compound of any one of claims 10 to 23, wherein Z is $-\text{C}(\text{O})-$.
26. The compound of claim 17, having the structure of Formula (XI):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

27. The compound of claim 26, having the structure of Formula (XIII):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

28. The compound of claim 18 or 19, having the structure of Formula (XXIII):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

29. The compound of claim 28, having the structure of Formula (XXV):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

30. The compound of claim 18 or 20, having the structure of Formula (XXVIII):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

31. The compound of claim 30, having the structure of Formula (XXX):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

32. The compound of claim 10, having the structure of Formula (XV):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

33. The compound of claim 32, wherein m is an integer of 1.
34. The compound of claim 32 or 33, wherein Z¹ is a bond.
35. The compound of any one of claims 32 to 34, wherein Z² is S.
36. The compound of any one of claims 32 to 34, wherein Z³ is S.
37. The compound of any one of claims 32 to 34, wherein Z⁴ is S.
38. The compound of claim 32 or 36, having the structure of Formula (XVI):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

39. The compound of claim 32, having the structure of Formula (XXXII):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

40. The compound of claim 32 or 39, having the structure of Formula (XXXIII):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

41. The compound of claim 32 or 39, having the structure of Formula (XXXVIII):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

42. The compound of any one of claims 32 to 41, wherein X is $-\text{CH}_2-$.
43. The compound of any one of claims 32 to 41, wherein X is $-\text{C}(\text{O})-$.
44. The compound of any one of claims 32 to 43, wherein R^2 is hydrogen.
45. The compound of any one of claims 32 to 44, wherein Z is $-\text{CH}_2-$.
46. The compound of any one of claims 32 to 44, wherein Z is $-\text{C}(\text{O})-$.
47. The compound of claim 32 or 38, having the structure of Formula (XVII):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

48. The compound of claim 47, having the structure of Formula (XIX):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

49. The compound of claim 39 or 40, having the structure of Formula (XXXIV):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

50. The compound of claim 49, having the structure of Formula (XXXVI):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.


51. The compound of claim 39 or 41, having the structure of Formula (XXXIX):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or

a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

52. The compound of claim 51, having the structure of Formula (XLI):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

53. The compound of any one of claims 19 to 25, 28 to 31, 40 to 46, and 52, wherein R^E is hydrogen or halo.

54. The compound of claim 53, wherein R^E is hydrogen or fluoro.

55. The compound of any one of claims 1 to 9, wherein R^E is a moiety having the structure of Formula (EC-XXVIII):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein:

A^E is a bond, $-O-$, $-N(R^{1b})-$, $-S-$, C_{1-6} alkylene, C_{1-6} heteroalkylene, C_{2-6} alkenylene, C_{2-6} heteroalkenylene, C_{2-6} alkynylene, C_{2-6} heteroalkynylene, C_{3-10} cycloalkylene, C_{6-14} arylene, C_{7-15} aralkylene, heteroarylene, heterocyclylene, C_{1-6} heteroalkylene- C_{6-14} arylene, or C_{2-6} alkynylene-heterocyclylene;

X^E is $C(R^{E1})$ or N;

m is an integer of 0, 1, or 2;

n is an integer of 0, 1, 2, or 3;

R^{E1} is hydrogen, deuterium, halo, or C₁₋₆ alkyl;


R^{E2} is hydrogen or C₁₋₆ alkyl;

each R^{E4} is independently (i) deuterium, cyano, halo, or nitro; (ii) C₁₋₆ alkyl, C₁₋₆ heteroalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, C₆₋₁₄ aryl, C₇₋₁₅ aralkyl, heteroaryl, or heterocyclyl; or (iii) -C(O)R^{1a}, -C(O)OR^{1a}, -C(O)NR^{1b}R^{1c}, -C(O)SR^{1a}, -C(NR^{1a})NR^{1b}R^{1c}, -C(S)R^{1a}, -C(S)OR^{1a}, -C(S)NR^{1b}R^{1c}, -OR^{1a}, -OC(O)R^{1a}, -OC(O)OR^{1a}, -OC(O)NR^{1b}R^{1c}, -OC(O)SR^{1a}, -OC(NR^{1a})NR^{1b}R^{1c}, -OC(S)R^{1a}, -OC(S)OR^{1a}, -OC(S)NR^{1b}R^{1c}, -OS(O)R^{1a}, -OS(O)₂R^{1a}, -OS(O)NR^{1b}R^{1c}, -OS(O)₂NR^{1b}R^{1c}, -NR^{1b}R^{1c}, -NR^{1a}C(O)R^{1d}, -NR^{1a}C(O)OR^{1d}, -NR^{1a}C(O)NR^{1b}R^{1c}, -NR^{1a}C(O)SR^{1d}, -NR^{1a}C(NR^{1d})NR^{1b}R^{1c}, -NR^{1a}C(S)R^{1d}, -NR^{1a}C(S)OR^{1d}, -NR^{1a}C(S)NR^{1b}R^{1c}, -NR^{1a}S(O)R^{1d}, -NR^{1a}S(O)₂R^{1d}, -NR^{1a}S(O)NR^{1b}R^{1c}, -NR^{1a}S(O)₂NR^{1b}R^{1c}, -SR^{1a}, -S(O)R^{1a}, -S(O)₂R^{1a}, -S(O)NR^{1b}R^{1c}, or -S(O)₂NR^{1b}R^{1c}; and each R^{E5} is independently hydrogen or R^{E4}; and

R^{E6} is (i) hydrogen; (ii) C₁₋₆ alkyl, C₁₋₆ heteroalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, C₆₋₁₄ aryl, C₇₋₁₅ aralkyl, heteroaryl, or heterocyclyl; or (iii) -C(O)R^{1a}, -C(O)OR^{1a}, -C(O)NR^{1b}R^{1c}, -C(O)SR^{1a}, -C(NR^{1a})NR^{1b}R^{1c}, -C(S)R^{1a}, -C(S)OR^{1a}, -C(S)NR^{1b}R^{1c}, -OR^{1a}, -OC(O)R^{1a}, -OC(O)OR^{1a}, -OC(O)NR^{1b}R^{1c}, -OC(O)SR^{1a}, -OC(NR^{1a})NR^{1b}R^{1c}, -OC(S)R^{1a}, -OC(S)OR^{1a}, -OC(S)NR^{1b}R^{1c}, -OS(O)R^{1a}, -OS(O)₂R^{1a}, -OS(O)NR^{1b}R^{1c}, -OS(O)₂NR^{1b}R^{1c}, -NR^{1b}R^{1c}, -NR^{1a}C(O)R^{1d}, -NR^{1a}C(O)OR^{1d}, -NR^{1a}C(O)NR^{1b}R^{1c}, -NR^{1a}C(O)SR^{1d}, -NR^{1a}C(NR^{1d})NR^{1b}R^{1c}, -NR^{1a}C(S)R^{1d}, -NR^{1a}C(S)OR^{1d}, -NR^{1a}C(S)NR^{1b}R^{1c}, -NR^{1a}S(O)R^{1d}, -NR^{1a}S(O)₂R^{1d}, -NR^{1a}S(O)NR^{1b}R^{1c}, -NR^{1a}S(O)₂NR^{1b}R^{1c}, -S(O)R^{1a}, -S(O)₂R^{1a}, -S(O)NR^{1b}R^{1c}, or -S(O)₂NR^{1b}R^{1c};


wherein each alkyl, alkylene, heteroalkyl, heteroalkylene, alkenyl, alkenylene, heteroalkenylene, alkynyl, alkynylene, heteroalkynylene, cycloalkyl, cycloalkylene, aryl, arylene, aralkyl, aralkylene, heteroaryl, heteroarylene, heterocyclyl, and heterocyclylene is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q.

56. The compound of any one of claims 1 to 9 and 55, wherein R^E is a moiety having the structure of:




or an enantiomer, a mixture of enantiomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

57. The compound of any one of claims 1 to 9, 55, and 56, wherein R^E is a moiety having the structure of:



or an enantiomer, a mixture of enantiomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

58. The compound of any one of claims 1 to 9, wherein R^E is a moiety having the structure of Formula (EC-XXXV):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein:

A^E is a bond, $-O-$, $-N(R^{1b})-$, $-S-$, C_{1-6} alkylene, C_{1-6} heteroalkylene, C_{2-6} alkenylene, C_{2-6} heteroalkenylene, C_{2-6} alkynylene, C_{2-6} heteroalkynylene, C_{3-10} cycloalkylene, C_{6-14} arylene, C_{7-15} aralkylene, heteroarylene, heterocyclylene, C_{1-6} heteroalkylene- C_{6-14} arylene, or C_{2-6} alkynylene-heterocyclylene;

X^E is $C(R^{E1})$ or N ;

Y^E is a bond, C_{1-6} alkylene, $-O-$, $-S-$, $-S(O)-$, $-S(O)_2-$, or $-N(R^{E7})-$;

m is an integer of 0, 1, or 2;

n is an integer of 0, 1, 2, or 3;

R^{E1} is hydrogen, deuterium, halo, or C_{1-6} alkyl;


R^{E2} is hydrogen or C_{1-6} alkyl;

each R^{E4} is independently (i) deuterium, cyano, halo, or nitro; (ii) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (iii) $-C(O)R^{1a}$, $-C(O)OR^{1a}$, $-C(O)NR^{1b}R^{1c}$, $-C(O)SR^{1a}$, $-C(NR^{1a})NR^{1b}R^{1c}$, $-C(S)R^{1a}$, $-C(S)OR^{1a}$, $-C(S)NR^{1b}R^{1c}$, $-OR^{1a}$, $-OC(O)R^{1a}$, $-OC(O)OR^{1a}$, $-OC(O)NR^{1b}R^{1c}$, $-OC(O)SR^{1a}$, $-OC(NR^{1a})NR^{1b}R^{1c}$, $-OC(S)R^{1a}$, $-OC(S)OR^{1a}$, $-OC(S)NR^{1b}R^{1c}$, $-OS(O)R^{1a}$, $-OS(O)_2R^{1a}$, $-OS(O)NR^{1b}R^{1c}$, $-OS(O)_2NR^{1b}R^{1c}$, $-NR^{1b}R^{1c}$, $-NR^{1a}C(O)R^{1d}$, $-NR^{1a}C(O)OR^{1d}$, $-NR^{1a}C(O)NR^{1b}R^{1c}$, $-NR^{1a}C(O)SR^{1d}$, $-NR^{1a}C(NR^{1d})NR^{1b}R^{1c}$, $-NR^{1a}C(S)R^{1d}$, $-NR^{1a}C(S)OR^{1d}$, $-NR^{1a}C(S)NR^{1b}R^{1c}$, $-NR^{1a}S(O)R^{1d}$, $-NR^{1a}S(O)_2R^{1d}$, $-NR^{1a}S(O)NR^{1b}R^{1c}$, $-NR^{1a}S(O)_2NR^{1b}R^{1c}$, $-SR^{1a}$, $-S(O)R^{1a}$, $-S(O)_2R^{1a}$, $-S(O)NR^{1b}R^{1c}$, or $-S(O)_2NR^{1b}R^{1c}$; and each R^{E5} is independently hydrogen or R^{E4} ; and

R^{E7} is hydrogen or C_{1-6} alkyl;


wherein each alkyl, alkylene, heteroalkyl, heteroalkylene, alkenyl, alkenylene, heteroalkenylene, alkynyl, alkynylene, heteroalkynylene, cycloalkyl, cycloalkylene, aryl, arylene, aralkyl, aralkylene, heteroaryl, heteroarylene, heterocyclyl, and heterocyclylene is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q .


59. The compound of any one of claims 1 to 9 and 58, wherein R^E is a moiety having the structure of:



or an enantiomer, a mixture of enantiomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

60. The compound of any one of claims 1 to 9, 58, and 59, wherein R^E is a moiety having the structure of:





or an enantiomer, a mixture of enantiomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

61. The compound of any one of claims 1 to 60, wherein R^1 is C_{1-6} alkyl or C_{3-7} cycloalkyl, each optionally substituted with one or more substituents Q.

62. The compound of any one of claims 1 to 61, wherein R^1 is C_{1-6} alkyl, optionally substituted with one or more substituents Q.

63. The compound of any one of claims 1 to 62, wherein R^1 is methyl.

64. The compound of any one of claims 1 to 63, wherein R^{3b} is C_{1-6} alkyl or C_{3-7} cycloalkyl, each optionally substituted with one or more substituents Q.

65. The compound of any one of claims 1 to 64, wherein R^{3b} is C_{1-6} alkyl, optionally substituted with one or more substituents Q.

66. The compound of any one of claims 1 to 65, wherein R^{3b} is ethyl.

67. The compound of any one of claims 1 to 66, wherein R^{3c} is C_{1-6} alkyl or C_{3-7} cycloalkyl, each optionally substituted with one or more substituents Q.

68. The compound of any one of claims 1 to 67, wherein R^{3c} is C_{1-6} alkyl, optionally substituted with one or more substituents Q.

69. The compound of any one of claims 1 to 68, wherein R^{3c} is methyl.

70. The compound of any one of claims 7 to 10 and 32 to 69, wherein R^4 is hydrogen or $-NR^{1a}C(O)R^{1d}$.

71. The compound of claim 70, wherein R^4 is $-NHC(O)-C_{1-6}$ alkyl.


72. The compound of claim 70 or 71, wherein R^4 is $-NHC(O)CH_3$.

73. The compound of any one of claims 11 to 56, 58, 59, and 61 to 72, wherein A^E is a bond, $-O-$, $-NH-$, ethynediyl, piperidindiyl, piperazindiyl, (phendiyl)oxymethanediyl, or (piperidindiyl)ethynediyl.

74. The compound of any one of claims 11 to 56, 58, 59, and 61 to 73, wherein A^E is a bond, $-NH-$, piperidin-1,4-diyl, piperaz-1,4-diyl, (phen-1,4-diyl)oxymethanediyl, or (piperidin-1,4-diyl)ethynediyl.

75. The compound of any one of claims 1 to 8, wherein R^E is a moiety of a von Hippel-Lindau (VHL) E3 ligand.

76. The compound of any one of claims 1 to 8 and 75, wherein R^E has the structure of Formula (EV-I):




or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein:

R^{E6} , R^{E8} , and R^{E9} are each independently hydrogen, deuterium, C_{1-6} alkyl, or C_{3-10} cycloalkyl; and

R^{E7} is hydrogen, deuterium, halo, hydroxyl, $-OC_{1-6}$ alkyl, or $-OC_{3-10}$ cycloalkyl;


wherein each alkyl and cycloalkyl is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q.

77. The compound of claim 76, having the structure of Formula (XLIII):




or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

78. The compound of claim 76, having the structure of Formula (XLV):



or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

79. The compound of claim 76, having the structure of Formula (EV-III):




or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein:

R^{E6} , R^{E8} , and R^{E9} are each independently hydrogen, deuterium, C_{1-6} alkyl, or C_{3-10} cycloalkyl; and

R^{E10} is $-NHC(O)C_{1-6}$ alkyl, $-NHC(O)C_{3-10}$ cycloalkyl, or heterocyclyl;

wherein each alkyl, cycloalkyl, and heterocyclyl is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q.

80. The compound of any one of claims 1 to 8 and 75, wherein R^E is a moiety having the structure of:



or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

81. The compound of any one of claims 1 to 80, wherein L is C₁₋₂₀ alkylene, C₁₋₂₀ heteroalkylene, C₂₋₂₀ alkenylene, C₂₋₂₀ heteroalkenylene, C₂₋₂₀ alkynylene, C₂₋₂₀ heteroalkynylene, C₃₋₁₀ cycloalkylene, C₆₋₁₄ arylene, heteroarylene, or heterocyclylene, each of which is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q.


82. The compound of any one of claims 1 to 81, wherein L is C₁₋₂₀ alkylene, C₁₋₂₀ heteroalkylene, C₂₋₂₀ alkynylene, or C₂₋₂₀ heteroalkynylene, each of which is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents O.


83. The compound of any one of claims 1 to 80, wherein L is C₁₋₂₀ alkylene, C₁₋₂₀ heteroalkylene, C₂₋₂₀ alkenylene, C₂₋₂₀ heteroalkenylene, C₂₋₂₀ alkynylene, or C₂₋₂₀ heteroalkynylene, where one or more methylene groups are each independently replaced by a divalent group, and each divalent group is independently C₃₋₁₀ cycloalkylene, C₆₋₁₄ arylene, heteroarylene, or heterocyclylene; and wherein the alkylene, heteroalkylene, alkenylene, heteroalkenylene, alkynylene, heteroalkynylene, cycloalkylene, arylene, heteroarylene, and heterocyclylene are each optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents O.


84. The compound of claim 83, wherein L is C₁₋₂₀ alkylene or C₁₋₂₀ heteroalkylene, where one or more methylene groups are each independently replaced by a divalent group, and each divalent group is independently C₃₋₁₀ cycloalkylene, C₆₋₁₄ arylene, heteroarylene, or

heterocyclylene; and wherein the alkylene, cycloalkylene, arylene, heteroarylene, and heterocyclylene are each optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q.

85. The compound of any one of claims 1 to 80, wherein L is:







86. The compound of claim 1, wherein the compound is:

N-(6-(7-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)heptyl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide **A1**;

N-(6-(7-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)hept-1-yn-1-yl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide **A2**;

N-(6-(5-(4-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)ethynyl)piperidin-1-yl)-5-oxopentyl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide **A3**;

14-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)-3,6,9,12-tetraoxatetradecan-1-amide **A4**;

N-(6-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)propyl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide **A5**;

12-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)dodecanamide **A6**;

9-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-5-yl)piperidin-1-yl)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)-nonanamide **A7**;

N-(6-(7-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)piperidin-4-yl)heptyl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide **A8**;

3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)ethoxy)-ethoxy)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)propanamide **A9**;

3-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)ethoxy)-ethoxy)ethoxy)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)propanamide **A10**;

3-((4-((2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)ethoxy)-methyl)benzyl)oxy)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)propanamide **A11**;

9-((4-((5-(2,6-dioxopiperidin-3-yl)-4-oxo-5,6-dihydro-4*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy)benzyl)amino)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)nonanamide **A12**;

9-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)-nonanamide **A13**;

N-(6-(12-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)dodecyl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide **A14**;

9-{1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl]-piperidin-4-yl}-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}nonanamide **A15**;

9-({[4-({[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]oxy}-methyl)phenyl]methyl}amino)-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}nonanamide **A16**;

N-[7-(12-{4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]piperidin-1-yl}dodecyl)-2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl]acetamide **A17**;

4-amino-7-(12-{4-[2-(2,6-Dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]piperidin-1-yl}dodecyl)-2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl]-2,3-dihydro-1*H*-isoindole-1,3-dione **A18**;

10-{4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1*H*-isoindol-5-

yl]piperidin-1-yl}-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}decanamide **A19**;

9-(4-{2-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1*H*-isoindol-5-yl]ethynyl}piperidin-1-yl)-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}nonanamide **A20**;

9-{4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1*H*-isoindol-5-yl]piperidin-1-yl}-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}nonanamide **A21**;

8-{4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1*H*-isoindol-5-yl]piperidin-1-yl}-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}octanamide **A22**;

9-{4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1*H*-isoindol-5-yl]-1*H*-1,2,3-triazol-1-yl}-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}nonanamide **A23**;

4-[1-(2-{4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1*H*-isoindol-5-yl]piperidin-1-yl}ethyl)-1*H*-1,2,3-triazol-4-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}butanamide **A24**;

4-[(9-{4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1*H*-isoindol-5-yl]piperidin-1-yl}nonyl)amino]-2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-2,3-dihydro-1*H*-isoindole-1,3-dione **A25**;

9-{4-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1*H*-isoindol-5-yl]piperidin-1-yl}-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}nonanamide **A26**;

4-(10-{4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1*H*-isoindol-5-yl]piperidin-1-yl}decyl)-2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-2,3-dihydro-1*H*-isoindole-1,3-dione **A27**;

2-[4-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1*H*-isoindol-5-yl]piperidin-1-yl}butyl)piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}acetamide **A28**;

6-{4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1*H*-isoindol-5-yl]-[1,4'-bipiperidin]-1'-yl}-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-

dioxo-2,3-dihydro-1*H*-isoindol-4-yl}hexanamide **A29**;

5-{4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1*H*-isoindol-5-yl]-[1,4'-bipiperidin]-1'-yl}-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}pentanamide **A30**;

3-[4-(3-{4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1*H*-isoindol-5-yl]piperidin-1-yl}propyl)piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}propanamide **A31**;

8-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)-octanamide **A32**;

3-(2-(2-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)amino)propoxy)-ethoxy)ethoxy)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)propanamide **A33**;

N-(6-(2-(2-(2-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)amino)-propoxy)-ethoxy)ethoxy)ethyl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide **A34**;

6-(4-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)ethynyl)piperidin-1-yl)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)-6-oxohexanamide **A35**;

8-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)piperidin-1-yl)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)octanamide **A36**;

N-(6-(7-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)piperidin-1-yl)-heptyl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide **A37**;

7-((4-((5-((*S*)-2,6-dioxopiperidin-3-yl)-4-oxo-5,6-dihydro-4*H*-thieno[3,4-*c*]pyrrol-1-yl)-methoxy)benzyl)amino)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)heptanamide **A38**;

5-((4-((5-(2,6-dioxopiperidin-3-yl)-4-oxo-5,6-dihydro-4*H*-thieno[3,4-*c*]pyrrol-1-yl)-methoxy)benzyl)amino)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)pentanamide **A39**;

2-[4-[(4-{[5-(2,6-dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]methoxy}phenyl)methyl]morpholin-2-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}acetamide **A40**;

3-[2-(2-{[(4-{[5-(2,6-dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]methoxy}phenyl)methyl]amino}ethoxy)ethoxy]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}propanamide **A41**;

4-[4-(2-{[(4-{[5-(2,6-Dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]methoxy}phenyl)methyl]amino}ethyl)phenyl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}butanamide **A42**;

11-[(4-{[5-(2,6-dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]methoxy}phenyl)methyl]amino}-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}undecanamide **A43**;

4-[(9-{[(4-{[5-(2,6-dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]methoxy}phenyl)methyl]amino}nonyl)amino]-2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-2,3-dihydro-1*H*-isoindole-1,3-dione **A44**;

4-[4-(2-{[(4-{[5-(2,6-dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]methoxy}phenyl)methyl]amino}ethyl)piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}butanamide **A45**;

11-[(4-{[5-(2,6-dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]-methoxy}phenyl)methyl](methyl)amino}-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}undecanamide **A46**;

8-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisoindolin-4-yl)piperidin-1-yl)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)octanamide **A47**;

4-[1-(2-{[(4-{[5-(2,6-dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]methoxy}phenyl)methyl]amino}ethyl)-1*H*-1,2,3-triazol-4-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}butanamide **A48**;

4-(10-{[(4-{[5-(2,6-dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl]methoxy}phenyl)methyl]amino}decyl)-2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-2,3-dihydro-1*H*-isoindole-1,3-dione **A49**;

4-[(9-{[(4-{[5-(2,6-dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy}phenyl)methyl]amino}nonyl)oxy]-2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-2,3-dihydro-1*H*-isoindole-1,3-dione **A50**;

4-({2-[4-(4-{[(4-{[5-(2,6-dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy}phenyl)methyl]amino}butyl)phenyl]ethyl}amino)-2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-2,3-dihydro-1*H*-isoindole-1,3-dione **A51**;

4-[(11-{[(4-{[5-(2,6-dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy}phenyl)methyl]amino}undecyl)amino]-2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-2,3-dihydro-1*H*-isoindole-1,3-dione **A52**;

4-({4-[4-(2-{[(4-{[5-(2,6-dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy}phenyl)methyl]amino}ethyl)phenyl]butyl}amino)-2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-2,3-dihydro-1*H*-isoindole-1,3-dione **A53**;

9-[4-(2-{[5-(2,6-dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy}acetyl)piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}nonanamide **A54**;

4-[4-(2-{[(4-{[5-(2,6-dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy}phenyl)methyl](methyl)amino}ethyl)phenyl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}butanamide **A55**;

11-(4-{[5-(2,6-dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy}phenyl)-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}undecanamide **A56**;

11-(4-{[5-(2,6-dioxopiperidin-3-yl)-4-oxo-4*H*,5*H*,6*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy}phenyl)-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}undecanamide **A57**;

8-(4-((5-(2,6-dioxopiperidin-3-yl)-4-oxo-5,6-dihydro-4*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy)phenyl)-*N*-(2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)octanamide **A58**;

N-(6-(7-(4-((5-(2,6-dioxopiperidin-3-yl)-4-oxo-5,6-dihydro-4*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy)phenyl)heptyl)-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)acetamide **A59**;

*N*¹-(2-((*S*)-1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxo-

isoindolin-4-yl)-*N*¹⁰-((*S*)-1-((2*S*,4*R*)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)-pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)decanediamide **A60**;

(2*S*,4*R*)-1-[(2*S*)-2-(13-{7-acetamido-2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-5-yl}tridecanamido)-3,3-dimethylbutanoyl]-4-hydroxy-*N*-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide **A61**;

(2*S*,4*R*)-1-[(2*S*)-2-(11-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}undecanamido)-3,3-dimethylbutanoyl]-4-hydroxy-*N*-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide **A62**;

(2*S*,4*R*)-1-[(2*S*)-2-(2-{4-[4-({2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}carbamoyl)butyl]piperazin-1-yl}acetamido)-3,3-dimethylbutanoyl]-4-hydroxy-*N*-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide **A63**;

N-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}-*N'*-[(2*S*)-1-[(2*S*,4*R*)-4-hydroxy-2-({[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]dodecanediamide **A64**;

(2*S*,4*R*)-1-[(2*S*)-2-{[9-({2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}carbamoyl)nonyl]amino}-3,3-dimethylbutanoyl]-4-hydroxy-*N*-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide **A65**;

(2*S*,4*R*)-1-[(2*S*)-2-(5-{4-[2-({2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}amino)acetyl]piperazin-1-yl}pentanamido)-3,3-dimethylbutanoyl]-4-hydroxy-*N*-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide **A66**;

N-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}-*N'*-[(2*S*)-1-[(2*S*,4*R*)-4-hydroxy-2-({[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]octanediamide **A67**;

(2*S*,4*R*)-1-[(2*S*)-2-(2-{4-[4-({2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}carbamoyl)butyl]piperidin-1-yl}acetamido)-3,3-dimethylbutanoyl]-4-hydroxy-*N*-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}-

pyrrolidine-2-carboxamide **A68**;

(2*S*,4*R*)-1-[(2*S*)-2-{[10-({2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}amino)decyl]amino}-3,3-dimethylbutanoyl]-4-hydroxy-*N*-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide **A69**;

(2*S*,4*R*)-1-[(2*S*)-2-{6-[4-(2-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl)ethyl)piperidin-1-yl]hexanamido}-3,3-dimethylbutanoyl]-4-hydroxy-*N*-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide **A70**;

(2*S*,4*R*)-1-[(2*S*)-2-(5-{1-[2-({2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}amino)acetyl]piperidin-4-yl}pentanamido)-3,3-dimethylbutanoyl]-4-hydroxy-*N*-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide **A71**;

(2*S*,4*R*)-1-((*S*)-2-((8-((2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-4-yl)amino)-8-oxooctyl)amino)-3,3-dimethylbutanoyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide **A72**;

(2*S*,4*R*)-1-((*S*)-2-((7-(7-acetamido-2-((*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisindolin-5-yl)heptyl)amino)-3,3-dimethylbutanoyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide **A73**;

(2*S*,4*R*)-1-[(2*S*)-2-acetamido-3,3-dimethylbutanoyl]-*N*-[(2-{[8-({2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl)-carbamoyl]octyl]oxy}-4-(4-methyl-1,3-thiazol-5-yl)phenyl)methyl]-4-hydroxypyrrolidine-2-carboxamide **A74**;

(2*S*,4*R*)-1-[(2*S*)-2-acetamido-3,3-dimethylbutanoyl]-*N*-[(2-{[10-({2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl)-carbamoyl]decyl]oxy}-4-(4-methyl-1,3-thiazol-5-yl)phenyl)methyl]-4-hydroxypyrrolidine-2-carboxamide **A75**;

(2*S*,4*R*)-1-[(2*S*)-2-acetamido-3,3-dimethylbutanoyl]-*N*-[(2-{[6-({2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl]ethyl}-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl)-carbamoyl]hexyl]oxy}-4-(4-methyl-1,3-thiazol-5-yl)phenyl)methyl]-4-hydroxypyrrolidine-2-carboxamide **A76**;

8-[4-([3-(2,6-dioxopiperidin-3-yl)-1-methyl-1*H*-indazol-6-yl]carbamoyl)-methyl]piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}octanamide **A77**;

6-[4-([3-(2,6-dioxopiperidin-3-yl)-1-methyl-1*H*-indazol-6-yl]carbamoyl)-methyl]piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}hexanamide **A78**;

10-[4-([3-(2,6-dioxopiperidin-3-yl)-1-methyl-1*H*-indazol-6-yl]carbamoyl)-methyl]piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}decanamide **A79**;

8-[4-([3-(2,6-dioxopiperidin-3-yl)-1-methyl-1*H*-indazol-7-yl]carbamoyl)-methyl]piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}octanamide **A80**;

10-[4-([3-(2,6-dioxopiperidin-3-yl)-1-methyl-1*H*-indazol-7-yl]carbamoyl)-methyl]piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}decanamide **A81**;

6-[4-([3-(2,6-dioxopiperidin-3-yl)-1-methyl-1*H*-indazol-7-yl]carbamoyl)-methyl]piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}hexanamide **A82**;

6-[4-([4-(2,6-dioxopiperidin-3-yl)phenyl]carbamoyl)methyl]piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}hexanamide **A83**;

8-[4-([4-(2,6-dioxopiperidin-3-yl)phenyl]carbamoyl)methyl]piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}octanamide **A84**;

8-[4-([3-(2,6-dioxopiperidin-3-yl)phenyl]carbamoyl)methyl]piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}octanamide **A85**;

10-[4-([4-(2,6-dioxopiperidin-3-yl)phenyl]carbamoyl)methyl]piperazin-1-yl]-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}decanamide **A86**;

6-[4-([3-(2,6-dioxopiperidin-3-yl)phenyl]carbamoyl)methyl]piperazin-1-yl]-*N*-

{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}hexanamide **A87**;

10-[4-({3-(2,6-dioxopiperidin-3-yl)phenyl}carbamoyl)methyl]piperazin-1-yl)-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}decanamide **A88**;

N-{6-[12-({3-[(2,6-dioxopiperidin-3-yl)amino]phenyl}amino)dodecyl]-2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}acetamide **A89**;


4-amino-6-[12-({3-[(2,6-dioxopiperidin-3-yl)amino]phenyl}amino)dodecyl]-2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-2,3-dihydro-1*H*-isoindole-1,3-dione **A90**;

9-({3-[(2,6-dioxopiperidin-3-yl)amino]phenyl}amino)-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}nonanamide **A91**; or

6-{4-[(3-[(2,6-dioxopiperidin-3-yl)amino]phenyl)carbamoyl)methyl]piperazin-1-yl}-*N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}hexanamide **A92**;

or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

87. A compound of Formula (IA):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:

L is a linker;

R^E is an E3 ubiquitin ligase binding moiety;

each R^{5a} is independently (i) deuterium, cyano, halo, or nitro; (ii) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (iii) $-C(O)R^{1a}$, $-C(O)OR^{1a}$, $-C(O)NR^{1b}R^{1c}$, $-C(O)SR^{1a}$, $-C(NR^{1a})NR^{1b}R^{1c}$, $-C(S)R^{1a}$, $-C(S)OR^{1a}$, $-C(S)NR^{1b}R^{1c}$, $-OR^{1a}$, $-OC(O)R^{1a}$, $-OC(O)OR^{1a}$, $-OC(O)NR^{1b}R^{1c}$, $-OC(O)SR^{1a}$, $-OC(NR^{1a})NR^{1b}R^{1c}$, $-OC(S)R^{1a}$, $-OC(S)OR^{1a}$, $-OC(S)NR^{1b}R^{1c}$, $-OS(O)R^{1a}$, $-OS(O)_2R^{1a}$, $-OS(O)NR^{1b}R^{1c}$, $-OS(O)_2NR^{1b}R^{1c}$, $-NR^{1b}R^{1c}$, $-NR^{1a}C(O)R^{1d}$, $-NR^{1a}C(O)OR^{1d}$, $-NR^{1a}C(O)NR^{1b}R^{1c}$, $-NR^{1a}C(O)SR^{1d}$, $-NR^{1a}C(NR^{1d})NR^{1b}R^{1c}$, $-NR^{1a}C(S)R^{1d}$, $-NR^{1a}C(S)OR^{1d}$, $-NR^{1a}C(S)NR^{1b}R^{1c}$, $-NR^{1a}S(O)R^{1d}$, $-NR^{1a}S(O)_2R^{1d}$, $-NR^{1a}S(O)NR^{1b}R^{1c}$, $-NR^{1a}S(O)_2NR^{1b}R^{1c}$, $-SR^{1a}$, $-S(O)R^{1a}$, $-S(O)_2R^{1a}$, $-S(O)NR^{1b}R^{1c}$, or $-S(O)_2NR^{1b}R^{1c}$; and R^5 is hydrogen or R^{5a} ;

R^6 is hydrogen, C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl;

R^{7a} , R^{7b} , R^{7c} , and R^{7d} are each independently (i) hydrogen, deuterium, cyano, halo, or nitro; (ii) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (iii) $-C(O)R^{1a}$, $-C(O)OR^{1a}$, $-C(O)NR^{1b}R^{1c}$, $-C(O)SR^{1a}$, $-C(NR^{1a})NR^{1b}R^{1c}$, $-C(S)R^{1a}$, $-C(S)OR^{1a}$, $-C(S)NR^{1b}R^{1c}$, $-OR^{1a}$, $-OC(O)R^{1a}$, $-OC(O)OR^{1a}$, $-OC(O)NR^{1b}R^{1c}$, $-OC(O)SR^{1a}$, $-OC(NR^{1a})NR^{1b}R^{1c}$, $-OC(S)R^{1a}$, $-OC(S)OR^{1a}$, $-OC(S)NR^{1b}R^{1c}$, $-OS(O)R^{1a}$, $-OS(O)_2R^{1a}$, $-OS(O)NR^{1b}R^{1c}$, $-OS(O)_2NR^{1b}R^{1c}$, $-NR^{1b}R^{1c}$, $-NR^{1a}C(O)R^{1d}$, $-NR^{1a}C(O)OR^{1d}$, $-NR^{1a}C(O)NR^{1b}R^{1c}$, $-NR^{1a}C(O)SR^{1d}$, $-NR^{1a}C(NR^{1d})NR^{1b}R^{1c}$, $-NR^{1a}C(S)R^{1d}$, $-NR^{1a}C(S)OR^{1d}$, $-NR^{1a}C(S)NR^{1b}R^{1c}$, $-NR^{1a}S(O)R^{1d}$, $-NR^{1a}S(O)_2R^{1d}$, $-NR^{1a}S(O)NR^{1b}R^{1c}$, $-NR^{1a}S(O)_2NR^{1b}R^{1c}$, $-SR^{1a}$, $-S(O)R^{1a}$, $-S(O)_2R^{1a}$, $-S(O)NR^{1b}R^{1c}$, or $-S(O)_2NR^{1b}R^{1c}$;

each R^{1a} , R^{1b} , R^{1c} , and R^{1d} is independently hydrogen, deuterium, C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; and


b is an integer of 0, 1, 2, 3, or 4;

wherein each alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q , wherein each Q is independently selected from: (a) deuterium, cyano, halo, imino, nitro, and oxo; (b) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, and heterocyclyl, each of which is further

optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a ; and (c) $-C(O)R^a$, $-C(O)OR^a$, $-C(O)NR^bR^c$, $-C(O)SR^a$, $-C(NR^a)NR^bR^c$, $-C(S)R^a$, $-C(S)OR^a$, $-C(S)NR^bR^c$, $-OR^a$, $-OC(O)R^a$, $-OC(O)OR^a$, $-OC(O)NR^bR^c$, $-OC(O)SR^a$, $-OC(NR^a)NR^bR^c$, $-OC(S)R^a$, $-OC(S)OR^a$, $-OC(S)NR^bR^c$, $-OP(O)(OR^a)OR^d$, $-OS(O)R^a$, $-OS(O)_2R^a$, $-OS(O)NR^bR^c$, $-OS(O)_2NR^bR^c$, $-NR^bR^c$, $-NR^aC(O)R^d$, $-NR^aC(O)OR^d$, $-NR^aC(O)NR^bR^c$, $-NR^aC(O)SR^d$, $-NR^aC(NR^d)NR^bR^c$, $-NR^aC(S)R^d$, $-NR^aC(S)OR^d$, $-NR^aC(S)NR^bR^c$, $-NR^aS(O)R^d$, $-NR^aS(O)_2R^d$, $-NR^aS(O)NR^bR^c$, $-NR^aS(O)_2NR^bR^c$, $-SR^a$, $-S(O)R^a$, $-S(O)_2R^a$, $-S(O)NR^bR^c$, and $-S(O)_2NR^bR^c$, wherein each R^a , R^b , R^c , and R^d is independently (i) hydrogen or deuterium; (ii) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a ; or (iii) R^b and R^c together with the N atom to which they are attached form heterocyclyl, optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q^a ;


wherein each Q^a is independently selected from: (a) deuterium, cyano, halo, nitro, imino, and oxo; (b) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, and heterocyclyl; and (c) $-C(O)R^e$, $-C(O)OR^e$, $-C(O)NR^fR^g$, $-C(O)SR^e$, $-C(NR^e)NR^fR^g$, $-C(S)R^e$, $-C(S)OR^e$, $-C(S)NR^fR^g$, $-OR^e$, $-OC(O)R^e$, $-OC(O)OR^e$, $-OC(O)NR^fR^g$, $-OC(O)SR^e$, $-OC(NR^e)NR^fR^g$, $-OC(S)R^e$, $-OC(S)OR^e$, $-OC(S)NR^fR^g$, $-OP(O)(OR^f)OR^g$, $-OS(O)R^e$, $-OS(O)_2R^e$, $-OS(O)NR^fR^g$, $-OS(O)_2NR^fR^g$, $-NR^fR^g$, $-NR^eC(O)R^h$, $-NR^eC(O)OR^f$, $-NR^eC(O)NR^fR^g$, $-NR^eC(O)SR^f$, $-NR^eC(NR^h)NR^fR^g$, $-NR^eC(S)R^h$, $-NR^eC(S)OR^f$, $-NR^eC(S)NR^fR^g$, $-NR^eS(O)R^h$, $-NR^eS(O)_2R^h$, $-NR^eS(O)NR^fR^g$, $-NR^eS(O)_2NR^fR^g$, $-SR^e$, $-S(O)R^e$, $-S(O)_2R^e$, $-S(O)NR^fR^g$, and $-S(O)_2NR^fR^g$; wherein each R^e , R^f , R^g , and R^h is independently (i) hydrogen or deuterium; (ii) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (iii) R^f and R^g together with the N atom to which they are attached form heterocyclyl.

88. The compound of claims 87, having the structure of Formula (IIA):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.


89. The compound of claims 87, having the structure of Formula (IIIA):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

90. The compound of any one of claims 87 to 89, wherein R^E is a moiety of a cereblon (CRBN) E3 ligand.

91. The compound of any one of claims 87 to 90, wherein R^E is a moiety having the structure of Formula (EC-I):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more

diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein:

A^E is a bond, $-O-$, $-N(R^{1b})-$, $-S-$, C_{1-6} alkylene, C_{1-6} heteroalkylene, C_{2-6} alkenylene, C_{2-6} heteroalkenylene, C_{2-6} alkynylene, C_{2-6} heteroalkynylene, C_{3-10} cycloalkylene, C_{6-14} arylene, C_{7-15} aralkylene, heteroarylene, heterocyclylene, C_{1-6} heteroalkylene- C_{6-14} arylene, or C_{2-6} alkynylene-heterocyclylene;

Z is $-CH_2-$ or $-C(O)-$;

one of Z^1 , Z^2 , Z^3 , and Z^4 is $-C=$ and the remaining three of Z^1 , Z^2 , Z^3 , and Z^4 are each independently $-C(R^{E5})=$; or Z^1 is a bond, one of Z^2 , Z^3 , and Z^4 is $-C=$, and the remaining two of Z^2 , Z^3 , and Z^4 are each independently $-C(R^{E5})=$ or $-S-$;

m is an integer of 0, 1, or 2;

R^{E1} is hydrogen, deuterium, halo, or C_{1-6} alkyl;

R^{E2} is hydrogen or C_{1-6} alkyl; and


each R^{E4} is independently (i) deuterium, cyano, halo, or nitro; (ii) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (iii) $-C(O)R^{1a}$, $-C(O)OR^{1a}$, $-C(O)NR^{1b}R^{1c}$, $-C(O)SR^{1a}$, $-C(NR^{1a})NR^{1b}R^{1c}$, $-C(S)R^{1a}$, $-C(S)OR^{1a}$, $-C(S)NR^{1b}R^{1c}$, $-OR^{1a}$, $-OC(O)R^{1a}$, $-OC(O)OR^{1a}$, $-OC(O)NR^{1b}R^{1c}$, $-OC(O)SR^{1a}$, $-OC(NR^{1a})NR^{1b}R^{1c}$, $-OC(S)R^{1a}$, $-OC(S)OR^{1a}$, $-OC(S)NR^{1b}R^{1c}$, $-OS(O)R^{1a}$, $-OS(O)_2R^{1a}$, $-OS(O)NR^{1b}R^{1c}$, $-OS(O)_2NR^{1b}R^{1c}$, $-NR^{1b}R^{1c}$, $-NR^{1a}C(O)R^{1d}$, $-NR^{1a}C(O)OR^{1d}$, $-NR^{1a}C(O)NR^{1b}R^{1c}$, $-NR^{1a}C(O)SR^{1d}$, $-NR^{1a}C(NR^{1d})NR^{1b}R^{1c}$, $-NR^{1a}C(S)R^{1d}$, $-NR^{1a}C(S)OR^{1d}$, $-NR^{1a}C(S)NR^{1b}R^{1c}$, $-NR^{1a}S(O)R^{1d}$, $-NR^{1a}S(O)_2R^{1d}$, $-NR^{1a}S(O)NR^{1b}R^{1c}$, $-NR^{1a}S(O)_2NR^{1b}R^{1c}$, $-SR^{1a}$, $-S(O)R^{1a}$, $-S(O)_2R^{1a}$, $-S(O)NR^{1b}R^{1c}$, or $-S(O)_2NR^{1b}R^{1c}$; and R^{E5} is hydrogen or R^{E4} ;

wherein each alkyl, alkylene, heteroalkyl, heteroalkylene, alkenyl, alkenylene, heteroalkenylene, alkynyl, alkynylene, heteroalkynylene, cycloalkyl, cycloalkylene, aryl, arylene, aralkyl, aralkylene, heteroaryl, heteroarylene, heterocyclyl, and heterocyclylene is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q.

92. The compound of claim 91, wherein m is an integer of 1.


93. The compound of claims 91 or 92, wherein Z^1 is a bond.

94. The compound of any one of claims 91 to 93, wherein Z^2 is S.
95. The compound of any one of claims 91 to 93, wherein Z^3 is S.
96. The compound of any one of claims 91 to 93, wherein Z^4 is S.
97. The compound of claim 91 or 95, having the structure of Formula (VIIA):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

98. The compound of claim 91, having the structure of Formula (XA):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

99. The compound of claim 91, having the structure of Formula (XIIIA):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or

a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

100. The compound of any one of claims 91 to 99, wherein Z is $-\text{CH}_2-$.


101. The compound of any one of claims 91 to 99, wherein Z is $-\text{C}(\text{O})-$.

102. The compound of claim 97, having the structure of Formula (VIIIa):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

103. The compound of claim 102, having the structure of Formula (IXa):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.


104. The compound of claim 98, having the structure of Formula (XIa):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or


a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

105. The compound of claim 104, having the structure of Formula (XIIA):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

106. The compound of claim 99, having the structure of Formula (XIVA):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

107. The compound of claim 106, having the structure of Formula (XVA):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

108. The compound of claim 91, having the structure of Formula (XVIIA):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

109. The compound of claim 91, having the structure of Formula (XXA):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

110. The compound of claim 91, having the structure of Formula (XXIIIA):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

111. The compound of any one of claims 108 to 110, wherein Z is $-\text{CH}_2-$.


112. The compound of any one of claims 108 to 110, wherein Z is $-\text{C(O)}-$.

113. The compound of claim 108, having the structure of Formula (XVIII):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

114. The compound of claim 113, having the structure of Formula (XIXA):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

115. The compound of claim 109, having the structure of Formula (XXIA):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

116. The compound of claim 115, having the structure of Formula (XXIIA):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

117. The compound of claim 110, having the structure of Formula (XXIVA):




or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

118. The compound of claim 117, having the structure of Formula (XXVA):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

119. The compound of any one of claims 87 to 90, wherein R^E is a moiety having the structure of Formula (EC-XXVIII):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein:

A^E is a bond, $-O-$, $-N(R^{1b})-$, $-S-$, C_{1-6} alkylene, C_{1-6} heteroalkylene, C_{2-6} alkenylene, C_{2-6} heteroalkenylene, C_{2-6} alkynylene, C_{2-6} heteroalkynylene, C_{3-10} cycloalkylene, C_{6-14} arylene, C_{7-15} aralkylene, heteroarylene, heterocyclylene, C_{1-6} heteroalkylene- C_{6-14} arylene, or C_{2-6} alkynylene-heterocyclylene;

X^E is $C(R^{E1})$ or N ;

m is an integer of 0, 1, or 2;

n is an integer of 0, 1, 2, or 3;

R^{E1} is hydrogen, deuterium, halo, or C_{1-6} alkyl;

R^{E2} is hydrogen or C_{1-6} alkyl;


each R^{E4} is independently (i) deuterium, cyano, halo, or nitro; (ii) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (iii) $-C(O)R^{1a}$, $-C(O)OR^{1a}$, $-C(O)NR^{1b}R^{1c}$, $-C(O)SR^{1a}$, $-C(NR^{1a})NR^{1b}R^{1c}$, $-C(S)R^{1a}$, $-C(S)OR^{1a}$, $-C(S)NR^{1b}R^{1c}$, $-OR^{1a}$, $-OC(O)R^{1a}$, $-OC(O)OR^{1a}$, $-OC(O)NR^{1b}R^{1c}$, $-OC(O)SR^{1a}$, $-OC(NR^{1a})NR^{1b}R^{1c}$, $-OC(S)R^{1a}$, $-OC(S)OR^{1a}$, $-OC(S)NR^{1b}R^{1c}$, $-OS(O)R^{1a}$, $-OS(O)_2R^{1a}$, $-OS(O)NR^{1b}R^{1c}$, $-OS(O)_2NR^{1b}R^{1c}$, $-NR^{1b}R^{1c}$, $-NR^{1a}C(O)R^{1d}$, $-NR^{1a}C(O)OR^{1d}$, $-NR^{1a}C(O)NR^{1b}R^{1c}$, $-NR^{1a}C(O)SR^{1d}$, $-NR^{1a}C(NR^{1d})NR^{1b}R^{1c}$, $-NR^{1a}C(S)R^{1d}$, $-NR^{1a}C(S)OR^{1d}$, $-NR^{1a}C(S)NR^{1b}R^{1c}$, $-NR^{1a}S(O)R^{1d}$, $-NR^{1a}S(O)_2R^{1d}$, $-NR^{1a}S(O)NR^{1b}R^{1c}$, $-NR^{1a}S(O)_2NR^{1b}R^{1c}$, $-SR^{1a}$, $-S(O)R^{1a}$, $-S(O)_2R^{1a}$, $-S(O)NR^{1b}R^{1c}$, or $-S(O)_2NR^{1b}R^{1c}$; and each R^{E5} is independently hydrogen or R^{E4} ; and

R^{E6} is (i) hydrogen; (ii) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (iii) $-C(O)R^{1a}$, $-C(O)OR^{1a}$, $-C(O)NR^{1b}R^{1c}$, $-C(O)SR^{1a}$, $-C(NR^{1a})NR^{1b}R^{1c}$, $-C(S)R^{1a}$, $-C(S)OR^{1a}$, $-C(S)NR^{1b}R^{1c}$, $-OR^{1a}$, $-OC(O)R^{1a}$, $-OC(O)OR^{1a}$, $-OC(O)NR^{1b}R^{1c}$, $-OC(O)SR^{1a}$, $-OC(NR^{1a})NR^{1b}R^{1c}$, $-OC(S)R^{1a}$, $-OC(S)OR^{1a}$, $-OC(S)NR^{1b}R^{1c}$, $-OS(O)R^{1a}$, $-OS(O)_2R^{1a}$, $-OS(O)NR^{1b}R^{1c}$, $-OS(O)_2NR^{1b}R^{1c}$,

$-\text{NR}^{\text{lb}}\text{R}^{\text{lc}}$, $-\text{NR}^{\text{la}}\text{C}(\text{O})\text{R}^{\text{ld}}$, $-\text{NR}^{\text{la}}\text{C}(\text{O})\text{OR}^{\text{ld}}$, $-\text{NR}^{\text{la}}\text{C}(\text{O})\text{NR}^{\text{lb}}\text{R}^{\text{lc}}$, $-\text{NR}^{\text{la}}\text{C}(\text{O})\text{SR}^{\text{ld}}$,
 $-\text{NR}^{\text{la}}\text{C}(\text{NR}^{\text{ld}})\text{NR}^{\text{lb}}\text{R}^{\text{lc}}$, $-\text{NR}^{\text{la}}\text{C}(\text{S})\text{R}^{\text{ld}}$, $-\text{NR}^{\text{la}}\text{C}(\text{S})\text{OR}^{\text{ld}}$, $-\text{NR}^{\text{la}}\text{C}(\text{S})\text{NR}^{\text{lb}}\text{R}^{\text{lc}}$, $-\text{NR}^{\text{la}}\text{S}(\text{O})\text{R}^{\text{ld}}$,
 $-\text{NR}^{\text{la}}\text{S}(\text{O})_2\text{R}^{\text{ld}}$, $-\text{NR}^{\text{la}}\text{S}(\text{O})\text{NR}^{\text{lb}}\text{R}^{\text{lc}}$, $-\text{NR}^{\text{la}}\text{S}(\text{O})_2\text{NR}^{\text{lb}}\text{R}^{\text{lc}}$, $-\text{S}(\text{O})\text{R}^{\text{la}}$, $-\text{S}(\text{O})_2\text{R}^{\text{la}}$, $-\text{S}(\text{O})\text{NR}^{\text{lb}}\text{R}^{\text{lc}}$,
 or $-\text{S}(\text{O})_2\text{NR}^{\text{lb}}\text{R}^{\text{lc}}$;


wherein each alkyl, alkylene, heteroalkyl, heteroalkylene, alkenyl, alkenylene, heteroalkenylene, alkynyl, alkynylene, heteroalkynylene, cycloalkyl, cycloalkylene, aryl, arylene, aralkyl, aralkylene, heteroaryl, heteroarylene, heterocyclyl, and heterocyclylene is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q.

120. The compound of claim 119, wherein R^{E} is a moiety having the structure of:




or an enantiomer, a mixture of enantiomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

121. The compound of claim 119 or 120, wherein R^{E} is a moiety having the structure of:



or an enantiomer, a mixture of enantiomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

122. The compound of any one of claims 87 to 90, wherein R^E is a moiety having the structure of Formula (EC-XXXV):



or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein:

A^E is a bond, $-O-$, $-N(R^{1b})-$, $-S-$, C_{1-6} alkylene, C_{1-6} heteroalkylene, C_{2-6} alkenylene, C_{2-6} heteroalkenylene, C_{2-6} alkynylene, C_{2-6} heteroalkynylene, C_{3-10} cycloalkylene, C_{6-14} arylene, C_{7-15} aralkylene, heteroarylene, heterocyclylene, C_{1-6} heteroalkylene- C_{6-14} arylene, or C_{2-6} alkynylene-heterocyclylene;

X^E is $C(R^{E1})$ or N ;

Y^E is a bond, C_{1-6} alkylene, $-O-$, $-S-$, $-S(O)-$, $-S(O)_2-$, or $-N(R^{E7})-$;

m is an integer of 0, 1, or 2;

n is an integer of 0, 1, 2, or 3;

R^{E1} is hydrogen, deuterium, halo, or C_{1-6} alkyl;


R^{E2} is hydrogen or C_{1-6} alkyl;

each R^{E4} is independently (i) deuterium, cyano, halo, or nitro; (ii) C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (iii) $-C(O)R^{1a}$, $-C(O)OR^{1a}$, $-C(O)NR^{1b}R^{1c}$, $-C(O)SR^{1a}$, $-C(NR^{1a})NR^{1b}R^{1c}$, $-C(S)R^{1a}$, $-C(S)OR^{1a}$, $-C(S)NR^{1b}R^{1c}$, $-OR^{1a}$, $-OC(O)R^{1a}$, $-OC(O)OR^{1a}$, $-OC(O)NR^{1b}R^{1c}$, $-OC(O)SR^{1a}$, $-OC(NR^{1a})NR^{1b}R^{1c}$, $-OC(S)R^{1a}$, $-OC(S)OR^{1a}$, $-OC(S)NR^{1b}R^{1c}$, $-OS(O)R^{1a}$, $-OS(O)_2R^{1a}$, $-OS(O)NR^{1b}R^{1c}$, $-OS(O)_2NR^{1b}R^{1c}$, $-NR^{1b}R^{1c}$, $-NR^{1a}C(O)R^{1d}$, $-NR^{1a}C(O)OR^{1d}$, $-NR^{1a}C(O)NR^{1b}R^{1c}$, $-NR^{1a}C(O)SR^{1d}$, $-NR^{1a}C(NR^{1d})NR^{1b}R^{1c}$, $-NR^{1a}C(S)R^{1d}$, $-NR^{1a}C(S)OR^{1d}$, $-NR^{1a}C(S)NR^{1b}R^{1c}$, $-NR^{1a}S(O)R^{1d}$, $-NR^{1a}S(O)_2R^{1d}$, $-NR^{1a}S(O)NR^{1b}R^{1c}$, $-NR^{1a}S(O)_2NR^{1b}R^{1c}$, $-SR^{1a}$, $-S(O)R^{1a}$, $-S(O)_2R^{1a}$, $-S(O)NR^{1b}R^{1c}$, or $-S(O)_2NR^{1b}R^{1c}$; and each R^{E5} is independently hydrogen or R^{E4} ; and

R^{E7} is hydrogen or C_{1-6} alkyl;


wherein each alkyl, alkylene, heteroalkyl, heteroalkylene, alkenyl, alkenylene, heteroalkenylene, alkynyl, alkynylene, heteroalkynylene, cycloalkyl, cycloalkylene, aryl, arylene, aralkyl, aralkylene, heteroaryl, heteroarylene, heterocyclyl, and heterocyclylene is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q.


123. The compound of claim 122, wherein R^E is a moiety having the structure of:



or an enantiomer, a mixture of enantiomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

124. The compound of claim 121 or 122, wherein R^E is a moiety having the structure of:





or an enantiomer, a mixture of enantiomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

125. The compound of any one of claims 87 to 124, wherein R^5 is (i) hydrogen or deuterium; (ii) C_{1-6} alkyl, optionally substituted with one or more substituents Q; or (iii) $-OR^{1a}$.

126. The compound of any one of claims 87 to 125, wherein R^5 is $-OR^{1a}$.

127. The compound of any one of claims 87 to 126, wherein R^5 is methoxy, difluoromethoxy, trifluoromethoxy, ethoxy, or cyclopropylmethoxy.

128. The compound of any one of claims 87 to 127, wherein R^{7a} is hydrogen or halo.

129. The compound of claim 128, wherein R^{7a} is chloro.

130. The compound of any one of claims 87 to 129, wherein R^{7d} is hydrogen or halo.

131. The compound of claim 130, wherein R^{7d} is chloro.

132. The compound of any one of claims 98 to 101, 104 to 107, 109 to 112, 115 to 118, and 125 to 131, wherein R^{E5} is hydrogen or halo.


133. The compound of claim 132, wherein R^{E5} is hydrogen or fluoro.

134. The compound of any one of claims 91 to 133, wherein A^E is a bond, $-O-$, $-NH-$, ethynediyl, piperidindiyl, piperazindiyl, (phendiyl)oxymethanediyl, or (piperidindiyl)ethynediyl.

135. The compound of any one of claims 91 to 134, wherein A^E is a bond, $-NH-$, piperidin-1,4-diyl, piperaz-1,4-diyl, (phen-1,4-diyl)oxymethanediyl, or (piperidin-1,4-diyl)ethynediyl.

136. The compound of any one of claims 87 to 89, wherein R^E is a moiety of a von Hippel-Lindau (VHL) E3 ligand.

137. The compound of any one of claims 87 to 89 and 136, wherein R^E has the structure of Formula (EV-I):




or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; wherein:

R^{E6} , R^{E8} , and R^{E9} are each independently hydrogen, deuterium, C_{1-6} alkyl, or C_{3-10} cycloalkyl; and

R^{E7} is hydrogen, deuterium, halo, hydroxyl, $-OC_{1-6}$ alkyl, or $-OC_{3-10}$ cycloalkyl;


wherein each alkyl and cycloalkyl is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q.

138. The compound of claim 137, having the structure of Formula (XXVIA):



or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

139. The compound of claim 138, having the structure of Formula (XXVIII):



or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof.

140. The compound of any one of claims 87 to 139, wherein L is C₁₋₂₀ alkylene, C₁₋₂₀ heteroalkylene, C₂₋₂₀ alkenylene, C₂₋₂₀ heteroalkenylene, C₂₋₂₀ alkynylene, C₂₋₂₀ heteroalkynylene, C₃₋₁₀ cycloalkylene, C₆₋₁₄ arylene, heteroarylene, or heterocyclylene, each of which is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q.


141. The compound of claim 140, wherein L is C₁₋₂₀ alkylene, C₁₋₂₀ heteroalkylene, C₂₋₂₀ alkynylene, or C₂₋₂₀ heteroalkynylene, each of which is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q.


142. The compound of any one of claims 87 to 139, wherein L is C₁₋₂₀ alkylene, C₁₋₂₀ heteroalkylene, C₂₋₂₀ alkenylene, C₂₋₂₀ heteroalkenylene, C₂₋₂₀ alkynylene, or C₂₋₂₀ heteroalkynylene, where one or more methylene groups are each independently replaced by a divalent group, and each divalent group is independently C₃₋₁₀ cycloalkylene, C₆₋₁₄ arylene, heteroarylene, or heterocyclylene; and wherein the alkylene, heteroalkylene, alkenylene, heteroalkenylene, alkynylene, heteroalkynylene, cycloalkylene, arylene, heteroarylene, and heterocyclylene are each optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q.


143. The compound of claim 142, wherein L is C₁₋₂₀ alkylene or C₁₋₂₀ heteroalkylene, where one or more methylene groups are each independently replaced by a divalent group, and each divalent group is independently C₃₋₁₀ cycloalkylene, C₆₋₁₄ arylene, heteroarylene, or heterocyclylene; and wherein the alkylene, cycloalkylene, arylene, heteroarylene, and heterocyclylene are each optionally substituted with one or more, in one embodiment, one, two,

three, or four, substituents Q.

144. The compound of any one of claims 87 to 139, wherein L is:







145. The compound of claim 87, wherein the compound is:

N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-(4-(2-(2,6-dioxo-piperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)heptyl)oxy)benzamide **B1**;

N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((5-(4-((2-(2,6-dioxo-piperidin-3-yl)-1-oxoisindolin-4-yl)ethynyl)piperidin-1-yl)-5-oxopentyl)oxy)benzamide **B2**;

N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-(4-(2-(2,6-dioxo-piperidin-3-yl)-6-fluoro-1-oxoisindolin-5-yl)piperidin-1-yl)heptyl)oxy)benzamide **B3**;

N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((9-(4-(2-(2,6-dioxo-piperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)nonyl)oxy)benzamide **B4**;

N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((5-(4-(2-(2,6-dioxo-piperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)pentyl)oxy)benzamide **B5**;

N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)heptyl)oxy)benzamide **B6**;

N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((12-(4-(2-(2,6-dioxo-piperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)dodecyl)oxy)benzamide **B7**;

N-(3,5-dichloropyridin-4-yl)-3-(difluoromethoxy)-4-(2-(2-(2-(2-((2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)ethoxy)benzamide **B8**;

3-(cyclopropylmethoxy)-*N*-(3,5-dichloropyridin-4-yl)-4-(2-(2-(2-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)amino)propoxy)ethoxy)ethoxy)ethoxy)benzamide **B9**;

3-(cyclopropylmethoxy)-*N*-(3,5-dichloropyridin-4-yl)-4-((7-(4-(2-(2,6-dioxo-piperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)heptyl)oxy)benzamide **B10**;

N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)propoxy)benzamide **B11**;

3-(cyclopropylmethoxy)-*N*-(3,5-dichloropyridin-4-yl)-4-((9-(4-(2-(2,6-dioxo-

piperidin-3-yl)-6-fluoro-1-oxoisindolin-4-yl)piperidin-1-yl)nonyl)oxy)benzamide **B12**;

3-((9-(4-(2-(1-acetamido-1-oxopropan-2-yl)-6-fluoro-1-oxoisindolin-4-yl)-piperidin-1-yl)nonyl)oxy)-*N*-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide **B13**;

N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-(1-(2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxoisindolin-4-yl)piperidin-4-yl)heptyl)oxy)benzamide **B14**;

N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-(2-{4-[2-(2,6-dioxo-piperidin-3-yl)-6-fluoro-1-oxo-2,3-dihydro-1*H*-isoindol-5-yl]piperidin-1-yl}ethoxy)benzamide **B15**;

N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-(2-(2-(2-(3-((2-(2,6-dioxo-piperidin-3-yl)-1-oxoisindolin-4-yl)amino)propoxy)ethoxy)ethoxy)ethoxy)benzamide **B16**;

N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-(4-(2-(2,6-dioxo-piperidin-3-yl)-1-oxoisindolin-4-yl)piperidin-1-yl)heptyl)oxy)benzamide **B17**;

N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-((4-((5-(2,6-dioxo-piperidin-3-yl)-4-oxo-5,6-dihydro-4*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy)benzyl)amino)heptyl)-oxy)benzamide **B18**;

N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-((7-(4-((5-(2,6-dioxo-piperidin-3-yl)-4-oxo-5,6-dihydro-4*H*-thieno[3,4-*c*]pyrrol-1-yl)methoxy)phenyl)heptyl)oxy)-benzamide **B19**;

(2*S*,4*R*)-1-((*S*)-2-(9-(5-((3,5-dichloropyridin-4-yl)carbamoyl)-2-(difluoromethoxy)phenoxy)nonanamido)-3,3-dimethylbutanoyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide **B20**;

(2*S*,4*R*)-1-((*S*)-2-(11-(5-((3,5-dichloropyridin-4-yl)carbamoyl)-2-(difluoromethoxy)phenoxy)undecanamido)-3,3-dimethylbutanoyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide **B21**;

(2*S*,4*R*)-1-((*S*)-2-(9-(2-(cyclopropylmethoxy)-5-((3,5-dichloropyridin-4-yl)-carbamoyl)phenoxy)nonanamido)-3,3-dimethylbutanoyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide **B22**;

(2*S*,4*R*)-1-((*S*)-2-((7-(5-((3,5-dichloropyridin-4-yl)carbamoyl)-2-(difluoromethoxy)-phenoxy)heptyl)amino)-3,3-dimethylbutanoyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)-pyrrolidine-2-carboxamide **B23**;

N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-(2-(4-(2-((3-((2,6-dioxo-

piperidin-3-yl)amino)phenyl)amino)-2-oxoethyl)piperazin-1-yl)ethoxy)benzamide **B24**; or
N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-(4-(4-(2-((3-((2,6-dioxo-
piperidin-3-yl)amino)phenyl)amino)-2-oxoethyl)piperazin-1-yl)butoxy)benzamide **B25**;
or a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more
tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate,
or prodrug thereof.

146. A pharmaceutical composition comprising a compound of any one of claims 1 to 145, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

147. A method of treating, preventing, or ameliorating one or more symptoms of a disease, disorder, or condition mediated by a PDE4 in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of a compound of any one of claims 1 to 145.

148. The method of claim 147, wherein the disease, disorder, or condition associated with a PDE4 is an inflammatory disease.

149. A method of treating, preventing, or ameliorating one or more symptoms of an inflammatory disease in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of a compound of any one of claims 1 to 145.

150. The method of claim 148 or 149, wherein the inflammatory disease is arthritis, ankylosing spondylitis, osteoarthritis, rheumatoid arthritis, Behcet's disease, inflammatory bowel disease, psoriasis, psoriatic arthritis, atopic dermatitis, or contact dermatitis, chronic or obstructive pulmonary disease (COPD).

151. The method of any one of claims 147 to 150, wherein the compound is administered orally or topically.

152. The method of any one of claims 147 to 151, wherein the subject is a human.

153. A method of inhibiting the activity of a PDE4, comprising contacting the PDE4 with an effective amount of a compound of any one of claims 1 to 145.

154. A method of inducing degradation of a PDE4, comprising contacting the PDE4 with an effective amount of a compound of any one of claims 1 to 145.

155. The method of claim 153 or 154, wherein the PDE4 is PDE4D.

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2021/062995

A. CLASSIFICATION OF SUBJECT MATTER INV. C07D401/12 C07D401/14 C07D495/04 C07K5/062 A61P11/00 A61P17/06 A61P19/02 A61P29/00 A61K31/4545 ADD. According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) C07D Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EPO-Internal, WPI Data, BIOSIS, CHEM ABS Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	WO 2021/119571 A1 (BIOTHERYX INC [US]) 17 June 2021 (2021-06-17) the whole document -----	1-155
Y	WO 01/34606 A1 (CELGENE CORP [US]; MAN HON WAH [US]; MULLER GEORGE [US]) 17 May 2001 (2001-05-17) all examples on pages 25ff. with a methylsulfonylethyl moiety; claims -----	1-86, 146-155
Y	US 5 340 827 A (BEELEY NIGEL R A [GB] ET AL) 23 August 1994 (1994-08-23) claims; examples 4, 7, 8 ----- -/-	87-155
☒ Further documents are listed in the continuation of Box C. ☒ See patent family annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 1 March 2022		Date of mailing of the international search report 11/03/2022
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016		Authorized officer Stroeter, Thomas

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2021/062995

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	YIN LINA ET AL: "Chimera induced protein degradation: PROTACs and beyond", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 206, 19 July 2020 (2020-07-19), XP086299069, ISSN: 0223-5234, DOI: 10.1016/J.EJMECH.2020.112494 [retrieved on 2020-07-19] figure 1; table 3 (last entry) -----	1-155

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2021/062995

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2021119571 A1	17-06-2021	TW 202136273 A WO 2021119571 A1	01-10-2021 17-06-2021
WO 0134606 A1	17-05-2001	AT 357913 T AT 506058 T AT 544451 T AT 544452 T AU 782409 B2 AU 2005202964 A1 CA 2392081 A1 CN 1420889 A CY 1107610 T1 CY 1112707 T1 DE 60034139 T2 DK 1228071 T3 DK 2263669 T3 EP 1228071 A1 EP 1698334 A1 EP 2255801 A1 EP 2263669 A1 ES 2282147 T3 ES 2363933 T3 ES 2380574 T3 ES 2381174 T3 FI 20020892 A HK 1049158 A1 HK 1053467 A1 JP 5116201 B2 JP 2004500346 A MX PA02004793 A NO 323633 B1 NO 336210 B1 NZ 519459 A PT 1228071 E PT 2263669 E SI 1228071 T1 US 6667316 B1 WO 0134606 A1	15-04-2007 15-05-2011 15-02-2012 15-02-2012 28-07-2005 11-08-2005 17-05-2001 28-05-2003 13-03-2013 10-02-2016 06-12-2007 06-08-2007 23-04-2012 07-08-2002 06-09-2006 01-12-2010 22-12-2010 16-10-2007 19-08-2011 16-05-2012 23-05-2012 20-06-2002 02-05-2003 24-10-2003 09-01-2013 08-01-2004 14-10-2003 18-06-2007 15-06-2015 28-11-2003 31-05-2007 23-04-2012 31-08-2007 23-12-2003 17-05-2001
US 5340827 A	23-08-1994	HU 211647 A9 US 5340827 A	28-12-1995 23-08-1994